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SCOPE AND OUTLINE OF THIS THESIS
The immune system is a vast network of cells and molecules that protects the body from 
pathogens and cancerous cells. To efficiently manage threats, the immune system is equipped 
with powerful effector functions that induce inflammation, drive infected or cancerous 
body cells into apoptosis, and trap pathogens in a net of DNA and anti-microbial proteins. 
Dysregulation of the immune system can severely harm the body and cause, for instance, 
allergies or autoimmune diseases. To minimize such risks, complex communication networks 
between the immune system, body cells, the microbiota, and the environment make sure that 
those weapons are only used at the right time and at the right place.
 The principal agents of the immune system are single cells that integrate information from 
the environment and turn them into actions. Immune cells are generated in the bone marrow 
and spread all over the body to patrol tissues and organs. The cells of the immune system are 
subject to great variation, meaning that no two immune cells are alike – even if they belong 
to the same class. This variation originates from the vast number of possible states that the 
molecules inside a cell can assume and leads to the circumstance that even very similar cells 
can react very differently in a given immunological setting. This phenomenon is called cellular 
heterogeneity and is now recognized as a ubiquitous feature of all biological systems. Despite 
our appreciation for the existence of cellular heterogeneity, its physiological role and the 
molecular mechanisms that control it remains largely unknown.
 Dendritic cells are a central signaling hub in the immune network as they integrate various 
environmental signals to decide about the activation of the adaptive immune systems with 
its potent effector mechanisms. The adaptive immune system is composed of T cells, that 
can induce apoptosis and enhance the effector function of many immune cells, and B cells, 
that produce antibodies that neutralize pathogens and flag them for immune recognition. 
Due to their role as orchestrators of the immune network, dendritic cells are in the focus of 
therapeutic interventions, such as personalized vaccines, and their ability to activate cytotoxic 
T cells makes them a target for therapeutic strategies in cancer. Current investigations aim at 
isolating dendritic cells from patients, activating and instructing them ex vivo, and re-injecting 
them as potent vaccine. Recent efforts harness the rare dendritic cells that circulate through 
the blood and early clinical trials indicate the potency of these cells in generating anti-tumor 
immune responses. Naturally, cellular heterogeneity plays an important role during dendritic 
cell therapy. Blood circulating dendritic cells, for instance, are comprised of different subsets 
with distinct functions ranging from the activation of T cells to the secretion of cytokines. 
Plasmacytoid dendritic cells emerge as an especially enigmatic cell in this group, as they are 
known to produce large amounts of the antiviral mediator IFNa but also appear to have a 
range of other functions. Additionally, dendritic cells can induce vast heterogeneity during the 
activation of the adaptive immune response.
Many aspects of cellular heterogeneity in the immune system, remain unstudied as suitable 
techniques are lacking. Microfluidics, which deals with the behavior of liquids at small 
volumes, enables new possibilities to analyze variations between single cells. Picoliter droplets, 
generated with microfluidic chips, can be exploited as uniform and standardized bioreactors 
that allow the analysis of cellular activation at the single cell level and are ideally suited to 
investigate functional cellular heterogeneity.
In this thesis, we investigated how functional cellular heterogeneity impacts the antigen-
specific B and T cell responses induced by dendritic cell-based immunotherapy in melanoma 
patients. Furthermore, we developed novel microfluidic techniques for the study of protein 
secretion by single cells activated individually in picoliter droplets. Finally, we exploited 
these single cell techniques to investigate the functional heterogeneity during plasmacytoid 
dendritic cell activation and determined how this phenomenon is controlled by cues from the 
microenvironment.
Introduction
Chapter 1 introduces cancer immunotherapy in general and dendritic cell-based vaccination 
in specific and describes the development of dendritic cell-based therapy from the first 
proof-of-principle trials with monocyte-derived dendritic cells to current efforts employing 
naturally circulating dendritic cell subsets. Future approaches, aiming to exploit the synergy 
between different dendritic cell subsets in a comprehensive treatment paradigm, are further 
discussed. Chapter 2 explores how different dendritic cell subsets communicate with innate 
and innate-like effector cells and how these interactions could be employed to improve cancer 
immunotherapy. In Chapter 3, the idea of cellular heterogeneity is introduced and its influence 
on biological paradigms is discussed. Furthermore, recent technological advances for the 
analysis of single cells, including microfluidic approaches, are reviewed.
Part I
In part I, single cell techniques are employed to analyze the adaptive immune response 
induced by dendritic cell vaccination in melanoma patients. Chapter 4 reports on a clinical trial 
exploring the feasibility and safety of myeloid dendritic cell-based vaccination. In comparison 
to previous trials, strong functional T cell response could be observed in a range of patients 
and those patients survived longer on average. Chapter 5 explores the phenomenon of 
multifunctional T cells. These T cells are able to exert several functions simultaneously, such 
as secretion of various cytokines or induction of apoptosis. Generally, tumor-specific T cells 
showed poor functionality. Dendritic cell-based immunotherapy, however, was able to boost T 
cell functionality leading to long-lasting multifunctional T cell responses. In Chapter 6, a novel 
technique to investigate antigen-specific B cell responses on the single cell level is presented. 
This technique allowed sensitive and specific in-depth phenotyping of vaccine-specific B 
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cells and revealed that dendritic cell-based immunotherapy is able to induce massive B cell 
responses.
Part II
Part II is all about the world of microfluidics and how we can exploit this technique to gain a 
greater understanding of biological processes at the single cell level. In Part I, we employed 
currently available single cell techniques based on flow cytometry. Those techniques only 
serve as an endpoint measurement and don’t allow the stimulation and manipulation of 
single cells. The actual experiments are still conducted with thousands of cells per well in 
microtiter plates. For truly single cell experiments, cells need to be compartmentalized and 
stimulated individually in addition to single cell measurements. Only this approach allows 
investigating functional heterogeneity at the single cell level and elucidating the effect of the 
microenvironment on these processes.
 Here, we explored novel ways to assess protein secretion and surface marker expression 
by individually activated immune cells. Chapter 7 presents a pipette tip-based technique for 
efficiently encapsulating cells in droplets to enable the use of scarce human primary cells 
and clinical samples. Previously, encapsulation of cells in droplets was accompanied by 
massive cell loss due to large dead volumes and cell sedimentation during droplet production. 
This tip-based loading technique allows for experiments with small amounts of cell solution 
and enables routine droplet microfluidic experiments with limited samples. An important 
application for this technique is the pairing of two different cells in a single droplet which allows 
to study cellular interactions on the single cell level. In Chapter 8, a hydrogel-based technique 
for the measurement of cytokine-secretion by single immune cells is presented. Cells were 
encapsulated in droplets containing agarose solution that remains liquid at room temperature. 
After stimulation, the produced droplets were cooled and the agarose gelled turning the droplets 
into solid hydrogel beads with cells and a cytokine detection system entrapped. These beads 
were analyzed via flow cytometry and enabled us to discover intrinsic functional heterogeneity 
within T cell populations. Chapter 9 reports on the development of a membrane-anchored 
aptamer sensor for the detection of IFNg. Using this sensor in combination with fluorescence 
microscopy, we were able to detect the secretion of IFNg by primary T cells that were stimulated 
individually in droplets. In Chapter 10, a novel droplet microfluidics-based cytokine secretion 
assay was employed to investigate the functional heterogeneity of plasmacytoid dendritic cells. 
Plasmacytoid dendritic cells were activated individually in droplets and the impact of various 
environmental factors on their functional heterogeneity was explored.
Summarizing discussion and future perspective
Finally, Chapter 11 summarizes the findings of this thesis and sets them in the context of 
cancer immunotherapy and cellular heterogeneity. Furthermore, the impact of cellular 
heterogeneity on future developments in cancer and immunology is discussed.
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INTRODUCTION
ABSTRACT
Dendritic cell-based immunotherapy employs the patients’ immune system to fight neoplastic 
lesions spread over the entire body. This makes it an important therapy option for patients 
suffering from metastatic melanoma, which is often resistant to chemotherapy. However, 
conventional cellular vaccination approaches, based on monocyte-derived dendritic cells, 
only achieved modest response rates despite continued optimization of various vaccination 
parameters. In addition, the generation of monocyte-derived dendritic cells requires extensive 
ex vivo culture conceivably hampering the immunogenicity of the vaccine. Recent studies, 
thus, focused on vaccines that make use of primary dendritic cells. Though rare in the 
blood, these naturally circulating dendritic cells can be readily isolated and activated thereby 
circumventing lengthy ex vivo culture periods. The first clinical trials not only showed increased 
survival rates but also the induction of diversified anticancer immune responses. Upcoming 
treatment paradigms aim to include several primary dendritic cell subsets in a single vaccine 
as preclinical studies identified synergistic effects between various antigen-presenting cells.
INTRODUCTION
Melanoma is a malignant transformation of melanocytes – the pigment producing cells of the 
epidermis – and the most aggressive cancer of the skin (1). Over the past years, the number of 
melanoma incidences rose worldwide and reached 232,130 diagnosed cases in 2012 (2-4). Once 
melanoma patients develop metastatic disease, life expectancy drops and survival rates are low 
(1, 5, 6). Traditional treatment methods focus on chemotherapy and radiation therapy, which are 
highly invasive and often fail to induce objective clinical response (6). 
 Novel treatments strategies focus on melanoma patients that carry an activating mutation 
in protein kinases involved in MAPK or AKT signaling (7). Recently approved small molecule 
inhibitors, such as Vemurafenib, allow specific targeting of these mutated kinases and lead to 
rapid tumor regression and prolonged survival in treated patients (7-9). However, due to the 
prompt development of resistance in many cases, and major cutaneous side effects, including the 
induction of neoplastic lesions, small molecule inhibitors are so far of limited clinical use (6, 8). 
 As pharmacological treatment paradigms fail to induce lasting responses, researchers, 
clinicians, and patients turn to immunotherapy, which – due to major advances – was recently 
declared as Breakthrough of the Year 2013 by scientific journal Science (10). 
 The ability of the immune system to fight tumors was first described by William B Coley, who 
in the 19th century observed cancer regression in patients suffering from inoperable sarcoma 
after injecting bacterial toxins into neoplastic lesions (11). Today, cytotoxic CD8+ T lymphocytes 
(CTLs) are considered to be the fundamental mediators of anticancer immunity (12-16). In vitro 
experiments and studies in mice showed that CTLs are able to specifically target cancerous cells 
and destroy them by inducing apoptosis (12, 13, 17). Clinical evidence confirmed the importance 
of CTLs in patients suffering from melanoma and other cancers, as infiltrating CD8+ T cells found 
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in tumor biopsies were strongly associated with improved life expectancy (18-20). Furthermore, 
melanoma patients with tumor-specific T cells in peripheral blood displayed increased clinical 
response rates (21). Immunotherapy hence aims to induce a potent and lasting T cell response 
against malignant cells.
 One approach to potentiate the patient’s own immune response is to prolong the activity 
phase of the T cell response. Immunomodulatory drugs, such as the CTLA-4-blocking antibody 
ipilimumab or the PD-1 blocking antibody nivolumab, aim to unleash the patients’ natural 
anticancer T cell responses by interfering with inhibitory pathways (22-27). Neoplastic cells 
frequently exploit e.g. the PD-1 pathways to suppress the immune system leading to immune 
escape and disease progression (28, 29). Notably, ipilimumab was the first treatment agent to 
provide survival benefit for patients suffering from melanoma and is now standard treatment 
for this type of cancer (10, 26, 28). Although only effective in a minority of patients, ipilimumab 
frequently induces objective responses that are remarkably long lasting (26, 30). Due to their 
broad mechanism of action, immunomodulatory antibodies can, however, cause severe and 
potentially fatal side effects by activating autoreactive T cells. Patients with e.g. skin rash, colitis, 
hypophysitis, or high-grade hepatic adverse events were reported (6, 30). To overcome these side 
effects targeted therapies that only activate cancer specific T cells are desired.
 Specific T cell responses are naturally induced by dendritic cells (DCs) (31, 32). DCs are 
professional antigen presenting cells (APCs) that sample the body for antigens and danger 
signals derived from pathogens or tumors (33). After encountering such signals, DCs become 
activated and migrate to the lymph node, where they activate naïve T cells to become CTLs or 
helper T cells (32, 33). Due to their great regulatory capacities and outstanding ability to activate 
antigen-specific T cells, DCs have become an attractive target in several immunotherapeutic 
approaches in cancer.
 Cellular vaccination therapies were developed in the mid 1990s, when new laboratory 
techniques allowed the enrichment of DCs from peripheral blood (34-37). Murine DCs were 
isolated from peripheral blood by density gradients, loaded ex vivo with tumor antigens, and 
injected back into the blood (17, 38). This technique was rapidly transferred to the clinical 
setting when in 1996 pioneer Frank Hsu treated patients suffering from B-cell lymphoma with 
autologous, antigen-loaded DCs (39). Strikingly, clinical response could be detected in a majority 
of patients, kickstarting the field of therapeutic DC vaccination (Figure 1).
 However, only after Sallusto and colleagues discovered a method to differentiate DCs from 
monocytes in vitro, sufficient cellular material was available to start clinical trials that went 
further than pure proof of principal (40). Following this development, Nestle and colleagues 
conducted the first DC vaccination trail in melanoma patients in 1998 (41). In this study, the group 
isolated autologous monocytes from peripheral blood of the patients and generated dendritic 
cells ex-vivo. Monocyte-derived DCs (moDCs) were subsequently pulsed with tumor-associated 
antigen (TAA) peptides or tumor lysate, and injected into the lymph nodes of the patients to 
activate the immune system. The results of this study were promising, as complete and partial 
responses could be observed in a number of patients. Furthermore, tumor-specific T cells were 
found in vaccinated patients, indicating the induction of a melanoma specific immune response.
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 In the following years, a considerable number of phase I/II clinical trials explored the impact 
of various vaccination parameters on the treatment outcome. In this review, we will give an 
overview of the major advances in the field of therapeutic DC vaccination against melanoma 
since the initial study by Nestle. Further, we will highlight current developments focusing on 
natural DC subsets and their impact on immunotherapy, and we will conclude with an outlook 
on future vaccination strategies including the synergistic effects of DC subsets.
Figure 1. Development of DC-based immunotherapy against melanoma.
MATURATION OF DCS
A major disadvantage of the DC vaccination protocol employed by Nestle et al. was the lack 
of activation signals. After differentiation, most moDCs possess an immature phenotype, 
which is dominated by high antigen-uptake capabilities and poor T cell stimulatory abilities 
(42-45). Activation of DCs leads to the development of a mature phenotype characterized by 
upregulation of co-stimulatory molecules, major histocompatibility complex (MHC) molecules 
and certain chemokine receptors (33, 46, 47). Especially the latter are of great importance for 
vaccination efficacy, as expression of the chemokine receptor CCR7 promotes the migration of 
injected DCs to the lymph nodes where the activation of T- and B-cells occurs (42, 47, 48). In 
addition to their inferior stimulatory capabilities, immature DCs were shown to induce antigen-
specific tolerance, proposing that injection without activation signals is not only ineffective but 
also potentially detrimental (49).
 While in vivo maturation signals primarily come from contact with pathogens or tissue 
injury, immature DCs can be matured by incubation with pathogen recognition receptor (PRR) 
agonists or cytokines such as TNF-α, and prostaglandin E2 (50, 51). In a clinical setting, CD40 
ligation has also been used for DC activation (52, 53).
23
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 In 2003, a phase I/II clinical trial treating stage IV metastatic melanoma patients with 
autologous, antigen-loaded moDCs confirmed the superiority of mature DCs to induce strong 
immunity, as the immunological response against both included TAAs and the control antigen 
keyhole limpet hemocyanin (KLH) was improved in the majority of patients treated with mature 
DCs, as opposed to immature DCs (54). Strikingly tumor regression could only be observed in 
patients of the mature DC arm, indicating that activating DCs prior injection improves clinical 
response as well. Other groups that employed modified maturation cocktails made the similar 
observations that DC maturation is necessary for the induction of a superior immune response 
(55-59). These results confirmed in a clinical setting what was already known for in vitro 
models: infused DCs need to express potent stimulatory molecules to generate a strong T cell 
response, especially when presenting cancer antigens with low immunogenicity. Nevertheless, 
as proper homing to the lymph nodes is a prerequisite for DC-mediated T cell activation, 
upregulation of CCR7 may also partly explain the observed differences (42).  
ROUTE OF ADMINISTRATION
In addition to maturation-induced upregulation of CCR7, the route of administration has a 
major impact on the migration of DCs to the T cell rich zones in the lymph nodes (42). Since 
intravenously (i.v.) injected, ex vivo generated DCs fail to induce potent skin-homing T cells in 
mice and appeared to be less efficient in inducing TH1 responses in humans, previous clinical 
trials focused on subcutaneous or intradermal (i.d.) administration of the vaccines (60-62). 
However, using 111In-labeling and scintigraphy, we could show that most of the injected DCs 
remain at the injection site, where they rapidly die to be phagocytosed by macrophages (42, 63, 
64). Pretreatment of the skin with cytokines, toll-like receptor (TLR) ligands, or activated DCs did 
not lead to increased migration (64). Interestingly, Aarntzen et al. identified the number of injected 
DCs as an important factor for migration as a low cell density at the injection site correlated with 
high migration efficiency (64).
 To further improve migration of DCs to lymph nodes and enhance the induced immune 
responses, different routes of administration have been explored in various studies (65, 
66).  Direct injection of DCs into the lymphatic system of the skin appeared to be a promising 
approach, as it ensures that most of the DCs reach the T- and B-cell rich zones of the lymph 
nodes. To test this hypothesis, our group conducted a phase I/II clinical trial and vaccinated 
melanoma patients with ex vivo generated, antigen-loaded, mature moDCs that were injected 
either intranodally or intradermally (65). Although intranodal vaccination led to increased DC 
migration to efferent lymph nodes, no difference in the frequency of tetramer-specific T cells 
could be detected. Furthermore, melanoma-specific T cells induced by i.d. vaccination turned 
out to be more functional, which might be caused by bystander activation of APCs at the injection 
site. Similar results have been found by Kyte et al. using mRNA transfected moDCs (66). Taking 
the complicated procedure of intranodal vaccination into account, intradermal injection of DCs 
appears to be the optimal route of administration in case of sufficient cellular material.
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T CELL HELP
In the late 90s several groups independently discovered that, in absence of a strong inflammatory 
stimulus, DCs need to interact with CD4+ T cells to induce potent cytotoxic CD8+ T cells – a 
process called DC licensing (67-70). These findings, together with other important discoveries 
in the early 2000s, shifted the focus of therapeutic anti-cancer vaccination towards the CD4+ 
T cells and the impact of helper responses (71-73). Besides licensing DCs, T cell help plays a 
crucial role in memory generation and maintenance as well as affinity maturation of tumor-
specific antibodies (72, 74, 75). Additionally, CD4+ T cells were shown to activate the innate 
immune system, to enhance the cytolytic function of macrophages, to induce senescence in 
malignant cells, and to destroy neoplastic cells directly (76, 77). The latter is of particular 
importance in the melanoma setting, where transformed melanocytes tend to constitutively 
express MHC class II molecules (78, 79). In particular, TH1 cells appear to be associated with 
favorable clinical outcome and overall survival (80). Despite this knowledge, integration of CD4+ 
T cell help in clinical trials was hampered due to the lack of defined TAA peptides binding to 
MHC-class II molecules. To partly overcome this limitation, DCs were pulsed with unrelated 
antigens such as KLH or tetanus toxoid. The CD4+ T cells generated against these antigens 
were supposed to secrete interleukin (IL)-2 and pro-inflammatory cytokines, and to further 
activate the injected DCs, leading to an improved priming of cancer-specific CTLs (81). Whether 
or not the antigen-independent CD4+ T cell help had a strong effect on T cell priming could 
however not been definitely proven.
 This changed when several groups characterized immunogenic melanoma-associated 
MHC class II epitopes of the tumor antigens gp100 and tyrosinase leading to a comparative 
study of melanoma patients treated with moDC pulsed with both MHC class I and class II 
epitopes or MHC class I epitopes alone (79, 82-84). Analysis of patient samples showed that 
the simultaneous administration of TAAs restricted to both MHC classes lead to a broader 
anti-cancer T cell response with higher functionality compared to patients who received DCs 
loaded with epitopes for MHC class I only (79). Importantly, the tumor-specific CD4+ T cells 
were Foxp3 negative and displayed a TH1 phenotype, indicating that the vaccination did not 
induce regulatory T cells. This trend was reflected in the clinical response, as patients of the 
MHC class I/II arm showed increased progression free and overall survival, whereas no clinical 
benefit could be detected in patients of the MHC class I arm. The results thus indicate that 
antigen-specific CD4+ T cell help is indeed beneficial for the induction of a strong cancer-
specific immune response, which is in line with a number of other studies (57, 85).
ANTIGEN LOADING AND HETEROCLITIC PEPTIDES
Antigen loading was revolutionized when clinical grade mRNA electroporated moDCs became 
available. MRNAs coding for full-length TAA proteins containing multiple immunogenic 
epitopes were synthesized and used to transfect DCs (86, 87). In this approach, the transfected 
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DCs translate the injected mRNA into full-length proteins, which are subsequently degraded by 
the proteasome and presented on MHC class I molecules (86). Adding a MHC class II targeting 
tag to the mRNA leads to the transport of translated proteins to exosomes and presentation 
on MHC class II molecules, necessary for priming CD4+ T cells (88, 89). Using electroporated 
DCs, several problems were solved: due to the presence of multiple immunogenic epitopes 
within the same protein, CD8+ and CD4+ T cells could be stimulated at the same time, and 
the induced immune responses became broader. The same effect rendered human leukocyte 
antigen (HLA)-restriction obsolete, as the various epitopes contained in each protein are able 
to bind to different HLA molecules. This made the enrollment of a much larger number of 
melanoma patients possible and increased the number of individuals potentially benefitting 
from this treatment (90, 91). These improvements however come with the price of reduced 
viability, which can turn into a serious problem when cellular material is scarce (92).
 Studies using electroporated moDCs conducted by our group and others indeed showed the 
induction of specific CD4+ and CD8+ T cells in patients suffering from metastatic melanoma (63, 
90, 91, 93). Interestingly, T cells specific for epitopes different from the TAA peptides employed 
in previous vaccines were readily detected in a number of patients, thus indicating an increased 
breadth of the immune response (93).
 Soon after the first studies with electroporated moDCs were published, Bonehill et al. simplified 
the loading and activation process for moDCs distinctly. In their approach, they transfected DCs 
with mRNA, not only coding for TAA proteins, but also for the maturation-inducing molecules 
CD40L and caTLR4 (constitutively active form of TLR4) as well as the T cell co-stimulatory 
molecule CD70. This led to prolonged and enhanced maturation of DCs (90, 94, 95). 
 In parallel to the development of mRNA-based DC vaccines, various groups tried to improve 
the immunogenicity of the traditional peptide-pulsing approach to load DCs. Using rational 
design, researchers modified known TAA peptides by replacing single amino acids to improve 
binding to the MHC groove creating so called heteroclitic peptides (96-98). Due to tighter 
binding, heteroclitic peptides are presented for an extended time period, supposedly leading 
to stronger T cell activation. However, whereas many pre-clinical studies showed increased 
immunogenicity in vitro, clinical trials directly comparing modified and wild type peptides failed 
to measure any positive effect of heteroclitic peptides and even showed decreased frequencies 
of TAA-specific T cells in some patients (98). It appeared that the modified epitopes differed too 
much from the wild type peptide leading to the induction of T cells that were unable to detect 
endogenously presented antigens (99).
 In summary, the development of mRNA electroporated moDCs simplified anticancer 
immunotherapy significantly as transfection of DCs not only induces a broad, HLA-independent 
CD4+ and CD8+ immune response but also reduces the time and costs for vaccine preparation. 
In contrast, heteroclitic peptides failed to proof superior immunogenicity in immunotherapy 
against melanoma.
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Although various vaccination parameters could be optimized and lasting responses were 
observed in selected patients, so far none of the conducted clinical trials using monocyte-
derived dendritic cells could demonstrate statistically supportable evidence for survival benefits 
in vaccinated patients. This became especially evident when in 2006 Schadendorf et al. published 
the first and so far only randomized phase III trial designed to demonstrate the clinical efficacy 
of moDC therapy in melanoma patients (100). The study was aborted early, as the Data Safety & 
Monitoring Board did not expect the group to reach the study goal. Analysis of the preliminary 
data could demonstrate the induction of an anticancer immune response in various patients but 
failed to show improved overall survival. Further, objective response was lower in the group of 
patients treated with DC vaccination as opposed to chemotherapy with dacarbazine (DTIC); thus 
no clinical benefit of moDC therapy could be detected. 
 One explanation for the observed lack of clinical response could be the inferior capacity of 
moDCs to induce effective anticancer immunity. However, as the study was already initiated in 
1999 – thus only one year after the publication of the first phase I trial on moDC-based vaccines 
in melanoma by Nestle et al. – many of the aforementioned developments, including proper 
maturation of DCs, were not yet translated to the clinics (54, 100-103). Furthermore, several 
studies suggest that the employed maturation cocktail based on pro-inflammatory cytokines 
might not have been optimal for the induction of a strong anticancer immune response (51). DCs 
solely activated by these cytokines show only limited capabilities to produce polarizing cytokines 
that further decrease soon after activation – a phenomenon called exhaustion (51, 104, 105). At 
the time of injection, DCs thus might have possessed only limited capabilities to induce TH1 cells 
and CTLs. Additionally, the employed clinical protocols were not suited for multicenter trials 
leading to highly variable maturation levels and low numbers of generated DCs (100). 
 Interestingly, in the same year as Schadendorf et al. published their moDC study, Small et 
al. presented the results of a placebo-controlled phase III trial on DC-based immunotherapy in 
patients with metastatic asymptomatic hormone refractory prostate cancer (106). In contrast to 
Schadendorf et al., the authors employed a heterogeneous mixture of readily isolated leukocytes 
enriched for naturally circulating dendritic cells by gradient centrifugation, thus avoiding long 
term in vitro culture. The leukocytes were activated and antigen-loaded using a recombinant 
fusion protein consisting of granulocyte-macrophage colony-stimulating factor and the TAA 
protein prostatic acid phosphatase. The prepared leukocytes were subsequently injected i.v. – 
less than 48h after isolation. Strikingly, significantly increased overall survival and prolonged 
time to disease progression could be observed among patients of the treatment arm, thereby 
proving clinical efficacy of DC-based immunotherapy. Together with supporting studies, these 
results finally led to the first FDA approval for a cell-based therapy, Provenge®, in 2010 (107).
27
1
PARADIGM SHIFT IN DC-BASED IMMUNOTHERAPY
NATURALLY CIRCULATING DCS
Inspired by the promising results of the Provenge® trial, we postulated that purified naturally 
circulating DCs would be superior in anticancer immunotherapy against melanoma (51). Not 
only are these DCs efficient in generating CTLs, they can also be readily isolated from the blood 
(108, 109). This allows immediate activation and antigen loading, thus avoiding long incubation 
periods and enabling robust standardization for use in multicenter trials. Therefore, natural 
DCs, despite their rare occurrence in peripheral blood, display various advantages over moDCs 
that are making them an attractive target for anticancer therapy.
 Human naturally circulating DCs can be divided into two main subsets: plasmacytoid DCs 
(pDCs) and myeloid DCs (mDCs), each with distinct phenotype and function during the immune 
response (Figure 2) (110).  MDCs can be further subdivided in CD1c+ (BDCA1) DCs, CD141+ 
(BDCA3) DCs, and CD16+ cells, where the latter are considered to be more monocyte-like (111-
115). MDCs are specialized in immunity against fungi and bacteria and have an enhanced ability 
to sense tissue injuries (110, 111). They are able to capture environmental- and cell-associated 
antigens and show high phagocytic activity (116).
Figure 2. Biology of immunotherapy-relevant human DC subsets. Depicted are major DC functions relevant for pathogen 
recognition and DC activation, T cell priming, and anti-cancer immunity.
 CD141+ DCs are specialized in the detection and uptake of necrotic cells and excel in cross-
presenting these antigens to T cells (117-120). Remarkably, CD141+ DCs uniquely express 
the C-type lectin CLEC9A (DNGR-1), which allows sensing of damaged cells by binding to 
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exposed actin filaments (121, 122). In addition, CD141+ DCs can be activated using a distinct 
set of Toll-like receptors including TLR1, 2, 3, 6 and 8 (117, 123). Especially, TLR3 is strongly 
expressed and leads to upregulation of co-stimulatory molecules, as well as the secretion of 
pro-inflammatory cytokines and chemokines (117, 123). Upon activation, CD141+ DCs are able 
to secrete IFN-γ and IL-12, which allows the effective induction of TH1 and CTL responses (117, 
119). However, due to the limited availability in blood and lack of GMP-grade isolation reagents, 
CD141+ DCs are currently not feasible for cellular immunotherapy. Several developments 
focusing on improved isolation and culturing, nevertheless, might allow their employment in 
future DC vaccination.
 CD1c+ DCs are responsive to a great variety of microbial and fungal stimuli (124). Triggering 
of TLRs 1/2/6 by bacterial ligands leads to the activation of CD1c+ DCs and secretion of 
large amounts of the TH1-scewing cytokine IL-12 (123, 125, 126). Due to their potent antigen 
processing and presentation machinery, activated CD1c+ DCs are able to induce TH1 cells and 
cytotoxic T cells leading to a potent cellular immune response (108, 112, 117, 123, 126, 127). 
Moreover, in vitro studies showed that CD1c+ DCs isolated from healthy donors and prostate 
cancer patients are able to prime tumor specific CD8+ T cells (108, 128).
 In contrast to mDCs, pDCs are specialized in the detection and control of viral infections 
(110, 129). Viral infections are rapidly detected by pDCs via the engagement of TLR7 and/
or TLR9 (116, 129). TLR triggering by viral agents leads to a rapid burst of type I interferons 
(IFNs) and induces cytotoxic functions in pDCs as well as natural killer (NK) cells (110, 130, 
131). These outstanding antiviral activities make pDCs the key effector cells in early antiviral 
immunity (110). In a steady state, pDCs are characterized by low expression of MHC class II and 
co-stimulatory molecules (111). This phenotype is associated with tolerance induction and TH2 
immunity, properties that are unfavorable for anticancer immunity (132). However, activation 
of pDCs leads to an upregulation of these proteins, turning pDCs into professional APCs that 
efficiently prime both, CD4+ and CD8+ T cells (108, 110, 131, 133). The strong release of type I 
IFN by pDCs leads to an IL-12 independent TH1 polarization characterized by strong secretion 
of IFN-γ and IL-10 (110, 134-136). Despite low antigen uptake and limited phagocytosis, pDCs 
isolated from blood, tonsils, and spleen were shown to efficiently cross-present antigens to 
CD8+ T cells (113, 120, 127, 137). Moreover, several studies reported that pDCs are able to 
prime potent melanoma-specific CD8+ T cells, which produce IFN-γ and are able to locate to 
melanoma lesions (108, 120, 138, 139). Finally, pre-clinical mouse models showed that pDCs 
are able to induce a tumor specific T cell response in vivo, leading to control of tumor growth 
(138, 140).
NATURALLY CIRCULATING DC-BASED IMMUNOTHERAPY
Due to the low occurrence of naturally circulating DCs in blood, conclusive clinical evidence on 
their usability for immunotherapy is lacking. In 2006, a small-scale study by Davis et al. reported 
on a vaccine that employed Flt3 ligand (Flt3L)-mobilized naturally circulating dendritic cells (53). 
29
1
PARADIGM SHIFT IN DC-BASED IMMUNOTHERAPY
The treatment was safe and strong immune responses were detected in several patients. However, 
the purity of the employed DCs was generally low and, as it turned out, the administration of Flt3L 
induced the expansion of regulatory T cells in melanoma patients (53, 141).
 Encouraged by the promising pre-clinical data, we initiated the first clinical trial on a 
cellular vaccine based on purified pDC in 2008 at RadboudUMC in the Netherlands (142). 
PDCs were isolated from leukapheresis products using MACS separation kits and cultured 
overnight in IL-3. On the next morning, pDCs were activated with a conventional Frühsommer-
Meningocencephalitis (FSME; English: Tick-borne encephalitis) vaccine, which has the benefit 
of sustained secretion of T cell stimulatory cytokines due to natural triggering of TLRs (143). 
Subsequently, pDCs were loaded with TAA peptides, and injected intranodally. 
 Initial tests revealed only mild side effects of pDC vaccinations and the toxicity was even 
lower as compared to moDC vaccinations (142). Further, pDCs were able to activate the innate 
immune system, indicated by a systemic type I IFN signature. PDCs were also shown to 
efficiently migrate to efferent lymph nodes and FSME specific adaptive immune responses were 
detected in 14 of 15 enrolled patients. The potent stimulatory capacities of pDCs were reflected 
in the cancer-specific immune response, as 7 of 15 patients showed increased frequencies of 
gp100-specific T cells after vaccination. Strikingly, TAA-specific T cell clones with high avidity 
could be identified after vaccination, indicating the induction of a strong functional response. 
Nevertheless, the overall magnitude of the induced melanoma-specific immune response 
appeared to be limited compared to previous moDC vaccination trials, as the total frequency of 
specific T cells in blood of pDC-vaccine patients was rather low (65, 93). Further analysis of skin-
infiltrating lymphocytes obtained from delayed-type hypersensitivity reactions against tumor 
antigens – a sensitive assay to analyze functionality, migration, and specificity of anticancer T 
cells – showed positive responses in only 2 out of 15 tested patients (142, 144). Despite this, the 
overall survival of patients treated with pDCs was greatly increased in comparison to matched 
controls treated with standard chemotherapy. However, assumptions on clinical efficacy have 
to be taken with caution, as the study was primarily designed to assess the safety and toxicity 
of pDC-based immunotherapy.
 Nevertheless, the prominent survival benefit of vaccinated patients is especially interesting 
in respect to the low frequency of TAA-specific T cells. Two explanations for this phenomenon 
are likely: (I) T cells induced by pDCs might be more potent and functional as compared to 
moDC primed T cells. This could be due to different cytokine secretion patterns, differential 
expression of co-stimulatory molecules, improved migratory capacities, or prolonged survival. 
(II) Alternatively, instead of – or in addition to – inducing T cell responses, the focus of pDC 
mediated anticancer immunity might lie on the activation of NK cells and the innate immune 
system. Evidence for this comes from the lasting type I IFN signature induced in vaccinated 
patients (142). Strikingly, various studies report on pDC-dependent, IFN-α-mediated activation 
of natural DC subsets in arteriosclerosis, autoimmunity, and infections (145-147). Furthermore, 
it could be shown that type I IFNs are able to activate NK cells, induce IFN-γ secretion, and 
enhance cytotoxicity (148, 149). However, in comparison to subjects that underwent recombinant 
IFN-α therapy, patients vaccinated with pDCs showed longer overall survival indicating that the 
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observed clinical benefits were not induced by type I IFNs alone (150-152). Interestingly, it was 
shown that contact-dependent interactions between pDCs and lymph node DCs greatly enhance 
Ag presentation and priming of anti-herpes simplex virus CTLs (153). The authors identified 
CD2-CD2L and CD40-CD40L as key mediators of this effect. PDCs can thus activate other DC 
subsets, for instance mDCs, to potentiate the immune response. However, this synergy not only 
acts in one direction: mDCs were shown to mature pDCs and enhance their Ag presentation 
capabilities during bacterial exposure (116, 154). Interestingly, in one scenario pDCs only act 
as antigen presenting cells without instructing T cells with polarizing cytokines (116). Together, 
these results show that natural DCs of various subsets cooperate with each other to enhance 
the immune response and that the roles in this regulatory network are variable and depending 
on the stimulus. However, the studies also indicate a hierarchical organization within natural 
DC synergies, with one DC subset orchestrating and polarizing the immune response, and the 
other merely acting as “zombie” APC without instructive capabilities (116). 
 Strikingly, mouse experiments demonstrated that injection of a mixture of ex-vivo activated 
and antigen-loaded mDCs and pDCs induces a superior immune response against tumors 
(155). Moreover, therapeutic efficiency, as assessed by overall survival and tumor burden, 
was greatly improved when mice received simultaneous injections of both subsets compared 
to injections of one subset alone (155). The observed synergistic effect was mainly based on 
enhanced antigen presentation by mDCs induced by contact-dependent interactions with 
pDCs. These observations might explain why patients in our pDC vaccination trial showed 
significantly increased overall survival despite low frequencies of vaccination-specific CTLs 
(142, 155). Injected pDCs might have activated mDCs present at the site of injection leading 
to the induction of a TH1 and CTL response. As the in situ activated mDCs then would present 
naturally processed melanoma antigens expressed at the site of the tumor, the subsequently 
induced anticancer immune response would not be fully detectable when examining the 
vaccine-specific T cell response only.
 Subsequent to the pDC-based vaccine, we conducted a phase I trial vaccinating metastatic 
melanoma patients with ex-vivo activated and antigen loaded autologous blood CD1c+ mDCs. 
Preliminary results confirm the safety and feasibility of mDC-based vaccines and could identify 
clinical responses in a number of patients (manuscript in preparation). Considering the results 
of these studies and the synergistic effects of pDCs and mDCs observed in mice and in in 
vitro models, the next step would be to initialize a human vaccination trial using a cocktail 
of activated and antigen loaded mDCs and pDCs. Once injected in e.g. the lymph node, these 
natural DC subsets might synergize and potentiate the T cell response. 
 Importantly, before clinical trials can exploit the synergy between mDCs and pDCs a 
number of questions need to be addressed: First: What ratio of mDCs and pDCs should be 
chosen and should one DC subset dominate the immune response? How should both DC 
subsets be activated in vitro? How does the simultaneous secretion of two different T cell 
polarizing cytokines (IFN-α by pDCs, IL-12 by mDCs) influence naive T cell priming? And what 
impact does this have on other immune cells? In addition, does the synergy between mDCs and 
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pDCs also help to induce tumor-specific antibodies by B cells? Does it increase the anticancer 
activity of the innate immune system?
 In vitro studies and pre-clinical mouse models suggest answers to some of these questions. 
Mouse models for instance indicate that activated pDCs need to be cocultured with immature 
mDCs to induce maximal expression of IL-12 as well as co-stimulatory molecules CD40, 
CD80 and CD86 (Table 1) (155). This was cell-cell contact dependent and also crucial for the 
induction of a superior CD8+ T cell response. Secretion of IFN-α by pDCs did not influence the 
secretion of IL-12 by mDCs, indicating that mDCs retain their strong TH1 polarizing capacities 
when administered together with pDCs. In vitro studies on human DCs, however, are not as 
Tabel 1. Controversial effect of IL-12 and IFN-α on immune activation and T cell priming.
Species Experimental setup Observation Reference
Mouse Isolated pDCs were 
activated and cocultured 
with immature mDCs. 
This mixture or single 
DC subsets were then 
injected in tumor-bearing 
mice
The coculture of pDCs and mDCs induced 
strong expression of co-stimulatory molecules 
CD40, CD80 and CD86 on mDCs and led to 
superior secretion of IL-12 by mDCs. This 
process appeared to be contact-dependent. 
The induced T cell response was superior 
when both subsets were injected together and 
also led to improved tumor control. 
(155)
Human Coculture of irradiated 
allogeneic moDCs and 
naive CD4+ T cells in 
αCD3-coated wells.
Addition of type I IFNs to the cocultures led to 
decreased IL-12p40 production by DCs and the 
induction of IL-10 producing T cells.
(156)
Human PDCs and mDCs were 
isolated from blood 
and cocultured with 
cytokines. Subsequently, 
DCs were cultured with 
allogeneic, naive CD4+ T 
cells.
IFN-α induced mDC maturation leading to 
IL-10 but not IL-12 production. IFN-α matured 
mDCs further induced IL-10 producing T cells.
(157)
Human/
mouse
MoDCs were activated in 
cytokine-supplemented 
media.
The presence of type I IFNs at low levels 
augmented the production of IL-12p70.
(158)
Human MoDCs were activated 
using TLR ligands. IFN-α 
was added at different 
stages and secretion of 
IL-12 was measured.
The presence of IFN-α during maturation 
increased the secretion of IL-12p70 by moDCs. 
When added after maturation IFN-α inhibited 
the secretion of IL-12p70.
(159)
Human/
mouse
Naive CD4+ T cells were 
activated in cytokine-
supplemented media.
In contrast to IL-12, IFN-α was not sufficient 
to induce stable T-bet expression and thus 
TH1 differentiation. However, no significant 
reduction in TH1 induction could be observed 
when both cytokines were administered 
together.
(162)
Human Naive CD8+ T cells were 
cultured and activated 
in αCD3/αCD28-coated 
plates. The media was 
supplemented with 
polarizing cytokines.
Whereas IL-12 induced fast-dividing, IFN-γ 
secreting effector memory T cells, IFN-α 
primed slowly dividing central memory T cells. 
For a comprehensive T cell response, both 
cytokines were necessary. 
(161)
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Human/
mouse
Naive CD8+ T cells were 
cultured and activated 
via αCD3/αCD28-coated 
beats. The media was 
supplemented with 
polarizing cytokines.
Priming of naive CD8+ T cells in IFN-α-
supplemented media induced stem cell-like 
memory T cells with increased ability to 
respond to homeostatic cytokines, increased 
persistence upon adoptive transfer, and 
reduced effector functions. These T cells 
were able to mount robust recall responses 
and showed superior ability to contain tumor 
progression after adoptive transfer.
(160)
conclusive and report on both, impaired and increased production of IL-12 by mDCs when 
cultured in IFN-α supplemented media (156-159). The induction of CD8+ T cells, however, 
seems to be augmented by the combined effect of IFN-α and IL-12 as comprehensive and 
lasting immune responses including effector and memory T cells could only be detected when 
T cells were cocultured with both cytokines (160, 161).
 Although many studies report synergistic effects of IFN-α and IL-12 on T cell priming and 
immune activation, it is hard to predict how these and other factors integrate in the complex 
microenvironment found in neoplastic lesions of melanoma patients. Following initial clinical 
trials focusing on safety and feasibility, many studies thus have to follow in order to improve 
various vaccination parameters.
CONCLUDING REMARKS
Although randomized clinical trials are needed to further proof the clinical efficacy of 
vaccination with natural blood DCs, DC-therapy has major advantages over treatment with FDA-
approved checkpoint inhibitors like Ipilimumab, as DC therapy with natural DC is less costly and 
associated with only very mild side effects. Before anti-cancer therapy with natural DCs can 
be implemented as standard therapy for melanoma, some issues still need to be overcome. 
First, DC vaccination, in particular DC vaccination with natural DCs, is currently performed 
only in a limited number of medical centers. However, the isolation technique with magnetic 
beads is FDA-approved for stem cell isolation and common practice, thus enabling robust 
standardization for use in multiple centers in the future. In addition, as it is not feasible yet 
to perform mRNA electroporation on these rare cells, antigen loading still depends on HLA-
binding tumor-peptides, thus excluding patients that do not have the matching HLA-phenotype. 
Efforts are made to enable peptide-loading for a broader HLA-repertoire, including MHC class II 
epitopes, to induce broader immune responses and enable inclusion of more patients. 
 As the field of moDC vaccinations appears to have reached some level of maturity, naturally 
circulating DC-based vaccinations are just at the beginning of their clinical development. 
However, the lessons learned from moDC-based vaccination trials will surely contribute to 
accelerate the development of mDC/pDC based vaccines, hopefully leading to highly efficient 
DC-based immunotherapies and benefits for an increasing number of cancer patients.
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CHAPTER 2
DC crosstalk with innate and innate-like 
effector cells in antitumor immunity: 
implications for DC vaccination
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ABSTRACT
Dendritic cells (DCs) are key players in the induction of immune responses. Adoptive transfer 
of autologous mature DCs loaded with tumor-associated antigens is a promising therapy 
for the treatment of immunogenic tumors. For long, its therapeutic activity was thought 
to depend solely on the induction of tumor-specific CD8+ and CD4+ T cell responses. More 
recently, DCs were shown to bidirectionally interact with innate and innate-like immune cells, 
including natural killer (NK), invariant natural killer T (iNKT) and γδ T cells. These effector 
cells can amplify responses induced by DCs via several mechanisms, including induction of 
DC maturation and conventional T cell priming. In addition, NK, iNKT and γδ T cells possess 
cytolytic activity and can act directly on tumor cells. Therapeutic strategies targeting these 
innate and innate-like immune cells hence hold potential to improve current DC vaccination 
protocols. 
INTRODUCTION
DCs are professional antigen-presenting cells (APCs) with the ability to activate and polarize 
naïve T cells.(1) This has made them attractive targets in a vast number of cell-based, antitumor 
immunotherapeutic approaches. In short, autologous DCs are pulsed ex vivo with tumor-
associated antigens (TAAs) and then infused back into the patient, harnessing the patient’s own 
immune system to eradicate tumor cells. DCs derived ex vivo from either monocytes (moDCs) 
or CD34+ progenitor cells have been most frequently used as immunotherapy. However, an 
up and coming strategy is to use naturally occurring DCs that can be isolated from blood. 
Several DC subsets have been identified in human peripheral blood, generally divided into 
myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs). Vaccines based on 
these naturally occurring DCs have shown promising results in melanoma patients,(2) as they 
seem to surpass moDC-based vaccines in prolonging overall survival. 
 Much has been learnt about DC biology and the requirements for inducing antitumor 
immune responses since the first DC-based vaccination was tested in cancer patients, and 
the potency of immunotherapy in cancer treatment has recently gained renewed interest.(2,3) 
Tumor cells are typically recognized by CD8+ cytotoxic T lymphocytes (CTLs) and the presence 
of tumor-specific CD8+ T cells correlates with improved clinical outcome.(4) Induction of strong 
CTL responses is mediated by DCs that cross-present antigens on major histocompatibility 
complex (MHC) class I molecules. Hence, DCs used as immunotherapeutics are usually pulsed 
with TAAs recognized by CD8+ T cells. To be able to properly activate antigen-specific CD8+ 
T cells though, DCs need to be licensed by interferon (IFN)-γ-producing CD4+ T helper (Th) 
1 cells. This was highlighted in a recent study, showing that DCs pulsed with antigens for 
both CD8+ and CD4+ T cells induce a stronger antitumor response compared to vaccines only 
targeting CD8+ T cells.(5) Consequently, the CD8+ T cell is not the sole effector cell that is 
crucial for antitumor responses induced by DC vaccination. 
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 Although advancements are being made in optimizing the critical factors in DC vaccination, 
objective responses in melanoma patients vaccinated with DCs are still rare. This has been 
partly explained by the immunosuppressive microenvironment formed in many tumors. 
The use of check-point blocking antibodies in combination with DC-based immunotherapy 
is, hence, a promising new strategy to combat the inhibition of T cell effector functions.(6) 
Alternatively, additional effector mechanisms might be needed for ultimate control of tumor 
growth. Important players in local tumor recognition are tissue residing innate and innate-like 
lymphocytes. Tumors that escape CTL recognition by down-regulating MHC class I molecules 
are often recognized and subsequently killed by NK cells, a function that has also been 
ascribed to iNKT cells and γδ T cells.(7) The levels of these subsets are typically diminished 
in cancer patients, and immunotherapeutic strategies to target or expand them have shown 
beneficial effects.(8,9) Recently, interactions between DCs and NK, iNKT, and γδ T cells have 
gained attention. This review summarizes DC interactions with innate(-like) effector cells, and 
their importance for antitumor responses. Exploring this crosstalk might provide strategies to 
exploit the innate arm of the immune system to further enhance the efficacy DC vaccination.
NATURAL KILLER CELLS
NK cells play a central role in innate immunity and are able to react quickly to viral infections 
and tumor development. Activated NK cells secrete high levels of IFN-γ and tumor necrosis 
factor (TNF)-α, providing stimulation to additional immune cells, and possess cytolytic activity. 
The killing of target cells is mediated via release of perforin and granzyme or via receptor-
mediated cell death. This process is regulated by a range of activating and inhibitory receptors 
expressed by the NK cells.(10,11) In addition, NK cells also respond to inflammatory cytokines, 
such as interleukin (IL)-12, IL-15, IL-18, and type I IFNs.(12,13) NK cells are crucial in antitumor 
immune responses, as they are able to kill MHC-Ilow tumor cells that escape lysis by CTLs.(14) 
In addition, tumor cells expressing normal levels of MHC-I molecules can also be killed by NK 
cells if they express elevated levels of stress-induced ligands that are recognized by activating 
receptors on the NK cell.(15) Furthermore, activated NK cells appear to function as weak 
APCs.(16) They can upregulate MHC class II and co-stimulatory molecules, including CD86, 
CD80 and OX40L, enabling them to induce CD4+ T cell proliferation and Th1 polarization.(16,17) 
Moreover, a mouse study suggested the possibility that NK cells are able to cross-present 
antigens to CD8+ T cells.(18) 
Dc-induced nk cell activation 
DCs and NK cells provide signals that support each other’s activity (Figure 1). This additional 
stimulation is essential for generating beneficial effects during DC immunotherapy. Studies 
using B16 melanoma-bearing mice showed that in vivo depletion of NK cells before DC 
vaccination abolished the beneficial effect of the vaccination.(19,20) 
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 DCs can activate NK cells through both soluble and contact-dependent factors. A major 
contact-dependent factor is IL-15 presented in trans, complexed to IL-15Rα on DC surface.(21) 
This factor enhances NK cell survival, proliferation and activation.(21–23) OX40-OX40L 
interactions between NK cells and pDCs have been shown to enhance IFN-γ secretion by NK 
cells.(24) Other contact-dependent signaling is mediated by engagement of NK receptors, such 
as NKG2D, NKp30, and NKp46.(25,26) Recently, a tetraspanin-like membrane glycoprotein 
named IFN regulatory factor 3-dependent NK-activating molecule, was discovered to mediate 
crosstalk between NK cells and polyinosinic-polycytidylic acid-treated DCs in mice, leading to 
IFN-y secretion.(27)
 
Figure 1. DC-NK cell crosstalk. Mature DCs can activate NK cells through various pro-inflammatory cytokines and 
contact-dependent factors. In turn, NK cells release IFN-γ that stimulates IL-12 production in DCs. Crosstalk with DCs 
enhances antitumor activities of NK cells via 1) increased IFN- γ secretion, that inhibits tumor growth and activates NK 
cells and αβ T cells and 2) enhanced killing of tumor cells, which generates the release of tumor antigens. Other antitumor 
activities of NK cells are 3) antigen-presentation to CD4+ T cells and 4) interactions with iDCs, which results in either 
apoptosis or maturation of those DCs. A-NKR, activating NK receptor; I-NKR, inhibitory NK receptor; iDC, immature DC
 Pro-inflammatory cytokines released by activated DCs have the ability to activate NK 
cells.(12,22,28,29) IL-12 is mainly produced by mDCs and stimulates NK cells to secrete high 
levels of IFN-γ.(12,22) In turn, IFN-γ increases IL-12 secretion by DCs, thus forming a positive 
feedback loop.(30,31) IL-18 was reported to prime NK cells to respond stronger to IL-12.(28) 
Recently, the role of DC-derived IL-27 in antitumor immune responses was explored.(32) 
This IL-12 family cytokine has been shown to induce NK cell activation and increase tumor 
susceptibility to NK-mediated killing.(33,34) A study by Wei et al. showed that IL-27 from DCs 
induces chemokine (C-X-C motif) ligand (CXCL) 10 production in myeloid-derived suppressor 
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cells, leading to recruitment and infiltration of NK cells.(29) NK cell-derived IFN-γ in turn 
boosts this CXCL10 production. Thus, DCs and NK cells can work together to modulate the 
tumor microenvironment in assisting in tumor rejection. 
 Although mDCs are able to induce NK cell-derived IFN-γ secretion, enhancement of 
cytolytic activity is strongly dependent on type I IFNs, which are produced in high amounts by 
activated pDCs.(12,35,36) pDCs are furthermore able to recruit NK cells to malignant tissue, 
and have been shown to induce proliferation of cytolytic NK cells.(24,37) This suggests that 
mDCs and pDCs have differential roles in their crosstalk with NK cells and act in synergy to 
modulate NK cell function.
Nk cell-induced dc activation 
Reciprocally, activated NK cells have been shown to act as an endogenous adjuvant and 
stimulate DC functions via various mechanisms. First, ligation of cell surface receptors and 
secretion of TNF-α and IFN-γ induces maturation of DCs,(26) which includes upregulation 
of co-stimulatory molecules and secretion of pro-inflammatory cytokines and chemokines. 
Secreted chemokines, including CXCL9, CXCL10, CXCL11, and chemokine (C-C motif) ligand 
(CCL) 5, attract CD8+ T cells and additional NK cells, further enhancing the antitumor immune 
response.(38–40) Additionally, activated NK cells themselves secrete CCL3 and CCL4 to further 
attract immature DCs.(40) Secondly, tumor cell lysis by NK cells also provides DCs with tumor 
antigens that can be presented to naïve T cells.(41,42) This NK cell-mediated tumor cell 
killing will additionally promote cross-priming of tumor-specific CTLs, thus boosting a tumor-
specific Th1 response.(24) Lastly, NK cells are able to kill immature DCs in a process called 
DC editing.(43–46) This killing mechanism involves engagement of activating receptors NKp30 
and DNAM-1.(44,47) Mature DCs are protected from NK cell-induced lysis by upregulation of 
MHC class I complexes, including HLA-E, which is recognized by the CD94/NKG2A inhibitory 
receptor.(45) By selective killing of immature DCs, NK cells select for the more immunogenic, 
mature DCs. This is favorable in a cancerous setting, as it prevents immature DCs from inducing 
immune tolerance.(48) Indeed, NK cell-mediated DC editing was recently shown to promote 
the induction of antitumor CTL responses in vivo.(43) Whether NK cells induce maturation or 
killing of immature DCs seems to partially depend on the ratio between both cell types. At low 
NK:DC ratios, DCs are mostly stimulated, while at high NK:DC ratios, NK cells mainly induce 
lysis of immature DCs.(46) 
Nk cells in dc vaccination
Due to the bidirectional nature of DC-NK cell crosstalk, DC vaccination not only leads to short 
term NK cell activation, but also promotes increased NK cell responsiveness after termination 
of the initial immune activation phase.(38,49–51) Long-term innate immune activity is likely 
caused by host DCs and CD4+ T cells that continue the generation of active NK cells after initial 
induction by vaccine DCs.(38,51,52) The interplay between pDCs, mDCs, and NK cells during 
vaccination with Toll-like receptor-activated pDCs was demonstrated in a study using the murine 
B16 melanoma model.(24) In this model, adoptively transferred CpG oligodeoxynucleotide-
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activated pDCs produced large amounts of CCL3, CCL4 and CCL5 chemokines, leading to 
CCR5-based recruitment of NK cells. Through secretion of type I IFNs and ligation of surface 
receptors, pDCs activated NK cells, which in turn killed tumor cells. The authors proposed that 
released TAAs were subsequently captured by host mDCs, that matured through interactions 
with NK cells and pDCs. Activated, tumor antigen-presenting mDCs would then ultimately 
cross-prime antigen-specific T cells in tumor draining lymph nodes. 
 To date, NK cell responses have only been monitored in a few DC vaccination trails. Several 
of these studies reported a correlation between total NK cell numbers, activated NK cell 
numbers, or NK cytotoxic activity, with favorable clinical outcome.(53) A study on nine patients 
with different tumor types even suggested that NK cell responses may correlate more closely 
with clinical responses than T cell responses.(54) It is therefore desirable to implement the 
monitoring of NK cell responses in future clinical DC vaccination trials.(53) 
 To harness the beneficial effects of NK cells for DC vaccination, the right choice of DC 
stimuli is important. mDCs or moDCs both efficiently activate NK cell cytokine production, and 
should preferentially be stimulated to produce maximal amounts of IL-12, whereas pDCs should 
produce high amounts of IFN-α to enhance the cytolytic effect of NK cells.(12,35) An additional 
important consideration is where a DC-based immunotherapeutic should be administered for 
maximal effect of the DC:NK cell crosstalk. Injection of activated and chemokine secreting 
DCs into the tumor site enables increased recruitment of NK cells that can both lyse tumor 
cells to provide an additional source of tumor antigens, and edit the repertoire of injected 
DCs so that only the most appropriately equipped cells migrate to the neighboring lymph 
nodes.(24,43) Alternatively, DCs injected directly into tissue lymph node might activate, and 
get further activated by, local NK cells, which via increased IFN-γ production help the DCs to 
induce a strong Th1 adaptive immune response.(31,53) Furthermore, as NK cells can induce 
DC maturation and Th1 polarization, they might be used to improve DC maturation in vitro 
in clinical settings.(55) Hence, simultaneous transfer of autologous NK cells and DCs might 
improve antitumor immune responses by augmenting the chance that DCs and NK cells can 
interact due to increased NK cell numbers in close proximity of DCs. 
INVARIANT NATURAL KILLER T CELLS
Natural killer T (NKT) cells are lymphocytes that express both T cell and NK cell lineage 
markers.(56) This population makes up about 0.1% of human lymphocytes and it serves an 
important function in recognizing glycolipid antigens presented by APCs on the MHC-I-like 
CD1d molecule.(57–59) Two NKT cell subsets are distinguished based on the expression of 
their T cell receptor (TCR): an invariant subset (iNKT cells, type I NKT cells) and a variant 
subset (type II NKT cells).(60) iNKT cells represent approximately 80% of total NKT cells in 
vivo and express a TCR composed of a Vα24Jα18 α-chain and a Vβ11 β-chain.(58) Most studies 
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have focused on the more abundant iNKT cells, leading to their further subdivision into Th1-, 
Th2-, or Th17-like subsets, depending on chemokine receptor, cytokine and transcription 
factor expression.(59) 
 In contrast to conventional αβ T cells, which only recognize highly specific peptide antigens, 
iNKT cells respond to a variety of both endogenous and exogenous antigens.(61) The nature 
of the endogenous glycolipids recognized by iNKT cells is still not well understood and only 
a few have been identified. Interestingly, iNKT cells have been shown to recognize several 
bacterial glycolipid antigens. A strong inducer of iNKT cell responses is an antigen originally 
derived from α-galactosylceramides found in the marine sponge Agelas mauritianus.(62,63) A 
synthetic version of α-galactosylceramide (α-GalCer) is predominantly employed for iNKT cell 
activation, and has been used in the majority of clinical studies targeting iNKT cells.(60,61,64) 
 iNKT cells can be activated via CD1d/glycolipid-TCR engagement and/or signaling via pro-
inflammatory cytokines such as Type I IFNs, IL-12, IL-18, IL-23, or IL-25.(59,65,66) Depending 
on iNKT cell subset, microenvironment, and CD1d-ligand, the contribution of either mechanism 
appears to be variable and signaling via cytokines might be equally, or in some situations, even 
stronger than TCR engagement.(59) In addition, iNKT cells were shown to induce receptor-
mediated killing using activating receptors similar to classical NK cells.(67,68) Activated iNKT 
cells possess several antitumor effector functions. Tumor cells expressing CD1d molecules can 
be lysed directly by iNKT cells through perforin/granzyme-, FasL- or TNF-related apoptosis-
inducing ligand (TRAIL)-based mechanisms.(67,69) In a similar fashion, iNKT cells have been 
shown to actively kill tumor-associated macrophages (TAMs),(70) which are known to suppress 
immune cell function and contribute to tumor regression.(71) Furthermore, recognition 
of CD1d expression together with CD40-CD40L interactions enables iNKT cells to induce 
conversion of myeloid-derived suppressor cells and, in the presence of tumor-induced serum 
amyloid A1, tumor-associated neutrophils to more immunostimulatory phenotypes.(72,73) A 
highly important antitumor mechanism of the iNKT cells is their production of large amounts 
of TNF-α and IFN-γ upon activation, which in turn can activate additional effector cells, such 
as NK cells and γδ T cells.(74,75) Taken together, iNKT cells can support both innate and 
adaptive immunity against tumor cells and may reverse immunosuppression in the tumor 
microenvironment. Care should be taken however, as it recently came to light that in some 
tumors iNKT cells might acquire immunosuppressive functions and may control DC populations 
in tumor and draining lymph nodes, as demonstrated in a mouse model of aggressive breast 
cancer.(76)
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Figure 2. DC-iNKT cell crosstalk. Both mature and immature DCs may activate iNKT cells through secretion of pro-
inflammatory cytokines and/or contact-dependent factors, including presentation of glycolipids on CD1d and ligation of 
various activating NK receptors. In turn, iNKT cells mature DCs mainly through CD40-CD40L interactions, while IFN-γ 
stimulates IL-12 production in DCs. Crosstalk with DCs enhances antitumor activities of iNKT cells via 1) increased 
secretion of IFN-γ, which inhibits tumor growth and activates NK and αβ T cells, and TNF-α, which can activate γδ T cells 
and 2) enhanced direct killing of tumor cells, which generates the release of tumor antigens. Other reported antitumor 
activities of iNKT cells are 3) direct killing of TAMs and 4) conversion of MDSCs and TANs to more immunostimulatory 
phenotypes, in which MDSCs function as APCs, while TANs secrete more IL-12 and less IL-10. A-NKR, activating NK 
receptor; iDC, immature DC; MDSC, myeloid-derived suppressor cell; TAN, tumor-associated neutrophil
DC-iNKT cell crosstalk
Similar to DC crosstalk with NK cells, bidirectional interaction between iNKT cells and DCs 
play an important role in the iNKT cell-mediated antitumor responses (Figure 2). There are 
several immunosuppressive factors within the tumor microenvironment with the ability to 
block DC maturation.(77) As a consequence, immature DCs can take up tumor antigens, but 
are unable to activate naïve T cells. However, immature DCs presenting glycolipid ligands on 
CD1d molecules can activate iNKT cells, since in contrast to conventional T cells, iNKT cells do 
not require stimulation via co-stimulatory molecules for activation,(78) although co-stimulation 
may still play a role in iNKT cell responses.(79) Engagement of CD40 on DCs by CD40L on iNKT 
cells in turn promotes IL-12 production in DCs, which reciprocally stimulates the release of 
TNF-α and IFN-γ from iNKT cells and further enhances the DC maturation process.(63,80) 
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Among the lymphocyte populations, iNKT cells are the first to respond to infections, and 
crosstalk between CD1d expressing, pro-inflammatory cytokine-producing mature DCs and 
iNKT cells potentiates the ability of DCs to stimulate naïve T cell responses.(66,81) 
 Unlike mDCs, pDCs do not express the CD1d molecule, and hence cannot present glycolipids 
to iNKT cells. However, pDC-derived cytokines, mainly TNF-α and IFN-α, are important for the 
activation of NKT cells.(82) In addition, activated pDCs can interact in a contact-dependent 
manner with iNKT cells via ligation of OX40L with OX40 on the iNKT cell surface.(83) In this way, 
CpG oligodeoxynucleotide-stimulated pDCs license iNKT cells to respond effectively to iNKT 
ligand-presenting mDCs.(82,83) Reversely, OX40-OX40L interactions with iNKT cells stimulate 
IFN-α production by pDCs.(84) Thus, DC-iNKT crosstalk is not restricted to mDCs. 
 In addition to direct cross-activation, iNKT cells can also indirectly contribute to DC function. 
Since iNKT cells can kill CD1d-expressing tumor cells, iNKT cell-mediated tumor cell lysis has 
been shown to provide DCs with tumor antigens and to induce adaptive responses.(67,85) DC 
editing can under certain conditions also be mediated by iNKT cells, when NK cell-mediated 
killing is inhibited by high HLA-E expression.(86)
iNKT cells in DC vaccination 
Several reports have shown that iNKT cells can be activated by a combination of DC-derived 
cytokines and CD1d-presentation of self-antigens,(65,66) or by DC-derived cytokines 
alone.(87,88) This suggests that iNKT cells can amplify responses induced by mature DCs. 
Indeed, greater numbers of circulating or tumor-infiltrating NKT cells have been reported to 
correlate with improved clinical outcome in patients with various types of cancer.(58,89) 
 Targeting iNKT cells by injecting α-GalCer in vivo in various murine cancer models have 
shown promising results, both when used in therapeutic as well as prophylactic settings.(64) 
However, early clinical trials of direct α-GalCer injection in cancer patients did not show signs 
of clinical improvement, although the treatments were well tolerated.(90,91) Mouse studies 
subsequently showed that the initial activation of iNKT cells by injected α-GalCer is followed 
by a contraction phase of massive apoptosis, ultimately resulting in long-term iNKT cell 
anergy.(92,93) Also, multiple injections of α-GalCer can polarize the adaptive immune response 
towards a Th2 phenotype, which is unwanted in cancer immunotherapy.(94)
 To overcome these shortcomings, researchers explored the employment of ex vivo loaded 
DCs to stimulate iNKT cells. Experiments using α-GalCer-pulsed DCs in mouse models 
showed in vivo inhibition of tumor growth, and the induction of long term iNKT cell responses 
which, similar to NK cells, seemed to be dependent on continuous interactions with host DCs 
and CD4+ T cells.(51,95–97) Furthermore, α-GalCer-loaded DCs do not induce the strong iNKT 
cell anergy observed during α-GalCer administration.(96,98) Strikingly, human in vitro studies 
could confirm these results, as α-GalCer-pulsed DCs were shown to expand and activate 
patient-derived iNKT cells, paving the way for patient trials.(99) Several clinical studies using 
α-GalCer-pulsed DCs have since been performed, confirming the safety and feasibility of this 
approach.(100–107) Immunological responses, including iNKT cell proliferation,(103–107) 
their accumulation in the tumor microenvironment,(102) and their increased IFN-γ 
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production(100–104) were detected, with one study reporting a correlation between IFN-γ 
responses and increased patient survival.(101) 
 While the use of immature DCs loaded with α-GalCer induced only moderate iNKT cell 
responses,(100,107) stronger responses were achieved when matured DCs loaded with 
α-GalCer were administered.(104) In addition, synergistic action of Toll-like receptor ligands 
and CD1d-binding glycolipids on DC maturation and iNKT cell activation were reported.(81,83) 
Vaccination with ex vivo matured DCs loaded with both TAA and CD1d agonist might therefore 
be a promising strategy to enhance antitumor immune responses. 
 A recurring problem with iNKT cell-based therapies is the low number of these cells in 
humans, especially in cancer patients with decreased frequencies of iNKT cells.(57,58,89) 
Accordingly, methods for adoptive transfer of activated iNKT cells expanded in vitro have been 
developed.(60,108,109) Clinical trials combining this approach together with the transfer of 
α-GalCer-pulsed DCs have generated promising results, with several patients showing tumor 
regression.(9,110)
γδ T CELLS
Like NKT cells, γδ T cells are lymphocytes that share properties with both NK cells and 
conventional αβ T cells. Although often characterized as part of the adaptive arm of the 
immune system, γδ T cells do not differentiate to memory cells to the same extent as αβ T cells 
and they display several innate effector functions. In peripheral blood of healthy individuals, 
γδ T cells represent up to 5% of the T lymphocytes and can dramatically expand following 
bacterial infections.(111) γδ T cells express a TCR composed of a γ- and a δ-subunit in contrast 
to conventional αβ TCRs. γδ TCRs are less diverse than αβ variants and less stringent in 
their antigen specificity. Depending on the particular γ- and δ-chains expressed, γδ T cells 
can be divided into specific subsets.(111,112) The majority of human peripheral blood γδ T 
cells express the Vγ9Vδ2 TCR, while other TCR-variants are mainly expressed by their tissue-
resident counterparts. The Vγ9Vδ2 T cells recognizes phosphoantigens, which are non-peptidic 
phosphorylated molecules produced in high levels by microorganisms, stressed cells, and 
tumor cells.(113–115) Unlike conventional αβ T cells, γδ T cells do not require antigens to be 
presented on MHC molecules to get activated.(116) The receptor presenting phosphoantigens 
is still not characterized, but lipid antigens presented on CD1 molecules are recognized by 
tissue residing Vδ1-expressing γδ T cells.(111,112)
 γδ T cells display potent antitumor activity. Due to increased metabolic processes, 
tumor cells accumulate phosphoantigens, such as isopentenyl pyrophosphate, which are 
recognized by Vγ9Vδ2 T cells.(117) In addition to isopentenyl pyrophosphate, the Vγ9Vδ2 TCR 
may also recognize mitochondrial F1-ATPase, which is expressed by some tumor cells.(118) 
Also, γδ T cells can recognize opsonized tumor cells and stress-induced molecules such 
as heat shock proteins and NKG2D ligands expressed on tumor cells.(119–122) Activated 
γδ T cells can upon recognition directly lyse tumor cells through release of perforins and 
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granzymes, FasL engagement, and TNF-related apoptosis-inducing ligand (TRAIL)-dependent 
mechanisms.(123–125) In addition to their direct antitumor effects, activated γδ T cells can 
boost the activity of surrounding immune cells by secreting large amounts of TNF-α and 
IFN-γ.(31,126,127) Vγ9Vδ2 T cells have also been shown to act as APCs and present antigens to 
αβ T cells,(111,112) a characteristic that has lead to the proposal of using TAA-presenting γδ T 
cells as a vaccine in cancer immunotherapy.(128) 
Figure 3. DC-γδ T cell crosstalk. Both mature and immature DCs may activate γδ T cells through secretion of pro-
inflammatory cytokines and/or contact-dependent factors, including presentation of phosphoantigens. In turn, γδ T 
cells mature DCs through various interactions and secretion of TNF-α, while IFN-γ stimulates IL-12 production in DCs. 
Crosstalk with DCs enhances antitumor activities of γδ T cells via 1) increased secretion of IFN-γ, which inhibits tumor 
growth and activates NK and αβ T cells and 2) enhanced direct killing of tumor cells, which generates the release of tumor 
antigens. Another antitumor activity of γδ T cells is 3) antigen presentation to αβ T cells. A-NKR, activating NK receptor; 
iDC, immature DC
 However, certain γδ T cell-derived factors may also promote tumor growth.(129) Vδ1-
expressing γδ T cells are negatively correlated with clinical outcome in breast cancer and they 
can secrete cytokines that suppress DC maturation and T cell effector function.(130–132) Vγ4+ 
γδ T cells are reported as the main source of γδ T cell-derived IL-17.(133) IL-17-producing γδ 
T cells have a dual role in tumor immunity. As such, in vivo models showed that they can be 
tumor-promoting,(133,134) but may also contribute to antitumor effects in other anticancer 
treatment modalities.(135,136) For application in cancer immunotherapy, strategies that focus 
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on activation of Vγ9Vδ2 T cells seem to be the most attractive, although other γδ T cell subsets 
should not be neglected.(137) 
DC-γδ T cell crosstalk 
Naïve γδ T cells can be activated by both mature and immature DCs (Figure 3). Cytokines 
produced by mature DCs, such as IL-1β, IL-12, IL-18, TNF-α, and type I IFNs, have been 
reported to mediate γδ T cell stimulation.(126,138–140) In addition to providing cytokines, 
DCs can induce contact-dependent γδ T cell activation via CD86-CD28 interactions and by 
presenting γδ T cell ligands, such as Lipid A and phosphoantigens.(127,141) Lack of maturation 
does not appear to negatively affect DC-γδ T cell crosstalk,(127,142) and some studies even 
conclude that immature DCs are more efficient in activating γδ T cells than their mature 
counterparts.(126,143) Reciprocally, activated γδ T cells can mature DCs via contact-dependent 
mechanisms and secretion of soluble factors. Immature DCs co-cultured with activated γδ 
T cells show up-regulation of MHC and costimulatory molecules such as CD86.(127,144) 
Moreover, lipopolysaccharide-induced DC maturation is enhanced by co-culture with γδ T 
cells.(145) This γδ T cell-induced DC maturation appears to be mediated by TCR-CD1, Fas-
FasL, CD40-CD40L, and CD28-CD86 interactions, as well as TNF-α secretion.(127,146–148) In 
addition, γδ T cell-derived IFN-γ induces IL-12 secretion by DCs and both cytokines polarize 
Th1 responses.(144,149,150) Finally, γδ T cell-induced tumor cell lysis generates tumor 
antigens that might be taken up and presented by DCs, which in turn would promote tumor 
antigen-specific adaptive immune responses.(41)
 Interestingly, Vγ9Vδ2 T cells may also stimulate NK cells. This costimulation enhances 
NK cell killing of tumor cell lines,(151) but may also affect DC-NK cell crosstalk. Antigen-
stimulated Vγ9Vδ2 T cells were shown to enhance the DC killing capacity of NK cells via ICOS/
ICOSL interactions.(152)
γδ T cells in DC vaccination
Several clinical trials utilizing in vivo expansion or adoptive transfer of γδ T cells have been 
performed.(153) Clinical activation of γδ T cells is commonly achieved with bisphosphonate 
drugs, such as zoledronate, which can enhance the expression of isopentenyl pyrophosphate 
and other phosphoantigens.(153) Zoledronate is commonly used to prevent osteoporosis, but has 
also been shown to have antitumor effects, correlated with increased activity of γδ T cells.(8,123) 
However, repeated doses of bisphosphonate drugs may lead to exhaustion and a decrease in 
γδ T cell numbers.(154) As the levels of γδ T cells are often reduced in cancer patients, and to 
circumvent the risk of exhaustion, adoptive transfer of ex vivo expanded autologous Vγ9Vδ2 T 
cells has been tested in a number of clinical studies with varying results.(153) Several in vitro 
studies reported on improved functionality of γδ T cells when co-cultured with zoledronate-
treated DCs, leading to the expansion of tumor-specific αβ T cells.(155,156) In a recent study, 
autologous DCs treated with zoledronate were shown to efficiently expand functional Vγ9Vδ2 
T cells from cancer patients ex vivo, indicating that DCs can be used to restore the impaired 
γδ T cell responses in patients.(157) Furthermore, injection of activated, TAA-pulsed DCs 
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treated with zoledronate induced detectable TAA-specific responses in two out of three acute 
myeloid leukemia patients, demonstrating the clinical feasibility of targeting γδ T cells in DC 
vaccination.(158) However, mechanistic insight in how DCs stimulate γδ T cells and how this 
affects the course of the disease is lacking, and further studies are needed before the efficiency 
of DC-based γδ T cell-targeting can be evaluated.
CONCLUDING REMARKS
DCs have the ability to interact with a great variety of both innate and adaptive immune cells 
and are often referred to as the bridging element between the two arms of the immune system. 
In addition to presenting antigens to adaptive immune cells, DCs also stimulate and boost 
local responses at the site of tumorous growth or infection. This is a major advantage over 
downstream effector cells when targeting the immune system for immunotherapy, and more 
insight would be constructive for future trial design.
 Both DCs and the effector cells discussed above have been tested clinically as cancer 
treatments, with mixed results. Importantly, the synergistic effects of crosstalk between DCs 
and innate(-like) effector cells have been described both in vitro and in vivo. Ex vivo matured 
DCs can induce in situ activation of NK, iNKT and γδ T cells. These effector cells subsequently 
promote direct antitumor effects and propagate immune responses by inducing further 
activation of tissue DCs. From these data, we can conclude that the innate arm of the immune 
system could play a pivotal role in potentiating DC vaccines, resulting in a stronger and more 
robust antitumor immune response. 
 Protocols for ex vivo expansion of iNKT cells or γδ T cells using autologous moDCs as APCs 
have already been developed, and vaccines based on combined or subsequent administration of 
effector cells and DCs might promote synergy to induce multifaceted responses. Furthermore, 
crosstalk between co-cultured DCs and NK, iNKT or γδ T cells enhances DC activation. Hence, 
in a vaccine setting, these effector cells might as well act as endogenous adjuvants during 
ex vivo stimulation of DCs, which can be beneficial when potent DC activators like Toll-like 
receptor ligands are lacking. Alternatively, the in vivo activity of innate(-like) lymphocytes could 
be boosted prior to administration of DC vaccines, or by ex vivo pulsing the DCs with iNKT cell- 
or γδ T cell antigens in addition to TAAs. Activation of innate(-like) lymphocytes in the tissue will 
increase tumor destruction, leading to elevated levels of tumor antigens and increased uptake 
by, and maturation of, DCs. Taken together, this would subsequently induce a broader adaptive 
antitumor response and a greater chance of disease regression.
 To conclude, despite strong evidence for the importance of adaptive lymphocytes in tumor 
control, their presence in cancer patients does not guarantee protection. This is possibly due 
to immune suppression and various immune escape mechanisms employed by tumor cells. 
NK, iNKT and γδ T cells have the ability to recognize many tumors that escaped surveillance by 
adaptive lymphocytes and their effector functions are often immediately available. Treatment 
strategies aiming at either adaptive or innate(-like) lymphocytes have, so far, been developed in 
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parallel with mixed results. In this review, we highlighted synergistic interactions between DCs 
and innate(-like) lymphocytes that could lead to robust immune activation. Vaccines targeting 
both, adaptive and innate(-like), lymphocytes simultaneously, could thus lead to superior 
tumor control by inducing a strong adaptive immune response for long-term tumor control 
and an effective innate(-like) lymphocyte response for immediate reduction of tumor burden 
and protection against escaping tumor variants. 
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CHAPTER 3
Cellular heterogeneity and its relevance 
in biology and medicine
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INTRODUCTION
WHAT IS CELLULAR HETEROGENEITY, WHEN DOES IT IMPACT 
BIOLOGICAL SYSTEMS, AND HOW CAN WE STUDY THIS?
Cells are incredibly complex systems that consist of millions of atoms which assemble to 
larger molecules such as proteins, nucleic acids, and sugars which then build the structures 
that make a cell. To achieve this, these molecules and atoms recombine and interact with each 
other in zillion ways which is the foundation of cellular life. 
 From this statement, Walter M. Elsasser deduced theoretically that heterogeneity is a 
fundamental property of life.1 He argued, that the number of ways, in which molecules in a cell 
interact with each other, is so immense, that it is impossible to compute and fully simulate 
the dynamics of a living cell. Cells can assume so many states, that there would always be 
more than one path from a given cellular state to the next, following the same physical laws. 
From that follows that deterministic rules alone are not sufficient to unambiguously describe 
a cellular system. Two cells would always be different from each other, even if they followed 
the same instructions.1 Elsasser even goes as far as to conclude that no two cells in the 
history of life on earth have ever been identical in a rigorous sense.2 Eventually, this would 
mean, that it is impossible to accurately predict the future state of a cell given its current 
state, making heterogeneity and randomness – or stochasticity – a fundamental and inherent 
property of cellular systems. Similar to thermodynamics, this brings a probabilistic view of 
biology about where cellular states can only be predicted with a certain chance to occur but 
never with absolute certainty. This unpredictability at the cellular level is in strong contrast 
to the predictability of biological systems at the macroscopic level.2 Tissues and organs, for 
instance, have a clearly defined structure and adults develop from embryos in a very controlled, 
determined, and replicable way. In biology, there is the dominance of macrodeterminism, 
meaning that groups of cells can be very well described using deterministic rules even though 
single cells cannot.3 Life is thus existing between the two contrasting edges of randomness on 
the (sub)cellular level and determinism at hierarchically higher levels.4, 5
 One of the earliest examples of cellular heterogeneity was the discovery that β-galactosidase 
expression in E. coli is digital – meaning either “on” or “off” – and heterogeneous over the 
population – meaning some cells were “on” and others were “off”.6 Furthermore, when 
increasing the stimulus concentration and the enzyme activity of the entire population 
increased, not the enzyme activity in each cell increased, but rather the fraction of cells 
expressing the enzyme. For the macroscopically minded observer, these details might seem 
trivial as the general enzyme activity in the culture increases either way. However, knowing 
these details of population self-organization enables entirely new approaches to manipulate 
biological systems and allows for highly targeted interventions.
 In practice, cellular heterogeneity is a measurement for difference between the single cells 
in a given population.7 Generally, in biology it was assumed that population averages represent 
the dominant biological function of a population of cells and that this would be sufficient to 
describe this biological system. There are, however, situations when tiny subpopulations, 
such as in the example above, conduct biologically meaningful activities which are not visible 
71
3
CELLULAR HETEROGENEITY IN BIOLOGY AND MEDICINE
in the population average. This scenario can arise under different circumstances as laid out 
by Altschuler et al (Figure 1).7 The behavior of a population of single cells, for instance, can 
be summarized in a distribution with an average and a spread. Normally, we would assume 
that the spread is due to biochemical noise and wouldn’t necessarily contain any important 
information. Cells at every position of the distribution would behave more or less equally. In 
some situations, however, cells that are closer to the extremes of the distribution can behave 
very differently than cells at the center of the distribution (Figure 1A). The population average 
would not inform of the presence of those cell and they would remain undiscovered. In a 
different situation, a certain biological process might be mainly driven by a rare subpopulation 
with very potent biological activity (Figure 1B). Here, population averages would wrongly ascribe 
an intermediate activity to all cells of the population. In another example, a population of cells 
might actually consist of two groups of cells with completely opposing properties (Figure 1C). 
Population averages would lead to the assumption that all cells express an intermediate level 
of this property, whereas, in reality, no cell in this population is actually having this property. 
These examples are based on univariate settings where only one parameter is taken into 
account. Often, however, cellular heterogeneity is only revealed when looking at more than 
one parameter at the same time. Therefore, in many cases, it can be necessary to look at a 
multitude of parameters to discover distinct subpopulations.
Figure 1 – Schematic overview of situations where population average measurements conceal biologically meaningful 
cellular heterogeneity. A) Cells at the extreme behave differently than the rest of the population. B) A rare subpopulation 
of cells with high biological activity remains unidentified by the population average which indicates low activity for all cells. 
C) Two cell population show opposing properties. The population average measurement indicates an intermediate level of 
this property. In this example, no cell with this intermediate property actually exists.
 Although population averages miss detailed information on population properties, single 
cell analysis and assessment of cellular heterogeneity does not automatically reveal important 
insights. It is therefore crucial to link cellular heterogeneity to biologically relevant readouts 
in order to identify truly meaningful differences. One approach to achieve this, is to isolate 
identified subpopulations and conduct functional assays on them separately. This allows to 
investigate whether certain cell subsets behave differently from the population average and thus 
convey biologically meaningful functions. Alternatively, if subpopulations cannot be isolated, 
cell populations containing different ratios of subpopulations can be subjected to functional 
assays and the readout can be plotted against the fraction of a subpopulation of interest. 
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Generally, every workflow that has the aim to extract biologically relevant information from 
cellular heterogeneity should thus consists of three steps: 1) measuring cellular heterogeneity 
and extracting population statistics, 2) identifying significant patterns, 3) and testing whether 
those patterns contain biologically relevant information or function.7
 In summary, there is now no doubt that cellular heterogeneity exists as a fundamental 
property of all living systems and domains of life i.e. bacteria, archaea and eukaryotes.5, 
7, 8 Current research efforts hence need to focus on investigating the mechanisms that are 
responsible for cellular heterogeneity and on distinguishing between heterogeneity that serves 
significant biological function vs meaningless variation.7 
WHAT ARE THE ORIGINS OF CELLULAR HETEROGENEITY?
Whereas differences in the environment, genetic makeup or cellular composition display 
potent sources of cellular heterogeneity, we assume today that most of the phenotypic 
variability derives from random processes during gene expression.4, 7, 9, 10 Most variation in 
this process is generated by the transcription of genes rather than the translation of mRNA.11 
Gene expression heterogeneity, also called noise, is often defined as the ratio between the 
standard deviation and the mean expression level of the population. As most genes only exist 
as one or few copies in a cell, for gene expression to happen, all molecular components of the 
transcription machinery must arrive at the one copy of the gene at the same time, which makes 
the process very stochastic and prone to random differences. A feature that derives from this 
and adds to cellular heterogeneity is the observation that gene expression appears to happen 
in short burst of high transcriptional activity.4 Small differences in burst frequency, duration 
and magnitude can thus easily lead to large differences in mRNA levels between cells. Noise 
during gene expression cannot easily be averaged out and is propagated to protein expression 
levels if no further mechanisms control it leading to differences in cellular behavior. Elowitz 
distinguished between two sources of noise during gene expression: intrinsic and extrinsic 
noise.12 Extrinsic noise effects all observed genes in a single cell to the same extend and 
originates from differences in e.g. the number of RNA polymerase molecules per cell. Intrinsic 
noise, however, is due to the inherently random process of gene transcription and therefore 
exclusive to a given gene. Studies showed that genes proximal to each other show similar 
patterns of gene expression bursts, thus having correlated intrinsic noise, whereas this was 
not true for distal gene pairs.13, 14 These studies show that differences in gene accessibility 
mediated by chromatin rearrangements and other epigenetic mechanisms might control gene 
expression variability, contributing to cellular heterogeneity.
 Various factors thus contribute to cellular heterogeneity and depending on cell state, cell 
type, tissue, individual, and organism the contribution of each factor most likely changes. To 
fully understand cellular heterogeneity, single cell analysis needs to be investigated on all 
functional and regulatory levels.
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TECHNOLOGIES FOR THE INVESTIGATION OF CELLULAR HETEROGENEITY
The field of cellular heterogeneity is strongly driven by technological advances in single cell 
analysis. Recent years saw an explosion of technological breakthroughs which go beyond the 
scope of this introduction. The reader is therefore referred to a number of excellent reviews for 
an exhaustive treatment of the subject whereas this paragraph only provides a brief overview 
of the most important developments.15, 16, 17, 18, 19, 20, 21
 Early work on cellular heterogeneity relied on bulk analysis of clonal populations generated 
by limiting dilution and, thus, did not fully capture cellular heterogeneity on the single cell level.6 
Subsequent research was limited to large unicellular models, such as the Xenopus oocyte, 
which contained enough material to enable single cell analysis using traditional techniques such 
as Western blot.22 With the development of fluorescent reporter molecules in the mid 1990s, 
microscopy and flow cytometry studies propelled the field and allowed cellular heterogeneity 
to be investigated in depth and on a single cell level (Figure 2A). Due to these advances, many 
paradigms, such as the burst theory of gene expression, could be established and practically 
proven.12, 23, 24 Extension of the fluorophore palette and development of monoclonal antibodies 
enabled an increasingly detailed phenotypic dissection of cellular populations leading to the 
discovery of a plethora of new cell types.25, 26 Intracellular cytokine and phosphoprotein staining 
furthermore allowed to unravel heterogeneity on the functional level and led for instance to 
the discovery of multifunctional T cells.27, 28, 29, 30 Currently, a combination of mass spectrometry 
and flow cytometry, called CyTOF, uses antibodies labeled with different metal isotopes to 
enable the simultaneous detection of more than 30 markers per cell.31 Due to its versatility, 
widespread use, established data acquisition and analysis pipelines, and high throughput, flow 
cytometry is now the dominant technique for single cell analysis. However, due to limitations in 
the number of different labels that can be measured simultaneously, flow cytometry is always 
biased towards a set of preselected markers hampering the discovery of new subpopulations. 
 In the late 1980s, researchers published a first report of a technique that adapted a 
polymerase chain reaction assay for single cell analysis to quantify gene expression within 
single sperms.32 Whereas single cell real-time RT-PCR is still an important method to 
quantitatively determine genes in single cells, technological developments in the field of next 
generation sequencing during the early 2010s enabled the unbiased investigation of the entire 
transcriptome in single cells.33, 34, 35 Single cell RNA sequencing (sc-RNAseq), due to its largely 
unbiased global analysis of cell states, is emerging as the new big player in the field of cellular 
heterogeneity (Figure 2B). In sc-RNAseq, cells are compartmentalized individually and then 
lysed to isolate cell-specific RNA. CDNA libraries are generated for each cell and provided with 
a unique sequence that serves as cell-specific ID. Depending on the technique, an additional 
molecule-specific sequence is attached to every nucleotide strand. The material is amplified 
and libraries generated from different single cells are mixed and sequenced together. During 
analysis, cell-specific transcripts can be identified based on the cell ID. The molecule-specific ID 
serves for more reliable quantification of transcripts, free of amplification bias. Three systems 
are competing with each other and mainly differ in the way of cell compartmentalization and 
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library preparation: 1) microtiter plate-based approaches where single cells are sorted in 
separate wells, 2) droplet-microfluidic approaches, where single cells are encapsulated in 
small aqueous droplets, and 3) microfluidic chip approaches, where cells are entrapped in 
small chambers on microfluidic chips.34, 36, 37 These distinct approaches lead to differences in 
throughput, cost efficiency, and sensitivity.19 Especially droplet-microfluidic approaches allow 
for high throughput by analyzing several thousand cells at relatively low cost.34 This comes 
however at the price of reduced depths.19 Microtiter plate-based approaches, in contrast, can 
be easily paired with fluorescence-activated cell sorting, which allows for the enrichment 
of e.g. rare subpopulations, and differences in protein expression, detected during sorting, 
can later be linked to variations in mRNA expression. To answer certain research questions, 
it is furthermore important to know in what spatial context cellular heterogeneity arises. 
Fluorescence in situ hybridization (FISH) allows to link gene expression to the position of a cell 
in the tissue (Figure 2C). FISH employs fluorescently labeled RNA probes, complementary to 
the transcript of interest, which are incubated with fixed cells and tissues and measured via 
fluorescence microcopy.38, 39 This enables investigators to measure, e.g. how gene expression 
patterns spread spatially in a population of cells.40 Current efforts focus on extending unbiased 
and global single cell analysis to other relevant areas of systems biology including genetics, 
epigenetics – where the fact that DNA molecules are present at only one or few copies are 
posing challenges regarding unbiased material amplification – and proteomics with the aim 
to eventually combine measurements of different hierarchy levels in the same cell.41, 42, 43, 44, 45 
This will yield important information on the regulation of cellular behavior by investigating, for 
instance, how mRNA and protein levels correlate on a global level in different single cells.46, 47
 Whereas the mentioned techniques only allow to take a snapshot of the heterogeneity 
within a population, other approaches enable researchers to follow single cells over time and 
to analyze time-encoded heterogeneity within the same cell. With the advent of automated 
image analysis techniques, live microscopy, which allows for the extraction of a plethora 
of parameters, such as cell area, roundness, diameter, nucleus location, and fluorescence 
intensity, became an important tool for the dynamic analysis of processes in single cells 
(Figure 2D).48 Analysis, however, is often hampered by limitations in the detection of functional 
markers and lack the ability to manipulate cells individually.
Progress in the field of microfluidics finally allowed for the compartmentalization of single 
cells in small reactors enabling precise control of the cellular microenvironment and single 
cell manipulation (Figure 2E). Chamber-based microfluidic devices, where single cells are 
entrapped in valve-controlled compartments on plastic chips coupled with live cell imaging, 
allow for the time-resolved extraction of features from single cells.49 Advanced microfluidic 
chips, consisting of large networks of connected channels and chambers, even allow 
researchers to program complex sequences of perturbations and measurements such as 
the rhythmic stimulation of single cells and the periodic probing of the chamber content for 
cytokines – all coupled to optical feature extraction via live microscopy.50 Similarly, cells can 
be entrapped in nanowells where their activity is monitored with live microscopy.51, 52 Cells can 
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be manipulated by adding stimuli to the wells and samples of the cell culture supernatant 
can be analyzed for secreted molecules. However, chamber- and nanowell-based approaches 
are limited in their throughput and demand sophisticated and expensive control equipment. 
Droplet microfluidics, in contrast, where single cells are encapsulated in picoliter droplets 
of cell culture medium at rates of several kilo hertz, allow for extremely high throughput 
analysis of hundreds to ten thousands of single cells.16 Produced droplets serve as pico- to 
nanoliter reactors to culture single cells individually under very standardized and controlled 
conditions. Various in-droplet assays were developed that allowed to measure e.g. cell viability 
in response to drugs and cells in droplets can be manipulated by fusing or splitting droplets 
or by pinching in small volumes of liquid containing e.g. stimulants or detection reagents 16, 53, 
54 After incubation, cells can be isolated from droplets and used for downstream application.53 
The detection of secreted molecules – an important measurement in immunology and other 
areas of medical research – is however hampered. Conventional assays, such as intracellular 
cytokine staining, rely on adding fluorescent antibodies after incubation to detect secreted 
molecules. These so-called heterologous assays, which imply washing steps and addition of 
reagents after droplet production, are difficult to implement at high throughput. Few approaches 
exist to tackle this problem and are limited to fluorescence-detection on the droplet production 
chip using customized equipment and self-developed analysis platforms.53 Novel microfluidic 
approaches, that built on existing single cell analysis pipelines to detect cytokine production, are 
needed. We recently developed two approaches that allow the detection of cytokine-secretion 
by individually stimulated cells in droplets based on aptamer sensors and agarose hydrogel 
droplets containing cytokine-capture beads.55, 56 For the detection of cytokine production, 
we relied on fluorescence microscopy and flow cytometry, respectively, which facilitated 
experiment design and data analysis and enabled us to readily detect functional heterogeneity 
within an activated T cell line. As we learn more about the individual behavior of single cells, 
the question of heterogeneity within cellular interactions automatically emerges. If two cells 
can never be identical, how does that influences processes such as T cell priming, which are 
based on a single dendritic cell interacting with a single T cell. Microfluidic techniques offer 
ample opportunity for the development of assays that can help explore such questions. Using 
a network of microchambers, Frank et al, for instance, show how cytokines, produced from a 
single sender cell, can influence an array of receiver cells and how heterogeneity is a critical 
feature in this process.57 However, high throughput analysis of single cell pairs is still difficult 
to achieve and proper techniques are currently lacking. Despite the elevated rate at which 
microfluidic techniques are adopted by biologist, assays need to further adapt to the needs of 
medical research by optimizing sample use and assay robustness. Furthermore, microfluidic 
workflows need to be simplified by establishing common standards and protocols allowing 
operation by non-specialized personnel.
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Figure 2 – Schematic overview of single cell techniques. A) Flow cytometry-based analysis of single cells. B) Single cell 
RNA sequencing using unique identifiers for RNA originating from a particular cell. C) Fluorescence in situ hybridization 
analysis employs probes consisting of typically 20 nucleotides that are complementary to the gene or RNA of interest. The 
probe is labeled with a fluorescent molecule to allow microscopic detection. D) Live microscopy allows to determine a 
variety of features on the single cell level and can be used to dynamically follow cellular processes. E) Different microfluidic 
techniques were developed that are all based on the compartmentalization of single cells or small groups of cells.
 Finally, new discoveries in cellular heterogeneity are often enabled by advances in 
analytical tools and bioinformatics techniques. Algorithms for the reduction of complexity, 
such as principal component analysis, t-Distributed Stochastic Neighbor Embedding (t-SNE), 
or SPADE combine several parameters in a few components and display cells grouped 
by similarity in a 2D scatter plot.18, 58, 59 This allows the identification of subpopulations and 
gives an overview of the heterogeneity that is easily accessible to human comprehension. 
SPICE (Simplified Presentation of Incredibly Complex Evaluations) on the other hand allows 
to visualize and investigate the coexpression of numerous flow-cytometric parameters on 
single cells which found widespread use in the investigation of antigen-specific, functional 
T cell responses.60 COMPASS extended this concept and enabled the unbiased analysis of 
combinatorial multifunctionality for large cohorts of clinical samples.61 Other algorithms, such 
as RaceID, allow the identification of rare cell populations based on outlier detection taking 
background and gene expression noise into account.62 Current efforts focus on the development 
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of algorithms that allow to model differentiation trajectories, dynamic processes, and to link 
sc-RNA sequencing data to the physical location of the cell in the tissue.18
 In summary, new techniques allow unprecedented insights into processes on the single 
cell level and current research aims at optimizing analysis pipelines and combining omics data 
from different hierarchical levels with spatial information. 
CELLULAR HETEROGENEITY IN CANCER THERAPY
Building on a body of theoretical work and technological advances, cellular heterogeneity is 
beginning to impact medical and clinical research. Researchers are exploring whether cellular 
heterogeneity has an impact on the wellness of the body and how cellular heterogeneity could 
be modified or exploited for treatment.
 Cellular heterogeneity was first picked up by cancer researchers who noticed that tumor 
cells are heterogeneous in respect to their morphology, capacity to metastasize, resistance to 
drugs, and immune recognition.2 Inspired by Elsasser’s theoretical work, some researchers 
even claimed that tumorigenesis follows directly from cellular heterogeneity once the 
macrodeterministic hierarchical control systems fail.2 Variations between single tumor cells 
were first detected as morphological features and, with the improvement of sequencing 
techniques, more and more in the genetic markup of tumor cells.63 Later, phenotypical 
differences with respect to therapy resistance and proliferation were discovered in genetically 
identical, clonal cell populations proofing that non-genetic sources of heterogeneity play an 
important role in cancer as well.64 Various sources of non-genetic heterogeneity are now known. 
The cancer stem cell hierarchy, for instance, generates functional heterogeneity within a tumor 
and can be maintained by epigenetic variations within the cells or microenvironmental changes, 
where stem cells are nurtured by a niche containing stem cell factors.65 An additional level of 
heterogeneity is generated by the metabolic environment. For instance, anaerobic and normoxic 
areas within a tumor lead to the activation of different metabolic programs in residing cells 
indicating that the microenvironment also acts as a potent source of variation.66 Evolutionary 
pressure is another dominant driver of heterogeneity and can originate, for instance, from 
different subclones within the tumor fighting for nutrients and space or the immune system 
which recognizes certain features of tumor cells and forces them into apoptosis.67 Various 
aspects of a tumors’ existence are thus contributing to cellular heterogeneity leading to often 
very heterogeneous tumors.
 As a major reason for therapy resistance and relapse, cellular heterogeneity is also 
interesting from a clinical point of view. In the clinic, many features of a tumor are used to 
determine the prognosis for the patient including molecular markers such as KRAS, HER2, 
ER.63 Cellular heterogeneity has a great impact on the quality of such prognostic markers as 
the tumor might be very heterogeneous regarding their expression. Different regions of the 
same tumor, for instance, can express good or bad prognostic markers leading to a wrong 
prognosis depending on where in the tumor the biopsy for the molecular analysis is taken.68 
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Furthermore, large scale sequencing projects such as The Cancer Genome Atlas project ( 
http://cancergenome.nih.gov) revealed great variation between the same type of tumor 
originating from different individuals indicating that each tumor evolves in a unique way. This 
raises the question whether a limited set of prognostic markers would ever be suitable for 
this heterogeneous mix.63 A different study, however, showed that a molecular signature of 16 
genes could reliably predict the recurrence of renal cancer after surgery in a cohort of patients 
and that this signature was stable over various biopsies at different locations within the same 
tumor.69 It thus appears that the degree of heterogeneity within a tumor depends on a number 
of factors including tumor type, size, stage, treatment, and the biomarker one is looking at.63
 Besides its prognostic challenges, cellular heterogeneity itself can also be exploited as 
a prognostic factor if approached from an evolutionary perspective. The foundation for this 
argument is the believe that diverse tumors with high degrees of cellular heterogeneity 
are better prepared to respond to perturbations, such as chemotherapy, and have a higher 
probability to contain a subclone that is able to survive the treatment.63 Tumors with a high 
degree of cellular heterogeneity should, thus, have a worse prognosis. Indeed, studies in 
breast cancer, head and neck cancer, acute myeloid leukemia, ovarian cancer, and lung cancer 
showed that patients with bad prognosis carried a tumor with increased clonal diversity.70, 71, 
72, 73, 74 These observations were extended to non-genetic heterogeneity by studies that linked 
variability in tissue organization and heterogeneity in PET signals of tumors to outcome.75, 76 It 
seems, however, that there is a threshold to which extend cellular heterogeneity is beneficial 
for the tumor. Tumors with defects in the DNA repair machinery – a modification that creates 
great cellular heterogeneity due to high level of somatic mutations – have good prognosis 
possibly due to the fact that such highly mutated cells are not viable anymore and are better 
recognized by the immune system.63, 77
 Due to the large size, that tumors often have at the time they are detected in the clinic, 
various clones that are more or less therapy-resistant are almost surely present within the 
tumor cell population. The most resistant cells grow out when treatment is applied and 
generate the second-generation tumor leading to relapse. Researchers therefore suggested 
to first target drivers of cellular heterogeneity in order to generate a more homogeneous tumor 
which would then responds better to treatment.78 Other investigators proposed to directly 
exploit cellular heterogeneity to treat the patient.79 Gatenby et al, for instance, developed an 
approach of pulsed therapy. Here, chemotherapy is given in pulses that ensure a reduction of 
the dominant, chemotherapy-sensitive tumor cells, reducing the tumor mass to a level that 
guarantees safety for the patient. At the same time, this dominant clone should remain large 
enough to keep chemotherapy-resistant subclones, which are under normal conditions less fit, 
in check and prevent them from outgrowth.80 This would turn cancer into a chronic, manageable 
disease and showed promise in a melanoma xenograft model.81 Its clinical application is, 
however, hindered by a lack of monitoring techniques that can distinguish between treatment-
receptive and -resistant clones.63 Other strategies to tackle cellular heterogeneity include 
targeting several molecular pathways simultaneously, thereby attacking different subclones, 
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which showed promising results in melanoma and other types of cancer.82, 83 These combination 
therapies, however, come at the price of increased toxicity.82
 Research in this field is just at its infancy. However, the first proof-of-concept examples 
display powerfully that cellular heterogeneity does have direct implications on clinically 
relevant processes and requires further investigation.
CELLULAR HETEROGENEITY IN IMMUNOLOGY: IMPLICATIONS FOR BASIC 
RESEARCH
The immune system consists of a complex network of different cells and molecules and is 
heavily influenced by cellular heterogeneity, as immune cells, similar to cancer cells, vary 
greatly on various hierarchical layers.46
 The adaptive immune system, for instance, is fundamentally based on genomic 
heterogeneity. During maturation, B and T cells rearrange a set of gene sequences and insert 
random mutations in a process called V(D)J recombination to generate a plethora of different 
T and B cell receptors.84, 85 This genomic variation is exploited to generate receptors that 
can precisely bind a multitude of molecular patterns and allow the specific recognition of a 
great variety of pathogens and cancerous cells.84 To avoid mutations that lead to cancerous 
transformations as well as DNA sequences that generate receptors specific for host protein 
structures, various mechanisms are at work that tightly control the V(D)J recombination 
process and delete or inactivate any potentially dangerous T or B cell.86, 87, 88, 89
 Apart from the variation in their specific TCR/BCR genes, variation in immune cells is 
also caused by noise in gene expression and differences in protein levels. For instance, the 
production of cytokines from the family of type I interferons (IFN), a fundamental component 
of the immune response against viral infections and cancer, is governed by stochastic gene 
expression. IFNb, a member of this cytokine family, is produced randomly by virus-infected 
cells and only a small subset of cells expresses the cytokine during the antiviral response. 
Variation is manifested in both, the decision of a cell to express the cytokine and the time until 
the cytokine expression is initiated.90, 91 IFNβ expression is thus not determined by infection 
status and the randomness must originate mostly from cell specific factors although some 
studies link viral factors such as replication and viral transcription to IFNβ expression.90, 92 Most 
authors now agree that the stochasticity in IFNβ production mostly originates from 1) variation 
in the expression of crucial signaling components of the IFNβ expression pathway with the 
transcription factor IRF7 being one of the most crucial factors, and 2) general stochasticity of 
gene expression.90, 92 It is likely that the limiting factors are varying between cells, cell types, 
organisms, and individuals. Furthermore, the model system employed for the analysis could 
have great influence on the results – e.g. endogenous vs recombinant reporter IFNβ gene; 
cells selected for homogeneity vs cell lines vs wild type cells.92 Interestingly, despite the great 
heterogeneity on the single cell level, the IFNβ response is very deterministic and robust on 
the population level. Strong IFNβ responses are generated against viral infections in various 
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model systems and against a variety of viruses.90, 91 This is achieved by employing a powerful 
positive feedback loop. IFNb produced by randomly activated cells acts on neighboring cells 
to a) increase the expression of important components of the IFNβ expression pathway, thus 
increasing the probability of that cell to also produce IFNβ, and b) to induce the expression of 
interferon response genes, which protect the cells from further infection and viral replication.90, 
91, 93 A small fraction of randomly activated early-responder cells can, hence, effectively protect 
the entire cell population from viral infection.91, 92 This way, production of IFNβ, which is able 
to induce potent tissue damage, is limited to few cells whereas the antiviral state is induced in 
all cells.92 In this case, great heterogeneity is combined with a higher level of control, namely a 
paracrine positive feedback loop, to generate robust population responses. Another important 
example of stochastic gene expression in the immune system is the induction of T helper 2 (Th2) 
cell responses against parasites where the transcription of the cytokine interleukin (IL)-4 is 
initially a source of great noise.46 Epigenetic factors, that are altered later during the response, 
increase chromatin accessibility and allow more efficient cytokine production leading to a 
stabilization of the Th2 phenotype.94, 95, 96 Overall, stochastic gene expression appears to a be a 
common regulatory feature in the immune system possibly employed to generate responses 
that are more robust to external perturbations.
 Apart from stochastic gene expression, gradual changes in protein expression levels can 
affect immunological processes as well and represent a source of functional heterogeneity. 
Subtle differences in the continuous expression spectrum of key TCR signaling components 
can for example determine whether a cell responds to antigen stimulation or not and by this 
define the antigen recognition threshold of the entire T cell population.97 The same holds true 
for components of cytokine signaling pathways, especially IL-2.98 Differences in the expression 
level of the high affinity IL-2 receptor CD25 can influence important fate decisions and decide 
whether a T cells goes into apoptosis at the end of an acute immune response or differentiates 
into a long-lived memory cell.99, 100 Lu et al systematically analyzed the variation in expression of 
important immunological markers over a cohort of healthy volunteers and developed an index 
that summarizes this heterogeneity.101  Whereas the variation in protein expression was very 
stable within individuals over time, huge variation was observed between individuals. Further 
analysis revealed that this cellular heterogeneity was correlated with the age and genotype of 
the tested individuals indicating both genetic and non-genetic origins. 
 Subsetting of established cell types based on functional or phenotypical markers and 
defining new subtypes of more specialized cells is a common approach to immunological 
research. With the advent of sc-RNAseq, the unbiased investigation of immune cell populations 
became possible, which omits the need of previously selected, hypotheses-based markers. 
Villani and See applied sc-RNAseq- and CyTOF-based single cell analysis to blood dendritic 
cells and monocytes and discovered new subpopulations based on dimensionality reduction 
analysis and cell clustering.102, 103 Functional analysis of purified subpopulations revealed 
indeed several, previously unknown dendritic cell subsets with distinct functions including a 
finally recognized dendritic cell progenitor cell which showed proliferative potential in vitro.
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 Interestingly, Villani et al found that the newly discovered DCs can acquire a broad spectrum 
of states, ranging from classical DCs to plasmacytoid DCs.103 Similar observations of gradually 
progressing immune cell states were recently made in the setting of T helper 17 cell-mediated 
pathogenicity, T cell differentiation, and DC responses to LPS.93, 104, 105 These reports further 
emphasize on heterogeneity as a major organizational principle within the immune system 
and challenge our current views of cell differentiation and lineage.46 It might be more accurate 
to think of cellular states as local energy dips in a plane of possible phenotypes rather than 
permanent ends in a hierarchical tree of origin. Further research is warranted to investigate 
this phenomenon and could be assisted by new tools, such as single cell epigenome analysis, 
to achieve a more robust definition of cellular states.106
CELLULAR HETEROGENEITY IN IMMUNOLOGY: IMPLICATIONS FOR 
CLINICAL MONITORING
Cellular heterogeneity in the immune system is exploited in several clinical settings. In 2009 
Oved et al analyzed the phenotype of tumor infiltrating lymphocytes (TILs) and correlated the 
presence of different subsets with the responsiveness of the total TIL population to the tumor.107 
Using a decision tree approach, the authors predicted the responsiveness of a TIL population 
just by the distribution of the contained subsets. Furthermore, by controlling and designing 
the cellular heterogeneity within the TIL populations, the authors modified the responsiveness 
of the TIL population and created more desirable outcomes. Approaches like this aid our 
understanding of the functional relevance of different T cell populations in tumors and might 
help to better classify tumor biopsies.
 Heterogeneity in T cell functionality is increasingly considered as a correlate of protection in 
vaccination studies where researchers investigate how the number and type of simultaneously-
expressed T cell functions affects host protection. Investigators believe that multifunctional T 
cells, T cells that execute multiple effector functions at the same time, are able to control 
infections more efficiently and could therefore act as a clinical marker for immunity. In 
2004, Roederer et al introduced multifunctionality as a T cell property by measuring IL-2, 
CCL4- TNF-α, IFNγ, and IL-4 in HBV-specific T cell.28, 29 Later, authors extended the number 
and varied the type of markers measured exploiting advances in CyTOF and microfluidics 
technique.108, 109 The effect of T cell multifunctionality on clinical outcome was tested in several 
vaccination trials and in patients naturally controlling infectious diseases. Several studies on 
T cell responses in non-progressing or protected HIV patients revealed that not the frequency 
of antigen-specific T cells but their multifunctionality correlated with viral load and protection. 
110 99, 100 Two studies examined the functionality of T cells in human individuals that are known 
for a high chance of HIV control.111, 112 In both cases the authors could detect high levels of 
antigen-specific, multifunctional T cells compared to patients with no disease control. Similar 
observations were made in studies on T cell responses in Leishmania major.113 A number of 
studies in mice examined the induction and maintenance of multifunctional T cells after various 
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vaccination or cell-transfer regiments. In several settings, including melanoma, fibrosarcoma, 
or infection with Mycobacterium and vaccinia virus, the regiment, that induced the highest 
fraction of multifunctional T cells, also showed the greatest degree of protection or highest 
reduction in tumor burden.114, 115, 116, 117 Similar results were found in a rhesus marqacue study 
on an adeno virus-based SIV vaccine.118 Furthermore, CD8+ T cells generated by a vaccinia 
virus Ankara formulation, known to generate live-long protection against smallpox, were 
shown to be highly multifunctional.119 Not so clear is the situation, however, in a number of 
studies on Mycobacterium tuberculosis infection. The functionality of T cells, for instance, 
was significantly increased in patients with active tuberculosis and almost undetectable in 
latently infected patients indicating that in tuberculosis highly multifunctional T cells are rather 
a sign of active disease than disease control.120, 121, 122 We recently showed that melanoma-
specific T cells in cancer patients display very low functionality and that dendritic cell-based 
vaccination could increase the functionality of those T cells.123, 124 In addition, multifunctional T 
cells preferentially appeared in patients that displayed long survival.
 Despite this body of research, analysis of T cell multifunctionality is still not standard 
clinical practice. Widespread use of multifunctionality as a correlate of protection is hindered 
by the complexity of the generated data and a lack of standardized assay and analysis pipelines. 
COMPASS, the unbiased automated analysis framework for the extraction of a polyfunctionality 
index, published in 2015 by Lin et al, proposed a computational approach that summarizes 
the multivariate functionality data in a univariate score.61 This number, thus, describes the 
heterogeneity and variability of the responding T cell population and allows direct correlation to 
clinical parameters such as viral load or survival time. Using COMPASS, the group discovered 
new correlates of cellular protection in three different HIV vaccine cohorts that were not detect 
with previous techniques.
 Following this example, future efforts need to focus on simplifying the complex measures of 
cellular heterogeneity for clinical use to facilitate correlations with clinical outcome measures 
and integration in clinical analysis pipelines.
CONCLUSION
In summary, whereas the theoretical framework for cellular heterogeneity is long established, its 
experimental analysis is a rather young field of research. During the last 20 years, several studies 
made important progress in identifying the sources of cellular heterogeneity and determining 
the factors that influence and modulate it. The application of those paradigms to clinical settings 
and the investigation of the biological impact of cellular heterogeneity is, however, only slowly 
progressing. It remains difficult to adequately measure, summarize, and present cellular 
heterogeneity which is a prerequisite for its correlation with clinical outcome parameters. An 
important goal is to determine when cellular heterogeneity is an important factor for treatment 
and when it is just negligible variation. If situations with biological impact are discovered, 
strategies to exploit or modify cellular heterogeneity in favor of the patient need to be developed.
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PART I –IMMUNOMONITORING WITH SINGLE CELL TECHNIQUES
ABSTRACT
Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based on in vitro-
generated monocyte-derived DC, which require extensive in vitro manipulation. Here, we report 
on a clinical study exploiting primary CD1c+ myeloid DC, naturally circulating in the blood. 
Fourteen stage IV melanoma patients, without previous systemic treatment for metastatic 
disease, received autologous CD1c+ myeloid DC, activated by only brief (16 hours) ex vivo 
culture and loaded with tumor-associated antigens of tyrosinase and gp100. Our results show 
that therapeutic vaccination against melanoma with small amounts (3-10 x 106) of myeloid 
DC is feasible and without substantial toxicity. Four out of 14 patients showed long-term 
progression-free survival (12-35 months), which directly correlated with the development of 
multifunctional CD8+ T cell responses in three of these patients. In particular, high CD107a 
expression, indicative for cytolytic activity, and IFNγ as well as TNFα and CCL4 production was 
observed. Apparently, these T cell responses are essential to induce tumor regression and 
promote long-term survival by stalling tumor growth. In conclusion, we show that vaccination 
of metastatic melanoma patients with primary myeloid DC is feasible and safe and results in 
induction of effective antitumor immune responses that coincide with improved progression-
free survival. 
TRANSLATIONAL RELEVANCE 
Vaccination with DC loaded with tumor peptides is feasible, safe, and can induce tumor-
specific immune responses in advanced cancer patients. Thus far, DC-based immunotherapy 
of cancer was primarily based on in vitro-generated monocyte-derived DC that require 
extensive in vitro manipulation, which may affect the survival of these cells in vivo, their 
capacity to migrate to the lymph nodes, as well as their immunogenic potential. Here, we 
vaccinated metastatic melanoma patients with primary myeloid DC, directly isolated from 
patient’s blood and activated by only brief ex vivo culture. We found that vaccination is well 
tolerated and can induce de novo immune responses and objective clinical responses, which 
were associated with the presence of multifunctional tumor antigen-specific T cells in both 
blood and tissues. The rapid vaccine production procedure is highly standardized and will 
therefore expedite larger randomized multicenter trials.
INTRODUCTION
DC are central players in immune responses. As professional antigen-presenting cells, DC 
sample the tissue microenvironment and phagocytose both pathogen-derived products and 
dying host cells, including tumor cells.1 DC have the unique capacity to attract and activate naive 
(tumor) antigen-specific CD4+ and CD8+ T cells. DC-based immunotherapy exploits this property 
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of DC: tumor antigen-loaded DC are injected into cancer patients to stimulate T cells and initiate 
tumor eradication.2, 3 In clinical trials, this approach resulted in effective immunologic responses 
that coincided with favorable clinical outcomes.4, 5 However, the number of objective clinical 
responses is limited, hampering its implementation as standard treatment. 
 In the majority of clinical DC vaccination studies performed so far, DC differentiated in 
vitro from monocytes or CD34+ progenitors have been used, which may not be the optimal DC 
source for immunotherapy.6 The extensive culture period (8-9 days) and compounds required 
to differentiate these cells into DC may negatively affect their immunologic potential and their 
capacity to migrate to the T cell areas of the lymph nodes.7, 8 Therefore, naturally circulating 
primary DC may be a potent alternative for monocyte-derived DC (moDC), irrespective of the 
fact that they are relatively scarce (ranging from 1 x 107 to 1 x 108 DC in a single apheresis). 
A major advantage of exploiting primary DC instead of moDC is the brief ex vivo exposure to 
activate the cells and load them with tumor antigens, usually less than 24 hours. This might 
better preserve their functional capacities and prevent exhaustion.
 Two main populations of naturally circulating primary DC can be distinguished in human 
peripheral blood: myeloid (m)DC and plasmacytoid (p)DC. These subsets differ in function, 
localization, and phenotype. mDC mainly migrate to, or reside in, the marginal zone of the 
lymph nodes (a primary entry point for blood-borne antigens) and are specialized in immunity 
against bacteria and fungi.9-11 pDC on the other hand, mainly localize to the T cell areas of lymph 
nodes and seem specialized for viral antigen recognition.9 Depending on the pathogens they 
encounter, both DC subsets have the capacity to initiate suitable T cell responses. Antitumor 
responses induced by both mDC and pDC have been reported in animal models.12, 13
 Recently, we completed the first vaccination trial exploiting ex vivo-activated and tumor 
antigen-loaded autologous primary pDC in metastatic melanoma patients. Although the trial 
was designed as a safety and feasibility study, we obtained promising clinical results; 7 of 
15 metastatic melanoma patients were still alive two years after the initiation of treatment.14 
Both activated pDC, which produce high amounts of IFNα, and activated mDC have the 
capacity to induce T helper 1 cells, cytotoxic T cells, natural killer cells, and natural killer 
T cells, leading to a potent cellular immune response.15-17 Moreover, primary mDC isolated 
from healthy donors and cancer patients are able to prime tumor-specific CD8+ T cells in 
vitro.18 Human mDC can be further subdivided into two populations, based on their differential 
surface expression of CD1c (BDCA1) and CD141 (BDCA3).10, 19 Here, we studied the feasibility 
and safety of vaccination of metastatic melanoma patients with ex vivo-activated and tumor 
antigen-loaded autologous CD1c+ mDC and investigated whether primary mDC are capable 
of inducing antitumor responses. In peripheral blood and cultures of skin test biopsies of 
vaccinated patients, we monitored the presence and functionality of tumor antigen-specific T 
cells. The results show that mDC vaccines induce cytotoxic T cells in vivo that express multiple 
functional markers simultaneously. The presence of these multifunctional T cells coincided 
with improved progression-free survival, demonstrating the potential of primary mDC for 
anticancer immunotherapy.
94
PART I –IMMUNOMONITORING WITH SINGLE CELL TECHNIQUES
PATIENTS AND METHODS
Patient characteristics and clinical protocol
The study, CMO2004/093, was approved by the local Institutional Review Board (Committee 
on Research involving Human Subjects Arnhem-Nijmegen) and in concordance with the 
Declaration of Helsinki. Clinical trial registration number is NCT01690377. Written informed 
consent was obtained from all patients. Fifteen metastatic melanoma patients (stage IV or 
irresectable stage IIIc according to the 2009 American Joint Committee on Cancer staging 
system20) were enrolled in this phase I/II feasibility study (Table 1). One patient was excluded 
from analysis due to a protocol violation, the patient did not meet an inclusion criterion (VI-
B-15; HLA-A*02:01 negative). Therefore, fourteen patients were considered evaluable for 
immunologic and clinical response. However, one patient did not complete the scheduled 
vaccinations due to rapid progression of disease (VI-B-04) so a delayed-type hypersensitivity 
(DTH) skin test was not available for immunomonitoring. Eligibility criteria included a 
measurable target lesion, HLA-A*02:01 phenotype, histologically documented melanoma 
expressing gp100 (compulsory) and tyrosinase (non-compulsory), no serious active infection 
or immune suppressive conditions, serum LDH concentration within normal limits, and WHO 
performance status 0 or 1. All vaccinations were administered between November 2010 and 
October 2013. The primary objective of this study was to generate clinical grade mature mDC 
preparations and to determine a safe and immunologically effective dosage of the vaccine. 
When the appropriate dosage of the vaccine was determined, we evaluated the efficacy of the 
mDC to initiate antitumor T cell responses in patients with metastatic melanoma. 
CliniMACS mDC isolation and immunization schedule
Patients were vaccinated with autologous mDC loaded with HLA-A*02:01-binding tumor 
peptides derived from the melanoma-associated antigens gp100 and tyrosinase. The 
first patient received a maximum of 3 x 106 mDC per vaccination, patients 2 and 3 received 
maximally 5 x 106 mDC per vaccination, and patients 4 and 5 received maximally 10 x 106 mDC 
per injection. Considering the yield from mDC isolation, this is the maximum feasible dose, 
which was also given to patients 6 to 15. Three subsequent intranodal injections were given 
once every two weeks followed by a DTH challenge. In the absence of disease progression, 
patients were eligible for a maximum of two maintenance cycles consisting of three biweekly 
vaccinations and a DTH challenge, each with a 6-month interval. 
 mDC were directly isolated from apheresis products using the fully closed immunomagnetic 
CliniMACS isolation system (Miltenyi Biotec; Supplementary Figure 1). GMP-grade magnetic 
bead-coupled antibodies were used, following the manufacturer’s guidelines. First, B cells 
were depleted using magnetic bead-coupled CD19 antibodies, followed by positive selection 
of CD1c+ mDC with biotin-coated CD1c antibodies and magnetic bead-coupled anti-biotin 
antibodies. This procedure resulted in clinically applicable purified mDC, which had an average 
purity of 93% and a yield between 27 x 106 and 96 x 106 cells (Figure 1A, B). After apheresis and 
CliniMACS isolation, mDC were cultured overnight (16 hours) at a concentration of 106 cells/mL 
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in X-VIVO-15 (Lonza) containing 2% pooled human serum (HS; Sanquin), supplemented with 800 
U/mL recombinant human GM-CSF (Cellgenix) and 1 mg/mL keyhole limpet hemocyanin (KLH; 
Immucothel, Biosyn Arzneimittel GmbH) for immunomonitoring. This procedure gave rise to 
mature mDC meeting the following release criteria: more than 50% viability, high expression 
of MHC class I, MHC class II, CD83, and CD86.2 Part of these mDC were directly loaded with the 
melanoma-associated HLA-A*02:01-restricted peptides gp100154-162 (KTWGQYWQV), gp100280-
288 (YLEPGPVTA), and tyrosinase369-377 (YMNGTMSQV) for the first vaccination, which was given 
directly after the peptide loading.21 The remainder of the mDC was frozen with 10% DMSO 
for subsequent vaccinations or DTH. Upon subsequent vaccinations/DTH, frozen mDC were 
thawed and loaded with the melanoma-associated peptides. The peptide-loaded mDC were 
administered intranodally in a clinically tumor-free lymph node under ultrasound guidance. 
Flow cytometry
The purity of mDC after CliniMACS isolation and the phenotype of the mDC were determined 
by flow cytometry. The following primary monoclonal antibodies (mAbs) and the appropriate 
isotype controls were used: anti-CD1b/c-FITC (Diaclone), anti-CD20-PE, anti-CD45-PerCP, 
anti-CD14-APC, anti-HLA-DQ-PE (all BioLegend), anti-HLA-ABC-PE, anti-HLA-DR-PE, anti-
CD80-PE, anti-CD83-PE, and CD86-PE (all BD Pharmingen). Flow cytometry was performed 
with a FACS Calibur (BD Biosciences). 
Immunomonitoring
Peripheral blood mononuclear cells (PBMC) and serum samples were obtained before the 
start of the vaccination regimen and after each individual vaccination. Samples were tested for 
the presence of KLH-specific T cells by proliferation and 3H-thymidine incorporation, and the 
presence of KLH-specific antibodies in serum using ELISA.22 
 Within one to two weeks after the third vaccination, a DTH skin test was performed as 
described previously.4, 5 Briefly, moDC (1 x 106; cultured as previously described21) and mDC (0.5 
x 106), pulsed with gp100 or tyrosinase peptides, were injected intradermally in the skin of the 
back of the patient at four different sites. The maximum diameter of induration was measured 
after 48 hours. Punch biopsies (6 mm) were obtained from all DTH sites and cultured as 
previously described.4, 5 After a culture period of 2 to 5 weeks, skin-infiltrating lymphocytes 
(SKILs) were tested for specificity against gp100 and tyrosinase. 
 PBMC and SKILs were stained with tetrameric-MHC complexes containing the gp100154-
162, gp100280-288 or tyrosinase369-377 peptide (Sanquin) combined with CD8 staining as described 
previously.5 All samples were tested with HIV77–85-HLA-A*02:01-tetramers recognizing the 
irrelevant HIV-peptide (SLYNTVATL) for background staining. 
 Antigen recognition was determined by the production of cytokines by SKILs in response 
to T2 cells pulsed with the indicated peptides or BLM cells transfected with control antigen 
G250, with gp100, or with tyrosinase, or the allogeneic HLA-A*02:01-positive, gp100-positive, 
and tyrosinase-positive Mel624 tumor cell line. Cytokine production was measured in the 
supernatants after 16 hours of coculture by a cytometric bead array (eBioscience). 
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Analysis of multifunctional T cells in peripheral blood
Analysis was performed as previously described.23 Cryopreserved PBMC or peripheral blood 
lymphocytes (PBL) were thawed and suspended in Iscove Modified Dulbecco’s Medium (IMDM; 
Gibco) supplemented with 10% HS (Sigma Aldrich) and antibiotic-antimycotic (Gibco). T cells 
were stimulated using CD28/49c-coated beads (BD Bioscience), either alone or in combination 
with 10 µg/mL peptide gp100154–162, gp100280–288 or tyrosinase369–376. Brefeldin A (10 µg/mL; Sigma 
Aldrich) and Monensine (2 µmol/L; eBioscience) were added and cells were incubated for 5 
to 6 hours at 37°C and 10% CO2. After incubation, T cells were stained with Fixable Viability 
Dye eFluor780 (eBioscience) and surface markers APC-Cy7- or PE-Cy7-labeled anti-CD4 
(BD Pharmingen; eBioscience) and PE-CF594- or BV510-conjugated anti-CD8 (BD Horizon). 
Subsequently, the cells were fixed using 4% paraformaldehyde (Merck), permeabilized using 
0.5% Saponin (Riedel-de Haën), and stained with PerCP-Cy5.5- or BV421-conjugated anti-
IFNγ (BD Pharmingen), PE-labeled anti-IL-2 (eBioscience), Alexa700- or APC-labeled anti-
CD107a (BD Pharmingen), FITC-labeled anti-CCL4 (R&D systems), and PE-Cy7- or PerCP-
Cy5.5-labled anti-TNFα (eBioscience). Fluorescence was acquired using a CyAn ADP Analyzer 
(Beckman Coulter), a FACSAria or a FACSVerse (both Becton Dickinson) and analyzed with 
FlowJo software (Tree Star). For SEB- and peptide-stimulated samples, at least 10,000 and 
25,000 viable CD8+ T cells were recorded. For each patient and time point, 1 to 4 samples 
treated only with costimulatory beads were analyzed and at least 18,000 viable CD8+ T cells 
were recorded for each replicate sample. To analyze the functional diversity of CD8+ T cells, 
combination gates were created using the built-in Boolean gating algorithm of FlowJo. To 
account for unspecific activation, samples were background subtracted using the average 
values of 1 to 3 corresponding replicate samples stimulated only with costimulatory beads. 
To account for the different magnitude of total antigen-specific CD8+ T cell responses, the 
frequencies of cytokine combinations were normalized and given as the percentage of total 
tumor antigen-specific response. To reduce noise in the dataset, only samples with a minimum 
of 0.2% responding CD8+ T cells after background subtraction were considered positive based 
on an escalating variance model. Analysis and presentation of distributions was performed 
using SPICE version 5.3, downloaded from http://exon.niaid.nih.gov and PRISM for windows 
version 5.03 (GraphPad Software Inc.).24
Analysis of surgically resected tumors
Resected tumors were partially embedded in paraffin for immunohistochemistry and part of the 
resected tumors was used to make cell suspensions as described previously.25 Briefly, tumor 
tissue was cut into small fragments in Hanks balanced salt solution medium (Gibco) with 50 µg/
mL collagenase type 1A, 10 µg/mL DNase, and 1 µg/mL trypsin inhibitor (Sigma Chemical Co.). 
The fragments were incubated for 30 minutes at 37°C. The resulting cell suspension was put on a 
modified Ficoll gradient and tumor-infiltrating lymphocytes were harvested from the interphase. 
Flow cytometric analysis was performed with a FACS Calibur (BD Biosciences) using directly labeled 
mAbs against CD4, CD8, CD25, CD127 (all BD Pharmingen), FoxP3 (eBioscience), and tetrameric-
MHC complexes containing the gp100154-162, gp100280-288, or tyrosinase369-377 peptide.
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 Immunohistochemical staining of tumor tissue was done on paraffin-embedded tissue 
sections using mAbs against gp100, CD8 (both Dako), tyrosinase (Monosan), CD4 (Thermo 
Scientific), and FoxP3 (eBioscience). Antigen retrieval was done by microwave boiling in 10 
mmol/L sodium citrate buffer (pH 6.0) for 10 minutes. After rinsing with PBS, slides were 
pretreated with 20% normal horse serum for 10 minutes to reduce nonspecific staining. All 
sera and antibodies were dissolved in PBS with 1% bovine serum albumin. Subsequently, slides 
were incubated with the primary antibody at 4°C for 16 to 20 hours. The avidin-biotin complex 
(Vector Laboratories) method was used for visualization with 3-amino-9-ethyl-carbazole or 
3,3′-diaminobenzide hydrochloride solution. Slides were counterstained with hematoxylin 
solution or nuclear fast red, dehydrated, and mounted in Permount (Fisher Chemicals).
Statistical analysis
Kaplan-Meier probability estimates of progression-free survival and overall survival were 
calculated, statistical differences between the survival of the groups were determined with 
a log-rank test. Progression-free survival and overall survival were defined as time from 
apheresis to the onset of progression of disease or to death of any cause, respectively. Patients 
without progression of disease or still alive at analysis, respectively, were censored at the time 
of last follow-up. The hazard ratio was calculated by the Cox proportional hazards model. 
Statistical significance was defined as p<0.05. SPSS20.0 was used for survival analyses.
RESULTS
Patient and vaccine characteristics
In this study, we vaccinated metastatic melanoma patients with autologous, tumor peptide-
loaded primary CD1c+ mDC that were freshly isolated from peripheral blood and cultured 
overnight in the presence of GM-CSF (Supplementary Figure 1). Freshly isolated mDC had an 
average purity of 93% (Figure 1A, B). The phenotype of the ex vivo-activated DC was determined 
by flow cytometry; all produced vaccines expressed high levels of MHC class I and II, CD83, and 
CD86 and met the predefined release criteria (Figure 1C, D). Expression of CD80 and CCR7 was 
lower and highly variable. The mean viability of injected DC was 86% (range 53-100%) of the 
first (fresh) vaccination and 87% (range 55-98%) of thawed mDC vaccines (vaccinations 2 and 
3; Figure 1E). Patients received on average, 6 × 106 DC per vaccination, depending on the yield 
of mDC after harvesting, with a maximum of 10 × 106 DC per vaccination. The yield, combined 
with lower CCR7 expression, provided the rationale to administer mDC vaccines intranodally.
 A total of 14 HLA-A*02:01-positive melanoma patients were vaccinated with three vaccinations 
at bi-weekly intervals. Patient characteristics are summarized in Table 1. One patient (VI-B-04) 
did not complete the scheduled vaccinations and immune monitoring due to rapid progression 
of disease and was excluded from further analysis of immunologic responses (Supplementary 
Figure 2). Thirteen patients were considered evaluable for immunologic response. Five patients 
received a second cycle of three vaccinations and 3 of these patients completed the full three 
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cycles. The vaccines were very well tolerated and no signs of severe toxicity were observed. The 
most common side effects associated with DC vaccination consist of transient flu-like symptoms, 
including fever, and erythema at the site of injection. However, none of the vaccinated patients 
experienced injection site reactions, and only 4 patients developed grade 1, and one patient grade 
2 flu-like symptoms (Table 2). Besides one patient with grade 1 pain at the injection site and 4 
patients with grade 1 fatigue, no other vaccine-related side effects were observed. From this, we 
conclude that it is feasible and safe to administer activated and tumor peptide-loaded mDC to 
melanoma patients.
Figure 1. mDC vaccine characteristics. (A) Purity (%) and yield (number of cells) in 22 CliniMACS-based CD1c+ mDC 
isolations on patients’ apheresis material. Each dot represents the result of one mDC isolation. Lines represent the 
mean of all isolations. *mDC of patient VI-B-06 had lower purity with unknown cause. (B) Representative example of 
flow cytometric analysis of mDC purity after CliniMACS isolation. (C) Expression of HLA-ABC, HLA-DQ, HLA-DR, CD80, 
CD83, CD86 and CCR7 on mDC after overnight culture in the presence of GM-CSF was analyzed by flow cytometry. Data 
are shown as percentage of positive DC used for the first vaccination cycle. (D) Representative flow cytometry plots of 
phenotype analysis. Filled histograms indicates marker expression, black line is the isotype control. (E) Viability of freshly 
administered mDC (vaccination 1) and thawed mDC (vaccination 2 and 3) of the first vaccination cycle of each patient. Each 
dot represents an mDC vaccine. The line represents the mean of all vaccines.
mDC vaccination induces anti-KLH responses in metastatic melanoma patients
For immunomonitoring purposes and to provide CD4+ T cell help, all DC have been loaded with the 
control antigen KLH. PBMC, isolated after each vaccination, showed increased proliferation upon 
stimulation with KLH after the first cycle of vaccinations in 11 of 13 patients (Supplementary Figure 
3A; Table 2), indicating that the vaccine effectively induced de novo immune responses in these 
patients. We also followed the levels of serum anti-KLH antibody after each cycle of vaccinations. 
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In 4 of 13 patients, anti-KLH IgG could be detected, albeit just above detection limits in two of these 
patients (Supplementary Figure 3B; Table 2). In 2 patients, anti-KLH IgG was already detectable 
before vaccination, but these patients showed increased levels after subsequent vaccinations. 
Patient VI-B-01 showed a clear IgG response after the second cycle of mDC vaccinations, which 
coincided with the presence of anti-KLH IgA. Anti-KLH IgM was not detected. 
mDC induce multifunctional tumor antigen-specific T cell responses in vivo
Cytotoxic T cells are crucial for immune-mediated tumor eradication. Previously, we showed 
that the presence of tumor antigen-specific T cells in DTH skin tests positively correlates with 
clinical outcome in metastatic melanoma patients after moDC vaccination.4, 5 We analyzed the 
presence of tumor antigen-specific SKILs in biopsies taken from DTH skin tests after each 
cycle of vaccinations. In 4 of 13 patients tested, tetramer-positive CD8+ T cells were detected 
in SKIL cultures (Table 2; Figure 2A, 2D). In 3 of these patients (VI-B-01, -08, and -13), the 
antigen-specific CD8+ T cells were fully functional and produced high levels of IFNγ upon 
antigen-specific stimulation with HLA-A*02:01-binding gp100 or tyrosinase peptides (peptide 
recognition). SKILs of patient VI-B-01 recognized gp100154-162, gp100280-288, and tyrosinase369-277, 
whereas SKILs of patient VI-B-08 recognized gp100154-162 and SKILs of patient VI-B-13 recognized 
both gp100 epitopes (Table 2; Figure 2B, 2E). SKILs of all three patients also produced high 
levels of IFNγ upon coculture with tumor cells expressing gp100 or tyrosinase protein (protein 
recognition). Interestingly, all 3 patients showed progression-free survival of more than 15 
months and two of them showed objective clinical responses (see below).
 Tetramer analysis of PBMC after each cycle of 3 mDC vaccinations revealed tumor peptide-
specific CD8+ T cells in peripheral blood of 4 out of 12 patients tested (VI-B-01, -08, -11, and -13) 
(Table 2; Figure 3A). Recent studies showed that T cell functionality is an important indicator 
for an effective immune response. In HIV patients, the presence of T cells that simultaneously 
express more than three effector functions correlates with long-term disease control26, 27 and 
also in DC-vaccinated melanoma patients, these cells preferentially appear in patients with 
extended overall survival.23 We assessed the functionality of tumor-specific CD8+ T cells by 
measuring the simultaneous expression of CD107a (as a surrogate marker for cytolytic activity; 
expressed on the cell surface upon release of perforin and granzymes), the proinflammatory 
cytokines IFNγ, TNFα, and IL-2, and the chemokine CCL4 by tumor antigen-specific T cells 
after in vitro stimulation (Figure 3B). Functional T cells, that is, cells expressing at least one 
of the functional markers upon antigen stimulation, could be identified in PBMC of 3 of the 4 
patients that exhibited tetramer-positive CD8+ T cells in the blood, completely overlapping the 
three patients with IFNγ-producing SKILs (VI-B-01, -08, -13; Table 2; Figure 3C). We could not 
detect functional tumor antigen-specific T cells in blood of patients VI-B-03, VI-B-10, or VI-B-11, 
despite these patients were long survivors (VI-B-03, VI-B-10) or showed tetramer-positive CD8+ 
T cells in PBMC (VI-B-11). Patient VI-B-08 already harboured high frequencies of tyrosinase-
specific CD8+ T cells in the peripheral blood even before vaccination, which further increased 
after DC vaccination. However, tyrosinase-specific T cells were not detected in the SKILs of this 
same patient, indicative of the possible incapacity of these cells to home into the skin.
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Figure 2. Immunological and clinical responses of patients VI-B-13 and VI-B-08. (A-C) The presence and functionality of 
tumor antigen-specific T cells were tested in lymphocytes cultured from skin test biopsies (SKILs) of patient VI-B-13. (A) 
Example of tetramer analysis by flow cytometry of SKILs cultured from a biopsy of a positive post-treatment DTH reactions 
of patient VI-B-13 after the first cycle of three DC vaccinations. SKILs were stained with tetramers encompassing the 
HLA-A*02:01-specific gp100154-162, gp100280-288, tyrosinase369-377 peptide or an irrelevant peptide (HIV) and with anti-CD8. 
The percentage in the upper right quadrant represents the percentage of CD8+ tetramer+ cells. (B) IFNγ production by 
the same T cells after stimulation with T2 cells loaded with gp100154-162, gp100280-288 or tyrosinase369-377 peptide (peptide 
recognition), BLM cells expressing gp100 or tyrosinase protein (protein recognition), or Mel624 cells expressing both 
gp100 and tyrosinase (tumor recognition). (C) CT scans of the chest of patient VI-B-13 showed clear reduction in size of 
a pulmonary metastasis after one cycle of mDC vaccinations (middle) and complete remission after three cycles of mDC 
vaccinations (right). (D-H) The presence and functionality of tumor antigen-specific T cells were tested in lymphocytes 
cultured from skin test biopsies of (SKILs) patient VI-B-08. (D) Example of tetramer analysis by flow cytometry of SKILs 
cultured from a biopsy of a positive post-treatment DTH reaction of patient VI-B-08 after the first cycle of three DC 
vaccinations. SKILs were stained with tetramers as in Figure 2A. (E) IFNγ production by the same T cells after stimulation 
with target cells as in Figure 2B. (F) CT scan of patient VI-B-08 before (left), after 1 cycle of mDC vaccinations (middle) 
and after 2 cycles of mDC vaccinations (right), showing an evident subcutaneous lesion dorsally of the left os ilium, which 
clearly reduces after the first cycle of DC vaccinations and further reduces after the second cycle of DC vaccinations. (G) 
Immunohistochemistry of progressive tumor showing that the melanoma-associated antigen gp100 is still expressed 
(left, gp100 in red). Both CD8+ T cells (middle, CD8 in brown) as well as FoxP3+ cells (right, FoxP3 in brown) are present 
in the tumor. (H) Flow cytometric analysis of tumor infiltrating lymphocytes isolated from a progressive tumor showing 
CD4+FoxP3+ lymphocytes. 
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Figure 3. Tumor antigen-specific T cell responses in peripheral blood. (A) Examples of tetramer analysis of peripheral 
blood mononuclear cells (PBMCs) of patients VI-B-01, -03, -08, -10, -11 and -13. PBMCs were stained with tetramers 
encompassing the HLA-A*02:01 specific peptides gp100154-162, gp100280-288, tyrosinase369-377 or an irrelevant peptide (HIV) 
and with anti-CD8. The percentage in the upper right quadrant represents the percentage of CD8+ tetramer+ cells. Best 
results of all vaccination cycles per patient are shown. (B) To analyze the functionality of tumor antigen-specific CD8+ T 
cell responses, PBMCs or peripheral blood lymphocytess were stimulated with tumor peptides (gp100154-162, gp100280-288, 
tyrosinase369-377) for 5-6 h and subsequently analyzed for expression of CD107a, IFNγ, CCL4, TNFα and IL-2 using flow 
cytometry. (C) Shown is the frequency of total tumor antigen-specific CD8+ T cells. Horizontal red line indicates cut-off 
value of 0.2% responding CD8+ T cells. (D+E) Displayed for each patient is the CD8+ T cell response with the highest 
fraction of T cells expressing 3 or more functions (indicated by Ø in C). (D) The relative contribution of each functional 
marker was measured. (E) Fractions of tumor antigen-specific CD8+ T cells with 1, 2, 3, 4, or 5 functions. 
 Functional T cell responses were dominated by CD107a expression, followed by secretion 
of IFNγ, CCL4, and TNFα (Figure 3D). Production of IL-2 was not observed. The functionality of 
tumor antigen-specific CD8+ T cells differed markedly between and within tested individuals 
and reached from high fractions of T cells with 3 or 4 functions (VI-B-01, -08) to mainly 
monofunctional responses (VI-B-01, -13). Patient VI-B-08 displayed high fractions of T 
cells with three functions already before vaccination, which increased after one cycle of DC 
vaccinations (Figure 3E). Furthermore, patient VI-B-01 displayed considerable fractions of 
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tumor antigen-specific T cells with three functions after vaccination. T cells exhibiting four or 
more functions were only found in less than 4% of tumor antigen-specific T cells. From these 
data, we conclude that vaccination with small numbers of primary CD1c+ mDC can induce 
multifunctional tumor-specific CD8+ T cell responses in metastatic melanoma patients. 
Clinical responses
Five patients showed at least stable disease upon the first vaccination cycle (7, 12, 15, 18, and 
35+ months duration, respectively) and were therefore eligible for an additional vaccination cycle 
consisting of another three mDC vaccinations (Tables 1 and 2). In two of these patients, disease 
progression occurred after the second vaccination cycle. The three remaining patients also received 
a third cycle of three mDC vaccinations, of which one M1a, one M1b, and one M1c patient. All patients 
were evaluated for clinical response at 3-month intervals with CT scans. Two patients showed 
objective tumor responses, which coincided with the presence of functional T cells in peripheral 
blood and DTH skin tests (Figure 2, 3). CT scans of patient VI-B-13 showed evident regression of 
pulmonary and mediastinal nodal metastases already after one cycle of DC vaccinations, which 
converted into a complete response after the second cycle of DC vaccinations (Figure 2C). The 
patient is in ongoing complete remission and good clinical condition 35 months after initiation of 
vaccinations with mDC. 
 Patient VI-B-08 showed a mixed response; a subcutaneous lesion was strongly reduced in size 
after the first cycle of DC vaccinations and reduced even further after the second cycle (Figure 
2F), while two other lesions remained stable. However, a subcutaneous metastasis on the scalp 
increased in size during the same time period. This lesion was resected during the second cycle 
of vaccinations and analyzed by flow cytometry and immunohistochemistry. Tumor antigens gp100 
(90% of the tumor cells strongly positive) and tyrosinase (70% of the tumor cells weakly positive; 
not shown), and MHC class I (not shown) were still expressed by the tumor cells and CD8+ T cells 
were present both peritumorally and intratumorally (Figure 2G). Intriguingly, a massive infiltration 
of FoxP3+ T cells was observed (34% of CD4+ T cells; Figure 2G, 2H), indicative of regulatory T 
cells that might have locally inhibited an effective antitumor response. As no other lesions showed 
progression at this stage, the patient received a third cycle of vaccinations. Unfortunately, shortly 
after completion of the third cycle the patient progressed. Two further lesions were resected, 
which also expressed gp100, tyrosinase, and MHC class I and were infiltrated by both CD8+ T cells 
and, to a lesser extent, CD4+ and FoxP3+ cells (data not shown). Subsequent treatments with both 
ipilimumab 3mg/kg (3 cycles) and vemurafenib (3 months) did not improve the clinical status and 
the patient died of disease 29 months after initiation of mDC vaccinations. 
 Despite the small sample size, our data strongly suggest a correlation between the immunologic 
responses and progression-free survival (Figure 4A). The median progression-free survival was 
17.6 months for patients with functional T cells in blood and IFNγ-producing SKILs (n=3), compared 
to 2.3 months for patients with no functional T cells (p=0.019; HR 0.15; 95%CI, 0.04-0.57). The 
median overall survival of patients with functional T cells was 29.0 months, whereas in the absence 
of functional T cells, the median overall survival was 10.9 months (Figure 4B; p=0.103; HR 0.43; 
95%CI, 0.12-1.54). The median overall survival of all patients was 13.3 months.
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Figure 4. Correlation between the presence of functional specific T cells and clinical outcome. Kaplan–Meier analyses 
of progression-free survival (A) and overall survival (B) according to the presence of functional tumor antigen-specific T 
cells in peripheral blood or skin-infiltrating lymphocytes. Statistical significance between mDC-vaccinated patients with 
functional T cell responses compared to patients without functional T cell responses was determined by a log rank test. 
DISCUSSION
Three conclusions can be drawn from this study: (i) vaccination with naturally circulating primary 
CD1c+ mDC can induce de novo immune responses and objective clinical responses, even in 
advanced metastatic melanoma patients. The treatment is well tolerated and warrants follow-up 
by a prospective randomized trial. (ii) Prolonged progression-free survival was associated with 
the presence of multifunctional tumor antigen-specific T cells in the blood and the DTH (SKILs). 
(iii) Primary mDC vaccines can, even at numbers as low as 3-10 x 106 mDC per vaccination, induce 
de novo immune responses. This highly standardized and rapid vaccine production procedure 
(within a period of 48 hours) will certainly expedite larger randomized multicenter trials.
 By overnight culture in the presence of GM-CSF, we obtained mDC that highly expressed 
MHC class I, MHC class II, CD83, and CD86. CD80 and CCR7 were expressed at lower and 
highly variable levels, which may be suboptimal. DC activation with appropriate adjuvants, 
such as TLR ligands, will induce increased levels of costimulatory molecules and production of 
proinflammatory cytokines, which is favorable for potent antitumor responses. Unfortunately, 
limited availability of GMP-compliant produced products impeded the use of TLR ligands 
for mDC maturation in this study. We recently optimized DC maturation with clinical-grade 
protamine-mRNA complexes that induce TLR7/8-mediated upregulation of maturation 
markers and production of proinflammatory cytokines in mDC as well as pDC,28 which will be 
used in our future studies. 
 Five of 14 vaccinated patients, including patients with widespread disease, showed long-
term overall survival (22-40 months). In three of these patients, this coincided with the presence 
of tumor antigen-specific T cells and prolonged progression-free survival, while in the two 
patients without tumor antigen-specific T cells progression-free survival was short. Recent 
studies in HIV-infected patients showed that the functional quality, rather than the magnitude 
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of the T cell response, is an important indicator for effective immune responses. In those HIV 
patients, the presence of T cells that simultaneously express more than three effector functions 
correlated with long-term disease control.26, 27 Similarly, to obtain more insight in the functional 
capabilities of T cells from mDC-vaccinated melanoma patients, we examined their capacity 
to exert multiple functions at the same time. Besides cytotoxicity, necessary for induction 
of tumor cell apoptosis (analyzed by the expression of degranulation marker CD107a), also 
secretion of proinflammatory cytokines and chemokines such as IFNγ, TNFα, IL-2, and CCL4 
proved important for long-term tumor control by increasing immune recognition and inducing 
permanent senescence in cancer cells and by activation and recruitment of other immune 
cells, such as DC and NK cells.23, 29-31 Although the phenotype of induced peripheral blood 
CD8+ T cells was dominated by CD107a expression, also IFNγ, CCL4, and TNFα were secreted. 
Various levels of T cell functionality could be observed; two patients displayed high fractions of 
T cells expressing three or more functions (VI-B-01 and VI-B-08). Regression of the tumor was 
seen in two patients harboring functional T cells in their peripheral blood and DTH skin test 
(VI-B-08 and VI-B-13). Apparently, robust T cell responses are essential for tumor cell killing. 
These results highlight the ability of primary mDC to induce comprehensive T cell responses in 
vivo. 
 Interestingly, patient VI-B-08 already displayed high frequencies of multifunctional 
tyrosinase-specific CD8+ T cells in the peripheral blood even before vaccination. mDC 
vaccination increased the frequency as well as the functionality of these T cells. However, as 
tyrosinase-specific T cells were not detected in the SKILs of this same patient, these cells may 
not have the capacity to home into the skin and tumor. By contrast, IFNγ-secreting gp100-
specific cytotoxic T lymphocytes were detected in SKILs of this patient. Possibly, these gp100-
specific T cells were responsible for regression of the responding lesion. Unfortunately, we 
could not obtain tumor material of this regressing lesion to confirm this hypothesis. 
 Five of 14 patients (36%) had tetramer-positive T cells in peripheral blood or SKILs. In 3 of 
these 5 patients (21%) functional T cells were detected. This response rate is similar to that of 
moDC-vaccinated stage IV melanoma patients in our previous studies.4 The high tumor burden 
in stage IV melanoma patients may hamper the induction of effective immune responses and 
cause the lack of response in the remaining patients, which is underscored by our observation 
that response rates in stage III melanoma patients are higher.32, 33 Therefore, we hypothesize 
that DC vaccination may be more potent in the adjuvant setting.
 Until 2013, the recommended standard therapy for metastatic melanoma patients was 
DTIC, which did not considerably affect overall survival.34 Recently, anti-CTLA4 antibodies 
(ipilimumab)35, 36 and anti-PD-1 antibodies (nivolumab and pembrolizumab)37, 38 proved to be 
effective forms of immunotherapy for patients with metastatic melanoma and replaced DTIC 
as standard treatment. Although the number of patients studied here is too small for direct 
comparison and to allow any conclusions regarding significant clinical efficacy, it is notable that 
the overall survival of mDC-vaccinated patients appeared to be comparable with that of similar 
patients treated with ipilimumab reported in literature.35, 36 However, four patients included in 
our study received ipilimumab upon disease progression, of which three patients were among 
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the five patients with long-term overall survival. Nevertheless, none of these patients showed 
an objective response or long-term stable disease upon ipilimumab treatment; progression 
occurred between 5 and 8 months. Only one patient (VI-B-08) with a functional tumor-specific 
T cell response after mDC vaccination received ipilimumab; she showed progressive disease 
7 months after start of ipilimumab treatment. Still, subsequent treatment has confounded 
the overall survival data. However, as the correlation of a functional T cell response with 
progression-free survival, where no such confounding has taken place, is significant, we believe 
this is due to mDC vaccination. We did not obtain sufficient data to speculate on the combination 
of mDC vaccination and checkpoint inhibitors, but as mDC vaccines specifically activate tumor 
antigen-specific T cells and immune-checkpoint inhibition activates T cells in a non-antigen-
specific manner, one can hypothesize that a combination of the two could be beneficial, as 
CTLA4- or PD-1 blockade could improve the functionality and limit exhaustion of mDC-induced 
tumor antigen-specific T cells. This is supported by data suggesting a correlation between 
prior DC vaccination and objective responses upon subsequent treatment with ipilimumab.39 
These results urge for a randomized phase II trial to explore the clinical efficacy of mDC as an 
anticancer vaccine, possibly in combination with immune checkpoint inhibitors.
 In our previous study, using naturally circulating pDC, vaccinated melanoma patients 
showed a beneficial effect on overall survival, irrespective of the observation that the induction 
of tumor antigen-specific T cells was not as prominent as in previous moDC-vaccination trials 
or in the current study.14 This might suggest that either the antigen-specific T cells that were 
induced by pDC are very potent or more functional in terms of migration, cytokine secretion, or 
survival, or that other mechanisms, such as activation of NK cells or other innate immune cells 
by the massive pDC-derived type I IFN secretion, are involved in pDC-related clinical outcome. 
mDC and pDC may utilize different mechanisms and could synergize in the induction of clinical 
responses in metastatic melanoma patients. We therefore hypothesize that coadministration 
of naturally circulating mDC and pDC, and thus activation of multiple, possibly complementary, 
antitumor mechanisms, may generate more potent and longer-lasting antitumor responses in 
cancer patients compared to administration of individual naturally circulating DC subsets.17, 
40 Indeed, in a murine tumor model, simultaneous injection of mDC and pDC proved superior 
in generating antitumor responses when compared to immunization with either DC subset 
alone.41 Future DC vaccination studies in cancer patients should elucidate whether this also 
holds true for human DC subsets. In vitro studies have already demonstrated that human mDC 
and pDC synergize via bidirectional cross-talk.11, 42 Addition of CD141+ myeloid DC may even 
further improve the potency of DC vaccines, as CD141+ DC are highly efficient in antigen cross-
presentation to CD8+ T cells and are able to secrete IFNγ and IL-12 upon activation, which allows 
the effective induction of T helper 1 and cytotoxic T lymphocyte responses.43-48. However, the 
limited presence of DC in blood and lack of GMP-grade isolation reagents currently impedes 
the use of CD141+ DC for DC-based immunotherapy.
 In conclusion, we showed that vaccination of metastatic melanoma patients with primary 
mDC is feasible and safe and results in the induction of effective antitumor immune responses 
that coincide with improved progression-free survival. The virtual lack of side effects of primary 
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mDC vaccines, their swift and highly controlled production, and their potency in inducing 
multifunctional antigen-specific T cell responses, warrants further exploration of these natural 
circulating DC subsets in larger randomized trials.
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SUPPLEMENTARY INFORMATION
Supplementary Figure 1. Schematic overview of the 44 h mDC vaccine preparation cycle and vaccination strategy.
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Supplementary Figure 2. Flow chart.
Supplementary Figure 3. KLH-specific immune responses before and after DC vaccination. (A) KLH-specific T cell 
proliferation was analyzed before the first vaccination and after each DC vaccination during the first vaccination cycle in 
peripheral blood of vaccinated metastatic melanoma patients. Per time point each dot represents 1 patient. Proliferative 
response to KLH is given as proliferation index (proliferation with KLH/proliferation without KLH). The two patients not 
showing a KLH-specific T cell response are shown in grey. (B) KLH-specific IgG, IgA, and IgM antibodies were quantitatively 
measured after each vaccination cycle in sera of vaccinated patients. Per isotype each dot represents one patient. Best 
KLH responses per patient are shown.
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CHAPTER 5
Long-lasting multifunctional CD8+ T cell responses 
in end-stage melanoma patients can be induced by 
dendritic cell vaccination.
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ABSTRACT
Cytotoxic T cells are considered crucial for antitumor immunity and their induction is the aim of 
various immunotherapeutic strategies. High frequencies of tumor-specific CD8+ T cells alone, 
however, are no guarantee for long-term tumor control. Here, we analyzed the functionality of 
tumor-specific CD8+ T cells in melanoma patients upon dendritic cell vaccination by measuring 
multiple T cell effector functions considered crucial for anticancer immunity, including the 
expression of pro-inflammatory cytokines, chemokines and cytotoxic markers (IFNγ, TNFα, 
IL-2, CCL4, CD107a). We identified small numbers of multifunctional (polyfunctional) tumor-
specific CD8+ T cells in several patients and dendritic cell therapy was able to improve the 
functionality of these pre-existing tumor-specific CD8+ T cells. Generated multifunctional CD8+ 
T cell responses could persist for up to ten years and within the same patient functionality 
could vary greatly for the different vaccination antigens. Importantly, after one cycle of DC 
vaccination highly functional CD8+ T cells were only detected in patients displaying prolonged 
overall survival. Our results shed light on the dynamics of multifunctional tumor-specific CD8+ 
T cells during metastatic melanoma and reveal a new feature of dendritic cell vaccination in 
vivo.
INTRODUCTION
T cells are crucial mediators of anticancer immunity and well-established in vitro and in 
vivo experiments proved their ability to destroy tumor cells 1, 2. The presence of circulating, 
tumor-infiltrating lymphocytes in cancer patients is linked to improved survival 3, 4. Monoclonal 
antibodies counteracting T cell suppression by inhibiting CTLA-4 (Ipilimumab) and PD-1 
(Pembrolizumab) signaling, provoke unprecedented response rates in metastatic melanoma 
patients 5, 6. Interestingly, in these, as well as in previous immunotherapeutic strategies 
aiming at the induction of cancer-specific T cell responses, a subset of patients experienced 
remarkably long lasting responses, suggesting a link between T cell activation and long-term 
tumor control 7, 8.
 To improve clinical efficacy of cancer immunotherapies, and our understanding of 
the mechanisms underlying favorable responses, it is essential to find biomarkers that 
distinguish responders from non-responders. Recent studies in the field of HIV highlight T cell 
functionality as an important indicator for an effective immune response, as T lymphocytes that 
simultaneously expressed more than 3 effector functions correlated with disease control 9, 10. 
Recent studies also report on the presence of polyfunctional T cells in melanoma patients and 
show that adoptively transferred T cells can maintain a multifunctional phenotype 11, 12. Little, 
however, is known about the in vivo induction of multifunctional T cells by immunotherapeutic 
intervention, their persistence and their impact on tumor control and survival. 
 To date, various T cell functions have been considered important for long-term tumor 
control.  Whereas cytotoxicity is necessary for the induction of apoptosis – a hallmark of 
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anticancer immunity – secretion of proinflammatory cytokines, such as TNFα, CCL4, and IFNγ, 
were shown to play an important role as well 1, 13, 14. Tumor cells treated with IFNγ upregulate 
antigen processing and presentation pathways leading to increased immunogenicity and IFNγ 
signaling during priming of T cells polarizes responses towards the favorable TH1 type 
13. 
Combined with TNFα, IFNγ is able to induce permanent senescence in cancer cells 14, 15. CCL4, 
induces the secretion of IL-12 by dendritic cells (DCs), and together with TNFα, enhances the 
recruitment of DC precursors to peripheral tissues 16. Finally, IL-2 allows cytotoxic CD8+ T 
lymphocytes to expand independently from CD4+ helper T cells and enhances NK cell activity 15.
 In this study we retrospectively analyzed the tumor-specific CD8+ T cell responses in 
peripheral blood from metastatic melanoma patients enrolled in ongoing dendritic cell 
vaccination trials. Patients were followed during the course of their disease and functional 
CD8+ T cell responses were assessed using a flow cytometry-based assay to simultaneously 
measure the production of the proinflammatory cytokines IFNγ, TNFα, CCL4, as well as IL-2, 
and the expression of CD107a as surrogate marker for cytotoxicity. 
 Our findings show that metastatic melanoma patients can harbor naturally-induced, 
tumor-specific multifunctional T cells, that dendritic cell based vaccination enhances the 
functionality of these cells and that induced responses can last for several years. Finally, in our 
patient cohort highly multifunctional T cell responses seem to preferentially appear in patients 
with prolonged survival.
RESULTS
Study design and patient characteristics
The primary aim of this retrospective study was to explore the functional composition of the 
tumor-specific CD8+ T cell responses in late-stage melanoma patients and to investigate the 
presence of multifunctional T cells. For this purposes we identified a set of 19 melanoma 
patients that previously displayed tumor-specific CD8+ T cell responses in blood or skin after 
DC vaccination at the Radboud university medical centre (Table 1). 
 As only few patients develop detectable tumor-specific CD8+ T cell responses during 
the therapy, the cohort was rather limited and due to the retrospective nature of the study 
sample availability was suboptimal. Patients were vaccinated in our institute from 1999 to 
2013 according to various protocols using autologous, antigen-loaded DCs (Supplementary 
Table 1 for protocol details). In short, patients were injected with ex-vivo generated, mature 
DCs, loaded with peptides derived from the gp100- or tyrosinase-proteins. Patients were 
injected three times per vaccination cycle. After vaccination, the induction of antigen-specific 
T cell responses was assessed using both a DTH-skin test and a tetramer-staining assay for 
peripheral blood T cells. Of 19 patients, tested in this study, six did not display detectable, 
functional T cell responses and are therefore excluded from analysis of functionality. In some 
patients we observed a disparity between the detection of responding tetramer-positive CD8+ T 
cells in peripheral blood as assessed by routine immunomonitoring during the original clinical 
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trials (Table 1). This could be based on different TCR affinities necessary to trigger an effector 
response or to strongly bind a tetramer as described by several studies 17, 18. Overall survival of 
included patients ranged from 5 to 179 months and the median survival time in this cohort of 
long-term and intermediate tumor controllers was 29 months. 
Few multifunctional, tumor-specific CD8+ T cells are detected in metastatic 
melanoma patients
To standardize monitoring, we based our initial analysis on the period after one cycle of 
dendritic cell vaccination, thus 1 to 8 months after apheresis, where samples were available 
for all patients (Figure 1). Functionality of tumor-specific CD8+ T cells was assessed by 
measuring the simultaneous expression of IFNγ, TNFα, CCL4, IL-2 and CD107a upon antigenic 
stimulation using a flow cytometry-based assay (Figure 2A). As tetramer-staining diminished 
upon stimulation with specific peptide or SEB in most tested samples and remaining tetramer-
positive T cells were skewed in some cases towards a highly multifunctional phenotype we 
gated on the total CD8+ T cell population for further analysis (Supplementary Figure 1). Figure 
2 displays the results of a representative response showing the expression of the functional 
markers by CD8+ T cells when stimulated with the specific peptide. To analyze the complexity 
of the detected T cell response we employed a Boolean gating algorithm that revealed the 
functional response patterns as represented by the 31 possible combinatorial phenotypes 
(Figure 2B). All samples were background-subtracted using the CD28/CD49d control.
 After one cycle of DC vaccination, the frequency of tumor-specific, responding CD8+ 
T cells was low in most tested individuals. Nevertheless, several patients showed strong 
responses against various vaccination antigens with up to 5% responding cells (Figure 
3A). In total, functional CD8+ T cell responses were detected in 10 of 19 patients after one 
cycle of DC vaccination and CD8+ T cells expressing CD107a clearly dominated the immune 
response against all tested antigens (Figure 3B).  Expression of TNFα was measured in ca. 
20% of responding cells and high fractions of CCL4 expressing cells were found within the 
tyrosinase-specific responses. In contrast, IFNγ expression contributed only marginally to most 
detected T cell responses. Likewise, only few CD8+ T cells expressed IL-2 possibly indicating a 
predominance of effectormemory T cells 15. Interestingly, none of the measured markers was 
consistently expressed by all CD8+ T cells emphasizing the importance of measuring several 
effector functions to assess anti-cancer immune responses comprehensively. 
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Figure 1 – Overview of the DC vaccination therapy treatment schedule. Melanoma patients underwent leukapharesis 
at the beginning of each vaccination cycle. The leukapharesis samples of the first DC vaccination cycle are referred to 
as “before vaccination” samples. After the first cycle of three biweekly DC injections, blood was drawn at several time 
points. These samples are referred to as “after one cycle of DC vaccination” samples. If the patient showed no progressive 
disease, he/she was qualified for a second and third cycle of DC vaccination. Blood drawn within 8 months after the third 
cycle of DC vaccination therapy are referred to as “after three cycles of DC vaccination”. Samples drawn after this time 
point are referred to as “follow-up”.
Figure 2 – Gating strategy to measure the functional CD8+ T cell response using flow cytometry and response 
pattern. CD8+ T cells were stimulated as described using αCD28/αCD49-coated beads with or without specific peptide 
(unstimulated, stimulated) and the expression of IFNγ, TNFα, CCL4, IL-2, and CD107a was measured. A) Shown is the 
gating strategy for one representative sample. Expression of functional markers was determined using single gates. 
B) Stimulated samples were background-subtracted using the unstimulated control and functional combinations were 
computed using the Boolean gating algorithm included in FlowJo. Displayed is the frequency of CD8+ T cells showing each 
of the 31 possible functional patterns. Non-responding cells are not shown.
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Figure 3 – Few tumor-specific, multifunctional CD8+ T cells were detected in melanoma patients after one cycle of 
DC vaccination. A) Responding CD8+ T cells were detected for all tested peptides. Most responses did however not reach 
the detection threshold of 0.2% responding cells. (Red dotted line) B) The relative contribution of each functional marker 
to the total response was measured. Most tumor-specific CD8+ T cells expressed CD107a. Only few cells expressed IL-
2. Lines indicate the median. C) and D) Normalized distribution of functional T cell response patterns.  Combinational 
analysis of expressed markers revealed small fractions of highly functional CD8+ T cells in a number of patients; most 
responding cells, however, were monofunctional. SEB-specific CD8+ T cells in contrast show high fractions of T cells with 
3 and more functions and are mainly multifunctional. Grey bars depict the interquartile range.
Next we analyzed the functionality of the detected tumor-specific CD8+ T cells. Comparing 
responses between different individuals required normalization. For this purpose, the total 
frequency of responding CD8+ T cells was set to 100% and the contribution of each functional 
pattern was displayed as fraction of the total response. gp100:280-specific CD8+ T cells appeared 
to be mainly monofunctional as sole expression of CD107a was the most prevalent response 
pattern (Figure 3C). Nevertheless, a subgroup of patients consistently harbored CD8+ T cells 
co-expressing three or more functional markers (multifunctional T cells). The combinatorial 
expression of all five functional markers, in contrast, was not observed. Interestingly, gp100:280-
specific CD8+ T cells acquired only a limited set of functional response patterns of which the 
most predominant functional phenotypes consisted of CD8+ T cells expressing IFNγ, CCL4 and/
122
PART I –IMMUNOMONITORING WITH SINGLE CELL TECHNIQUES
or TNFα with or without CD107a (Figure 3C). Immune responses against the other vaccination 
epitopes gp100:154 and tyrosinase were similarly dominated by monofunctional, CD107a 
expressing cells (Figure 3D). CD8+ T cells specific for tyrosinase appeared to show enhanced 
fractions of multifunctional T cells when compared to cells specific for the gp100 epitopes. 
 To investigate whether the tested melanoma patients were generally able to generate 
potent functional responses, CD8+ T cells were stimulated with Staphylococcal enterotoxin B 
(SEB). SEB crosslinks MHC molecules and T cell receptor complexes (TCR) leading to strong 
activation of T cells with various specificities. SEB-specific responses could be detected in all 
analyzed patients and multifunctional T cells dominated these responses (Figure 3C, D). 
 In summary, in metastatic melanoma patients, despite intact CD8+ T cell responses to SEB, 
only low numbers of multifunctional tumor-specific CD8+ T cells could be detected after one 
cycle of DC vaccination.
Dendritic cell-vaccination therapy improves CD8+ T cell functionality
Next, we explored whether naturally induced multifunctional CD8+ T cells were present already 
before DC vaccination and if DC vaccination was able to boost the functionality of these cells. 
Interestingly, we identified naturally occurring tumor-specific T cell responses in various 
patients with magnitudes of up to 2.7% responding CD8+ T cells (Figure 4). In general, CD107a-
expressing CD8+ T cells dominated the spontaneously induced antitumor immune response 
and most cells were monofunctional.
 To analyze whether the functionality of these pre-existing T cell responses could be 
generally increased by DC vaccination, we matched each pre-vaccination response with the 
first post-vaccination response. For three patients we could not detect a tumor-specific CD8+ 
T cell response after one cycle of DC vaccination, despite the presence of such a response 
before vaccination. In these cases we analyzed peripheral blood mononuclear cells (PBMCs) 
at a later time point and could identify tumor-specific CD8+ T cell responses directly after the 
third cycle of vaccination. Interestingly, whereas no apparent change in the total frequency of 
responding CD8+ T cells could be detected (Figure 5A), we could measure an increase in CD8+ 
T cell functionality after vaccination (Figure 5B). Tumor-specific CD8+ T cell responses at 1 or 3 
cycles of DC vaccination showed a significant increase in the fraction of multifunctional T cells. 
Consequently, the relative contribution of monofunctional CD8+ T cells to the overall tumor-
specific T cell response declined. 
 These data, thus, demonstrate that DC-based immunotherapy was able to enhance the 
functionality of pre-existing CD8+ T cells in the analyzed patient cohort.
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Highly functional tumor-specific CD8+ T cells are enriched in long-term tumor 
controllers
Next we investigated the generation of multifunctional CD8+ T cells in relation to patient survival. 
Interestingly, we found that after one cycle of dendritic cell vaccination tumor-specific, highly 
functional CD8+ T cell responses were only present in patients with overall survival above or 
equal to the median of analyzed patients (29 months) (Figure 6A). Monofunctional CD8+ T cell 
responses, in contrast, were detected in all patients. The highest magnitude of responding 
CD8+ T cells (frequency of total responding CD8+ T cells) was found in patients with above 
median overall survival, but strong responses could also be observed in patients with overall 
survival below median (Figure 6B). 
Figure 4 – The functional CD8+ T cell response before DC vaccination was dominated by monofunctional cells. A) 
Naturally occurring tumor-specific CD8+ T cell responses above detection threshold were detected for all tested 
peptides. B) The relative contribution of each functional marker to the total response was similar to after one cycle 
of DC vaccination. Most tumor-specific CD8+ T cells expressed CD107a. Only few cells expressed IL-2. Lines indicate 
the median. C) Combinational analysis of expressed markers revealed mainly monofunctional tumor-specific CD8+ T 
responses. SEB-specific CD8+ T cells in contrast displayed high fractions of T cells with 3 and more functions similar to 
the time point after one cycle of DC vaccination.
 We previously recognized that some patients only develop detectable CD8+ T cell responses 
after several cycles of DC vaccination. For this reason, we decided to extend our analysis to 
time points beyond one cycle of DC vaccination if material was available. We observed that 
patients without detectable T cell response after one cycle of DC vaccination could develop 
such a response after two or three cycles. Interestingly, over the entire observation period 
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highly multifunctional T cell responses were almost exclusively observed in patients with 
overall survival above median (Figure 6C).
Figure 5 – DC vaccination improved the functionality of pre-existing, tumor-specific CD8+ T cell responses. The 
functionality of tumor-specific CD8+ T cells was measured before and at the first available time point after DC vaccination. 
A) Shown is the development of the frequency of responding CD8+ T cells during the course of DC therapy. No significant 
trend could be observed. B) The fraction of multifunctional CD8+ T cells increased during DC vaccination therapy whereas 
the contribution of monofunctional T cells to the tumor-specific CD8+ T cell response declined. (n = 10, Wilcoxon matched-
pairs signed rank test, samples after 1 and 3 cycles of DC vaccination are analyzed together as one “after vaccination” 
time point).
 To account for responses against multiple tested antigens by the same individual, we then 
compared for each patient only the one response with the highest fraction of multifunctional 
T cells. After one cycle of vaccination high fractions of tumor-specific, multifunctional T cells 
only appeared in patients with prolonged survival (Figure 6E) and over the entire observation 
period we could observe a trend towards enrichment of highly multifunctional T cells in patients 
with prolonged survival (Figure 6F). Before vaccination, highly multifunctional CD8+ T cells were 
absent in most patients with the exception of one patient with above median overall survival 
(Figure 6D). Interestingly, we could not observe such a trend for the SEB-induced responses, 
which contained high fractions of multifunctional T cells in all patients and at all time points.
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 Together, our data indicate that highly multifunctional tumor-specific CD8+ T cells appear 
predominantly in patients with above median overall survival, whereas poorly functional 
responses are observed in patients of both survival groups.
Figure 6 – Highly functional CD8+ T cell responses preferentially appeared in patients with prolonged survival. A) 
Shown is the percentage of multifunctional T cells within the tumor-specific CD8+ T cell responses detected after one 
cycle of DC vaccination. High fractions of multifunctional T cells only appeared in responses of patients with above 
median overall survival. B) Depicted is the total frequency of responding, tumor-specific CD8+ T cells after one cycle of 
DC vaccination. The strongest responses were observed in patients with prolonged survival but also patients with below 
median survival displayed high frequencies of responding CD8+ T cells. The dotted line indicates the cut-off value for 
positivity of 0.2% specifically responding cells. C) Shown is the percentage of multifunctional T cells within the tumor-
specific CD8+ T cell responses detected after any cycle of DC vaccination including follow up. Highly functional T cell 
responses preferentially appeared in patients with prolonged overall survival. Multiple bars for the same patient represent 
responses to different tumor antigens (A and B) and/or at different time points (C). D, E, F) To account for responses 
against multiple tested antigens by the same individual, for each patient only the one response with the highest fraction 
of multifunctional T cells is shown. Highly functional T cell responses preferentially developed in patients with prolonged 
survival whereas there is no difference in the SEB-specific response.
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Multifunctional T cells show enhanced effector function as compared to 
monofunctional T cells
We assessed whether multifunctional T cells display enhanced effector functions. For this 
purpose, the median fluorescence intensity (MFI) of a set of detected CD8+ T cell responses was 
measured to estimate the relative cytokine expression by multifunctional versus monofunctional 
CD8+ T cells. Strikingly, in multifunctional CD8+ T cells the median expression of IFNγ and TNFα 
was 4 and 5 times higher, respectively, demonstrating significantly increased effector function 
(Figure 7). In the few cases where multifunctional CD8+ T cells expressed IL-2, we could likewise 
see a strong increase in the MFI of these cells as compared to monofunctional cells.
 Though rare in numbers, tumor-specific multifunctional CD8+ T cells with enhanced effector 
functions might thus be able to contribute significantly to the anti-cancer immune response.
Figure 7 – Multifunctional CD8+ T cells 
displayed elevated effector functions 
compared to monofunctional cells. The 
median fluorescence intensity of CD8+ 
T cells expressing 3 or more functions 
(3+) relative to CD8+ T cells expressing 1 
function was analyzed. T cells expressing 
3+ functions showed increased relative 
expression of IL-2, IFNγ and TNFα. (*** P 
) 0.001, **P ) 0.01, *P ) 0.05, Wilcoxon 
Signed Rank Test, IFNγ: n=10, TNFα: n=9; 
IL-2: n=6)
Persistence of multifunctional CD8+ T cells in long-term tumor controllers
To analyze the dynamics of multifunctional T cells and their persistence in melanoma patients, 
we decided to follow four individuals during the entire course of their disease.
 We could repeatedly detect multifunctional T cell responses in these patients over a time 
period of up to 128 months (Figure 8). Importantly, after the last cycle of vaccination, induced 
multifunctional CD8+ T cell responses persisted for several years, indicating the induction of 
long-lasting memory responses. In three of the four patients followed the highest fraction of 
multifunctional T cells was detectable in follow-up samples taken at later time points in life (up 
to 106 months after the last cycle of DC vaccination).
 T cell functionality appeared to be regulated on a antigen- or epitope-level as the fraction 
of multifunctional T cells developed differently for gp100:154 and gp100:280-specific T cells in 
patients VI-B-01 and I-C-04. Furthermore, the functionality of vaccine-induced CD8+ T cells 
developed independently from the SEB-induced CD8+ T cell responses (Supplementary Figure 
2) and analysis of all samples with CD8+ T cell responses against more than one tumor peptide 
revealed that in most cases the functionality differed between antigens (Supplementary 
Figure 3). Furthermore, the fraction of multifunctional T cells developed independently from 
the magnitude of the T cell response and high fractions of multifunctional CD8+ T cells could 
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be detected in responses of high and low magnitude (Figure 8). To investigate whether the 
antigen-specific reduction of functionality was depending on TCR affinity or intrinsic defects in 
effector functions, selected samples with high numbers of Tetramer+ T cells were stimulated 
be detected in responses of high and low magnitude (Figure 8). To investigate whether the 
antigen-specific reduction of functionality was depending on TCR affinity or intrinsic defects in 
effector functions, selected samples with high numbers of Tetramer+ T cells were stimulated 
with phorbol 12-myristate 13-acetate (PMA) and ionomycine (Iono) activating the TCR signaling 
cascade downstream of the TCR resulting in a strong avidity-independent stimulation. 
Despite TCR-independent stimulation, we observed a reduction in tetramer signal, although 
less pronounced as upon TCR-specific stimulation (Supplementary Figure 4A). Whereas the 
frequency of responding cells did not differ between total CD8+ and Tetramer+CD8+ T cells 
(Supplementary Figure 4B), functionality and functional composition did (Supplementary 
Figure 4C,D). We observed a total lack of IL-2 production in Tetramer+CD8+ T cells but not total 
CD8+ T cells stimulated with SEB or PMA/Iono. Likewise, peptide stimulated CD8+ T cells were 
not able to secrete IL-2. Furthermore, the functionality of Tetramer+CD8+ T cells as compared 
to total CD8+ T cells stimulated with PMA/Iono was reduced in all tested samples. Moreover, 
in two of the three samples CD8+ T cells stimulated with TAA-peptide showed further reduced 
functionality.
 These data demonstrate that induced multifunctional CD8+ T cells are persisting for several 
years and that within the same patient the multifunctionality of CD8+ T cells appears to develop 
differently for each tested tumor antigens.
DISCUSSION
Despite their established role in anti-cancer immunity, high frequencies of tumor-specific 
T cells in melanoma patients as measured by multimer-staining or IFNγ secretion have not 
been shown to guarantee tumor regression or survival benefit 4, 19. A study by Weide et al. 
demonstrated a positive correlation between naturally occurring tumor-specific T cells in 
melanoma, as measured by secretion of one out of six cytokines 4. However, that study focused 
on monofunctional CD8+ T cells without an in-depth analysis of the combinatorial secretion 
of cytokines. Interestingly, studies on HIV, a disease with similar dissonance between T cell 
frequency and clinical outcome, identified CD8+ T cells exhibiting multiple functions as a 
prognostic biomarker 9, 10. Here, we show that naturally occurring tumor-specific T cells in end-
stage melanoma patients were predominantly monofunctional. Subsequent DC vaccination 
enhanced their functionality and induced multifunctional CD8+ T cells that persisted for up 
to 10 years. These results indicate a long-lasting memory protection, which is in line with 
our finding that high levels of multifunctional CD8+ T cells are enriched in patients with above 
median survival.
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Figure 8 – Multifunctional, tumor-specific CD8+ T cells persist for several years. Patients with satisfactory sample 
availability were followed during the course of their disease. Dotted lines indicate the frequency of responding, tumor-
specific CD8+ T cells (right y-axis) and filled lines indicate the percentage of multifunctional T cells within these responses 
(left y-axis). Blue lines indicate the last administration of DC vaccination therapy. Orange lines indicate the time point of 
disease progression, red lines indicate the death of the patient. The functionality of DC vaccination-induced CD8+ T cell 
responses increased for most patients during the period of vaccination and remained steady afterwards. The functionality 
of T cell responses against different tumor antigens within the same patients developed differently. Induced multifunctional 
T cells persisted in some cases for more than 100 months after last administration of DC vaccination.
 Especially this latter finding suggests an important role for multifunctional T cells in 
antitumor immunity. Distinct mechanisms may explain the extended tumor control: first, the 
concerted action of several anti-cancer functions allows a more comprehensive attack on the 
tumor. IFNγ and TNFα were shown to synergistically mediate cytotoxicity, and indeed, most 
long-term tumor controllers showed increased fractions of IFNγ+TNFα+CD107a+ CD8+ T cells 
14, 15. Alternatively, highly functional T cells as major producers of IFNγ and TNFα (Figure 7) 
may boost local effector cell production. According to the “spark”-theory, vaccine-induced T 
cells might generate local conditions that favor in vivo priming of antitumor T cells, which in 
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turn reject the tumor 19. In this respect, potent production of TH1 cytokines by vaccine-induced 
T cells might be more important than cytolytic activity 12, 19. Furthermore, as the analysis of the 
MFI indicated, multifunctional T cells produce disproportionally high concentrations of effector 
cytokines, which could partly compensate for their low numbers. Despite their relatively low 
frequency, highly functional T cells thus appear to be a pivotal population of CD8+ T cells 
equipped with strong effector functions.
 In this study, the majority of tumor-specific monofunctional CD8+ T cells displayed a 
CD107a+ phenotype and overall CD107a was the most abundantly expressed molecule. In 
contrast, antigen-specific CD8+ T cell responses in HIV patients, as measured by other groups, 
were dominated by CCL4 expression and in blood of HIV progressing patients high fractions of 
monofunctional CCL4+ CD8+ T cells were observed 9, 10, 20, 21. However, high frequencies of CCL4+ 
monofunctional tumor-specific CD8+ T cells were absent in this study. As CCL4-binding to the 
CCR5 receptor can inhibit viral entry, production of CCL4 is likely one of the most important 
effector functions in HIV 22-25.  In melanoma, this mechanism does not play a role and cytotoxicity 
is more important hence CD107a expression. The expression of effector functions by antigen-
specific CD8+ T cells can differ between diseases and adapt to generate the most effective CD8+ 
T cell response for a particular threat as previously shown for CD4+ T cells 26.
 Strikingly, we found that DC vaccination enhances the functionality of pre-existing tumor-
specific CD8+ T cell responses. As this effect was restricted to a limited number of patients, 
further improvements of the treatment regiment are necessary. Studies suggest that repeated, 
but limited exposure to high levels of antigen are important to maintain highly functional CD4+ 
T cells 15. In this respect, earlier and continued administration of booster vaccines, as practiced 
by some groups, might be beneficial for the persistent maintenance of multifunctional T cells. 
Our findings, that some patients only developed detectable T cell responses after two or three 
cycles of DC vaccination might further support this theory. Unfortunately, longitudinal analysis 
in our study was hampered by the limited number of patients with sufficient material available 
at all time points, making it difficult to deduce further trends or common dynamic patterns 
from these data. 
 Interestingly, the fraction of multifunctional T cells differed between the employed 
vaccination antigens in the same patient. Patient VI-B-01, for instance, developed strong CD8+ 
T cell responses against both the gp100:154 and the gp100:280 peptide with more than 3% 
and 2% responding CD8+ T cells, respectively. Nevertheless, the CD8+ T cell response against 
the gp100:154 peptide developed highly multifunctional T cells already after two cycles of 
vaccination, the response against gp100:280 in contrast remained monofunctional until late 
after the third cycle of vaccination. Similarly, the functionality of the gp100:154 and gp100:280 
response in patient I-C-04 was unlinked. Furthermore, our data indicate differences in the 
functional composition of the CD8+ T cell responses against different antigens. Together, these 
results indicate that the fraction of multifunctional CD8+ T cells might be regulated on the clonal 
or antigen level. Several possible reasons come into account for this observation: dendritic 
cells are pulsed separately with the different peptides before injection into the patients and 
there could be differences in the expression of immunomodulatory factors. As all DCs were 
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activated together, it is however more likely that differences in the T cell repertoire of the melanoma 
patients might be causative for the observed differences. The presence or absence of high avidity T 
cell clones before vaccination for example could be responsible for differences in functionality and 
Harari et al. showed that low-avidity clones are more multifunctional than high-avidity clones 27, 28. 
Our data indicate that impaired signaling via the TCR – e.g. due to sub-optimal avidity between TCR 
and MHC:peptide complex – could be in part responsible for the reduced functionality observed 
in some patients. Stimulation of CD8+ T cells with PMA/Iono restored secretion of IFNγ, TNFα 
or CD107a, which was reduced when CD8+ T cells were stimulated with the relevant peptide. 
Furthermore, a recent study by Chiu et al. describes the influence of the antigen-concentration on 
the ability of T cells to perform multiple effector functions simultaneously 29. Despite the apparent 
influence of TCR signaling on CD8+ T cell functionality, we could observe a lack of IL-2 production by 
tumor-specific CD8+ T cells, which was independent of direct TCR engagement. Tetramer-specific 
CD8+ T cells activated with SEB or PMA/Iono as well as tumor peptide-stimulated CD8+ T cells 
were unable to secrete IL-2, whereas SEB- or PMA/Iono-stimulated total CD8+ T cells produced 
high amounts of this T cell growth factor.  These results indicate an intrinsic defect of the analyzed 
tumor-specific CD8+ T cells to produce IL-2 independent of suboptimal TCR avidity and possibly 
due to a (terminal) differentiation or exhaustion state 15, 30. Finally, selective induction of tolerance 
or exhaustion via e.g. regulatory T cells or myeloid-derived suppressor cells could account for the 
observed differences in functionality. Myeloid-derived suppressor cells, for example, are equipped 
with a variety of mechanism to suppress CD8+ T cells in an antigen-specific and non-specific way, 
e.g. via altering the specificity of TCRs by nitration of tyrosine residues 31-33. 
 The five reported markers of functionality described here are likely not the only mediators 
of tumor control, could, however, represent surrogate markers for a complex and successful 
antitumor immune response. In a recent study, Ulloa-Montoya et al., employing an unbiased 
gene-expression analysis approach, came to similar conclusions and showed that the activation of 
interferon (IFN)-stimulated genes, specific chemokine genes (including CCL4), and the activation 
of immune effector function genes (cytotoxic pathways) is characteristic for regressing metastatic 
melanoma lesions after immunotherapy 34.
 Our data show that highly functional CD8+ T cells primarily appear in patients with extended 
overall survival. After one cycle of DC vaccination, high fractions of multifunctional T cells were only 
observed in patients with above median survival. When extending the analysis to time points after 
two and three cycles of vaccination similar results could be observed. Markedly, of the below-median 
survivors only patient VI-B-01 developed highly functional CD8+ T cell responses in this extended 
analysis. However, with 22 months VI-B-01 displayed already prolonged overall survival compared 
to metastatic melanoma patients treated with e.g. chemotherapy. Although the retrospective 
study design and low patient numbers do not allow conclusive data on the causal relation it is 
tempting to speculate that multifunctional CD8+ T cells contribute to improved overall survival. 
Standardized studies, with large, diversified patient cohorts and fixed time points are needed to 
extend our findings and validate T cell functionality for routine immunomonitoring. Testing the five 
reported features is feasible with routine laboratory techniques allowing quick translation to local 
laboratories.
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 To summarize, in this study we could observe multifunctional, tumor-specific CD8+ T cell 
responses in metastatic melanoma patients that were preferably detected in individuals with 
extended overall survival. Furthermore, we showed that DC vaccination is able to improve CD8+ 
T cell functionality generating long-lasting, multifunctional CD8+ T cell responses. 
METHODS
Patients
PBMCs or peripheral blood lymphocytes (PBLs) were collected from melanoma patients with 
loco regional resectable disease (stage III) as well as irresectable loco regional or distant 
metastatic disease (stage IV) at different time points during the course of their disease (n=19) 
(Table 1 and Supplementary Table 1 for patient details). All patients underwent immunotherapy 
in our department as described in the original studies and indicated in Supplementary Table 1 
(Schreibelt et al., manuscript in preparation, 35-38. In short, patients underwent leukapheresis 
and either myeloid DCs or monocytes were isolated and the latter were differentiated to 
monocyte-derived DCs by incubating with IL-4 and GM-CSF. Subsequently, DCs were activated 
and loaded with antigen either by pulsing with gp100- or tyrosinase-derived peptides or by 
electroporation with TAA-coding mRNA (gp100, tyrosinase full protein). Finally, the prepared 
DC vaccination was administered to patients intravenously, intradermally or intranodally three 
times following a biweekly injection schedule. Patients were confirmed to be HLA*02:01 and, 
in some cases, HLA-DR4 positive and World Health Organization performance status 0 or 1. 
Primary tumors or metastases were tested for tumor-associated antigen expression (gp100 
and tyrosinase). The original studies were approved by the Regional Institutional Review Board 
and patients signed informed consent.
Sample acquisition
Various amounts of whole blood were obtained by venipuncture or leukapheresis using 
vacutainer collection tubes at the time points indicated in (Figure 1). In order to achieve 
processing within 6 hours, vacutainer tubes were transported within the RadboudUMC at room 
temperature to the Dapertment of Tumor Immunology. PBMCs were isolated via gradient 
centrifugation using Lymphoprep (Axis-Shield) following the manufacturer’s instructions. Cells 
were frozen in Xvivo 15 (Lonza) supplemented with 40% Albuman 200g/L (Sanquin) and 10% 
CryoSure-DMSO (WAK Chemie Medical GMBH) in Cryo.S vials (greiner bio-one) at 10 to 100×106 
cells per vial using Cryo 1°C Freezing Container (NALGENE) following the manufacturer’s 
instructions. The freezing container was placed at -80°C, and vials were transferred into the 
vapor phase of liquid nitrogen after about 72 hours for long-term storage.
 For intracellular cytokine secretion testing, 1 to 2 vials per sample with varying cell numbers 
depending on experimental setup and availability were thawed. In case of several time points 
measured for a single patient, we attempted to include all samples in one experiment which 
was however not always possible.
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T cell stimulation and staining
Cryopreserved PBMCs and PBLs were thawed, washed, and suspended at concentrations between 
2 and 5·106 cells/mL in Iscove’s Modified Dulbecco’s Medium (IMDM) (Gibco) supplemented with 
10% human serum (Sigma Aldrich, H1513), antibiotic-antimycotic (Gibco), and Alexa700- or 
APC-labeled anti-CD107a (H4A3, BD Pharmingen, 5 µL). The serum lot was not pretested for 
performance. T cells were stimulated using CD28/49c coated beads (BD Bioscience), either alone 
or in combination with 1 µg/mL Staphylococcus enterotoxin B (Sigma Aldrich), PMA/Ionomycin (50 
ng/mL / 1 µg/mL or 10ng/mL / 0.5 µg/mL) or 10 µg/mL peptide gp100154–167, gp100280–288 and wild-
type tyrosinase369–376. Peptides were generated in our research facility according to GMP standards. 
Brefeldine A (Sigma Aldrich, 10 µg/mL) and Monensine (eBioscience, 1:1000 [2 µM]) were added 
and cells were incubated for at least 5,5 hours but not more than 6 hours at 37°C and 5% CO2.
 After incubation, T cells were washed 3x with PBS and dead cells were stained using LIVE/
DEAD Fixable Far Red Dead Cell Stain Kit (Life Technologies, 1:2000 in PBS, 100 µL) or Fixable 
Viability Dye eFluor® 780 (eBioscience, 1:2000 in PBS, 100 µL) on ice for 30 minutes. Cells 
were washed 2x with PBS and 1x with PBS supplemented with 1% bovine serum albumin 
and 0,05% NaN3 (PBA). T cells were stained for surface marker expression in 50 µL PBA 
supplemented with APC-Cy7- or PE-Cy7-labeled anti-CD4 (RPA-T4, BD Pharmingen, 1:200; 
SK3, eBioscience, 1:500) and PE-CF594- or BV510-conjugated anti-CD8 (RPA-T8, BD Horizon, 
1:200; 1:16) at 4°C for 10 minutes. In some cases (Table 1), cells were also stained with APC-
labeled tetrameric MHC complexes containing the gp100154-167, gp100280-288, or tyrosinase369-376 
peptide (Sanquin). Several samples treated only with co-stimulatory beads, were incubated 
with HIV77-85-HLA-A2.1-tetramers specific for the irrelevant HIV-peptide (SLYNTVATL) or CEA-
peptide (YLSGANLNL) to account for background staining.
 Subsequently, the cells were 2x washed using PBA and then PBS, and fixed using PBS 
supplemented with 4% paraformaldehyde (Merck) for 4 minutes on ice. After that, cells were 
permeabilized by washing 2x with 0.5% Saponin-supplemented PBA (Riedel-de Haën). The 
cells were stained for cytokines in 50 µL PBA supplemented with 0.5% Saponin and PerCP-
Cy5.5- or BV421-conjugated anti-IFNγ (B27, BD Pharmingen, 1:10; 1:10), PE-labeled anti-IL-2 
(MQ1-17H12, eBioscience, 1:100), FITC-labeled anti-CCL4 (24006, R&D systems, 1:5) and PE-
Cy7- or PerCP-Cy5.5-labled anti-TNFα (MAb11, eBioscience, 1:100; 1:10) at 4°C for 30 minutes. 
Cells were washed 2x using PBA supplemented with 0.5% Saponin and PBA. Finally, cells were 
resuspended in PBA, kept at 4°C and measured within 2 hours after staining.
Flow cytometry and Gating strategy
Fluorescence was acquired using a CyAn ADP Analyzer (Beckman Coulter), a FACSVerse 
or a FACSAria (both Becton Dickinson) and analyzed with FlowJo software (Tree Star). For 
SEB- and peptide-stimulated samples at least 10,000 and 25,000 viable CD8+ T cells were 
recorded. For each patient and time point 1 to 4 samples treated only with co-stimulatory 
beads were analyzed and at least 18,000 viable CD8+ T cells were recorded for each replicate 
sample. Compensation was calculated using single stained samples. Using forward and 
sideward scatter (FSC, SSC) we first gated on the lymphocyte population. Subsequently, single 
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cells were selected plotting FSC area against pulse width or SSC area against SSC width and 
subsequently FSC area against FSC height. Living, CD4- lymphocytes were selected by plotting 
APC-Cy7 against CD8 and gating on APC-Cy7- cells (Figure 2A). Finally, we selected CD8+ cells 
by plotting CD8 against tetramers. Since the tetramer signal vanished in samples with strong 
cytokine-secretion, tetramer-positivity was not taken into account (Supplementary Figure 1). 
Alternatively, live, CD8+CD4- T cells were selected by first gating on APC-Cy7- cells and later 
on CD4-, CD8+ cells. Cytokine-secretion was determined using single gates defined for the 
CD8+ lymphocyte population. To analyze the functional diversity of CD8+ T cells combination 
gates were created using the built-in Boolean gating algorithm of FlowJo. To account for 
unspecific activation, samples were background subtracted using the average values of 1 to 4 
corresponding replicate samples stimulated only with co-stimulatory beads. To account for the 
different magnitude of total vaccine- and SEB-specific CD8+ T cell responses, the frequencies 
of cytokine combinations were normalized and given as the percentage of total vaccine- or 
SEB-specific response. For this purpose the frequency of CD8+ T cells expressing a particular 
functional combination was divided by the total frequency of responding CD8+ T cells in that 
sample. Positive reactivity to an experimental antigen was defined as 0.2% of responding 
CD8+ T cells after background-subtraction corresponding to 90% of CD28/CD49d-stimulated 
samples being below this threshold. Responses were not considered positive if the antigen-
specific reactivity level was below this threshold. Raw data can be provided upon request.
Data Analysis and Statistics
Analysis and presentation of distributions was performed using SPICE version 5.3 (downloaded 
from http://exon.niaid.nih.gov) 39, and PRISM for windows version 5.03 (GraphPad). For statistical 
analysis, the Wilcoxon matched-pairs test (all PRISM) was used to compare matched groups 
and the Wilcoxon signed rank test was used when comparing groups and constant values.
General Lab Operation
These studies were conducted in a laboratory that operates under exploratory research 
principles. The study was performed using established laboratory protocols.
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SUPPLEMENTARY INFORMATION
Supplementary Figure 1 – Reduced tetramer staining on CD8+ T cells after stimulation with specific peptide. T cells 
were either stimulated with CD28/CD49d beads (negative control) alone or in combination with SEB or TAA-peptide. After 
stimulation, T cells were stained for the five functional markers as well as an antigen. A) Gating strategy to identify 
tetramer-positive CD8+ T cells. Tetramer staining is reduced when T cells are stimulated with SEB and vanishes in some 
cases completely when stimulated with the specific peptide. B) Functionality of tetramer-specific CD8+ T cells and total 
CD8+ T cells after stimulation with specific peptide. 
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Supplementary Figure 2 – Functionality of tumor-specific CD8+ T cells can develop independently from SEB-specific 
CD8+ T cells. Patients with satisfactory sample availability were followed during the course of their disease. Lines indicate 
the percentage of multifunctional T cells within these responses. Blue dotted lines indicate the last administration of 
DC vaccination therapy. Orange lines indicate the time point the disease progressed, red lines indicate the death of the 
patient. The functionality of T cell responses against vaccination antigens and SEB developed differently within the same 
patients.
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Supplementary Figure 3 – Functionality of CD8+ T cell 
responses against different tumor antigens varies 
within the same sample. Shown is the percentage 
of multifunctional T cells within the T cell responses 
against different tumor peptides. Only samples with 
simultaneous CD8+ T cell responses against two 
or more antigens are shown and lines connect the 
different CD8+ T cell responses within each sample.
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Supplementary Figure 4 – Tumor-specific CD8+ T cells show an intrinsic lack of IL-2 production. Shown is the cytokine-
secretion of CD8+ T cells either stimulated with CD28/CD49d beads (negative control) or with CD28/CD49d beads in 
combination with either SEB, PMA/Ionomycin (50 ng/mL / 1 µg/mL for patients II-E-08, III-A-04; 10ng/mL/0.5 µg/mL 
for patient IV-D-06) or TAA-peptide. After stimulation, T cells were stained for the five functional markers as well as 
an antigen. Although we observed increased PMA-induced cell death in all tested patient samples, we could identify 
sufficient populations of live CD8+ T cells suitable for subsequent analysis. A) Gating strategy to identify tetramer-positive 
CD8+ T cells. B) The frequency of T cells expressing any of the five functional markers is shown for total CD8+ T cells and 
for tetramer-positive CD8+ T cells. C) The relative contribution of each functional marker to the total CD8+ T cell response 
is indicated for different stimuli and different CD8+ T cell populations. D) The functionality of CD8+ T cells stimulated with 
either a specific peptide or PMA/Ionomycin is shown.
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CHAPTER 6
Monitoring of dynamic changes in 
Keyhole Limpet Hemocyanin (KLH)-specific B cells 
in KLH-vaccinated cancer patients
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ABSTRACT
Keyhole limpet hemocyanin (KLH) is used as an immunogenic neo-antigen for various clinical 
applications and during vaccine development. For advanced monitoring of KLH-based interventions, 
we developed a flow cytometry-based assay for the ex vivo detection, phenotyping and isolation of 
KLH-specific Bcells. As proof-of-principle, we analyzed 10 melanoma patients exposed to KLH 
during anti-cancer dendritic cell vaccination. Our assay demonstrated sensitive and specific 
detection of KLH-specific B-cells in peripheral blood and KLH-specific B-cell frequencies strongly 
correlated with anti-KLH serum antibody titers. Profiling of B-cell subsets over the vaccination 
course revealed that KLH-specific B-cells matured from naïve to class-switched memory B-cells, 
confirming the prototypic B-cell response to a neo-antigen. We conclude that flow-cytometric 
detection and in-depth phenotyping of KLH-specific B-cells is specific, sensitive, and scalable. Our 
findings provide novel opportunities to monitor KLH-specific immune responses and serve as a 
blueprint for the development of new flow-cytometric protocols.
INTRODUCTION
Keyhole limpet hemocyanin (KLH) is a high-molecular-weight glycoprotein of marine origin 
that induces both cell-mediated and humoral responses in animals and humans. Because 
of its potent immunogenicity, its low-grade toxicity and its availability as a clinical grade 
product, KLH is used extensively as a natural immunostimulant for basic research and clinical 
applications 1-3. As a neo-antigen, KLH is ideally suited to study T cell-dependent primary and 
secondary immune responses and a recent study highlights its ability to stimulate the innate 
immune system. KLH was first introduced into the clinic in 1967 to assess immunocompetence 
of individuals 4. KLH is currently mainly employed as standard carrier protein for the production 
of monoclonal antibodies to haptens such as peptides and oligosaccharides.1 Besides this, 
KLH has been studied as a local treatment for patients with bladder cancer, but proved to be 
inferior to mitomycin treatment 5,6. Finally, KLH has progressed into clinical trials as either a 
carrier protein, an adjuvant- or immunomonitoring tool in a variety of cancer vaccines 7,8 and 
immunotherapeutic strategies against chronic infections and autoimmune disease 9,10. Strong 
inter-individual differences are typically observed in the immunological and clinical responses 
of individuals exposed to KLH 8. In-depth information about the dynamics and phenotype of the 
KLH-specific immune response may help to optimize its clinical use and provide biomarkers 
for selecting patients that will benefit most from KLH-based interventions.
 We currently lack appropriate monitoring tools that allow a detailed study of the KLH-
specific B cell response. So far, B cell responses to KLH have mainly been evaluated by 
quantifying KLH-specific antibodies in serum 11-16. Direct longitudinal analysis of KLH-specific 
B cells in peripheral blood could provide novel information on the magnitude and phenotype of 
the KLH-specific B cell response. A number of recent studies employed fluorescently-labeled 
antigens to directly monitor vaccine-, virus- or allergen-induced antigen-specific B cells 17-20. 
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 In this study, we established a novel flow-cytometric assay to detect, phenotype and isolate 
KLH-specific B cells in peripheral blood in a sensitive and specific manner. As proof of concept, 
we applied our novel assay to monitor KLH-specific B cell responses in a cohort of cancer 
patients that were vaccinated with autologous monocyte-derived matured dendritic cells (DC) 
loaded with KLH and tumor antigen. We found that the serum concentration of KLH-specific 
antibodies was highly correlated to the number and phenotype of KLH-specific B cells. Flow-
cytometric isolation of the fluorescently labeled KLH-specific B cells allowed ex vivo production 
of KLH-specific antibodies and confirmed the high specificity of the assay. By analyzing B cell 
maturation, we were able to visualize the dynamics of KLH-specific B cells following primary 
as well as booster vaccination. 
 Our novel assay allows detailed cellular monitoring of the KLH-specific B cell response. 
Applying this technique to the field of KLH-based interventions could provide new insight into 
the origin, development and maintenance of the KLH-specific response and may facilitate the 
development of novel KLH-applications.
RESULTS
To gain an understanding of the B cell response to KLH, we set out to examine the frequency 
and phenotype of KLH-specific B cells across the DC vaccination course of 10 stage III melanoma 
patients (Supplementary Table 1). To cover multiple stages of humoral immunity, we selected three 
time points during treatment to measure the primary response as well as the recall response 
within each patient. To examine the primary response, baseline frequencies were determined 7-22 
days before vaccination and after injection number 2-4 of the 1st cycle (designated 1st cycle). Recall 
responses were determined after 3 injections of the 3rd vaccination cycle (designated 3rd cycle). 
Detection of KLH-specific B cells via flow cytometry is specific and sensitive 
First, we sought to verify the specificity and sensitivity of the flow cytometry-based detection 
assay here presented. For this purpose, PBMC samples were stained for common leukocyte 
markers, together with two preparations of fluorescently-labeled KLH using either FITC or 
ReadiLink 700/713. KLH-specific B-cells were defined as double positive cells (KLH++) within 
the CD19+CD3-CD14-CD16-CD56- population (Figure 1a). We employed fluorescence-activated 
cell sorting to isolate live CD19+KLH++ and CD19+KLH-- B cells from patients 5 and 9 during 
their 3rd cycle of vaccination. Following sorting, cells were stimulated in vitro for six days to 
differentiate them into antibody secreting cells (ASCs). ELISPOT was then used to determine 
the total number of Ig-secreting ASCs as well as the number of KLH-specific B cells. Although 
both CD19+KLH++ and CD19+KLH-- B cells secreted detectable amounts of total IgG antibodies 
after in vitro differentiation (Figure 1b), only the CD19+KLH++ cells produced KLH-specific 
antibodies. Enumeration of duplicate wells of CD19+KLH++ B cells in patient 9 showed that 
nearly all IgG-secreting B cells were specific for KLH (Figure 1c), suggesting a high specificity 
of the assay. Similar findings were observed for IgM and IgA (Figure 1d-f).
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Figure 1 –KLH++ B cells produce antibodies that are specific for KLH. A) KLH++ and KLH-- CD19+ B cells from patient 
5 and patient 9 were FACS sorted and differentiated into antibody secreting cells (ASCs). Plates were coated with either 
KLH or with anti-IgG, IgM or IgA, after which differentiated KLH++ and KLH-- B cells were added to the wells. Subsequently, 
ASCs secreting anti-KLH and anti-total IgG- (B), anti-KLH and anti-total IgM- (D) and anti-KLH and anti-total IgA-
antibodies (E) were detected using ELISPOT. For patient 9, ASCs were enumerated and compared between specific and 
unspecific conditions (C, F white bars indicate KLH-specific ASCs, black bars total ASCs). The number of sorted and ex 
vivo differentiated cells is indicated below ELISPOT photographs. B, D, E) For each condition two technical replicates with 
different numbers of input cells (indicated below image) are shown. F) Quantification of 1 well representative for 2 – 3 
technical replicates with different number of input cells.
 To determine the frequency of circulating KLH-specific B cells via ELISPOT, total CD19+ B 
cells were sorted, differentiated into ASCs and seeded on ELISPOT plates either coated with 
KLH protein or anti-IgG antibodies (Figure 2a). Although some variation was observed in the 
number of IgG-secreting cells per 1000 seeded cells (n=5 technical replicates, representative 
for 4 samples), the frequency of anti-KLH IgG antibody producing cells per 1000 cells 
remained constant (Figure 2b). To estimate the frequency of KLH-specific IgG+ B cells within 
the sorted B cell population, we determined the ratio of KLH IgG : total IgG ASCs (Figure 
2c). The corresponding ratio was lower yet similar to the frequency of KLH++ CD19+IgG+ cells, 
as determined by flow cytometry, suggesting that flow cytometry has a similar sensitivity to 
ELISPOT. 
147
6
MONITORING OF KLH-SPECIFIC B CELLS
Figure 2 – Frequencies of KLH-specific B 
cells as determined by flow-cytometric 
analysis are confirmed by ELISPOT 
analysis. CD19+ B cells from patients 
2, 9, 10 and 12 after the 3rd cycle of 
vaccination were sorted and differentiated 
as described. A) Anti-KLH IgG and total 
IgG antibody secreting cells were detected 
using ELISPOT and B) the relative ASC 
number of both fractions was determined. 
C) From this data the KLH-specific B cell 
frequency within the IgG+ subset was 
determined and compared to the frequency 
of KLH-specific B cells as determined by 
flow cytometric data at the time of sorting, 
i.e. before differentiation. Error bars 
show standard deviation of 2 – 4 replicate 
differentiation cultures.
Frequency of circulating KLH-specific B cells correlates with anti-KLH antibody 
serum titers
Next, we correlated the frequency of KLH++ cells as determined by flow cytometry with serum levels 
of anti-KLH antibody titers (Figure 3). Spearman’s rank-order correlation analysis revealed a strong, 
positive correlation between the frequency of CD19+KLH++ cells and  anti-KLH IgG serum titers (rS 
= 0.91, p = 2·10-10, n = 26). This correlation was further improved when comparing serum titers with 
the frequency of KLH++ cells within the CD19+IgG+ subpopulation but not the CD19+CD38+-IgG+CD27+ 
subpopulation, which has previously been associated with high levels of somatic hyper mutation 
and a high degree of proliferative potential 23. Similar correlations, though to a weaker extent, could 
be found for anti-KLH IgA serum titers and anti-KLH IgM serum titers (Supplementary Figure 1).
KLH-specific B cell dynamics and phenotype
Next, we assessed to what extent KLH exposure induced expansion of KLH-specific B cells in our 
patient cohort (Figure 4). The baseline frequency of KLH++CD19+ B cells was low and did not exceed 
0.005% of CD19+ B cells. After the 1st cycle, we detected a moderate ~10-fold increase in KLH++ B 
cells in a subset of 3 patients (Figure 4a,b). After the 3rd cycle, a massive >100-fold expansion was 
observed in all patients analyzed, reaching frequencies of KLH-specific B cells as high as 1.3% of 
the total B cell pool (CD19+) and 8.9% of the class switched memory B cells (CD19+IgG+).
 To further investigate the phenotype of the KLH-specific B cells, we compared changes in 
expression of cell maturation markers after 1 and 3 cycles of vaccination (Figure 5). B cell subsets 
were defined as described (Supplementary Figure 2, Supplementary M&M). After the 1st cycle, 
CD19+KLH++ were predominantly unswitched IgM+CD27+ cells. Conversely, after the 3rd cycle, the 
vast majority of CD19+KLH++ cells were class switched B cells and predominantly displayed a 
IgG+CD27+ phenotype, indicative for repeated antigen exposure and late memory differentiation. 
These maturation changes were specifically observed in the KLH-specific B cell fraction and not in 
the total CD19+ B cell population, which was dominated by IgM+CD27- naïve B cells throughout the 
entire treatment period, suggesting that these changes specifically occur in KLH-specific B cells.
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Figure 3 – KLH-specific B cell frequencies correlate with anti-KLH IgG antibody titers in serum. Serum titers of anti-
KLH IgG antibodies were determined using ELISA and plotted against the frequency of KLH++ cells in the indicated B cell 
subsets. Linear curves were fitted on the data and key regression values are given in each plot.
Figure 4 – KLH-specific B cells were induced in all vaccinated melanoma patients. KLH-specific B cells were measured 
before vaccination, after the first cycle and after the third cycle. Days indicate the time to 1st vaccination. A) Dot plots 
of KLH-specific B cells of one representative melanoma patient. B) Frequencies of the KLH-specific B cells within the 
indicated B cell subsets for 10 melanoma patients.
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Figure 5 – Maturation of KLH-specific B cells during repeated DC vaccination.  A) Proportion of different B cell subsets 
of the total B cells before vaccination (Median values of all patients). B) Proportion of KLH-specific B cell subset after the 
1st and 3rd cycle of vaccination. C) In-depth analysis of the development of different B cell subsets within KLH-specific and 
total B cell population after 1st and 3rd cycle of vaccination (n= 10). Whisker plots represent median (line), 25% and 75%ile 
(box) and the minimum and maximum values (whiskers). For gating strategy see Supplementary Figure 2.
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Figure 6 – Dynamics of the KLH-specific B cell response during the course repeated KLH vaccinations in patient 5. A) 
The frequency of KLH++ B cells and the serum titer of anti-KLH antibodies at different time points during the treatment of 
patient 5 are shown. B) The distribution of the KLH++ B cells over the different B cell subsets during the course of patient 
5’s treatment is shown.
 Finally, we analyzed the dynamics of KLH-specific B cell development during the complete 
course of DC vaccination in patient 5 (Figure 6). Increased frequencies of KLH++ B cells could 
already be detected after three injections of DCs, in accordance with an increase in anti-KLH 
Ig titers in serum (Figure 6a). However, the strongest increase in KLH++ B cells was observed 
after the first vaccination during the 2nd and 3rd cycle. This increase in KLH-specific B cells 
was accompanied by an increase in anti-KLH IgG antibody titers. Immunophenotyping of KLH-
specific B cells confirmed the dynamic changes observed in the serum titers, demonstrating 
a classical pattern of primary and secondary B cell response (Figure 6b). Initially, the KLH-
specific B cell response was dominated by a subset of IgM+ B cells. However, towards the end 
of the 1st cycle, initial class-switching events were observed with small but detectable increase 
in IgG+ and IgA+ cells. During the 2nd cycle, we observed a major expansion of IgG+CD27+ memory 
B cells, and this subset remained the dominant population of KLH-specific B cells up until 
after the end of the follow-up period of the study.
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DISCUSSION
KLH is an immunogenic agent with various clinical applications and in-depth knowledge on the 
dynamics of KLH-induced immune responses could aid the understanding of KLH treatment 
effects. 
 In this project, we developed a sensitive assay for the ex vivo detection of KLH-specific 
B cells on the basis of the B cell receptor specificity for its cognate antigen and without 
requirement for B cell pre-stimulation. Using fluorescently labeled KLH, we were able to 
detect KLH-specific B cells after vaccination of stage III melanoma patients with ex vivo KLH-
loaded dendritic cells and to phenotype those cells. To verify the specificity and sensitivity, we 
compared our immunoassay to the current gold standard for the detection of antigen-specific 
memory B cells, i.e. memory B cell ELISPOT. ELISPOT analysis of sorted KLH++ B cells revealed 
that the great majority of KLH-stained cells was indeed secreting KLH-specific antibodies, 
demonstrating the high specificity of the assay. To assess the sensitivity, we analyzed the KLH-
specific antibody production of total CD19+ B cells and observed similar frequencies for both 
flow cytometry and ELISPOT, suggesting a comparable sensitivity. It should be noted that the 
frequency of KLH-specific IgG+ B cells as measured by flow cytometry was at the lower end of 
the frequency range as compared to the numbers found by ELISPOT. A potential explanation 
is that ELISPOT analysis involves an in vitro pre-activation step that might introduce bias. 
The different B cell subsets may not respond to the pre-stimulation conditions in the same 
manner and thus may not expand at a similar rate as shown, for instance, by Scholzen et 
al. using a similar protocol 27. On the other hand, our dual staining approach may lead to an 
under-representation of the actual KLH-specific B cells. Finally, we compared the frequency 
of KLH-specific B cells with serum anti-KLH antibody titers measured by ELISA. We observed 
a strong, positive correlation between anti-KLH IgG antibodies and the overall frequency of 
KLH-specific CD19+IgG+ B cells and weak correlation between the frequency of KLH-specific 
B cells and anti-KLH IgA antibodies or anti-KLH IgM serum titers. Overall, these experiments 
suggest that the detection of KLH-specific B cells using fluorescently-labeled KLH is feasible, 
scalable, and in good agreement with established experimental techniques. The advantage of 
the here described flow cytometric analysis of antigen-specific B cells over ELISPOT analysis 
is the possibility to combine quantification with extensive phenotyping and purification of cell 
subsets.
 In this study, we found KLH-specific B cell frequencies of up to 1.32% of the total CD19+ 
B cell pool and of up to 8.93% in the CD19+IgG+ B cell pool after 3 cycles of DC vaccination. 
Even 3 months after the last vaccination, KLH-specific B cell frequencies remained as high 
as 0.1% for CD19+ B cells and 0.85% for IgG+CD19+ B cells (data not shown). To put this in 
perspective, we compared our results with other published studies on flow cytometry-based 
detection of antigen-specific B cells. In healthy volunteers undergoing Tetanus toxoid (TT) 
booster vaccination, for instance, numbers of TT-specific CD19+ B cells peaked at 0.012%; two 
orders of magnitude lower than the numbers of KLH-specific CD19+ B cells we observed 17. Of 
note, the time points after booster vaccination may differ between the cited study and ours as 
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exact details are only given for a subset of TT-vaccinated volunteers. Other studies examined 
naturally induced B cell responses, for instance in allergic patients under oral immunotherapy. 
Here, up to 0.3% peanut allergen Arah1– and Arah2-specific CD19+ B cells were detected 18. 
Kerkman et al. observed up to 0.06% of CD19+ B cells being specific for a mimic of citrullinated 
protein antigens 20. When examining the IgG-specific B cell response in viremic HIV patients, 
Kardava et al. discovered up to 0.3% of Tetanus- or influenza-specific CD19+IgG+ B cells 19. 
In the same study, the authors could detect up to 6% of CD19+IgG+ B cells being specific for 
the HIV antigen gp140. Our results thus confirm the high immunogenicity of KLH but also 
show that direct comparison of specific B cell numbers are difficult between studies due to 
differences in timing and activation state of the immune system. 
 The KLH-specific B cell maturation patterns we observed in this study closely follow 
prototypic primary and secondary immune responses against a neo-antigen. The primary 
response was dominated by KLH++IgM+ B cells, which switched to an IgG-dominated response 
after secondary and tertiary immunization, aligning closely with earlier studies on anti-KLH 
serum antibody levels 28,29. Moreover, early KLH-specific IgG+ B cells were predominantly CD27- 
, whereas late KLH-specific IgG+ B cells were CD27+. This is in line with the concept that IgG+CD27- 
B cells underwent one germinal center reaction and become CD27+ upon subsequent antigen 
exposure and additional germinal center reactions 23. We also detected relatively high levels 
of IgA+ KLH-specific B cells in early responses, which were not detected at later time points. 
Although it remains unclear whether this B cell subset contracts after subsequent antigen 
exposure or whether these cells home to other (mucosal) tissues, the observed increase in 
anti-KLH IgA antibody titers in patients after multiple vaccinations argues for the latter option. 
Our data collectively indicate that the employed DC vaccination is inducing an IgG-dominated 
humoral immune response possibly driven by the induction of Th1 cells typically observed 
during this treatment 30. The question remains as to how far the induction of KLH-specific B 
cells early after vaccination can be predictive for the clinical response to dendritic cell-based 
vaccination. Further research in extended cohorts is necessary to investigate this.
 Although it is generally assumed that the primary activation signal of B cells is direct contact 
of the B cell receptor with its cognate antigen, it should be noted that the patients in our study 
were never vaccinated directly with the soluble KLH antigen. Instead, patients were injected with 
autologous ex vivo differentiated monocyte-derived dendritic cells. Following differentiation, 
DCs were incubated with soluble KLH, after which cells were washed thoroughly. Although this 
procedure efficiently removes soluble KLH, we still observe robust humoral KLH-responses. 
The mechanism by which KLH is able to induce a B cell response in these patients needs thus 
further investigation.
 In summary, this study shows a novel, fast, and robust method to quantify and phenotype 
circulating KLH-specific B cells. The use of flow cytometry does not only allow more in-depth 
phenotyping of KLH-specific B cells, but also allows isolation, functional analysis, molecular 
profiling, tracking of clonal evolution and production of fully human antibodies. By further 
standardization, the flow cytometric assay presented here may allow for inter-institutional 
comparisons and immunomonitoring of KLH-specific B cell responses. This will help to 
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increase our understanding of the human B cell response to KLH and further facilitate the 
development of novel clinical KLH applications.
METHODS
Patients
Peripheral blood mononuclear cells (PBMCs) or peripheral blood lymphocytes (PBLs) were 
collected from stage III melanoma patients at different time points during the course of their 
disease (n=10). All patients underwent immunotherapy using autologous monocyte-derived 
matured dendritic cells loaded with KLH and tumor antigen in our department as described 
in the original study and indicated in Supplementary Table 1 21. Patients received DCs in three 
cycles every 6 – 9 months, with three fortnightly injections per cycle, except for the 1st cycle 
where four injections were given. Patients were World Health Organization performance status 
0 or 1 22. The original study (Clinical trial registration number NCT00243594, registration 
date: 21.10.2005) was in accordance with relevant guidelines and regulations and approved 
by the Medical Research Ethics Committee (CMO Regio Arnhem-Nijmegen). Patients signed 
informed consent.
KLH-labeling
KLH protein (Vacmune, Immucothel) was labeled with either FITC or Readilink 700/713 using 
the FITC Antibody Labeling Kit (Pierce, 53027) or the ReadiLink 700/713 Antibody Labeling Kit 
(BioRad, 135-1008), respectively, following the manufacturer’s instructions.
B cell staining
Cryopreserved PBMCs and PBLs were thawed and washed 2x in Iscove’s Modified Dulbecco’s 
Medium (IMDM) (Gibco) supplemented with 1% fetal bovine serum (FBS) (Greiner Bio-One) and 
25 µg/mL DNAse 1 (Roche). The serum lot was pretested for performance. In case of several 
time points measured for a single patient, all samples were processed in one experiment, with 
the exception of patient 5. Subsequently, cells were washed 2x with PBS and dead cells were 
identified by staining with Fixable Viability Dye eFluor® 780 (eBioscience, 1:2000 in PBS, 100 
µL) at 4°C for 30 minutes. Cells were washed once with PBS followed by one wash with PBS 
supplemented with 2% FBS (wash buffer). B cells (5 – 50·106) were stained with 10 µg/mL FITC- 
and 1 µg/mL ReadiLink 700/713-labeled KLH in 120 µL wash buffer for 30 minutes on ice. Cells 
were pulse vortexed every 5 minutes during incubation. Subsequently, cells were incubated for 
20 minutes in a total volume of 200 µL of fluorescently labeled antibodies in wash buffer. See 
Supplementary Methods for the labeled monoclonal antibodies used in this study. Cells were 
washed 1x, resuspended in wash buffer and kept at 4°C for a maximum of 2h before analysis 
by flow cytometry.
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Flow cytometry and gating strategy
Cells were acquired using a LSRII and – for fluorescence-activated cell sorting – a FACSAria 
(both Becton Dickinson) and analyzed with FlowJo software (Tree Star). Per sample, between 
867,000 and 16,600,000 events were acquired, yielding 38,720 - 632,000 viable CD19+ B cells. The 
lymphocyte population was gated followed by exclusion of doublets and dead cells. B cells were 
defined as CD19+CD3-CD14-CD16-CD56- and KLH-specific B cells identified by dual staining 
for FITC and ReadiLink 700/713 (Figure 1). During the 1st vaccination cycle, the frequencies of 
KLH-specific B cells were relatively low and calculations were based on up to 30 KLH-specific 
B cells. B cell subsets were characterized using a gating strategy adapted from Berkowska et 
al. (Supplementary Figure 2 and Supplementary Methods) 23.
B cell expansion and ELISPOT
Sorted B cells were quantified and checked for antibody production using ELISPOT. See 
Supplementary Methods for a detailed description of the B cell expansion protocol and ELISPOT 
procedure.
KLH-specific antibody production
The concentration of KLH-specific antibodies was determined by ELISA (www.KLHanalysis.
com) in patients’ sera before and at various time points after vaccination. Serum samples were 
obtained at a maximum of +/- 10  days before/after the corresponding PBMC samples. See 
Supplementary Methods for a detailed description of the ELISA procedure.
Data Analysis and Statistics
Analysis and presentation of distributions was performed using PRISM for windows version 5.03 
(GraphPad) and The R Project for Statistical Computing using the ggplot2 and xlsx packages 
24-26. For statistical analysis, Spearman’s Rank-Order correlation analysis was employed.
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SUPPLEMENTARY INFORMATION
SUPPLEMENTARY DATA
Supplementary Figure 1 – Correlation of KLH-specific B cell frequencies and anti-KLH IgA and IgM antibodies. Serum 
titers of anti-KLH IgM (A) and IgA (B) antibodies were assessed via ELISA and plotted against the frequency of KLH++ cells 
in the indicated B cell subsets. Linear curves were fitted on the data and key regression values are indicated in each plot.
Supplementary Figure 2– Gating scheme for identification of KLH-specific B cells and memory subsets. PBMCs of 
melanoma patients were thawed, washed and stained using a FITC- and ReadiLink700/713-labeled KLH as well as a 
cocktail of fluorescently-labeled antibodies. KLH-specific B cells and various B cell subsets were identified using the 
illustrated gating scheme.
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SUPPLEMENTARY METHODS
Patients
Peripheral blood mononuclear cells (PBMCs) or peripheral blood lymphocytes (PBLs) were 
collected from melanoma patients with loco regional resectable disease (stage III), scheduled 
for regional lymph node dissection at different time points during the course of their disease 
(n=10). All patients underwent immunotherapy using autologous monocyte-derived matured 
dendritic cells loaded with KLH and tumor antigen in our department as described in the original 
study and indicated in Supplementary Table 1 (1). Briefly, patients underwent leukapheresis 
and monocytes were isolated and within 5 - 8 days were differentiated into monocyte-derived 
DCs using IL-4 and GM-CSF. KLH is added to this culture at day 4 after isolation. Subsequently, 
DCs were activated using monocyte-conditioned medium enriched with prostaglandin E2 and 
TNFa, and loaded with cancer antigens by pulsing with gp100- or tyrosinase-derived peptides. 
Finally, the prepared DC vaccine was administered to patients intradermally or intranodally at 
12 - 17´106 dendritic cells per injection. All patients received DCs in three cycles, with three 
fortnightly injections per cycle, except for the 1st cycle where four injections were given. A 
subset of the included patients also received subcutaneous injections of interleukin-2 (IL-2) (at 
9 MIU) once daily for one week starting at three days after each DC vaccination (Supplementary 
Table 1). Patients were confirmed to be HLA*02:01 and World Health Organization performance 
status 0 or 1 and primary tumors or metastases were tested for tumor-associated antigen 
expression (gp100 and tyrosinase) (2). The original study (Clinical trial registration number 
NCT00243594, registration date: 21.10.2005) was approved by the Medical Research Ethics 
Committee (CMO Regio Arnhem-Nijmegen) and patients signed informed consent.
Sample acquisition
Whole blood was obtained by venipuncture using sodium heparin-containing vacutainer 
collection tubes or leukapheresis. PBMCs were isolated via gradient centrifugation using 
Lymphoprep (Axis-Shield) following the manufacturer’s instructions. PBLs were obtained by 
depleting monocytes via plastic adherence. Cells were frozen in X-VIVO 15 (Lonza) supplemented 
with 40% Albuman 200g/L (Sanquin) and 10% CryoSure-DMSO (WAK Chemie Medical GMBH) 
at 10–100´106 cells per vial using Cryo 1°C Freezing Container (NALGENE) following the 
manufacturer’s instructions and transferred into the vapor phase of liquid nitrogen after 72 
hours for long-term storage. 
Monoclonal antibodies
For staining of B cells the following monoclonal antibodies were employed: BV510-labeled 
anti-CD19 (SJ25C1, 1:50),  PE-CF594-labeled anti-CD20 (2H7, 1:400) and BV421-labeled anti-
CD38 (HIT2, 1:20, all BD Horizon), PE-Cy7-lableld anti-CD27 (1A4CD27, 1:12) and  PE-labeled 
anti-IgM (SA-DA4, 1:100, both Beckman Coulter), PE-labeled anti-IgG (G18-145, BD 1:25) and 
APC-labeled anti-IgG (G18-145, 1:25, both BD Pharmingen),  APC-labeled anti-IgA (IS11-
8E10, Miltenyi, 1:100), PerCP-Cy5.5-labeled anti-CD3 (SK7, 1:400, eBioscience) and anti-CD14 
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(M5E2, 1:100), anti-CD16 (3G8, 1:100) and anti-CD56 (HCD56, 1:80, all Biolegend). Cells were 
washed 1x, resuspended in wash buffer and kept at 4°C for a maximum of 2h before analysis 
by flow cytometry.
Flow cytometry and Gating strategy
B cell subsets were characterized using a gating strategy adapted from Berkowska et 
al. (Supplementary Figure 1) (3). Briefly, naïve B cells were defined as CD38+/-IgM+CD27-, 
unswitched memory B cells were defined as CD38+/-IgM+CD27+, and class-switched memory 
B cells as CD38+/-IgG+CD27-/+ or CD38+/-IgA+CD27-/+. Transitional cells were identified by the 
expression of CD38++CD27-CD20+ and plasma blasts were defined as CD38++CD27+CD20-.
B cell expansion and ELISPOT
Sorted B cells were counted and resuspended in 200 µL IMDM containing 10% FBS, 1% antibiotic-
antimycotic (Gibco) (complete IMDM) supplemented with 10 ng/mL IL-21 (eBioscience), 40 U/
mL IL-2 (PROLEUKIN® 18·106 IU, Novartis), 10 ng/mL IL-10 (Immunotools), 1 µg/mL ODN-
2006 CpG (Enzo Lifesciences) and 5·103 CD40 ligand-transfected mouse fibroblasts. Mouse 
fibroblasts were cultured in complete IMDM with 1 mg/mL G418 Geneticine (Gibco/Invitrogen). 
Before coculture with B cells, fibroblasts were detached by treatment with 0.5 mg/mL trypsin 
(Difco) for 5 minutes at 37°C, collected, washed in complete IMDM, irradiated at 60 Gy and 
added to the stimulation mix. B cells were cultured in 96-well round bottom plates (Costar, 
polystyrene) for 6 days and medium including stimulation mix was refreshed after 3 days.
 MultiScreen Filter PVDF Immobilon plates (Millipore) were pre-wetted with 30 µL/well of a 
35% ethanol solution. Immediately after pre-wetting, plates were washed 2x with PBS. Plates 
were coated over night at 4°C with 50 µL PBS containing 10 µg/mL of anti-IgG (MT91/145, 
Mabtech) or KLH protein, washed with PBS containing 0.05% Tween 20 (PBST) (Sigma-Aldrich) 
and 3x PBS. Subsequently, plates were blocked with 100 µL complete IMDM for 2h at 37°C. 
B cells were washed in complete IMDM and – in case of sorted total CD19+ cells – counted. 
Cells were resuspended in 200 µL complete IMDM at the desired concentration. 100 µL cell 
suspension was added to each well coated with KLH or anti-IgG and incubated for 6h at 
37°C. Subsequently, plates were washed 4x with PBS and 4x with PBST and incubated over 
night at 4°C with 50 µL/well PBST containing 0.5% FBS and alkaline phosphatase-labeled 
polyclonal goat anti-human IgG (Fcγ) antibodies (1:1000, Mabtech). Plates were washed with 
4x PBST, 4x PBS and 3x deionized water. All washing steps were performed with 200 µL/well. 
Subsequently, plates were incubated with 50 µL/well 0.45 µm-filtered alkaline phosphatase 
substrate BCIP/NBT (Mabtech) and kept in the dark until fully developed. Finally, plates were 
rinsed with deionized water and protected from light until scanned and analyzed using ELI.
Analyse software (A.EL.VIS).
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KLH-specific antibody production
Microtiter plates (96 wells) were coated overnight at 4°C with 120 µL/well KLH (25 µg/mL in 
PBS). Wells were subsequently incubated for 1 hour at room temperature with milk powder 
blocking buffer (1% in 0.01 M PBS), 200 µL/well. Plates were washed in an automatic washer 
(Tecan). Each wash step in this protocol includes two automated wash-cycles using 300 µL/
well 0.01 M PBS. Patient serum was diluted in two concentrations (50 and 150 times diluted) 
in 0.01 M PBS and 100 µL/well was added in duplicate for 1 hour at room temperature. After 
washing, patient KLH-specific antibodies were detected with monoclonal mouse anti-human 
IgG (Invitrogen, clone HP6017, diluted 1000 times in 1% PBA), IgM (Invitrogen, clone HP6083, 
diluted 1500 times in 1% PBA) antibodies, or polyclonal goat anti-human IgA (Cappel, diluted 
3000 times in 1% PBA) that are labeled with horseradish peroxidase. After 1 hour of incubation, 
plates were washed and 100 µL/well 3,3′ 5,5-tetramethyl-benzidine was added as a substrate 
(Dako). After five minutes the reaction was stopped with 100 µL/well 1M sulfuric acid and plates 
were measured in a microtiter plate reader (Tecan) at 450 nm. An isotype-specific calibration 
curve for the KLH response was included on each microtiter plate (4).
General Lab Operation
These studies were conducted in a laboratory that operates under exploratory research 
principles. The study was performed using established laboratory protocols. 
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ABSTRACT
Droplet-based microfluidic platforms are emerging as a pivotal tool for probing single cells 
and cellular heterogeneity in biology. A key technical challenge is the high loss of cells during 
compartmentalisation. Here, we present a novel approach for the efficient encapsulation 
of rare and primary cells in picoliter-sized droplets. Our results show, that our pipette tip-
based approach yields encapsulation rates that closely follow Poisson predictions, indicating 
very efficient loading of cells to the microfluidic chip. We apply this technique to an agarose 
hydrogel-based co-culture system and pair two different cell populations for the analysis of 
cellular interactions. Using flow cytomety, we were able to accurately identify the number 
and type of cells in each agarose bead. This facilitates the adoption of microfluidic assays in 
settings where cell numbers are limited and allows for low cost and high throughput analysis 
for decoding cell-cell interactions.
GRAPHICAL ABSTRACT
INTRODUCTION
Droplet-microfluidics is emerging as a versatile and invaluable tool for cell biologists, as 
it allows for the rapid analysis of large amounts of single cells and for the highly sensitive 
detection of secreted molecules.1-3 Recent developments, such as techniques for the ultrahigh-
throughput analysis of single cell genomes and transcriptomes4-7 and the absolute detection of 
small numbers of DNA, mRNA and proteins,8-10 greatly expand the experimental possibilities 
for biologists to study complex cellular processes. Furthermore, tools that allow the detection 
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and live isolation of single protein-secreting cells11-13 have the potential to aid immunologists 
in the discovery and purification of rare cells. Finally, droplet-microfluidic assays that enable 
the discovery of rare mutations,14 the high-throughput analysis of drug libraries,15, 16 or the 
sensitive detection of circulating tumor cells17 are emerging as important tools for cancer 
research and diagnostics.
 A fundamental question in biology is how cells interact with each other to generate complex 
functional responses.18 Cell-cell interactions play a crucial role in various processes including 
the regulation of immune responses, the growth and control of cancer, and the maintenance 
and differentiation of stem cells.19, 20 Current bulk co-culture strategies are  confounded by 
unpredictable variation as cells in a particular experiment will differ in e.g. the number of cells 
they interacted with, the total time they interact with other cells, and the ratio of cells during 
a particular interaction. Furthermore, heterogeneity in one cell population can influence the 
readout in another population. When using bulk assays, researchers are hence limited in the 
depth and precision of their analysis and complex intercellular interactions can be missed 
.19, 20 To reduce noise from the microenvironment and to get a systems-level understanding 
of cellular interactions on the “single interaction level”, techniques for the analysis of single 
cell pairs are warranted. Several groups developed microfluidic assays for the pairing and 
co-culture of different cell types using droplet microfluidic techniques or micro chamber 
approaches which yielded important insights into immune cell function and development.18-22
 To unlock the full potential of these advances, researchers increasingly study primary cells 
and clinical samples. In these experiments, the availability of cells is very limited, and becomes 
a critical factor to be taken into account when studying cellular behavior in microfluidic 
experiments. Rare immune cell subsets, for example, occur at less than 0.1% of all isolated 
cells and often less 100 circulating tumor cells can be detected in a patient sample. For optimal 
experimental conditions and most efficient use of limited specimens, it is important that cell 
encapsulation is robust and highly efficient. Typically, cell encapsulation is random and can 
be estimated by a Poisson distribution.23 Encapsulation rates with >90% of single cells are 
preferred ,to guarantee single cell experiments leading inevitably to a large number of empty 
droplets.24 However, in most experiments with cells, Poisson statistics are not observed: during 
droplet production, cells attach, sediment or clump in the syringe, tubing, and production 
device, leading to reduced encapsulation rates, cell aggregates, and eventually a significant 
loss of precious specimen.12 Researchers tried to circumvent these problems by increasing the 
density of the cell culture medium using Iodixanol, which, however, only prevents the problem 
of cell sedimentation in the syringe.12 Furthermore, density-matching reagents are usually 
only tested to be biocompatible in respect to cell viability and proliferation. Much less is known 
about their influence on cellular function and a study described negative effects on cytokine 
production.25 Furthermore, the small volumes employed when handling rare cell types pose 
several practical issues as loading cells on a microfluidic chip involves dealing with significant 
dead volume.  
 This study aims to provide an optimized and robust workflow for the efficient encapsulation 
and culture of rare, primary cells in picoliter droplets. We propose a novel method for loading 
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cells on a microfluidic chip omitting the use of density-matching reagents. This method 
allows for optimal encapsulation rates for more than 20 minutes over a range of input cell 
concentrations. We apply this method to an agarose hydrogel-based culture system for cell-
pairing and show that co-encapsulated cells can be readily identified and analysed by flow-
cytometry.
MATERIAL AND METHODS
Cell Culturing and Isolation
Jurkat T cells were cultured in RPMI (Thermo Fischer Scientific) and A549 cells were cultured 
in DMEM (Thermo Fischer Scientific); both supplemented with 10% fetal calf serum (FCS; 
Greiner Bio-One) and 1% Antibiotic-Antimycotic (Life Technologies). Plasmacytoid dendritic 
cells (pDCs) were obtained from buffy coats of healthy donors in accordance with institutional 
guidelines. In short, peripheral blood mononuclear cells were isolated from donor blood using 
Ficol gradient. PDCs were isolated by positive cell selection using magnet-activated cell sorting 
(CD304 MicroBead Kit, Miltneyi Biotec).
 Cell labelling
Jurkat T cells were washed twice with PBS, dissolved at 1,000,000 cells/mL in 1.25 µM CellTrace 
CFSE, 1 µM CellTrace Far Red (both Invitrogen) or 1.25 µM Cell Proliferation Dye eFluor670 
(eBioscience) and incubated for 10 minutes at 37°C. The staining reaction was stopped by adding 
ice cold FCS and cells were washed twice with PBS before use in downstream applications.
Microfluidic device production and layout
Soft lithographic techniques were used to fabricate microfluidic channels (Suppl. Methods).26 
Liquids were dispensed from plastic syringes (Becton Dickinson), which were connected to the 
microfluidic device by polytetrafluoroethylene tubing (Novodirect GmbH). The syringes were 
driven by computer-controlled syringe pumps (neMESYS, Cetoni GmbH).
Production and analysis of aqueous phase droplets
Cells were harvested, washed with either PBS or PBS supplemented with 2 mM EDTA and 
0.1% bovine serum albumin, and resuspended in RPMI or X-Vivo supplemented with 10% FCS 
or 2% human serum (HS). For selected experiments, 12 v/v% Iodixanol (OptiPrep®) and/or 
0.1 v/v% Pluronic® F-68 (Gibco) was added to the cell solution. For the stability of droplets, 3 
w/w% Pico-Surf® surfactant was used in fluorinated HFE-7500 oil.27 Flow rates were adjusted 
to 900 - 1200 µL/h for the oil phase and 200 µL/h for the aqueous fractions. In all experiments, 
constant volumetric flow rates were used. To assess the encapsulation rate, images of the 
emulsion were acquired using an Olympus CKX41 at 10X magnification. Encapsulation rate 
was manually assessed using Fiji.28, 29
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Production and analysis of agarose hydrogel droplets
Ultra-low gelling temperature agarose (Sigma-Aldrich) was dissolved in PBS at 3% - 4% w/v, 
heated to 75°C, and stirred for 20 minutes. The agarose solution was then mixed with the 
labelled Jurkat T cells yielding an agarose concentration of 1.5% to 2% w/v at varying cell 
concentrations. For droplet production, 2 w/w% Pico-Surf® surfactant was used in fluorinated 
HFE-7500 oil. Droplets were produced at flow rates of 2000 µL/h for the oil phase and 200 
µL/h for the cell fractions. During the production, the system was kept at a temperature of 
30°C. After production, the droplets were collected and incubated at 4°C for 60 minutes. After 
complete gelation beads were washed with perfluorooctanoic acid (PFO, Sigma-Aldrich) to 
remove the oil phase and beads were suspended in PBS. Beads were then analyzed using flow 
cytometry (BD FACSCalibur) and a fluorescent microscopy (Olympus). FlowJo X (FlowJo, LLC) 
was used for analysis of flow cytometry data and Fiji was used for analysis of microscopy data.
RESULTS AND DISCUSSION
Cell loading approaches
To optimize encapsulation conditions for rare cells in droplet-microfluidic assays, we first 
explored available cell loading techniques using a Jurkat T cell line. Jurkat T cells were 
encapsulated in picoliter droplets using a common approach where cells are loaded in a 
syringe that is attached to the microfluidic chip via a tubing (Fig. 1A). A computer-controlled 
syringe pump was used to pump the cell solution from the syringe through the tubing to 
the microfluidic chip for droplet production. We encapsulated Jurkat T cells in picoliter 
droplets (84.10 pL, 95% CI: 81.36/86.84 pL) at various cell concentrations and determined the 
encapsulation efficiency using microscopic images of the produced emulsion. At all tested 
concentrations, the experimentally determined encapsulation rate was lower than theoretically 
predicted indicating cell loss in the syringe or tubing (Fig. 1B). In previous studies, researchers 
used stirring bars in the syringes to avoid settling and attachment of cells. However, when 
dealing with rare cells, i.e. cells that are only available in low numbers, the total volume of the 
cell suspension is often limited making the use of bigger syringes and stirring bars practically 
impossible.
Fig 1: Encapsulation of Jurkat T cells 
at different concentrations using a 
syringe that is connected via tubing to 
the microfluidic chip. A) Experimental 
setup B) Encapsulation rate as 
determined by light microscopy. Dots: 
experimentally determined values; 
Closed lines: Poisson distribution.
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 To avoid cell loss in the syringe, we tested a modified approach for loading the cells on 
the microfluidic chip (Fig. 2A). We attached the syringe to a long tubing and loaded both with 
HFE7500 oil. We then mounted the tubing at half the length to an elevated tripod and loaded 
the cell suspension in the half that was attached to the microfluidic chip. This allowed the use 
of smaller volumes of cell suspension and avoided that cells could settle in the syringe. Cell 
settling in the tubing was furthermore limited as the tubing was unloaded almost vertically. 
We encapsulated Jurkat T cells at different concentrations and determined the encapsulation 
rate. Similar to the previous experiments, the encapsulation rates were lower than theoretically 
predicted and showed no benefit compared to the syringe-loading approach (Fig. 2B). Next, we 
isolated pDCs, a rare immune cell subset, from blood of healthy donors. Due to the low amount 
of input material, it is crucial that cell encapsulation is efficient and reliable. Similar to Jurkat T 
cells, the encapsulation rate was below the theoretically predicted values leading to reduction of 
the total number of encapsulated cells and loss of scarce specimen (Fig. 2C). Previous studies 
employed density matching agents to improve encapsulation rate and avoid settling of cells.12 
As previously described, also in our hands, the density-matching agent Iodixanol (OptiPrep®) 
affects the function of pDCs as evidenced by a hampered production of the cytokine interferon a, 
making the unbiased detection of in-droplet cytokine production impossible (data not shown).25 
To test whether the use of density-matched cell suspensions could, nevertheless, improve the 
encapsulation rate, we encapsulated Jurkat T cells with and without density-matched media 
(Suppl. Fig. 1, Suppl. Fig. 2A). Density-matching could not improve the encapsulation rate. These 
results show, that the established approaches to load cell solutions on microfluidic chips were 
not feasible for the use with rare primary cell subsets. Furthermore, our experiments suggest 
that cell settling is not causative for the reduction in encapsulation rate.
Loss-less cell encapsulation using a pipette tip-based loading approach
Rho et al. recently presented in a blog entry how pipette tips can be used to load small amounts 
of chemicals, e.g. blue food dye, to a microfluidic chip.30 Here, we adapted this technique for 
the use with scarce biological samples and developed a pipette tip-based method to efficiently 
deliver small volumes of cell solution to microfluidic chips with minimal loss of specimen (Fig. 
3A, B). For this purpose, a syringe and tubing were filled with biocompatible mineral oil, that 
has a lower density than cell culture medium. The end of the tubing was attached to a PDMS 
plug which was then squeezed tightly into the large end of a pipette tip (200 mL maximum 
volume [yellow] or 1000 mL maximum volume [blue]). Subsequently, the pipette tip was filled 
with mineral oil from the syringe. To load cell suspension, the pipette tip was lowered into 
a cell solution and the syringe pump was used to aspirate the solution into the tip. Finally, 
the pipette tip was connected tightly to the inlet of a microfluidic chip and droplet production 
was started. Using the tip-loading approach, we observed a strong increase in encapsulation 
efficiency and the encapsulation rates of Jurkat T cells matched the theoretical predictions 
(Fig. 3C, Suppl. Fig. 3A). Adherent cells, such as primary keratinocytes and the epithelial cell 
line A549, grow attached to each other and the bottom of a cell culture flask and are therefore 
more “sticky” than suspension cells such as Jurkat T cells. This poses problems during 
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cell encapsulation in droplets as adherent cells easily attach to each other and the tubing, 
resulting in aggregates and reduced encapsulation rates. Using our tip-loading technique, 
we could achieve loss-less encapsulation rates even for adherent cells (Fig. 3D, Suppl. Fig. 
2B). Finally, we assessed the efficacy of our system to encapsulate pDCs. Importantly, at cell 
concentrations optimal for single cell experiments (1.3×106/mL), the measured encapsulation 
rates were enhanced and corresponded to the theoretically predicted values (Fig. 3E). When 
using higher cell concentrations, the deviation from the predicted values increased, mainly 
caused by aggregates of pDCs emerging at high cell concentrations in the microfluidic chip 
inlet (data not shown). To avoid this problem and lower the cell concentration at the inlet, we 
loaded cells from two inlets to the chip. Tests with Jurkat T cells showed that, under optimal 
conditions, providing cells from one or two inlets yields similar encapsulation rates (Suppl. Fig. 
3B). When using high concentrations of pDCs, we could observe an improved encapsulation rate 
when loading cells via two inlets (Suppl. Fig. 3C) facilitating the use of high cell concentrations 
on microfluidic chips.
Fig 2: Encapsulation of various cell types at 
different concentrations using the tubing-
loading technique. A) Experimental setup 
tubing-loading: Tubing, filled with HFE7500, is 
connected to the syringe and the microfluidic 
chip. The tubing is attached to a tripod and 
the cell suspension is loaded in the half 
of the tubing that is later connected to the 
microfluidic chip. B, C) Encapsulation rate 
of Jurkat T cells and pDCs using the tubing-
loading technique. B,C) Dots: experimentally 
determined values; Closed lines: Poisson 
distribution.
 To ensure that the encapsulation rate is constant over time, we followed the encapsulation 
rate for more than 20 minutes (Fig. 3F). Longer time points are usually not required as the 
volume of the cell suspension is limited when using small cell numbers. Importantly, the 
observed encapsulation rates were stable over time indicating a robust encapsulation. 
 Together these data indicate that the tip-loading approach presented here offers optimized 
encapsulation rates following theoretically predicted distributions.
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Fig 3: Encapsulation of various cell types at 
different concentrations using the tip-loading 
techniques. A) Schematic overview tip-loading. 
B) Experimental setup. C-E) Encapsulation rate 
of Jurkat T cells, A549 cells, and pDCs using 
the tip-loading technique. F) Encapsulation 
rate of Jurkat T cells using the tip-loading 
technique at different time points during 
droplet production. C-E) Dots: experimentally 
determined values; Closed lines: Poisson 
distribution.
Cell-pairing of two Jurkat T cell populations
Next, we applied our optimized tip-loading approach to a flow-cytometry based assay for 
the analysis of cell-cell interactions (Figure 4A). We divided Jurkat T cells in two groups and 
labelled each group with a different dye. We then resuspended the labelled cells in ultra-low 
gelling temperature agarose, loaded them on a microfluidic chip, and generated agarose 
droplets. After production, we gelled the agarose droplets at 4°C for approximately 1h and
analysed the generated hydrogel beads by fluorescence microscopy. Using forward scatter and 
sideward scatter data, which indicate size and granularity of the detected particles, we could
distinguish two populations of agarose beads (Figure 4B). Only one of the bead populations 
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      Fig 4: Cell pairing in agarose hydrogel 
beads. A) Two populations of differently 
labelled Jurkat T cells (106 cells/mL) were 
encapsulated in agarose droplets using 
the tip-loading technique. Droplets were 
gelled to form agarose hydrogel beads and 
subsequent analysed via flow cytometry. 
B) During flow-cytometric analysis, Jurkat 
T cell-containing agarose-hydrogel beads 
were selected using their distinct forward 
(FSC) and sideward (SSC) scatter pattern. 
Within this population, different groups 
of beads were identified based on the 
fluorescent signal from the encapsulated 
Jurkat T cells.
contained fluorescent signals from the cell dyes suggesting that these were the agarose beads 
that contained cells (Figure 4B). Furthermore, when analysing the fluorescent signal derived 
from the two employed cell dyes, 9 distinct populations emerged (Figure 4B). We identified 
these populations, according to the strength of their fluorescent signal, as beads containing 0, 
1 or 2 cells of either fluorescent dye group, or any combination of those. The resulting pattern 
matched the theoretically predicted Poisson distribution indicating that the detected signals 
indeed resembled the cellular occupation of the agarose hydrogel beads.
 To verify this, we co-encapsulated Jurkat T cells, labelled with either CellTrace CFSE or 
CellTrace Far Red, at different concentrations and analysed the generated agarose hydrogel 
beads using flow cytometry and fluorescence microscopy (Figure 5A). Quantitative analysis 
of at least three replicate experiments showed that the flow cytometric identification of cell 
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populations is in good agreement with microscopic analysis and Poisson predictions (Figure 
5B, C). Furthermore, as a strong and established single cell analysis tool flow cytometry now 
allows for specific gating on agarose gelbeads with desired numbers of distinct cell types in 
droplets on a high throughput level enabling to decode cellular interactions.
 Together, these results show that agarose hydrogel beads in and flow-cytometric analysis 
form a reliable tool for analysis of cell-pairing.
Fig 5: Cell pairing in agarose hydrogel beads at different cell concentration. A) Fluorescence microscopic overlays 
of hydrogel beads and labelled Jurkat T cells. B) Comparison of cell numbers in agarose hydrogel beads as detected 
by fluorescence microscopy and flow cytometry. n * 4, bars indicate mean, whiskers indicate standard error of mean. 
C) Fraction of agarose hydrogel beads containing exactly one cell [1(g):1(r)] of each population depending on input cell 
concentration.
CONCLUSIONS
To conclude, we present here a novel and robust approach to efficiently load limited numbers 
of cells on microfluidic chips with minimal loss of cells and reagents. Importantly, with our 
approach, we are able to reliably match the Poisson-predicted encapsulation rates and we can 
omit the use of density-matching reagents that influence the function of encapsulated cells. 
This allows for optimal use of scarce specimen and enables more efficient pairing of cells for 
cell interaction studies. We applied our method to an agarose hydrogel-based system for co-
175
7
TIP-LOADING FOR EFFICIENT CELL PAIRING IN DROPLETS
encapsulation of different cell populations. Using conventional flow cytometry, we were able to 
determine the number of different cells in each droplet at high throughput and with minimal 
material effort. Paired with e.g a cytokine detection assay,11 the here presented technique will 
enable the in-depth analysis of cellular interactions. 
 Our results will contribute to an accelerated adoption of microfluidics in clinical and 
biological settings where tools have to adapt to the requirements of sensitive primary cells and 
not the other way around.
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SUPPLEMENTARY INFORMATION
SUPPLEMENTARY METHODS
Soft lithographic procedure
The microfluidic device (Suppl. Fig. 4) was molded against an SU-8 photo resist structure on a 
silicon wafer using a commercially available polydimethylsiloxane (PDMS) silicone elastomer 
(Sylgard 184, Dow Corning). The surface of the Sylgard 184 was OH-terminated by exposure 
to plasma (Diener Electronic GmbH), and was sealed with another plasma-treated glass cover 
slide to yield closed micro channels. Channels were treated with a 2% silane solution.
Culture and encapsulation of keratinocytes
Primary pooled keratinocytes from human foreskin were obtained from Lonza. Keratinocytes 
were expanded and cultured as previously described.1 The cells were collected by trypsinization, 
washed with PBS and taken up in PBS supplemented with 10% Protein-Free Blocking Buffer 
(Thermo Scientific) and 8 v/v% Iodixanol (OptiPrep®). For droplet stability, 2.5 w/w% Pico-
Surf® surfactant was used in fluorinated HFE-7500 oil. Flow rates were adjusted to 90 µL/h for 
the oil phase and 200 µL/h for the aqueous fractions. In all experiments, constant volumetric 
flow rates were used. 
SUPPLEMENTARY DATA
Supp Fig 1 - Encapsulation of Jurkat T cells (1.65×106/
mL) using the tubing-loading approach. In some 
conditions, the cell suspension was supplemented 
with density-matching solution (12% v/v Optiprep) and 
surfactant (0.1% v/v Pluronic). The encapsulation rate 
was determined by light microscopy. Dots: experimentally 
determined values; Closed lines: Poisson distribution.
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Supp Fig 2 -   Encapsulation of keratinocytes cells at different concentrations in 2 nL droplets using A) syringe- or B) 
tip-loading technique. The cell suspension was supplemented with density-matching solution (8% v/v Optiprep). A flow 
focusing junction with 70 um height was used to produce 2 nL droplets. Dots: experimentally determined values; Closed 
lines: Poisson distribution. 
Supp Fig 3 - Encapsulation of various cell types at different concentrations using the tip-loading technique. The 
encapsulation rate was determined by light microscopy. Dots: experimentally determined values; Closed lines: Poisson 
distribution. A) Jurkat T cells were encapsulated using yellow tips (max volume: 200 µL) or blue tips (max volume: 1000 
µL). B, C) Jurkat T cells (B) and pDCs (C) were encapsulated from one inlet or two inlets in parallel.
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Supp Fig 4 - Chip layout. A) The device consists of three inlets for continuous oil phase, cell culture media, and cell 
suspension. The generated droplets are collected at the outlet. The samples flow laminarly to the flow-focusing junction 
where they are encapsulated into droplets. At the inlets, filter structures hold large particles like protein or cell aggregates 
back. The diameter of the gaps in the filter structure are indicated by blue lines. The diameter of the channels at the 
production nozzle are indicated by red lines. The channel height on the entire chip was 25 µm if not stated differently. B) 
Microscopic image of the flow-focusing junction during encapsulation of Jurkat T cells. C) Microscopic image of produced 
emulsion containing Jurkat T cells. B, C) Red arrows indicate Jurkat T cells.
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CHAPTER 8
Probing cellular heterogeneity in cytokine-secreting 
immune cells using droplet-based microfluidics
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ABSTRACT
Here, we present a platform to detect cytokine (IL-2, IFN-γ, TNF-α) secretion of single, 
activated T-cells in droplets over time. We use a novel droplet-based microfluidic approach 
to encapsulate cells in monodisperse agarose droplets together with functionalized cytokine-
capture beads for subsequent binding and detection of secreted cytokines from single cells. 
This method allows high throughput detection of cellular heterogeneity and maps subsets 
within cell populations with specific functions.
INTRODUCTION
Our current understanding of cellular responses to external stimuli has generally been 
obtained using bulk assays on populations of cells. These studies hide the response of 
individual cells, which do not necessarily reflect the bulk behavior1, 2. This lack of insight of 
cellular behavior at the single cell level is particularly important in immunology. This notion 
was recently supported by Shalek et al. who demonstrated a widespread bimodality in the 
individual transcriptional response of murine dendritic cells to LPS stimulation3. Another study 
demonstrated that the activation of NF-κB is heterogeneous and is a digital process at the 
single-cell level4, in contrast to what was found in bulk assays5. Our immune system comprises 
of a wide variety of cells all with their specific function; among these are the CD8+ cytotoxic T 
cells, regarded as the ‘soldiers’ of our immune system that lead the charge against tumors and 
viruses. It has been shown that the killer T cell responses and disease control depend on the 
quality rather than on the quantity of these killer T cells6-8. The quality of killer T cells is defined 
by multiple functions: killing, proliferation, migration and cytokine release. This implies that 
out of the complete population of activated killer T cells, only designated subsets may actually 
be important for immunity. Understanding how these multifunctional responses are induced 
and exerted by individual cells will provide pivotal information on how vaccines based on killer T 
cells, can be tuned and improved to facilitate superior immune protection. Therefore, we need 
new technologies to identify, quantify and probe these cellular sub-populations. 
 In recent years, microfluidic tools have emerged that allow the study of hundreds to a few 
thousands of individual cells under precisely defined conditions9-11. These techniques have 
contributed greatly to our quantitative understanding of cellular heterogeneity and temporal 
variations in cellular behaviour. However, the study of individual cells in fluidic devices also 
presents a number of challenges, as i) many cells cannot be cultured easily on-chip12, ii) the 
total number of cells is limited by the size of the chip13, iii) cellular behaviour might be different 
from other culture platforms14, and iv) the technology often requires a large investment in 
infrastructure. For our studies in immunology, the most important drawback is the difficulty of 
studying the secretion of molecules from individual cells using these advanced fluidic tools15. 
Flow cytometry is the standard tool in immunology for high-throughput detection-, sorting- and 
collection- of cells, but it is less well suited to study secreted molecules. Cytokine secretion is 
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inferred from intracellular staining of fixed individual cells, which merely indicates intracellular 
pools of cytokines but not actual secretion. Furthermore, the technique does not allow data 
collection over time at the individual cell level, precluding dynamic monitoring of individual 
cell functions. Droplet microfluidics enables the manipulation of discrete fluidic packets in the 
form of picolitre droplets and addresses the need for lower costs, higher throughput and higher 
sensitivities at which the assays can be performed. The technique is well adapted to perform 
operations and manipulations in series, like encapsulation and screening16, 17. Water-in-oil 
droplets have been used to compartmentalize individual cells and to study antibody production 
by single cells dating back to the 1950s18, and recent advances in droplet microfluidics have 
greatly expanded their potential for single cell studies9, 16, 19-23. Indeed, these picolitre droplets 
can be considered ‘nanolabs’ that accommodate both single cells and all factors secreted by 
that cell9, 24-26. In this paper, we present a droplet-based microfluidic strategy to encapsulate 
cells and cytokine-capture beads in monodisperse agarose droplets for detecting cytokine 
secretion, phenotypical maturation and proliferation of single, activated Jurkat T cells in 
droplets over time.
RESULTS
Figure 1 shows the schematic overview of our high-throughput microfluidic single-cell 
cytokine detection method. Two streams of dispersed aqueous phases of 1.8 w/v% ultra-low 
temperature gelling agarose (type IX-A, Sigma Aldrich Chemie BV) are mixed prior to the droplet 
formation junction using a PDMS chip (see SI for device fabrication). One stream contains 
Jurkat T cells (4·106 per mL) in culture medium and stimulated with ionomycine (0.2 µg/ml) 
and phorbol myristate acetate (PMA; 1 µg/ml). The other stream delivers polystyrene capture 
beads (500 nm, 2.422·1010 microspheres per mL, Bang Labs) functionalized with biotinylated 
mAbs specific for IL-2, TNF-α, or IFN-γ. Automated syringe pumps (Cetoni GmbH) controlled 
the flow rates inside the microfluidic device which was maintained above room temperature 
for a steady and uniform droplet production at the flow-focusing region of the device27 (69 pL; 
coefficient of variance < 1) at a production frequency of 450 droplets/sec (Fig. 1 and Suppl. 
Fig. S1). Droplets are stabilized using a biocompatible Krytox®-based tri-block copolymer 
surfactant28. Thereafter, the emulsion was collected at the outlet of the microfluidic channel 
incubated for 18-24 hrs at 37°C in a humidified atmosphere (Fig. 1). During incubation, single 
activated Jurkat T cells secreted cytokines that bind to functionalized capture beads confined 
within the same droplet. After incubation, the emulsion was cooled to 4 °C. Cooling the ultra-
low gelling agarose containing droplets, induces the formation of strong spherical gel beads. 
The agarose beads were stable and remained solid at room temperature. They were separated 
from oil by breaking the emulsion and subsequently carefully washed (see SI for details). The 
mechanical strength of the agarose beads allows centrifugation during the washing process 
which helped flexible downstream processes. After solidification and removal of the oil phase, 
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the agarose beads were incubated with fluorescently labeled antibodies against IL-2, TNF-α, 
and IFN-γ, and the intensity of staining of the beads was measured by flow cytometry.
Figure 1. Schematic overview of the work flow of the droplet-based microfluidic method for single cell encapsulation 
and detection of secreted cytokines. Single Jurkat T cells are encapsulated in agarose-gel droplets together with 
functionalized capture beads. After collection and during incubation, Jurkat cells secrete cytokines that bind to the 
capture beads confined within the same droplet. The droplets are gelled and washed to break the emulsion. The agarose 
beads are incubated with fluorescently labeled detection antibodies that bind to the cytokines. Subsequently, the secretion 
of cytokines by single cells and the signal intensity in the beads is quantified by flow cytometry.
 In accordance with previous studies, the process of encapsulation of cells inside droplets is 
random and follows a Poisson distribution9, 11, 29. To obtain the highest single-cell encapsulation 
efficiency, we used 2·106 and 4·106 cells per ml at the droplet production junction. Analysis 
revealed an encapsulation efficiency of approximately 11 and 19%, respectively (Poisson: λ=0.11 
and 0.23) (Suppl. Fig. S2A). The fraction of double and triple cell encapsulation depends on 
starting cell concentration and was tolerable and generally less than 1.5% and 0.5%. Analysis 
of all steps from production to analysis revealed that there is no specific loss of cell-containing 
droplets (Suppl. Fig. S2B). Next, we assessed the ability of Jurkat T cells to proliferate in 
picolitre droplets up to 48 hours after production. After production, the large majority of cell 
containing droplets contained one cell (80%) and only less than 20% contained two or more 
cells (Fig. 2A). The percentage of one cell containing droplets significantly decreased after 24 
hours of incubation, and at the same time we observed a significant increase in the number of 
droplets containing two cells (Fig. 2A). These data demonstrate that picolitre droplets contain 
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sufficient nutrients and space for Jurkat T cells to divide in. This notion is underscored by the 
observation that various stages of cell division of Jurkat T cells are present in droplets (Fig. 
2B). Furthermore, Jurkat T cells kept proliferating 72 hours after production, as evidenced by 
the decrease in the number of one and two cell-containing droplets, and a significant increase 
in the number of droplets containing multiple (more than three) cells. Bio-compatibility was 
achieved using fluorinated oil (HFE 7500, 3M) together with a custom made biocompatible 
surfactant. Fluorinated oil is well suited for cell growth applications as it has good solubility 
for gases30, 31 which is necessary for the viability of the encapsulated cells. The surfactant is 
synthesized by coupling a fluorinated poly(ethylene glycol) to a PEG diamine yielding an ABA 
triblock copolymer, as further described in the supporting information28, 32. The proliferation of 
Jurkat T cells provides evidence for cell viability, biocompatibility of the surfactant and shows 
that the encapsulated cells are not negatively impacted by compartmentalization-specific 
factors such as the oil and surfactant.
Figure 2. A) Cell survival during incubation in droplets: A increase in fraction of droplets containing two cells or more can 
be measured after 24 hours. Up to 48 hours of incubation, further expansion of this fraction can be found. B) Different 
stages in the proliferation of Jurkat cells were observed with the droplets:  i) single cells, ii) late anaphase, iii) telophase, 
iv) two cells.  C)  Detection of T cell co-receptor CD3 molecules expressed on the cell membrane: a) Empty agarose beads 
are not fluorescent. b) Encapsulated Jurkat cells show auto fluorescence at low intensity (16.5%). c) Incubation of agarose 
beads with isotype antibodies leads to weak staining of the empty and occupied agarose beads (2.93%). d) treatment with 
anti-CD3 antibodies leads to specific staining of jurkat cells expressing TCR co-receptor CD3 (15.4%).
 The gelation of agarose droplets into agarose gelbeads upon cooling to 4oC allowed us 
to study both the phenotype as well as the secretome of individual cells. An agarose droplet 
gelation method was developed for single molecule emulsion PCR methods11, 33. In our case, 
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gelbeads were first incubated with fluorescently labeled anti-CD3 or control antibodies to 
detect molecules expressed on the plasma membrane of cells. Control samples demonstrated 
that cell-containing droplets can readily be detected based on their auto-fluorescence (Fig. 
2C). In accordance with bulk experiments, we found that all single encapsulated Jurkat T cells 
expressed the T cell co-receptor CD3 (Fig. 2C). 
 Next, cytokine secretion was studied in gelbeads containing stimulated Jurkat T cells and 
cytokine-capture beads and compared to gelbeads containing non-stimulated Jurkat T cells. 
Although Jurkat T cells are known to constitutively produce low levels of IL-2, the secretion 
can be largely enhanced upon stimulation34. Our data show that stimulated Jurkat T cells 
secreted significantly higher levels of IL-2 compared to unstimulated Jurkat T cells (Fig. 3A). 
The concurrent detection of multiple cytokines is essential for understanding the different 
functions exerted by activated T cells. Therefore, the number of tested cytokines was extended 
with TNFα and IFNγ, and multidimensional analysis allowed us to perform cross-correlation 
on these secreted cytokines. Analysis of more than 60,000 gelbeads, of which 7415 are cell-
containing, revealed the presence of 8 different cellular subpopulations, and that 85% of all 
individual Jurkat T cells secreted one or more cytokines upon overnight in-droplet stimulation 
with PMA and Ionomycine (Fig. 3B). In the present study, we analyzed up to 8000 cell-containing 
gelbeads, however, the throughput of our system can easily be scaled up, by adjusting the 
collection time during droplet production (now 3 minutes). Furthermore, we show that almost 
57% of stimulated Jurkat T cells secreted all 3 tested cytokines (Fig. 3C). These findings are 
in line with recent studies, exploiting nanowells, that demonstrated that the production and 
secretion of cytokines by T- cells occurred in a dynamic and heterogeneous manner35, 36. 
Furthermore, the observed cellular heterogeneity is in accordance with intracellular cytokine 
staining performed in bulk assays (data not shown) and might be attributed to various factors, 
e.g. differences in cell cycle stage, genetic perturbations or the transcriptional activity35. More 
in depth analysis revealed that cells that secreted large amounts of IL-2 (>10 percentile) also 
secreted significant higher levels of TNFα and IFNγ (Fig. 3D). Moreover, we also observed 
a population of cells that secreted intermediate levels of IL-2, but significant higher levels 
of TNFα. Generally, these populations and individual responses would have been masked by 
the average response of the total cell population. Therefore, we believe that these findings 
underscore the strength of our developed system to probe cellular heterogeneity and unravel 
undefined cell populations with specific functions. 
 Obviously, the secretion of soluble proteins is only one parameter that cells can exploit 
when activated. Cells can also communicate with other cells in a contact dependent manner, 
highlighting the importance of concurrently understanding the cells’ phenotype. Furthermore, 
cells often only secrete proteins when activated, therefore it is highly interesting to see whether 
certain populations of cells can also be defined based on the phenotype of a cell, which would 
allow to isolate cells with specific features prior to activation and use in cellular vaccines. The 
ability to detect the phenotype of immune cells together with the secretome of a cell provides 
a high-throughput systems immunology platform to unravel functional properties of individual 
cells which is virtually impossible by current conventional methods.
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Figure 3. A) Secretion of IL-2: Stimulated Jurkat cells in droplets showed more secretion than the unstimulated cells. 
B) Fluorescence flow cytometry analysis of agarose beads resulting from single cell secretion of cytokines IL-2, TNFα, 
IFNγ by stimulated cells compared to the unstimulated cells.  C) Heterogeneity present in the secretion of different tested 
cytokines in the Jurkat cell population considered. Only 15% of the cells did not secrete any of the tested cytokines. D) 
Cross-correlation plot revealing the heterogeneity within the cell population.
CONCLUSION
The results from this study validate droplet microfluidics as a strong and innovative tool to study 
and manipulate single cell behaviour. The impact of rapid expansion of high throughput single 
cell analysis is evident in its great potential for numerous applications, including drug discovery, 
diagnostics, cancer research, regenerative medicine, system and synthetic biology, and many 
others. A better understanding of the immune response, including the heterogeneity of individual 
subpopulations of cells and the activation of killer T cells by other immune cells is of particular 
interest because it may facilitate the development of new vaccines and immunotherapies37-39.
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SUPPORTING INFORMATION
SUPPORTING RESULTS
Figure S1. Monodispersity of the 
produced droplets containing single 
cells and capture beads. The focus is 
maintained at the single cells and so, 
the capture beads (500nm) may look a 
little out-of-focus
Figure S2. (A) Cell encapsulation 
efficiency for 2·106 and 4·106 cells per ml 
is approximately 11 and 19% (Poisson: 
λ=0.11 and 0.23), respectively. (B) 
Analysis of all steps from production up 
to detection reveals no specific loss of 
cell containing droplets.
(A)
(B)
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PROTOCOLS
Breaking the emulsion (removing oil)
  Centrifuge the gelled agarose beads collected in a Costar® Spin-X®  centrifuge tube filter 
(Corning) for 5 minutes at 1800RPM 
 Discard the supernatant in the tube 
 Add 0.5 mL of PBS 
 Resuspend rigorously by pipetting up and down 
 Centrifuge the resuspended agarose beads for 7 minutes at 2700RPM 
 Discard the supernatant in the tube 
 Repeat the above steps 3 times to get rid of all the oil from the agarose beads
Incubation of agarose beads with detection antibodies and washing
  Add 50 µL of PBA and appropriate amount of detection antibody solutions, resuspend 
rigorously and incubate at 4°C for 30 minutes 
 Centrifuge for 7 minutes at 2700 RPM and discard the supernatant 
 Add 0.5 mL of PBA, resuspend rigorously and incubate at 4°C for 20 min 
 Centrifuge for 7 minutes at 2700 RPM and discard the supernatant 
 Add 0.5 mL of PBA, resuspend rigorously and incubate at 4°C for 5 minutes 
 Centrifuge for 7 minutes at 2700 RPM and discard the supernatant
Sample for FACS analysis
 Add 200 µL of PBA 
 Resuspend rigorously 
 Pipette 200 µL from the filter tube into the FACS sample tube
Synthesis of tri-block surfactant
In a Schlenk tube, 15.47 g of Krytox® 157 FSH (DuPont™) are degassed under stirring. 15 mL 
of HFE 7100 (3M™ Novec™) are added forming a two-phase mixture with Krytox. The Schlenk 
flask is manually shaken until the solution can be stirred with a stir bar. Under nitrogen flow, 
approximately 2 mL of oxalyl chloride are added. After adding a drop of dimethyl formamide, 
gas vigorously evolves from the reaction mixture which is removed through the gas bubbler of 
the Schlenk line. The solution is stirred over night at RT. 
 The solvent is removed and the residue is taken up in 15 mL of dry HFE 7100. 1.12 g of 
Jeffamine® ED-900 dissolved in 1 mL dry pyridine is added drop-wise.1 The turbid reaction 
1  Jeffamine is stirred with small pieces of CaH2 overnight under static nitrogen pressure. The mixture 
is divided into aliquots and centrifugated to remove CaH2 and Ca(OH)2. Dried Jeffamine is stored in a 
glove box prior to use.
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mixture is stirred overnight. To determine the conversion of acyl chloride using IR, 100 µL of 
the reaction mixture are added to 1 mL of methanol giving the methyl ester of unreacted acyl 
chloride. Supernatant methanol is decanted and 1 mL of HFE 7100 is added to the sample. HFE 
7100 and residues of methanol are removed in a rotary evaporator. After adding another 250 µL 
of HFE 7100, the solution is filtered through a small glass fiber filter. Conversion is determined 
using the ratio of methyl ester and amide bands at 1788 cm-1 and 1720 cm-1, respectively. A 
calculated amount of Jeffamine is added and the reaction mixture is stirred overnight. The 
conversion is checked by IR again.
 The reaction mixture is poured into 50 mL methanol. After vigorous shaking, methanol is 
decanted and the residue is washed with another 30 mL of methanol. The residue is dissolved 
in 10 mL of HFE 7100. These steps are repeated with acetone, THF and methanol. The residue 
is dried at 2 mbar at 35 °C overnight using a rotary evaporator. The residue is dissolved in 
15 mL HFE 7100 and filtered through a syringe filter (0.45 µm, cellulose). Again, the solvent 
is removed at 2 mbar overnight and finally dried in vacuum yielding a viscous clear oil with 
yellow-brown color.
Microfluidic chip fabrication
Photolithographic fabrication was employed to fabricate microchannels. SU-8 negative 
photoresist (Micro Resist Technology GmbH, Germany)  was used for fabrication purpose. The 
device fabrication started with creating a design in an AutoCAD program. A high resolution 
commercial image setter then printed this design on a transparency (JD Photo tools, UK). 
This transparency served as the photomask in contact photolithography to produce a negative 
relief in photoresist on a silicon wafer substrate. SU8-2025 photoresist is spin-coated on a 
round silicon wafer with 50 mm diameter (Simat silicon materials, Germany).  Spin coating 
parameters were optimized to achieve the desired film thickness. Subsequently, the sample 
was soft-baked for 1 min at 65°C, 3 mins at 95°C and 1 min at 65°C in order to evaporate the 
solvent and densify the film. Then, the samples were exposed to UV light (λ = 365 nm) in the 
mask aligner (Karl Suss MJB 3 UV 300/400) for 21 s through the photomask. After exposure, the 
sample was post-baked for a time which depended on the thickness of the photoresist (1 min at 
65°C, 2 min at 95°C and 1 min at 65°C). The samples were rinsed with developer solution (mr-
Dev600, Micro Resist Technology GmbH, Germany) to remove the non-crosslinked regions. The 
resulting height of the channels were 25 µm. Thus, depending on the design used in the mask, 
fabrication of SU-8 masters for droplet production was accomplished on a silicon wafer (Fig. SI 
3). Following the below mentioned protocol (Table SI 1) resulted in the production of the PDMS 
microfluidic chips.
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Table SI 1. PDMS fabrication steps
PDMS layer with channels -  Pour 10:1 ration PDMS on a SU-8 master with channels  
(~ 5mm thickness)
-  Bake at 65 °C in oven for at least 3 hours
- Peel off the PDMS 
- Punch holes with 1.0 mm diameter biopsy punch
Plasma bonding for closed channels -  Treat the PDMS slab and glass cover slip with plasma 
cleaner (15 sec, 85% power)
-  Bond PDMS slab with glass coverslip by pressing gently 
-  Bake at 100 °C for 20 minutes
Figure SI 3. Schematic overview of the microfluidic chip fabrication by photolithography. 
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Cell culture and stimulation
Jurkat cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM; Life Technologies, 
Grand Island, NY, USA) supplemented with 5% fetal calf serum (FCS; Greiner Bio-One, Alphen 
a/d Rijn, Netherlands) and 1% Antibiotic-Antimycotic (Life Technologies). In some experiments 
these steps were followed by a CFSE (Life Technologies) staining. For this purpose, the cells 
were re-suspended in 1 mL of phosphate buffered saline (PBS) with 0.001 µmol/mL CFSE 
staining solution followed by seven minutes of incubation at 37°C. Subsequently, 5 mL of 
FCS were added to stop the reaction. Thereafter the cells were washed and re-suspended 
in PBS or IMDM at a concentration of 1 to 4·106 cells per mL. To study cytokine secretion, 
Jurkat cells (4·106/mL) were stimulated and incubated for five to six hours at 37°C and 5% CO2 
with ionomycine (1 µg/mL) (Sigma) and 12-O-tetradecanoylphorbol-13-acetate (PMA; 0.1 µg/
mL) (Sigma) to mimic the intracellular signaling events following an activation of the T cell 
receptor (TCR). This TCR-independent stimulation was used to probe and study a broad range 
of responses.
Preparation of microspheres
Microspheres were washed three times with PBS containing 5·10-5 % v/v Tween 20. Spin speed 
was set at 14.000 rcf and the centrifugation time was 5 minutes. Subsequently, the microspheres 
were incubated for 30 minutes at room temperature in PBS containing biotinylated mAbs 
specific for IL-2  (BD Pharmingen, San Jose, CA, USA) TNF-α or IFN-γ (both Biolegend, San 
Diego, CA, USA), while being gently shaken. For the coupling 30 mg of IgG where used to 
saturate 1 g of microspheres. After three washing steps, the microspheres were resuspended 
at a concentration of 2.422·1010 microspheres per mL.
Cell surface/Cytokine staining assay in droplets
The solidified drops were transferred to a Costar Spin-X cellulose acetate spin column (pore 
size 0.22 µm; Coring Inc., Corning, USA). Subsequently, the oil was removed and droplets were 
washed three times. Afterwards, surface markers and secreted cytokines inside the droplets 
were stained using the following antibodies: anti-CD3-PE/FITC, anti-CD69-PerCP (both BD 
Pharmingen), anti-IL-2-Alexa Fluor® 488, anti-TNF-α-PE  and anti-IFN-γ-Alexa Fluor 647® 
(all three Biolegend). Finally, the droplets were washed and analyzed by flow cytometry using 
FACScalibur (BD Bioscience). 
Bright field microscopy
To acquire images of the cells at various stages of the assay, 10 µL of droplet solution in oil was 
given on a microscope slide. Subsequently, bright field images were taken using an Olympus 
CKX41 at different magnification. 
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CHAPTER 9
A membrane-anchored aptamer sensor for probing of 
IFN̈́ secretion by single cells
200
PART II – NOVEL MICROFLUIDIC TECHNIQUES FOR SINGLE CELL ANALYSIS
ABSTRACT
Insight into the behavior of individual immune cells, in particular cytokine secretion, will 
contribute to a more fundamental understanding of the immune system. In this work, we have 
developed a cell membrane-anchored sensor for detection of cytokines secreted by single 
cells using a combination of aptamer-based sensors and droplet microfluidics.
INTRODUCTION
Cellular heterogeneity is considered a hallmark of biological systems and has significant impact 
on various cellular processes especially in the immune system.1, 2 Key immunological functions 
such as the activation of NF-κB3 or the induction of anti-viral immunity4 emerge as heterogeneous 
processes and can display digital behaviour. Insight into immune cell behaviour, and in particular 
cytokine secretion, at the single-cell level is important to define cell-to-cell variation and to get a 
better understanding of how individual immune cells can contribute to and control global immune 
responses.5 So far, most experimental approaches, e.g. Enzyme-Linked ImmunoSorbent Assay 
(ELISA), only yield the global outcome of the bulk population, potentially blending and masking the 
unique contributions of individual cells.6, 7 This problem is particularly pronounced in immunology 
where the output of immune responses are often combined behaviours of highly heterogeneous 
ensembles of cells.  Although antibody-based flow cytometry assays are able to perform single cell 
cytokine readouts, they are designed as end-point assays and cannot be used to monitor cytokine 
production with high spatiotemporal resolution.
 Microfluidics enable the generation of picolitre water-in-oil droplets which serve as a versatile 
platform for the development of low-cost and high-throughput single-cell analysis tools.8-10 While 
microfluidic systems have been successfully used to compartmentalize individual cells dating back 
to the 1950s, the lack of easy-to-handle detection techniques with on-line implementation, high 
sensitivity, high selectivity and “signal-on” reporting mechanism have hampered the development 
of droplet-based single cell research.11 These challenges may be addressed by exploiting aptamers 
as biosensors. Aptamers are artificial nucleic acids generated through an in vitro selection method 
based on their specific binding with target molecules.12, 13 In addition to high binding affinity and 
high specificity, aptamers have the intrinsic advantages of flexible design, simple synthesis and 
convenient modification, making them promising molecular tools for the development of novel 
biological assays.14, 15 Meanwhile, cytokine secretion by immune cells is a transient biological 
process with rapid fluctuation.16  Cell membrane-anchored aptamer sensors, which directly 
measure cytokines produced by a cell, have a high potential for accurate real-time monitoring of 
cellular function.17, 18
 In this work, we developed a cell membrane-anchored fluorescent aptamer sensor and 
combined it with a droplet-microfluidic platform to detect cytokine secretion at the single-cell level 
(Scheme 1). As a proof of concept, the type III Interferon (IFNγ),19 a cytokine that is critical for both 
innate and adaptive immunity against a broad range of threats, was used as the target cytokine. 
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An IFNγ-specific aptamer20 was used as the recognition unit. The 3’ end of the IFNγ aptamer was 
extended with a short DNA sequence (9 mer, termed as cDNA1) which was complementary to the 
5’-end section of the aptamer. This extended aptamer could self-hybridize into a hairpin structure. 
For fluorescent signalling, its two ends were separately labelled with a ROX fluorophore and a TAO 
quencher. At the initiation stage, ROX and TAO were kept in close proximity due to the formation of the 
hairpin structure, resulting in quenched fluorescence. Upon binding with IFNγ, the aptamer probe 
(AP) will switch into a specific tertiary structure, separating the fluorophore from the quencher, 
thus leading to restoration of fluorescence. To engineer a cell-surface aptamer sensor, the 5’-end 
of AP was linked to a cholesterol tail. Based on hydrophobic interaction between the cholesterol tail 
and the cellular phospholipid layer, the AP can be efficiently anchored onto the membrane.21 This 
cell membrane-anchored AP can directly probe the extracellular microenvironment, thus enabling 
detection of cytokine secretion by immune cells. Finally, single aptamer-decorated T cells were 
encapsulated in droplets (65 pL) and stimulated, which allowed us to probe the cytokine production 
of single cells with high throughput.  
Scheme 1. Schematic Illustration of a T cell-surface aptamer sensor for measuring cytokine secretion at the single-cell 
level. The cholesterol-linked aptamer probe (CLAP) can efficiently anchor onto the cell surface based on the hydrophobic 
interaction between the cholesterol tail and the cellular phospholipid layer. On binding of the secreted target cytokine, 
the fluorescence of the aptamer probe will be turned on. By using the microfluidic chip system, the aptamer-decorated T 
cells could be individually encapsulated into droplets, thus enabling the detection of the cytokine secretion at the single-
cell level.
RESULTS AND DISCUSSION
The specific response of the cholesterol-linked aptamer probe (CLAP) to IFNγ was first evaluated 
in buffer solution by fluorescence spectroscopy. As shown in Figure 1A, the ROX fluorescence 
intensity (at 605 nm) enhanced gradually when increasing the IFNγ concentration from 17.2 
nM to 550.0 nM. The detection limit was approximately 10.0 nM (equal to 14.5 ng/mL), which 
correlated well with previously reported results20, indicating that linkage of a cholesterol tail to 
the end of the aptamer sequence is not sterically hindering and as such has no negative impact 
on the sensing performance of the AP. Since the extracellular microenvironment of activated 
immune cells usually contains various cytokines, it was necessary to test the specificity of 
this CLAP. For all tested non-target cytokines, including a type I IFN (IFNα), we observed only 
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very weak fluorescence signals which hardly exceeded background levels (Figure 1B), verifying 
excellent detection selectivity of this aptamer probe.
Figure 1. Fluorescence spectra of the aptamer probe (200 nM) with addition of IFNγ at different concentrations; Inset: 
plot of peak fluorescence intensity at 605 nm versus the IFNγ concentration. (B) Selectivity of the aptamer probe. The 
concentrations of IFNγ and other competing cytokines were all 400 nM. The fluorescent signal in response to IFNγ was 
defined as 100%, while that in response to other cytokines were calculated accordingly. Error bars represent the standard 
deviation of three independent experiments.
 Next, we evaluated the membrane anchor efficiency of the CLAP. Primary T cells isolated 
from human peripheral blood mononuclear cells (PBMCs) were used as a model cell type. In 
order to detect a fluorescent signal that indicates successful membrane anchoring of CLAP, a 
fully complementary DNA (termed as cDNA2) of the AP was added to separate the fluorophore 
and quencher through formation of a CLAP/cDNA hybrid. To optimize the membrane anchor 
process, T cells were incubated with the CLAP/cDNA hybrid at different concentrations at 
room temperature (RT) for 10 min, washed and subsequently analysed with flow cytometry. As 
shown in Figure 2A, a significant dose-dependent fluorescence increment was observed, and 
the fluorescence enhancement gradually plateaued after the probe concentration exceeded 0.5 
mM. Next, we studied the incubation time of cells with the CLAP/cDNA hybrid. The fluorescent 
signal reached saturation after 2.5 min, indicating an extremely efficient cell membrane 
anchor efficiency of CLAP (Figure 2B). To guarantee consistent cell surface modification, 
a CLAP concentration of 1 mM and incubation time of 10 min was used in all subsequent 
experiments. The surface density of the probe was measured with fluorescence spectrometry 
(data not shown), and a density of ~0.62×106 probes per cell was obtained corresponding to a 
cell surface coverage of 5.1% (The surface coverage was calculated by assuming a cell diameter 
of 7 µm and a DNA probe diameter of 2 nm). The cellular location of CLAP was visualized with 
confocal microscopy. Figure 2C shows a significant and uniform fluorescent signal on the cell 
membrane, providing additional proof for successful fabrication and surface integration of the 
cell membrane-anchored aptamer probe.
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Figure 2. (A) Flow cytometry assay of T cells 
incubated with the CLAP/cDNA hybrid of 
different concentrations at RT for 10 min. (B) 
Flow cytometry assay of T cells after incubation 
with the CLAP/cDNA hybrid (1 µM) at RT for 
different time spans. (C) Confocal microscope 
images of T cells after incubation with the CLAP/
cDNA hybrid (1 µM) at RT for 10 min. Scale bar 
represents 10 µm.
 Having successfully engineered a membrane-anchored AP, we proceeded to evaluate 
its ability to detect IFNγ in the extracellular microenvironment by confocal microscopy. For 
that purpose, non-activated T cells were decorated with CLAP and resuspended in culture 
medium. After addition of soluble recombinant IFNγ (600 nM), the membrane of T cells lighted 
up instantly, whereas little fluorescence was detected in the absence of IFNγ (Figure 3A). 
To further confirm IFNγ-dependent fluorescence as measured by confocal microscopy, we 
exploited flow cytometry which allows high-throughput analysis of a large number of cells. A 
clear peak shift in fluorescence intensity was observed in the presence of IFNγ, confirming that 
CLAP is a powerful and reliable molecular tool for online detection of IFNγ (Figure 3B).
 To challenge whether this cell membrane-anchored AP can be used to monitor IFNγ 
secretion, T cells were activated by phorbol myristate acetate (PMA, 0.05 mg/mL) and 
ionomycine (1 mg/mL) in order to stimulate cytokine secretion,22 The AP was anchored onto the 
T cell membrane, and fluorescence intensity was measured using flow cytometry at different 
time points after stimulation. Strikingly, the fluorescence signal enhanced gradually upon 
immune stimulation (Figure 3C). In contrast, negligible fluorescent changes were observed 
in unstimulated (control) T cell samples. As confirmed by ELISA, T cells started to secrete 
IFNγ two hours after stimulation and the secretion gradually increased when extending the 
stimulation time (Figure S1). The results obtained by the current cell membrane-anchored 
aptamer probe was comparable with those obtained by the commercial ELISA kit, indicating 
reliable analysis and performance of this aptamer-based sensing system (Figure 3D). To 
control for spontaneous activation of the CLAP, we used, an immortalized mouse dendritic 
cell, JAWS II, which was unable to secret human IFNγ (as demonstrated by ELISA, data not 
shown). As expected, no fluorescence change of the aptamer-decorated JAWS II cells was 
observed after stimulation (Figure S2). Together, these results demonstrate that the current 
cell membrane-anchored AP is able to specifically detect IFNγ secretion by activated T cells.
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Figure 3. Potential of a T cell membrane-
anchored biosensor for IFNγ detection. 
(A) Confocal microscope images of T cells 
modified with the aptamer probe and then 
treated with 600 nM IFNγ (i) or as a control, 
buffer only (ii). Scale bar represents 10 µm. 
(B) Flow cytometry assay of T cells modified 
with the aptamer probe after addition of 600 
nM IFNγ, or buffer only as a control. (C) Flow 
cytometry assay of aptamer decorated-T 
cells with (left) or without (right) stimulation 
of PMA/ionomycine for different time 
periods. (D) Corresponding kinetic flow 
cytometry assay of T cells stimulated with 
PMA/Ionomycine at different time intervals. 
Error bars represent the standard deviation 
of three independent experiments.
 To test whether the developed AP would be suitable as a tool for the real-time monitoring 
of cytokine production by individually activated immune cells in droplets, we set up a single cell 
analysis platform based on droplet microfluidics. For this purpose, a microfluidic PDMS chip 
system composed of two aqueous-phase streams and one organic-phase stream was used. The 
two aqueous-phase streams separately delivered aptamer probe-anchored cells and immune 
stimuli, and were mixed prior to the droplet formation junction (Scheme 1). The organic-phase 
stream was connected directly to the droplet generator to form discrete water-in-oil droplets (Figure 
S3). To obtain the highest single-cell encapsulation efficiency, the starting cell concentration was 
optimized and strictly fixed at 2.6×106 cells/mL.9 Under these conditions, approximately 15% of the 
droplets were loaded with only one cell, and the fraction loaded with more than one cell was less 
than 2%. Our previous work has demonstrated that these picolitre droplets provide a biocompatible 
environment and sufficient nutrients for cells to grow for more than 48 h.9 The cell-containing 
droplets were collected, placed on a glass, slide and imaged with fluorescence microscope. As 
shown in Figure 4A, uniform and mono-disperse water-in-oil droplets were obtained; some of 
them encapsulated single cell (as indicated by the yellow arrow). With high-resolution confocal 
microscope (inset of Figure 4A), we could show that the aptamer derived fluorescent signal was 
localized on the cell membrane, indicating the successful fabrication of a cell-surface sensor-
based single cell analysis platform. To detect the cytokine secretion of individual cells, the collected 
droplets were incubated at 37 oC with 5% C02 for 6 hours and then imaged with fluorescence 
microscopy. As shown in Figure 4B, a stronger fluorescent signal was observed from activated T 
cells, in comparison to that from unstimulated T cells. As measured with the ImageJ software, the 
background-subtracted fluorescence intensity from stimulated T cells was significantly higher than 
that from the unstimulated T cells (Figure 4C). To further confirm these results, the encapsulated 
cells were collected by breaking the emulsion using perfluoroctanol (PFO) and then analysed with 
flow cytometry. In line with the microscopy results, a clear fluorescent peak shift was observed 
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from the single stimulated T cells. Taken together, all these results demonstrate that the AP-based 
droplet-microfluidic assay, presented here, can be used to detect cytokine secretion at the single-
cell level.
CONCLUSION
In summary, by exploiting an aptamer as detection unit, we developed a cell membrane-
anchored sensor for detecting cytokine secretion by human immune cells in the extracellular 
microenvironment. Moreover, in combination with a droplet-based microfluidic system, we 
have successfully encapsulated single AP-decorated T cells into picoliter droplets. Taking 
advantage of simple operation, high throughput, high spatiotemporal resolution and a “signal 
on” mechanism, this droplet-based aptamer sensing platform was able to detect cytokine 
secretion at the single-cell level, positioning it as a powerful addition to the armamentarium 
for studying immune response at the single-cell level.
Figure 4. (A) Microscope images of T cell 
modified with the CLAP/cDNA hybrid and 
then encapsulated in droplets. Arrows 
indicate the cells. Scale bar represents 
100 µm. (B) Microscope images of T cell 
modified with CLAP with (i) or without 
(ii) stimulation of PMA/ionomycine. 
The yellow numbers indicate the 
droplet-encapsulated single cells. (C) 
Background-subtracted fluorescence 
intensity of the droplet-encapsulated, 
aptamer probe-decorated T cells with 
or without PMA/ionomycine stimulation. 
(D) Flow cytometry assay of the droplet-
encapsulated, aptamer probe-decorated 
T cells with or without PMA/ionomycine 
stimulation.
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SUPPORTING INFORMATION:
DNA SEQUENCES 
The cholesterol-linked IFNγ aptamer probe (CLAP, 5’-/ROXN/AGGGGTTGGTTGTG 
TTGGGTGTTGTGTCCAACCCCT/TAO//iSp18//3CholTEG/-3’) and its cDNA (cDNA2, 5’- AGG GGT 
TGG ACA CAA CAC CCA ACA CAA CCA ACC CCT-3’) were synthesized and purified by Integrated 
DNA Technologies. The nine added nucleotides at the 3’ end of the aptamer sequence for 
hairpin formation by base pairing to the 5’-end sequence are underlined.
EXPERIMENT SECTION
Fluorescence measurements
For fluorescence measurements, 5 µL aptamer probe (200 nM, in DPBS) and 5 µL cytokines of 
the indicated concentrations were mixed in a 0.5-mL centrifuge tube. After incubation at 37 oC for 
30 min, 90 µL DPBS was added. The mixture was transferred into a fluorescence microcuvette 
with an optical path length of 1.0 cm. Fluorescence emission spectra were collected from 590 
to 750 nm using FluoroMax-4 spectrofluorometer at the excitation wavelength of 570 nm. The 
fluorescence intensity at 605 nm was used to evaluate the analysis performance of the aptamer 
probe.
Cell Isolation, Modification and Analysis
Human peripheral blood monoculear cells (PBMCs) were isolated from fresh buffy coat through 
ficoll gradient centrifugation. T cells were isolated from PBMCs using Human Pan T Isolation 
Kit (Miltenyi Biotec) and suspended in culture medium (X-VIVO medium supplemented with 2% 
human serum). The isolated T cells were used directly or stored in fridge for no more than 2 
days. 
 For cell membrane engineering, T cells were washed twice with DPBS and incubated with 
the cholesterol-linked aptamer probe (CLAP) at room temperature (RT, ~20 oC) for certain time 
spans, as indicated in the text. Unless otherwise stated, a CLAP concentration of 1 µM and an 
incubation time of 10 min were used. Then, the cells were washed three times with DPBS to 
remove free probes and resuspended in fresh culture medium. 
 For immune stimulation assay, T cells were stimulated with 0.05 mg/mL phorbol myristate 
acetate (PMA) and 1 mg/mL ionomycine at 37 oC with 5% CO2 for a certain length of time. 
Subsequently, the cells were collected, decorated with CLAP, and resuspended in culture 
medium containing PMA and ionomycine. After incubation at 37 oC with 5% CO2 for another 
2 h, the cells were washed with DPBS twice, resuspended in DBPS, and then assayed by flow 
cytometry (BD FACS Calibur) and/or confocal microscope (FV-1000, Olympus).
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Fabrication of single cell-encapsulated microdroplets
PDMS microfluidic chip composed of two aqueous-phase streams and one organic-phase 
stream was fabricated according to our previous work.1 To engineer a single-cell analysis 
platform, the CLAP-decorated cells were suspended at a concentration of 2.6×106 cells/mL 
in culture medium and delivered by one aqueous-phase stream. The immune stimuli (0.1 mg/
mL PMA and 2 mg/mL ionomycine dissolved in culture medium) were delivered by the other 
aqueous-phase steam. Picosurf (3% w/w) in HFE 7500 was delivered by the organic-phase 
stream to produce water-in-oil droplets. The injection rate of both aqueous-phase streams 
was 200 mL/h, and that of the organic-phase stream was 900 mL/h. The cell-encapsulated 
droplets were collected and placed at 37 oC with 5% CO2 and incubated for a certain length of 
time. For fluorescence measurements, droplets were placed on a glass slide and imaged with 
fluorescence microscope (Olympus CKX41).
Figure S1. ELISA assay of primary T 
cells with stimulation of PMA/ionomycine 
for different time spans. Error bars 
represent the standard deviation of three 
independent experiments.
Figure S2. Flow cytometry assay of 
JAWS II cells with stimulation of PMA/
ionomycine for different time spans, 
modified with CLAP and then incubated at 
37 oC for another 1.5 h. 
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Figure S3. Fabrication of water-in-oil microdroplets with the 
microfluidic chip system.
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CHAPTER 10
Single cell analysis reveals functional heterogeneity 
within plasmacytoid dendritic cell populations and 
identifies host-derived environmental cues as drivers 
of type I IFN production
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ABSTRACT
Cellular heterogeneity has emerged as a key feature of antiviral immunity in which highly 
specialized cells orchestrate type I IFN responses. Little is known about the factors that 
modulate cellular heterogeneity in vivo and how it is shaped by cues from the microenvironment. 
Human plasmacytoid dendritic cells (pDCs) are equipped with unique capabilities to detect 
viral infections and are key producers of type I IFN during viral infection. Here, we show that 
the microenvironment orchestrates the stochastic type I IFN response in human pDCs. We 
developed a droplet-based microfluidic platform for the functional analysis of live single cells 
in completely controlled, identical microenvironments. Our experiments revealed a minute 
population of precocious pDCs that is able to produce IFNα when stimulated individually with 
pathogen analogs. Subsequently, we reconstructed the microenvironment of these cells in 
a bottom up approach and show that the fraction of IFNα-secreting pDCs correlates to the 
number of cells in the immediate surroundings. Finally, our findings identify type I IFN as an 
important factor to drive potent population-level type I IFN responses by pDCs. Together, these 
results imply that a major subset of pDCs integrates two environmental cues – a pathogenic 
signal and a host-derived signal (type I IFN) – to regulate their iconic release of type I IFNs. This 
response is most likely driven by a precocious subset of pDCs that only requires a pathogenic 
signal for type I IFN production. 
INTRODUCTION
Our immune system employs powerful effector mechanisms to protect us from a broad range 
of pathogens and developing tumors. To ascertain that these tools are only unleashed at the 
right moment at the right place and to avoid excessive tissue damage, the immune system 
is tightly regulated. This regulation demands complex decision making processes which are 
implemented by a sophisticated network of cells and molecules that interact cooperatively to 
generate functional responses.1, 2 The cellular components of this ensemble can be grouped into 
different cell types depending on their function.3 Dendritic cells (DCs) are of special importance 
as they act as key regulators that transform pathogen sensing signals into executive orders for 
the effector cells of the immune system.4-7
 Unbiased and in-depth profiling of the transcriptional activity in single cells revealed that 
cells of a certain lineage or cell type can be further divided into various subsets and different 
cell states.7-9 Cellular heterogeneity emerged from these studies as an important feature of 
immunological responses, especially against viral pathogens and cancer, which rely on the 
production of large amounts of type I interferon (IFN).8, 10, 11 Single cell RNA sequencing of 
activated bone-marrow-derived mouse DCs and microscopic analysis of stimulated human 
monocyte-derived DCs revealed that a minuscule population of type I IFN producing cells 
emerges early after stimulation.8, 12 Mathematical models predict that these precocious cells 
might be crucial to initiate the type I IFN response in cell populations.11-13 There is increasing 
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evidence for the importance of cellular heterogeneity as a regulatory feature and for an origin 
of this variation in stochastic gene expression. However, little is known about the impact of 
cellular heterogeneity on the functional response of primary human immune cells, due to 
differences between model systems and biases introduced by reporter constructs, which 
hamper the extrapolation to the in vivo situation.14, 15
 The microenvironment plays a crucial role in immunological decision making and 
orchestrates the behavior of involved cells. Differential access to cytokines and growth factors 
based on proximity to the producer cell, for instance, influences the fate of cells in tissue and 
generates heterogeneity in clonal T cell populations.16 Furthermore, a subset of precocious 
type I IFN-secreting cells is hypothesized to enable the cells in their microenvironment to 
produce type I IFN as well.8, 12 Other studies have shown that human and mouse DCs are 
critically dependent on type I IFN receptors to generate massive IFNα responses.17, 18
 Plasmacytoid dendritic cells (pDCs), discovered as the principal type I IFN producing cells, 
emerged as an interesting model to study these processes as they control infections by rapidly 
releasing large quantities of type I IFN.19, 20 Triggering the endosomal pattern recognition 
receptors (PRR) Toll-like receptors (TLR) 7 or 9 leads to activation of the transcription factor 
IRF7 which initiates IFNα production.21-23 Several studies show that IFNα production can be 
modulated by soluble factors, including type I IFNs, as well as several cell surface receptors 
implying cellular crosstalk as a regulatory feature in this process. 24-28 pDCs naturally occur 
as a rare subset of circulating cells in the blood that accumulate in lymphoid organs and have 
also been implicated in various pathologies ranging from autoimmune diseases to tumor 
development.20, 29-32  In contrast, vaccine-activated pDCs have received major interest in cancer 
therapy, where their strong type I IFN response is a major driver of anti-cancer immunity.33, 34 In 
vivo and in vitro studies showed that, upon activation, pDCs invade peripheral tissues and T cell 
priming zones to generate clusters suggesting collaborative behavior.20, 35-37 Finally, literature 
describes different subsets within the pDC lineage based on their capacity to produce type I IFNs 
and their ability to stimulate T cell activation.7, 38-40 Given the high degree of cellular interaction 
associated with IFN production and the heterogeneity within DC lineages, the question arises 
whether individually activated primary human pDCs, in a minimal microenvironment and 
shielded from cellular crosstalk, have the intrinsic potential to produce IFNα. Furthermore, 
it remains elusive how environmental factors influence the production of IFNα by individually 
activated pDCs and what role cellular crosstalk plays.
 To answer these questions, we developed a bottom-up approach that enabled us 
to reconstruct the pDC-driven type I IFN response to specific stimuli within a tunable 
microenvironment. Essential to this approach was the high throughput microfluidic assay 
presented here which allowed detection of cytokine secretion and activation marker expression 
by single cells in picoliter droplets. Changing various droplet parameters during stimulation 
of individual pDCs enabled us to directly couple heterogeneity to cellular crosstalk and 
microenvironmental factors. Finally, we investigated how single pDCs leverage the observed 
heterogeneity and collaborate to generate strong population driven IFNα responses.
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RESULTS
Individually activated pDCs display functional heterogeneity and produce IFNα in 
a stochastic manner in a minimal microenvironment
PDCs operate in complex tissue environments that influence their decision-making process 
and cellular state. To investigate the intrinsic potential of single pDCs to produce IFNα without 
interference of other cells, we developed a droplet microfluidic assay for the detection of cytokine 
secretion by single cells (Figure 1A). In short, pDCs were coated with cytokine capture-reagents 
and encapsulated in pico- to nanoliter droplets using a microfluidic device with a flow focusing 
nozzle (Figure 1B). In the microfluidic device, prior to encapsulation, pDCs were mixed with 
TLR ligands and the generated emulsion was collected for in-droplet incubation (Figure 1C). 
During incubation, produced IFNα and TNFα was captured on the cell surface by the cytokine 
capture reagents (Figure 1A). After incubation, the emulsion was broken, pDCs were isolated, 
stained using fluorescent antibodies against cell surface markers and captured cytokines, 
and analyzed via multicolor flow cytometry. Each droplet served, thus, as a standardized, and 
independent cell reactor and allowed for the assessment of pDC heterogeneity in respect to 
cytokine secretion and activation marker expression in a high throughput fashion.
 First, we encapsulated pDCs in picoliter droplets (average 92pL, SEM 1.8 pL, n=85) with 
an encapsulation efficiency of approximately 6% cell-containing drops (Figure 1D) of which 
96% contained a single cell (Figure 1E). Cells were incubated for varying amounts of time with 
either 5 or 50 µg/mL CpG-C and analyzed using flow cytometry. After incubation, two different 
populations of pDCs were observed based on forward- and sideward scatter: apoptotic pDCs 
and live pDCs (Figure 1F). Furthermore, the de-emulsification process generated two additional 
patterns originating from oil residuals and debris. To guarantee highest purity, we limited our 
analysis to viable CD14-CD19- pDCs in the remaining experiments (Figure 1F). When analyzing 
the cytokine production of these cells, only a minute subset of pDCs produced IFNα (Figure 1G, 
H). These cells emerged as early as 2h after stimulation and did not further increase in fraction 
after 6h of stimulation. Experiments with Jurkat cells showed that the employed cytokine 
detection method is specific (Supp Figure 1 A, B). Furthermore, binding of the cytokine capture 
system to CD45 on pDCs did not negatively affect cytokine production (Supp Figure 1C, D). 
Interestingly, when stimulating pDCs, lower concentrations of CpG-C led to a delay in the onset 
of IFNα secretion. In contrast to this, we observed that nearly all pDCs produced TNFα during 
incubation in droplets (Figure 1H). Similarly, the entire pDC population expressed the lymph 
node homing receptor CCR7 already 6h after incubation and the majority of cells expressed the 
costimulatory molecules CD40 and CD86 (Figure 1 I, J). Multicolor flow cytometry revealed that 
individually activated pDCs were highly multifunctional as more than 50% of IFNα+ pDCs co-
expressed TNFα, CCR7, CD40, and CD86 at 12h after incubation and nearly all cells expressed 
at least 3 of these markers (Figure 1K). A recent study found a small subset of Axl- and Siglec 
6-expressing DC progenitor cells, called AS DCs, comprised within the pDC population.7 To 
investigate whether this subset of cells is related to the here observed phenomenon, we 
stimulated pDCs in droplets and stained them for AS DCs and cytokine secretion. Our results
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Figure 1 – Single cell analysis reveals functional heterogeneity within individually stimulated pDCs. A) Schematic 
overview of the droplet-microfluidic assay. PDCs were coated with cytokine capture reagents, encapsulated in picoliter 
droplets and stimulated with TLR ligands. After incubation, cells were stained for viability, cytokine and surface marker 
expression, and analyzed via flow cytometry. B) Schematic overview of the employed microfluidic chip with microscopic 
image of the flow-focusing nozzle for the encapsulation of cells in droplets. C) Microscopic image of emulsion after droplet 
production. B, C) Red arrows indicate cells. Scale bars equal 100 µm. D) PDCs were encapsulated at a concentration of 
1,300,000 cells/mL in 92 pL droplets. The distribution of cells in droplets was measured by manual analysis of microscopic 
images showing the emulsion directly after production Shown is the fraction of droplets plotted against the number of 
cells per droplet. n=85, black line indicates median, red line indicates theoretical values. E) Shown is the fraction of 
cell-containing droplets with exactly one cell. n=85. F-K) PDCs were treated as described above and stimulated with 5 
µg/mL or 50 µg/mL CpG-C. F) Viable pDCs were detected by forward scatter (FSC) and sideward scatter (SSC) analysis 
and subsequent gating on CD14-CD19- and viability dye- cells. G) IFNa- and TNFa-secreting cells were detected within 
that population. H) Shown is the fraction of cytokine-secreting cells plotted against incubation time. n(5 µg/mL) = 3, 
n(50 µg/mL) = 6. I) Surface marker-expressing pDCs were identified comparing the expression levels to fluorescence-
minus-one controls. J) Shown is the fraction of surface marker-expressing cells plotted against the incubation time. K) 
The co-expression of CCR7, CD40, CD86, and TNFα by single IFNα+ and IFNα- pDCs was analyzed. Shown is the relative 
contribution of each functional response pattern to the total pDC population. H, J) Dots indicate mean, error bars indicate 
SEM.
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show that the marker Axl is down regulated early after activation, however, no AS DC secreted 
IFNα in the observation period (Supp Figure 2). From this we conclude that the multifunctional 
IFNa+ cells are probably not AS DCs.
 To validate the observed IFNα secretion pattern, we stimulated pDCs for 12h with 50 µg/mL 
CpG-C in droplets and isolated IFNα-secreting cells using fluorescence activated cell sorting 
(FACS) to conduct qPCR analysis (Supp Figure 3A). IFNα+ pDCs displayed highly upregulated 
levels of the interferon stimulated genes OAS2, RIG1, and MDA5 as compared to IFNα- pDCs 
indicating that droplets with IFNα+ pDCs contained type I IFN and confirming our approach 
(Supp Figure 3B). Interestingly, pDCs lost IRF7 expression after incubation, both in bulk and in 
droplets, with IFNα+ pDCs maintaining higher expression levels than IFNα- pDCs. Using flow-
cytometric analysis of pDCs stimulated with different concentrations of CpG-C in microtiter 
plates, we confirmed that the expression of IRF7 declined in activated pDCs in absence of 
IFNα production (Supp Figure 4A-C). Prestimulation of pDCs using type I IFNs induced IRF7 
expression and led to an increased number of IFNα-expressing cells (Supp Figure 4C). 
Interestingly, pDCs expressing higher levels of IRF7 also showed higher levels of IFNα- and 
TNFα-expressing cells as compared to cells expressing low levels of IRF7 (Supp Figure 4D). 
Together these data indicate that IRF7 expression in pDCs is transient after isolation from 
blood, that IFNα production by pDCs can maintain relatively high levels of IRF7 expression, and 
that cells expressing high levels of IRF7 are more likely to produce IFNα.
 Next, we wanted to investigate whether TLR signaling can modulate the production of IFNα 
by pDCs. We encapsulated cells with varying concentrations of CpG-C in picoliter droplets and 
measured the fraction of cells producing IFNα after 12h (Figure 2A). To our surprise, we only 
observed minor variations in the fraction of pDCs secreting IFNα and the fraction of responding 
cells did not correlate with the concentration of CpG-C. In contrast, the production of TNFα, 
the expression of the activation markers CCR7, CD40, and CD86, and cell viability all positively 
correlated with CpG-C concentration and showed reduced values at lower concentrations 
(Figure 2A, Supp Figure 5). Consequently, we employed a concentration of 50 µg/mL CpG-C in 
all subsequent experiments to warrant highest cell viability. This concentration also provided 
each pDC in a droplet with an absolute number of CpG-C molecules similar to the average 
number of absolute CpG-C molecules available to each cell in a microtiter plate at optimal 
conditions. To assess whether the low frequency of IFNα-secreting cells is caused by a TLR9-
specific effect, we stimulated pDC for 12h with various concentrations of the synthetic TLR7/8-
ligand R848 (Figure 2B). Similar to TLR9 stimulation, only a small fraction of pDCs produced 
IFNα and this effect was not depending on stimulus concentration. Finally, to exclude that 
the observed IFNα production was due to stimulus-independent constitutive secretion, we 
stimulated pDCs with either IL-3 or CpG-C. IL-3 is a survival factor for pDCs, which only survive 
briefly ex vivo when left unstimulated. When stimulated with IL-3 on average 0.03% of pDCs 
produced IFNa, which is on 20 times less than CpG-C stimulated cells (Figure 2C). To exclude 
that IFNa production by single pDCs is delayed compared to bulk analysis, we incubated pDCs 
for 12h and 24h (Figure 2D). However, we only observed a small, not significant, increase in 
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IFNa+ pDCs. Interestingly, stimulation with CpG-A, a related oligonucleotide that is a stronger 
inducer of IFNα, led to a somewhat larger fraction of IFNa-secreting cells (Supp Figure 6).
 Together, these data indicate that our microfluidic assay is optimally suited for the sensitive 
detection of cytokine secretion and protein expression by single cells. Individually stimulated 
pDCs respond ubiquitously to CpG-C by secreting TNFα and expressing cell surface markers 
whereas the secretion of IFNα appears to be stochastic, i.e. random, and not associated with 
cell activation. TLR signaling is able to increase the fraction of IFNα-secreting cells significantly 
compared to spontaneous IFNa production but variations in TLR signaling do not modulate this 
process further.
Figure 2 – TLR ligand concentration does not 
influence the fraction of IFNα-producing pDCs 
in droplets. A, B) PDCs were coated with capture 
reagent, encapsulated in picoliter droplets, and 
stimulated individually with A) CpG-C or B) R848 
for 12h. After staining for viability, surface marker 
expression and cytokine secretion, cytokine-
secreting cells and viable cells were detected via 
flow cytometry. Shown is the fraction of marker-
expressing cells plotted against TLR ligand 
concentration. Different concentrations were 
tested in different donors. C) PDCs were treated as 
described above and stimulated with 0.01 µg/mL 
IL- 3 or 50 µg/mL CpG-C. Shown is the fraction of 
cytokine-secreting cells plotted against treatment 
condition. n=5 Bars indicate mean and whiskers 
indicate SEM. D) PDCs were treated as described 
above and stimulated with 50 µg/mL CpG-C for 12h 
or 24h. Shown is the fraction of IFNa-secreting or 
viable cells plotted against treatment condition. C, 
D) Mann-Whitney test * p < 0.05, ** p<0.01.
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Droplet-size does not impact pDC functionality
Autocrine factors, metabolic products, and nutrients are all known to influence cellular 
behavior and were shown to influence IFNα production in various settings.41 To test whether 
IFNα production by pDCs would be influenced by such factors, we generated droplets of varying 
size covering several orders of magnitude (Figure 3A). In small droplets, autocrine factors and 
pollutants would accumulate much quicker than in large droplets, whereas nutrients would be 
consumed at a faster rate. Variation of droplet size would make such effects on pDC behavior 
visible. Single pDCs were encapsulated in droplets ranging from 31 pL to 1209 pL and stimulated 
for 12h with 50 µg/mL CpG-C (Figure 3B, C). However, no significant difference in the fraction 
of IFNα-secreting cells was detected (Figure 3B, D colored dots, same color indicates same 
donor). Comparison with pDCs from additional donors, which were encapsulated in droplets 
of up to 3371 pL – a volume comparable to the average volume of a single pDC in a perfectly 
mixed microtiter plate culture (assuming 100 uL total volume and 25,000 cells per well this 
would be 4000 pL) – showed further no increase in the fraction of IFNα-secreting cells (Figure 
3D grey dots, each dot indicates a different donor). This was despite a relative increase in the 
number of droplets containing more than one cell. In contrast, a decrease in the production 
of TNFα-secreting cells was observed and droplet size positively affected pDC viability (Supp 
Figure 7). The degree of multifunctionality of IFNα+ cells, however, did not change with varying 
droplet volume (Figure 3E).
 Together, these results argue against autocrine factors being involved in the initial decision 
of a cell to produce IFNα17 and also make the accumulation of metabolic products and the 
availability of nutrients in cell culture medium, at least in the tested range, unlikely effectors of 
IFNα production.
Cell number and density influence the fraction of IFNα-secreting cells
As neither TLR ligand concentration nor autologous factors appeared to influence the fraction 
of IFNa-secreting pDCs, we next investigated how the availability of cellular interaction in the 
microenvironment of pDC impacts their probability to produce IFNa. Previous studies indicated 
that pDCs build homologous cell clusters upon stimulation in vitro and in vivo indicating that 
cellular crosstalk might be involved in their activation process.
 To investigate how homologous interaction partners in the microenvironment affect 
their behavior, we stimulated pDCs with varying concentrations of CpG-C and at various cell 
densities in microtiter plates using a standard density of 25,000 cells per well. We assessed 
the fraction of cytokine producing cells via intracellular cytokine staining in combination 
with flow cytometry and the concentration of cytokines in supernatant via enzyme-linked 
immunosorbent assay (ELISA) at different time points (Figure 4A). Flow-cytometric analysis 
revealed that IFNα and TNFa production peaked between 4 and 12 hours after activation, 
similar to experiments in droplets, and that the onset and peak time point differed depending 
on the CpG-C concentration (Figure 4B, C, Supp Figure 8A). Higher concentrations of CpG-C 
lead to an earlier onset of cytokine production. Interestingly, even in bulk, only a subset of pDCs 
was producing IFNα and we never observed that the entire population of pDCs contributed to a 
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response. When combining flow cytometry and ELISA data to compute the cytokine secretion 
rates, we observed that all CpG-C concentrations induced a similar IFNα rate of about 105 
molecules per cell per 2 hours indicating a digital activation mechanism (Supp Figure 8B). 
Similar dynamics were observed for the production of TNFα, however the fraction of TNFα 
producing cells was considerably higher and approximately 45% – 75% of cells produced TNFα, 
depending on the CpG-C concentration. When stimulating cells with 50 µg/mL CpG-C, the 
fraction of IFNα+ cells was reduced as compared to 5 and 0.5 µg/mL and measurement of IFNα 
concentration in cell culture supernatants confirmed this finding (Supp Figure 8A). Previous 
studies showed that an initial lag-phase before the onset of IFNα secretion is crucial to prime 
pDCs via autocrine or paracrine mechanisms.17 The early onset of IFNα production by pDCs 
stimulated with 50 µg/mL CpG-C most-likely undercuts this threshold leading to the reduced 
number of responding cells. In accordance with this, we observed robust IFNa responses 
when pre-treating pDCs for 2h with 500U/mL of IFNb (Supp Figure 4C). Importantly, these 
measurements only identify cells that produced cytokines during the two-hour period prior to 
measurement whereas the droplet-microfluidic assay identifies cells that secreted cytokines 
at any given time prior to analysis.
Figure 3 – Droplet volume does not influence 
the fraction of IFNα-producing pDCs. A, 
B) PDCs were coated with cytokine capture 
reagents, encapsulated in picoliter droplets of 
varying size (A, scale bar equals 100 µm), and 
stimulated individually with 50 µg/mL CpG-C 
for 12h. After staining for viability and surface 
marker expression, viable cells and TNFα-
positive cells were detected via flow cytometry 
(B). C) The distribution of cells in droplets was 
measured by manual analysis of microscopic 
images after production. Shown is the fraction of 
cell-containing droplets with exactly one cell. D) 
The fraction of IFNa-secreting pDCs was plotted 
against droplet volume. Dots of the same color 
indicate cells from the same donor. Grey dots 
are all originating from different donors. Linear 
regression was employed to calculate a trend line. 
K) The co-expression of CCR7, CD40, CD86, and 
TNFα by single IFNα+ pDCs was analyzed. Shown 
is the relative contribution of each functional 
response pattern to the total pDC population.
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Figure 4 – Cell number and density determine the fraction of IFNα-producing pDCs. A) Two different experimental 
approaches were employed to investigate the influence of surrounding cells on the capability of pDCs to produce IFNa: 
1) pDCs were stimulated in microtiter plates at decreasing cell density. 2) PDCs were stimulated in picoliter droplets 
with an increasing fraction of droplets containing more than 1 cell. B-D) PDCs were stimulated with CpG-C in microtiter 
plates at varying cell densities. After incubation, cells were fixed, permeabilized, and stained for viability and cytokine 
expression. B) IFNα- and TNFα-expressing cells were detected using flow cytometry. C, D) Shown is the fraction of 
cytokine-expressing pDCs plotted against incubation time (C, n>=5) or cell density (D, n[5 µg/mL] = 3, n[50 µg/mL] = 
1). Dots indicate mean, error bars indicate SEM. E-F) PDCs were coated with cytokine capture reagents, encapsulated 
in picoliter droplets with increasing number of cells per droplet, and stimulated individually with 50 µg/mL CpG-C for 
12h. After staining for viability, surface marker expression and cytokine secretion, cytokine-secreting cells were detected 
via flow cytometry. E) Two different mechanisms can explain a cell density-dependent increase in the fraction of IFNa-
expressing cells. F) Shown is the fraction of IFNα-secreting cells plotted against the fraction of droplets containing more 
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than 1 cell. The Bayesian information criterions (BIC) was employed to compare models. G) PDCs were coated with 
capture reagent or left untreated and mixed at a 1:1 ratio. Subsequently, cells were encapsulated in picoliter droplets with 
either 0.1 or 7.6 cells per drop on average, and stimulated individually with 50 µg/mL CpG-C. Next to viability and surface 
marker expression, pDCs were also stained for cytokine capture reagent-coating using an antibody against mouse IgG1. 
Shown is the distribution of the fluorescence intensity of the capture reagent at each time point. 
 To analyze whether cell density – and thus cellular interactions – during pDC activation 
influences cytokine production, we seeded pDCs at different cell numbers and stimulated them 
with CpG-C. The fraction of cytokine-expressing pDCs, as indicated by intracellular cytokine 
staining, was assessed via flow cytometry at the peak of the response (Figure 4D). At low cell 
densities (750 – 1,500 cells per well), the fraction of IFNa-expressing pDCs was greatly reduced 
as compared to densities used more regularly in in vitro experiments (25,000 – 50,000 cells per 
well). In contrast to that, the percentage of pDCs involved in the production of TNFα varied only 
in pDC populations stimulated with 5 µg/mL and to a lesser extent.
 These results allow for two possible mechanisms of how pDC populations interact with 
each other to generate the observed cytokine responses: 1) a small subset of precocious IFNa-
secreting pDCs, possibly represented by the rare IFNa+ cells emerging in previous droplet 
experiments, activates surrounding pDCs to produce IFNa, 2) each pDC expresses cell surface 
molecules which positively influence the probability of an interacting pDC to produce IFNa 
(Figure 4E). Mathematically, model 1 can be expressed as a simple linear equation in which 
the intercept equals the cofactor of x with x being the relative number of droplets containing 
more than one cell and y being the relative number of IFNa+ pDCs (blue model). Model 2, in 
contrast, is an even simpler linear equation with the cofactor of x being 1 and the intercept 
being 0 (red model), meaning that fraction of IFNa+ pDCs equals the fraction of droplets with 
more than 1 cell. However, cytokines produced by one cell can diffuse inside the droplet and 
bind to the capture reagent of another cell encapsulated in the same droplet. This situation is 
mathematically identical to the situation of a precocious cell in a droplet that activates another 
cell in the same droplet to produce IFNa on its own. Furthermore, when encapsulating a 1:1 
mixture of pDCs that where either labeled with IFNa capture reagent or left unlabeled and 
stimulating cells for 12h, we observed a transfer of capture reagent from labeled to unlabeled 
cells (Figure 4G). Using the droplet-microfluidic assay, we can thus only exclude mechanism 
1) but not definitely confirm mechanism 2). To analyze whether crosstalk between two random 
interacting cells would be sufficient to enable IFNα production (red model), we encapsulated 
pDCs in 90 pL droplets and increased the fraction of droplets containing more than a single cell. 
The fraction of IFNa-secreting cells increased slightly with the fraction of droplets containing 
more than one cell (Figure 4F). This increase was best described by a model of precocious cells 
(blue) implying that not any two pDCs can amplify each other’s probability to produce IFNa. 
 Together, these results show that the microenvironment – in this case represented by 
surrounding pDCs – has a critical impact on the probability of a pDC to produce IFNa.
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Priming increases the probability of pDCs to produce IFNα
To investigate how the microenvironment influences the stochastic process of IFNa-production in 
single pDCs, we investigated whether soluble factors in the supernatant of microtiter plate-cultured 
pDCs can increase the fraction of IFNa+ pDCs individually stimulated in droplets. Previous studies 
indicated that  a number of cytokines, including IFNb, IL-3, IL-4, IL-7, and IL-15, can increase the 
production of IFNa.17, 24 To test this, we incubated fresh pDCs for 2h with conditioned medium (CM) 
harvested from overnight cultures of pDCs stimulated with 5 µg/mL CpG-C at a density of 25.000 
cells/well (Figure 5A). After pre-incubation – subsequently referred to as priming –  pDCs were 
thoroughly washed, coated with capture reagent, encapsulated in picoliter droplets, and stimulated 
individually with 50 µg/mL CpG-C. Priming cells with 10% CM significantly increased the fraction of 
single pDCs that produced IFNa (Figure 5B, C). In contrast, priming with remnant CpG-C or fresh cell 
culture medium did not induce this effect. Furthermore, priming without subsequent TLR stimulation 
did not induce high levels of IFNa either, indicating that priming is modulating the probability of a 
pDC to produce IFNa but not directly inducing IFNa production. Similar to previous experiments, 
IFNa-secreting cells were highly multifunctional with the great majority of cells co-expressing TNFa, 
CCR7, CD40, and CD86 (Figure 5D). Interestingly, the fraction of IFNa-secreting pDCs depended on 
the concentration of the CM but not on the concentration of CpG-C (Figure 5E, F).
 To identify what factor in the CM is responsible for the priming effect, we tested several cytokines 
described to have a positive effect on IFNa-production by pDCs.17, 24 An initial screening revealed 
that, apart from CM, only IFNb – which acts, like IFNa, via the IFNa/b-receptor –increased the per 
cell IFNa-production by pDCs cultured in microtiter plates at low cell density (Figure 5G, Supp 
Figure 9). Furthermore, blocking the IFNa/b-receptor and adding neutralizing antibodies against 
IFNa and b during priming inhibited the positive effect of CM on per cell IFNa-production by pDCs 
(Figure 5G). Priming of pDCs with IFNb led also to a strong increase in the fraction of low-density 
cultured pDCs producing IFNa as measured by flow cytometry (Figure 5H). Finally, priming with 
IFNb increased the fraction of IFNa-secreting cells in droplets to a similar extend as CM (Figure 5I).
 Together, these results indicate that signaling via the type I IFN receptor amplifies the positive 
effect of TLR stimulation on IFNa production thus modulating the patterns of heterogeneity within 
the pDC population.
DISCUSSION 
Production of type I IFNs is paramount for the containment of viral infections but the 
regulation of this process is not sufficiently understood. Due to the stochasticity of type I IFN 
production, single cell analysis is warranted to capture cell to cell variation in the production 
of the cytokine. So far, studies were restricted to the use of model organisms and genetically 
engineered cells which might not reflect the in vivo situation and are therefore prone to bias.10 
PDCs are a subset of rare and specialized circulating immune cells whose primary function is 
the rapid and robust production of type I IFNs in response to viral infections. In vivo, pDCs act 
in complex tissue environments, such as the lymph nodes or sites of ongoing inflammation,
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Figure 5 – pDCs primed with conditioned medium or IFNb showed an increased probability to produce IFNα. A) 
Schematic overview of the priming experiment. PDCs were stimulated for two hours with conditioned medium (CM), IFNb, 
or control medium, washed, coated with cytokine capture reagent, encapsulated in droplets, and stimulated individually 
with 0.01 µg/mL IL-3 or 50 µg/mL CpG-C. B) Cytokine-secreting cells were detected using flow cytometry. C) Shown is the 
fraction of IFNα--secreting cells plotted against different treatment conditions. D) The co-expression of CCR7, CD40, CD86, 
and TNFα by single IFNα+ and IFNα- pDCs was analyzed. Shown is the relative contribution of each functional response 
pattern to the total pDC population. E) PDCs treated as described above, were primed with different concentrations of CM 
and stimulated with 50 µg/mL CpG-C. Shown is the fraction of IFNα-secreting cells plotted against CM concentration. G) 
PDCs were treated as described above, primed with 10% CM, and stimulated with CpG-C. Shown is the fraction of IFNα-
secreting cells plotted against CpG-C concentration. F) PDCs were incubated with fresh medium, 10% CM or 500 U/mL 
IFNb for two hours or left untreated. In one condition, cells were pre-incubated with blocking antibodies against IFNAR2 
and CM was supplemented with neutralizing serum against IFNa and IFNb. Subsequently, pDCs were stimulated with 
50 µg/mL CpG-C in microtiter plates for 12h at varying cell densities and cytokine concentration in supernatants was 
measured using ELISA. Shown is the log cytokine concentration relative to the number of seeded cells plotted against 
cell density and priming condition. n=3 G) PDCs were stimulated with 50 µg/mL CpG-C for 8h in microtiter plates at a 
varying cell density. After incubation, cells were fixed, permeabilized, and stained for viability and cytokine expression. 
The fraction of IFNα-expressing cells was determined using flow cytometry and plotted against cell density. Values were 
compared to non-primed pDCs using the Mann-Whitney test. * p < 0.05, ** p<0.01. H) PDCs were treated as described in 
A). Shown is the fraction of IFNα-secreting cells plotted against treatment condition. C, H) Welch-corrected two sample 
t-test. * p < 0.05, ** p<0.01.
implying that much of their behavior is influenced by cells in their microenvironment. Due to 
their low occurrence and short ex vivo survival, single cell analysis of type I IFN responses by 
pDCs was hampered.
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 We present here a new droplet-microfluidic assay for the detection of cytokine secretion 
and protein expression by single cells. We employed this technique to probe the production of 
IFNa by single pDCs and to investigate how different environmental factors affect the intrinsic 
potential of each pDC to produce the cytokine. We found that the production of IFNa by single 
pDCs is intrinsically stochastic and can occur independently of TLR signaling. However, only 
a minute fraction of cells produced the cytokine in steady state. Activation of TLR signaling 
does increase the probability of IFNa production significantly compared to background levels, 
it is however not sufficient to induce robust IFNa responses by large fractions of pDCs. 
Environmental factors, in this case type I IFN signaling, amplified the effect of TLR signaling 
leading to robust IFNa responses similar to those observed from cultures of large pDC 
populations. Autocrine effects appeared to play no role in our system.
 The steady state expression of IFNa by pDCs has been proposed previously, however, 
to our knowledge, we present here for the first time direct evidence for this process.17 We 
observed that TLR signaling increased the probability of IFNa production in pDCs about 20-
fold. However, this was not sufficient to generate population level responses. Furthermore, 
in contrast to previous reports on IFNb production, our data imply that in pDCs the strength 
of PRR signaling does not influence the probability of IFNa production in a single cell.10, 11, 
14 In contrast, the production of proinflammatory cytokines and activation markers showed 
deterministic properties and the fraction of cells expressing those markers correlated with the 
concentrations of CpG-C or R848. At sufficiently high concentrations, all cells expressed TNFa 
and CCR7 and a great majority was positive for CD86 and CD40. Differences between the IFNa 
and the proinflammatory response might be explained by the signaling cascade within pDCs 
which is spatially and temporally separated. CpG-C and the related oligonucleotide CpG-A can 
be taken up and trafficked to the early endosome where TLR9 binding induces the assembly 
of the MyD88-IRAK-TRAF3 complex which activates IRF7 and initiates the IFNa transcription. 
42, 43 CpG-C and CpG-B, which is not taken up in early endosomes, can be taken up in late 
endosomes where TLR9 engagement leads to activation of the NF-kB and the MAPK pathway 
via the MyD88-IRAK complex.42 This leaves the possibility that the limiting factor for IFNa 
production is either the trafficking of CpG-C into early endosomes or IFN-specific components 
downstream of the MyD88-IRAK complex. We found here that priming of pDCs with type I IFNs 
leads to an increase in the fraction of IFNa-secreting cells. At the same time, we observed an 
increase of IRF7 levels in primed cells. Furthermore, pDCs with high expression of IRF7 were 
more likely to produce IFNa than pDCs with low IRF7 expression. Finally, pDCs rapidly loose 
IRF7 expression ex vivo. Together these data imply a role for IRF7 expression in regulating the 
stochastic expression of IFNa by pDCs. Previous studies suggested IRF7 as an important factor 
for the regulation of stochastic gene expression in infection models using cell lines or in vitro 
generated immune cells.10, 11, 14  However, at any given time less than half of the pDC population 
produced IFNa in our hands and even after priming more pDCs produced IFNa in microtiter 
plates than in droplets, implying that other factors such as timing might be important for IFNa 
production as well. Several studies, furthermore, show that IFNα production can be modulated 
by the PI(3)K/mTOR pathway25, 26 and osteopontin27 as well as several cell surface receptors.29, 32 
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Finally, stimulation with CpG-A lead to a small increase in the fractions of IFNa-secreting cells 
indicating that trafficking to the early endosome might be involved in this process as well.
 In this study, we employed our droplet-microfluidic assay to systematically explore the 
influence of certain environmental factors, such as droplet size and number of cells per 
droplet, on the probability of pDCs to produce IFNa. This approach enabled us to test various 
aspects of pDC activation which are impossible to analyze using traditional microtiter plate-
style experiments. First, we varied the droplet volume ranging from the average volume 
available to each cell in an ideally mixed microtiter plate culture – ~ 4000 pL – to droplets of 
about 1/100 of that size. No differences in the fraction of IFNa-secreting pDCs was observed. 
Kim et al suggested that pDCs constitutively produce type I IFNs at very low levels and that 
those cells would either autoprime themselves or prime surrounding cells to produce large 
amounts of IFNa.17 Differences in the rate of autopriming would generate heterogeneity robust 
IFNa responses after TLR stimulation. Our results argue against the involvement of a such an 
autocrine feed-forward loop as a drastic reduction in droplet size would lead to a much faster 
accumulation of the constitutively produced type I IFN and hence to a strong IFNa production 
in a large fraction of cells. We did not observe such a negative correlation of droplet size and 
probability of IFNa production indicating that the response is not driven by a low concentration 
constitutive IFNa production autocrine system. 
 In contrast to autocrine factors, we identified paracrine or juxtacrine factors as important 
regulators for IFNa production by pDCs. Microtiter plate cultures with a high density of pDCs 
displayed high fractions of IFNa-expressing cells. This effect was depending on cell density and 
only few cells in microtiter plate cultures with low density produced IFNa. Increasing the number 
of cells per droplet furthermore, revealed that juxtacrine crosstalk between a minimalistic 
cluster of two interacting cells were not responsible for the cell density-dependent increase 
in IFNa production. Our experiments using CM from pDCs stimulated at high density rather 
suggest that a paracrine messenger, based on type I IFN receptor signaling, is responsible for 
the increased fraction of IFNa-secreting pDCs at high cell density. This is in line with results 
on type I IFN signaling in other systems.10, 11, 14
 Stochastic gene expression is a known phenomenon in biology and one of the strongest 
drivers of cellular heterogeneity.15 Several cytokines, including IFNb, were shown to be 
regulated by stochastic gene expression meaning that after receiving a stimulus the cell 
decides randomly whether or not to produce the cytokine.10, 11, 14 Stochasticity can be caused by 
the small probability of all components of the transcription machinery to arrive at the one or 
few copies of the IFN gene in a relatively short time frame. Furthermore, components in the 
signaling pathway leading to the production of a cytokine can be limited so that the assembly 
of signaling complexes also becomes unlikely and dictated by stochasticity. 
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Figure 6 – Schematic model illustrating the regulation of stochastic IFNa-production by pDCs. Very few pDCs produce 
IFNa constitutively without stimulation by TLR ligands, here resembled by differentiation from a freshly isolated pDC (X0) to 
an IFNa-secreting pDC (X1) with at a rate of b0. Literature indicates that this process is not IRF7 dependent but NF-kB and 
AP-1.17 Upon TLR9 triggering the IRF7-dependent pathway is activated which also allows differentiation to IFNa-secreting 
pDC at the much higher rate of b1. However, despite involvement of the IRF7 pathway, still only very few pDCs produce 
IFNa. Paracrine signaling via the type I IFN receptor can increase b1, probably via the upregulation of IRF7 expression, 
leading to a large fraction of cells expressing IFNa. After producing IFNa, pDCs become refractory to re-stimulation (X2) 
and eventually die (F).
 Based on our results, we propose the following model of early pDC activation (Figure 6). 
PDCs are able to produce IFNa constitutively, a process that is very rare and stochastically 
controlled by transcription factors other than IRF7 such as NF-kB or AP-1.17 This spontaneous 
expression accounts for the very rare appearance of IFNa-secreting unstimulated cells. TLR-
triggering leads to the activation of the MyD88-IRF7 pathway, which is limited by components 
downstream of the MyD88-IRAK complex and by trafficking of CpG molecules to the early 
endosome in most cells but leads to an increase in stochastic IFNa expression of about 20 times. 
This is sufficient to generate a pool of early responder pDCs which secreted type I IFNs and 
prime surrounding cells. In those cells, the expression of factors important for IFNa production, 
including IRF7, are induced increasing the probability of IFNa expression and leading to a robust 
population response. TLR-mediated sensing is, in this model, a sensitive digital process, at 
least in the tested range of ligand concentrations. This system poses an efficient way to limit 
IFNa production by rogue pDCs in inappropriate settings such as autoimmunity. In the here 
proposed model, pDCs only produce IFNa at high probability if they either accumulate at a site 
with sufficiently high density or if they enter a microenvironment that is already inflamed and 
contains antiviral factors. This avoids that a few pDCs get unintentionally triggered by host-
derived nucleic acids leading to massive IFNa responses in an inappropriate setting. To our 
knowledge, this is the first report to describe the stochastic behavior of IFNa expression in 
primary human immune cells.
 PDCs are increasingly targeted in clinical interventions e.g. during cancer therapy or 
autoimmune diseases.31, 33, 34 Vaccine-activated pDCs, for instance, recently received major 
interest in cancer vaccination strategies as their strong type I IFN response is thought to be a 
major driver of anti-cancer immunity.33, 34  Our results identify the microenvironment and IRF7 
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as important regulators of pDC-mediated IFNa production during infection. New treatment 
strategies could exploit these factors to modulate IFNa responses by pDCs in clinical settings. 
Central to this is how pDCs maintain their high levels of IRF7 in vivo. Various studies report on 
the presence of low levels of IFNa and b in steady state and mice without type I IFN receptors 
are unable to mount strong pDC-based IFNa responses.18, 44 Plasma type I IFN levels thus 
might emerge as an important indicator for the magnitude of pDC-based IFNa responses in 
vivo and could be exploited in personalized medicine approaches to estimate the effect of pDC-
targeted treatments. Eventually, it might be possible to exploit systemic type I IFN levels to 
modulate the activity of pDCs. IFNa, for instance, is a well-tested clinical agent due to its role 
as an early cancer immunotherapeutic in the 1980s and 90s. One could imagine to combine 
systemic IFNa treatment with pDC-targeted approaches to turn tumor-resident tolerizing 
pDCs into IFNa-secreting tumoricidal pDCs.45 The opposite could be exploited in autoimmune 
situations. Systemic IFNa levels could, for instance, be lowered using neutralizing antibodies 
–  as currently tested in patients suffering from SLE46, 47 – and cells could be subsequently 
stimulated with ligands known to induce regulatory responses. 
 Additionally, the cell-density dependent effect of IFNa-production by pDCs can inform 
future dendritic cell vaccination studies regarding the conditions employed for the ex vivo 
activation of pDCs and the number of injected cells. Too low pDC density at the injection side, 
for instance, could prevent the generation of potent in vivo IFNa responses.
 We present here a droplet-microfluidic method for the detection of protein secretion and 
protein expression by single cells at high throughput. This technique facilitates the discovery 
of functional heterogeneity on the protein level and allows for the isolation of functionally 
distinct subsets for downstream application. Information on protein secretion and surface 
marker expression can thus be linked to genomic data if isolated cells are analyzed using 
RNA sequencing approaches. Furthermore, heterogeneity in protein secretion can be linked to 
differences in other behavior if isolated cells are subjected to functional assays. Additionally, 
the droplet environment enables the investigation of paracrine and autocrine factors during 
biological processes. Encapsulating single cells allows for probing cellular behavior in the 
complete absence of crosstalk and can unravel heterogeneity in biological processes that is 
otherwise concealed by paracrine signaling. Furthermore, heterogeneous cell mixtures can be 
tested in parallel on the single cell level when employing phenotypical markers to distinguish 
different subsets during analysis. This is difficult using competing high-throughput single 
cell techniques, e.g. intracellular cytokine staining or single cell RNA sequencing, as such 
techniques usually require cell lysis. This makes the droplet-microfluidic assay presented here 
a versatile tool to gain comprehensive insight into the factors governing cellular heterogeneity 
and their biological implications.
 During this study, we were able to reliably and routinely probe rare, primary immune cells 
using as few as 40,000 input cells. This technique is thus suited for the use of small biological 
specimen such as clinical samples and can aid to reveal functional heterogeneity in various 
immune related diseases. Furthermore, the technique is highly adaptable to environmental 
demands as key variables such as droplet size, medium supplements, cell numbers and 
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incubation times can be controlled over a wide range of values. Cellular interaction studies 
are furthermore possible in case of measurement of mutually-exclusively secreted molecules. 
The droplet-microfluidic assay presented here thus has potential as a platform for analysis of 
functional heterogeneity in clinical practice.
 In summary, this study shows a novel droplet-microfluidic assay to uncover functional 
heterogeneity within human pDCs after ex-vivo stimulation with synthetic TLR ligands. Using 
this assay, we demonstrate that this heterogeneity arises from stochastic secretion of IFNa. 
The probability of IFNa secretion can be modulated by TLR signaling from pathogenic factors 
and type I IFN signaling from the host microenvironment. Our study is the first to analyze this 
activation process in human primary pDCs on the single cell level and has implications for 
pDC-based treatments and diseases.
MATERIALS AND METHODS
Antibodies and cell stimuli
For a full list of utilized antibodies and reagents, the readers are referred to the supplementary 
methods.
Cell isolation and culture
Jurkat T cells were cultured in RPMI (Thermo Fischer Scientific) supplemented with 10% fetal 
calf serum (FCS; Greiner Bio-One) and 1% Antibiotic-Antimycotic (Life Technologies). PDCs 
were obtained from buffy coats of healthy donors (Sanquin) after written informed consent 
per the Declaration of Helsinki and according to institutional guidelines. In short, peripheral 
blood mononuclear cells (PBMCs) were isolated from donor blood via Ficol density gradient 
centrifugation (Axis-Shield). PDCs were subsequently isolated using magnet-activated cell 
sorting (MACS) or fluorescence-activated cell sorting (FACS).
 For MACS isolation, PBMCs were resuspended in X-Vivo 15 cell culture medium (Lonza) 
supplemented with 2% pooled human serum (HS; Sanquin) and incubated for 1h at 37°C in cell 
culture flasks T75 (Corning) to deplete monocytes. Cells were washed thrice with phosphate 
buffered saline (Braun; PBS) while non-adherent cells were collected. PDCs were isolated 
from this cell population by positive selection using the CD304 Microbeat Kit (Miltneyi Biotec) 
following manufacturer’s instructions. Cells were counted and purity was assessed using flow 
cytometry. For this purpose, cells were washed with PBS supplemented with 0.5% bovine 
serum albumin fraction V (BSA, Roche) and 0.01% NaN3 (Merck; subsequently referred to as 
PBA) and stained for 10 minutes at 4°C using APC-labeled anti-CD303 and FITC-labeled anti-
Lineage Cocktail 1 (LIN1) antibodies in 30 µL PBA. PDCs were identified as CD303+LIN- and 
purity was on average 93% (Std.: 3.76%, n = 67). 
 For FACS isolation, PBMCs were washed and FITC-labeled anti-LIN1 antibodies were 
added to the pellet. Cells were incubated for 20 minutes at 4°C. Subsequently, cells were 
washed with PBS supplemented with 4 mM ethylenediaminetetraacetic acid (Sigma; EDTA) 
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and 0.1% BSA (subsequently referred to as wash buffer) and anti-FITC microbeads (Miltenyi 
Biotec) were added to the pellet. Cells were incubated for 30 minutes at 4°C and subsequently 
washed with wash buffer. LIN1 positive cells were magnetically depleted using an LD column 
(Miltenyi Biotec) following manufacturer’s instructions. Cells were washed with wash buffer 
and VioBlue- or PE-Cy7-labeled anti-HLA-DR and BV510- or PE-labeled anti-CD304 antibodies 
were added to the pellet. Cells were incubated for 30 minutes at 4°C and afterwards washed 
with wash buffer. PDCs were sorted as LIN1-HLA-DR+CD304+ cells on a FACS Aria II (BD).
Microfluidic setup
Soft lithographic techniques were used to fabricate microfluidic channels (Suppl. Methods). Liquids 
were dispensed from plastic syringes (Becton Dickinson), which were connected to the microfluidic 
device by polytetrafluoroethylene tubing (Novodirect GmbH). The syringes were driven by computer-
controlled syringe pumps (Nemesys, Cetoni GmbH). For the stability of droplets, 3 w/w% Pico-
Surf® surfactant (Sphere Fluidics) was used in fluorinated HFE-7500 oil (Novec 7500, 3M). Cells 
were loaded on the microfluidic chip using the pipette tip-loading technique (See Chapter 7 in this 
thesis). Stimuli were loaded in tubing and directly provided to the chip.
Priming and blocking
To block type I IFN signaling, pDCs were incubated at 37°C for 30 minutes with medium 
containing blocking antibody against IFNAR2 (PBL Assay Science, 10 µg/mL) and neutralizing 
sera against IFNα and IFNβ (both PBL Biomedical Laboratories, both 1000 NU/mL). To prime, 
pDCs were resuspended in medium containing cytokines or conditioned medium and incubated 
for 2 hours, 37°C. Subsequently, cells were washed thrice with wash buffer and prepared for 
downstream applications.
Single cell activation assay
Cells were washed twice with wash buffer and incubated in 100 µL per 106 cells wash buffer 
containing Cytokine Catch Reagent (Miltenyi Biotec) at 4°C for at least 40 minutes. Cells were 
washed with wash buffer and medium and resuspended in medium at 2.6·106 cells/mL for 
single cell encapsulation in 70 - 100 pL droplets. In case of experiments using different droplet 
sizes or multiple cells per drop, these concentrations were adjusted to yield the desired Poisson 
distribution. Stimulus was dissolved in medium at twice the desired concentration to account 
for on-Chip dilution. For 90 pL droplet production, flow rates were adjusted to 900 µL/h for the 
oil phase and 200 µL/h for the aqueous fractions (Supplementary Table 4 for overview of all 
employed flow rates). In all experiments, constant volumetric flow rates were used. To assess 
the encapsulation rate, videos of the droplet production and images of the produced emulsion 
were acquired using a CKX41 microscope (Olympus) at 10X magnification. Encapsulation rate 
was manually assessed using Fiji.48, 49 The emulsion was collected and covered with medium 
to protect droplets from evaporation. Cells were incubated with open lid at 37°C and 5% CO2. 
Next, the emulsion was broken by adding 150 µL HFE 7500 containing 20% w/w 1H,1H,2H,2H-
Perfluoro-1-octanol and centrifuging briefly at 60 rcf. The cell-containing aqueous phase was 
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transferred into a new tube containing 500 µL PBA and left for 2 minutes to allow residual oil to 
settle. Finally, the aqueous phase was transferred into a clean tube and cells were washed with 
PBS. Dead cells were identified by staining with Fixable Viability Dye eFluor® 780 (eBioscience, 
1:2000 in PBS, 100 µL) for 30 minutes at 4°C. Cells were washed once with PBS and blocked 
with PBA supplemented with 1% HS for 10 minutes at 4°C. To stain for surface proteins and 
captured cytokines, cells were incubated with antibodies in 70 µL PBA supplemented with 1% 
HS for 10 minutes on ice. After incubation, cells were washed and resuspended in PBA and 
kept at 4°C until acquisition on a FACS Verse flow cytometer (BD). 
RNA isolation and quantitative PCR
RNA was isolated using Trizol (Life Technologies) following manufacturers protocol. RNA 
quantity was determined on NanoDrop 2000c (Thermo Scientific) and RNA quality was 
determined via agarose gel electrophoresis.  2 µg of RNA was DNAse I-treated to remove 
residual genomic DNA and reverse transcribed into cDNA by M-MLV reverse transcriptase 
(Life Technologies) to obtain 25 µL of cDNA. cDNA was diluted 25x in nuclease free water. For 
each reaction, 4 µL diluted cDNA, 300 nM primers, 10 µL SYBR Green (Roche) and water were 
added to a final volume of 20 µL. Each sample was amplified using a CFX96 sequence detection 
system (BioRad). The following qPCR cycling conditions were used: 50°C/2 min, 95°C/10 min, 
40 cycles of 95°C/15 s; 60°C/1 min, melt analysis 60°C - 95°C with increment 0.5°C/5 s. The 
gene-specific oligonucleotide primers used to determine the expression of the genes of interest 
are listed in Supplementary Table 2. To increase the chance of consistency qPCR primers were 
based on the MA probes with highest differential expression.  PCR products were monitored 
by measuring the increase of fluorescence caused by binding of SYBR Green. Quantitative PCR 
data were analyzed using CFX96 manager and relative expression of the gene of interest was 
determined using the cycle threshold method with GAPDH as reference genes.50
Stimulation in microtiter plate
PDCs were resuspended in 100 µL medium containing the appropriate stimulus (see 
supplementary methods) and cultured in 96-well round bottom plates (Costar, polystyrene) at a 
density of 25,000 cells per well if not stated differently. Depending on the experimental setting, 
Brefeldin A (Sigma, 10 µg/mL) was added 2 hours before harvesting the cells.
Antibody staining
Cells were washed once with PBS and dead cells were identified by staining with Fixable Viability 
Dye eFluor® 780 (eBioscience, 1:2000 in PBS, 100 µL) at 4°C for 30 minutes. Subsequently, 
cells were washed once with PBS and blocked with PBA supplemented with 1% HS at 4°C 
for 10 minutes. Cells were washed and incubated with antibodies against surface proteins in 
30 µL PBA supplemented with 1% HS for 10 minutes on ice. Afterwards, cells were washed 
with PBA followed by a wash with PBS. Cells were fixed and permeabilized with Cytofix/
Cytoperm solution (BD, 100 µL) for 20 minutes at 4°C. Next, cells were washed with Perm/
Wash buffer (BD) and blocked for 10 min at 4°C using Perm/Wash buffer supplemented with 
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1% HS. Subsequently, cells were incubated with antibodies against intracellular proteins in 
30 µL Perm/Wash buffer supplemented with 1% HS for 30 min at 4°C. Cells were washed 
twice with Perm/Wash buffer followed by a wash with PBA and resuspended in PBA. For IRF7 
staining, cells were instead fixed with 4% Paraformaldehyde (Merck) in PBS for 10 minutes at 
room temperature. After incubation, PBA was added and cells were washed twice with PBA, 
followed by a wash with PBA supplemented with 0.1% Triton X (Sigma). Cells blocked for 10 
min at 4°C using PBA supplemented with 0.1% Triton X and 1% HS. Subsequently, cells were 
incubated with antibodies against intracellular proteins in 30 µL PBA supplemented with 0.1% 
Triton X and 1% HS for 30 min at 4°C. Cells were washed twice with PBA supplemented with 
0.1% Triton X followed by a wash with PBA and resuspended in PBA. All cells were kept at 4°C 
until acquisition on a FACS Verse flow cytometer (BD).
ELISA analysis
ELISA plates (Nunc MaxiSorp ELISA Plates for IFNa, Greiner bio-one high binding microplates 
for TNFa ELISA) were incubated with PBS containing anti-cytokine antibodies at the 
manufacturer recommended concentration (Human IFN alpha matched antibody pairs, 
Human TNF alpha ELISA Ready-SET-Go, both eBioscience) overnight at 4°C. Next, plates, 
coated with antibodies against IFNa, were washed once with PBS supplemented with 0.05% 
Tween20 (Merck, subsequently referred to as ELISA wash buffer and used for all wash steps) 
and blocked using 250 µL ELISA wash buffer supplemented with 0.5% BSA for 2 hours at room 
temperature. Plates were washed twice and incubated with 50 µL of sample or standard and 50 
µL of st-HRP-conjugated detection antibody at the recommended concentration for 2 hours at 
room temperature. Plates coated with antibodies against TNFa were washed once and blocked 
with ELISA dilutent (eBioscience) for 2 hours at room temperature. Plates were washed once 
and incubated with 50 µL sample or standard. Next, plates were washed 4x and incubated with 
detection antibody at the recommended concentration. Subsequently, plates were washed 4x 
and incubated with Aviding-HRP at the recommended concentration for 30 minutes at room 
temperature. Finally, all plates were washed trice and incubated with 100 µL TMB Solution 
(eBioscience). Reaction was stopped by adding 100 µL of 1M H3PO4 and absorption was 
measured at 450 nm using a microplate reader (Biorad).
Data analysis
Flow cytometry data was analysed using FlowJo X (Tree Star) and SPICE (downloaded from 
http://exon.niaid.nih. Gov).45 Analysis and presentation of distributions was performed using 
PRISM for windows version 5.03 (GraphPad) and The R Project for Statistical Computing using 
the ggplot2, reshape, and xlsx packages.51-54 For statistical analysis, Students t-test and linear 
regression analysis using least square fit were performed.
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SUPPLEMENTARY INFORMATION
SUPPLEMENTARY FIGURES
Supp Figure 1 – Verification of specificity and biocompatibility of cytokine capture reagents. Jurkat T cells were 
coated with cytokine capture reagents specific for IL-2 and IFNα at different concentrations. Subsequently, cells were 
encapsulated in droplets and stimulated individually with PMA and Ionomycine over night. After antibody and viability 
staining, cytokine producing cells were detected via flow cytometry (A) and changes in fluorescence intensity were 
compared (B). PDCs were either coated with capture reagent, specific for IL-2, or left untreated and stimulated with 5 
µg/mL CpG-C. After incubation cells were fixed, permeabilized, and stained for cytokine expression. IFNα- and TNFα-
expressing cells were detected using flow cytometry and the fraction of cytokine producing cells at a given time point was 
plotted against the treatment condition (C, D).
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Supp Figure 2 – Axl expression by pDCs vanishes early after stimulation with CpG-C and AS DCs produce no IFNα. 
PDCs were coated with capture reagent, encapsulated in picoliter droplets, and stimulated individually with 50 µg/mL 
CpG-C. After staining for viability, surface marker expression and cytokine secretion, AS DCs were detected via flow 
cytometry (A). Cytokine expression in AS DCs and traditional pDCs was analyzed (B).
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Supp Figure 3 – Expression of interferon stimulated genes in individually activated, sorted pDCs. PDCs were incubated 
with 40% conditioned medium for 2h or left untreated. Subsequently, cells were coated with capture reagent, encapsulated 
in picoliter droplets, and stimulated individually with 50 µg/mL CpG-C for 12h. Control cells were stimulated with 5 µg/
mL CpG-C for 12h in a microtiter plate at a density of 25.000 cells (bulk) or left at 4°C (0h). After staining for viability and 
cytokine secretion, IFNα+ and IFNα- cells were isolated using fluorescence activated cell sorting (A). Sorted cells were 
lysed, RNA was isolated, and the expression of the interferon stimulated genes OAS2, RIG1, MDA-5, and IRF7 as well as 
the house keeping gene GAPDH was determined via quantitative PCR. Shown are the expression levels relative to GAPDH 
plotted against treatment conditions (B).
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Supp Figure 4 – IRF7 expression dynamics in primed and stimulated pDCs. PDCs were incubated with fresh medium 
or 500 U/mL recombinant IFNβ for 2h or left untreated. Subsequently, pDCs were stimulated with CpG-C in microtiter 
plates at a density of 25.000. After incubation, cells were fixed, permeabilized, and stained for viability, cytokine expression 
and IRF7 expression. IFNα-, TNFα-, and IRF7-expressing cells were detected using flow cytometry (A, B). The fraction 
of cytokine producing cells or the fluorescence intensity of IRF7 was plotted against the incubation time (C). The 25% 
pDCs that had the lowest or highest expression of IRF7 were further selected and cytokine expression in those cells was 
analyzed separately (B). The fraction of cytokine producing cells for each group was plotted against the incubation time 
(C).
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Supp Figure 5 – Expression of cell surface markers by individually stimulated pDCs is depending on CpG-C 
concentration. PDCs were coated with capture reagent, encapsulated in picoliter droplets, and stimulated individually 
with CpG-C for 12h. After staining for viability, surface marker expression and cytokine secretion, CCR7-, CD40- and 
CD86-expressing cells were detected via flow cytometry. Shown is the fraction of surface marker-expressing cells plotted 
against CpG-C concentration. Different concentrations were tested in different donors. n>=3
Supp Figure 6 – IFNα expression by pDCs stimulated with different CpG molecules. PDCs were coated with capture 
reagent, encapsulated in picoliter droplets, and stimulated individually with 50 µg/mL CpG-A, -B or -C for 12h. After 
staining for viability and cytokine secretion, IFNα-secreting cells were detected via flow cytometry. Shown is the fraction 
of IFNα-secreting cells plotted against treatment condition. n=2
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Supp Figure 7 – Expression of TNFα and pDC viability correlate with droplet size. PDCs were coated with cytokine 
capture reagents, encapsulated in picoliter droplets of varying size, and stimulated individually with 50 µg/mL CpG-C for 
12h. After staining for viability and surface marker expression, viable cells and TNFα-positive cells were detected via flow 
cytometry. Shown is the fraction of TNFα positive cells (A) or the fraction of viable cells (B) plotted against the droplet 
volume. Dots of the same color indicate cells from the same donor. Grey dots are all originating from different donors. 
Linear regression was employed to calculate a trend line.
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Supp Figure 8 – Kinetics of IFNa and TNFa secretion by pDCs. PDCs were stimulated with CpG-C in microtiter plates at a 
density of 25.000 cells and cytokine concentration in supernatants was measured using ELISA. Shown is the concentration 
of IFNα and TNFα plotted against the incubation time. n>=5 (A). Cytokine concentration from A) was combined with the 
number of cytokine-expressing cells, as determined via flow cytometric analysis in duplicate cultures (Figure 4), to 
calculate the average secretion rate of a single cell. Shown is the number of molecules added to the supernatant by a 
single cell every two hours plotted against the incubation time. n>=5 (B) Dots indicate mean, error bars indicate SEM.
241
10
FUNCTIONAL HETEROGENEITY WITHIN PDC POPULATIONS
Supp Figure 9 – Effect of priming with different cytokines on IFNα production by pDCs. PDCs were incubated with fresh 
medium, conditioned medium or different cytokines (0.01 µg/ml IL-3, 60 µg/ml IL-4, 50 µg/ml IL-7, 20 µg/ml IL-15) for 
two hours or left untreated. Subsequently, pDCs were stimulated with CpG-C in microtiter plates for 12h at varying cell 
densities and cytokine concentration in supernatants was measured using ELISA. Shown is the log cytokine concentration 
relative to the number of seeded cells plotted against cell density and priming condition (A, B). PDCs were incubated with 
fresh medium, conditioned medium or 500 U/mL recombinant IFNβ for 2h or left untreated. Subsequently, pDCs were 
stimulated with CpG-C for 8h in microtiter plates at a varying cell density. After incubation, cells were fixed, permeabilized, 
and stained for viability, cytokine expression, and IRF7 expression. IFNα-, TNFα-, and IRF7-expressing cells were detected 
using flow cytometry. Shown is the fraction of IFNα-expressing cells plotted against the number of seeded cells.
242
PART II – NOVEL MICROFLUIDIC TECHNIQUES FOR SINGLE CELL ANALYSIS
SUPPLEMENTARY METHODS
Supplementary Table 1 – Employed stimuli and cytokines
Stimulus Comment Standard 
conc bulk 
[µg/ml]
Standard 
conc drop 
[µg/ml]
Manufacturer
R848 Resiquimod 4 4 Enzo
CpG-A ODN 2216 5 50 Enzo
CpG-B ODN 2006 5 50 Enzo
CpG-C ODN M362 5 50 Enzo
PMA Phorbol 12-myristate 13-acetate 0.05 Calbiochem
Iono Ionomycine 1 Sigma
IL-3 Recombinant human interleukin-3 0.1 0.1 Cellgenix
IFNβ Recombinant human IFN-β 500 U/mL Peprotech
IL-4 Human IL-4, premium grade 60 Miltenyi Biotec
IL-7 50 R&D
IL-15 20 Biolegend
Supplementary Table 2 – Employed primers
Gene Name Direction Sequence (5’ to 3’)
GAPDH hGAPDH FW Forward GAAGGTGAAGGTCGGAGT
GAPDH hGAPDH RV Reverse AGATGGTGATGGGATTTC
IRF7 IRF-7.forw Forward GAGCCGTACCTGTCACCCT
IRF7 IRF-7.rev Reverse GGGCCGTATAGGAACGTGC
MDA5 MDA-5.forw Forward CAACATGGGCAGTGATTCAGG
MDA5 MDA-5.rev Reverse TGGGCAACTTCCATTTGGTAAG
OAS2 OAS2_fwd_1 Forward AAGCCCTACGAAGAATGT
OAS2 OAS2_rev_1 Reverse TTGGCTTCTCTTCTGATCCTGG
RIG-I RIG-I.forw Forward TGTGCTCCTACAGGTTGTGGA
RIG-I RIG-I.rev Reverse CACTGGGATCTGATTCGCAAAA
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Supplementary Table 3 – Employed antibodies and cytokine detection kits
Antigen Clone Label Manufacturer
CD303 AC144 APC Miltenyi Biotec
Lineage Cocktail 1
      CD3
      CD14
      CD16
      CD19
      CD20
      CD56
SK7
MφP9
3G8
SJ25C1
L27
NCAM16.2
FITC BD
CD304 AD5-17F6 PE Miltenyi Biotec
CD304 12C2 BV510 Biolegend
HLA-DR AC122 VioBlue, PE-Cy7 Miltenyi Biotec
PD-L1 MIH1 BV421 BD
CD80 2D10.4 PerCp-eFluor710 eBioscience
CD86 2331 BV510 BD
CD40 5C3 PE-Cy7 BD
CCR7 150503 FITC R&D
CD14
CD14
MφP9
M5E2
APC-H7
PerCP-Cy5.5
BD
eBioscience
CD19
CD19
SJ25C1
SJ25C1
APC-H7
BV510
BD
BD
IFNα LT27:295 PE Miltenyi Biotec
TNFα cA2 APC Miltenyi Biotec
IRF7 12G9A36 Alexa488 Biolegend
Axl 108724 Fluor488 R&D
Siglec6 767329 APC R&D
Mouse IgG1 Polyclonal Alex647 Life Technologies
IL-2 Cytokine capture reagent PE Miltenyi Biotec
IFNγ Cytokine capture reagent FITC Miltenyi Biotec
IFNα Cytokine capture reagent PE Miltenyi Biotec
TNFα Cytokine capture reagent APC Miltenyi Biotec
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Soft lithographic procedure
The microfluidic device was molded against an SU-8 photo resist structure on a silicon wafer 
using a commercially available polydimethylsiloxane (PDMS) silicone elastomer (Sylgard 184, 
Dow Corning). The surface of the Sylgard 184 was OH-terminated by exposure to plasma 
(Diener Electronic GmbH), and was sealed with another plasma-treated glass cover slide to 
yield closed micro channels. Channels were treated with a 2% silane solution.
Supplementary Table 4 – Flow rates and droplet sizes
V (droplet) Channel height Flow rate continuous phase Flow rate stimuli Flow rate cells
41 pL 25 µm 1200 µL/h 150 µL/h 150 µL/h
75 pL 25 µm 900 µL/h 200 µL/h 200 µL/h
243 pL 50 µm 900 µL/h 200 µL/h 200 µL/h
1022 pL 80 µm 1000 µL/h 1000 µL/h 1000 µL/h
3121 pL 80 µm 150 µL/h 225 µL/h 225 µL/h
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Manuscript in preparation.
CHAPTER 11
Single cell analysis and cellular heterogeneity in the 
immune system: implications for immunotherapy
250
DISCUSSION AND FUTURE PERSPECTIVE
INTRODUCTION
Cancer is a class of diseases, which is caused by abnormal cell growth, and was responsible 
for more than 8.8 million deaths worldwide in 2015, comprising more than 15% of all death 
causes.1 In an aging society, the incidence rate of cancer is thought to increase only further.2 
Cancer is a very heterogeneous disease with large variations observed between different types 
of tumors, but also variation between two individuals with the same type of tumor, and even 
within one tumor of a single individual (Chapter 3). Tumor heterogeneity poses problems to 
many treatment approaches as resistant cells often emerge leading to relapse. Immunotherapy 
is rapidly establishing itself as an important pillar of cancer treatment as it potentially allows 
for immune-mediated tumor eradication. Importantly, its versatile repertoire of recognition 
receptors and effector mechanisms provides many avenues to battle tumor heterogeneity. 
Furthermore, the ability of the immune system to induce memory responses might protect 
patients from relapsing. Indeed, novel immunotherapies lead to unprecedented levels of 
long-term survival.3, 4 Especially, therapies that target the inhibitive signaling pathways on T 
cells lead to the activation of a broad immune cell repertoire and show long-lasting effects 
in a subgroup of patients. This efficiency comes at the price of toxicity which is not related 
to treatment outcome meaning that many patients will suffer from immune-related diseases 
without benefit.5 A more targeted approach focuses therefore on the induction of tumor-specific 
T cells employing ex vivo activated dendritic cells (Chapter 1, Chapter 4). Dendritic cells are 
powerful activators of antigen-specific T cell responses and the rational is that ex vivo activated 
dendritic cells (DCs), when re-injected into the patient, generate a powerful T cell response 
targeted against the tumor (Chapter 1, 4). In early clinical trials, designed for dose-finding and 
safety evaluation, several patients with long survival times and strong tumor-specific T cell 
responses were observed.6, 7 The efficacy of DC-based immunotherapies, however, remains to 
be proven in large clinical trials. Furthermore, heterogeneity within the DC compartment is an 
ongoing challenge for novel vaccinations based on blood circulating dendritic cells (Chapter 
1, 4). Different DCs with different functional profiles are present at different fractions in blood 
and emerging data indicate additional heterogeneity within these apparently homogeneous 
subsets.8, 9 Currently, investigators are, thus, wondering which DC subset, or combination, 
should be exploited to induce the best immune responses against the tumor. Furthermore, 
it remains elusive how exactly DCs interact with each other and their environment during 
activation and T cell induction. Finally, it is currently unknown why some patients benefit from 
immunotherapy while others don’t and how we could distinguish between those groups before 
or early after treatment. Overall, insufficient knowledge on the interactions between immune 
system and tumor thus limits current treatment. Little is known about how both, the immune 
system and the tumor, generate directed and predictable behavior in the light of vast cellular 
heterogeneity.
251
11
CELLULAR HETEROGENEITY AND ITS IMPLICATIONS FOR IMMUNOTHERAPY
MONITORING OF VACCINE-INDUCED T AND B CELL RESPONSES IN 
MELANOMA PATIENTS AT THE SINGLE CELL LEVEL
In spite of their efficacy, modern immunotherapies often induce toxicity, are expensive, and 
induce lasting responses only in a minority of patients. Furthermore, the treatment window 
for patients suffering from cancer is often very narrow. An important goal to improve patient 
wellness and reduce the burden on health costs, therefore, is the establishment of biomarkers 
that can predict treatment response or indicate protective immunity. As simple blood-based 
immunomonitoring assays, such as the frequency of tumor-specific T cell in blood, failed 
to correlate with favorable prognosis in early immunotherapy trails, investigators started to 
assess the immune contexture in the tumor and other tissues.10 Those approaches showed 
success in predicting treatment outcome and used e.g. the ratio of intratumoral vs peritumoral 
T cells as predictor for DC vaccination efficiency.11 Furthermore, assays based on DC vaccine-
treated skin biopsies induce local tumor-specific recall responses which correlate with survival 
in melanoma patients.  This allows investigators to gain information of the functionality of 
induced T cells in tissue which is impossible using fixed tumor biopsies.10, 12 Nevertheless, 
tissue-based techniques are currently limited in the number of markers that can be detected 
simultaneously which hampers their ability to assess the enormous heterogeneity of immune 
cells found in the tumor microenvironment and sampling bias might skew the extracted 
information if only single biopsies are analyzed (Chapter 3). The fact that many immune cell 
types, found in tumor biopsies, were assigned ambiguous roles in tumor progression might 
follow from the incapability to adequately assess immune cell heterogeneity.13 Additionally, 
techniques that extract information from the tumor microenvironment depend on biopsies 
which require ambulant interventions and are related to patient distress. Efficient blood-based 
biomarkers, combined with multiparameter flow cytometry, remain therefore an important 
area of investigation and might be advantageous in discovering and evaluating cellular 
heterogeneity in the light of immunotherapy.
 In this thesis, we assessed two single cell techniques to investigate the induction of complex 
and heterogeneous vaccine-specific immune responses in blood of melanoma patients. In our 
studies, we focused on two important types of immune effector cells: T cells and B cells. Using 
single cell techniques, we could assess not only the fraction of antigen-specific cells but also 
deduce information on their phenotype and functional activity to increase their value as clinical 
biomarker.
The multifunctional T cell assay, presented here, allowed us to stimulate T cells with tumor 
antigens and monitor the production of the proinflammatory mediator TNFa, the chemotactic 
messenger CCL4, and the T cell growth factor IL-2 in combination with two markers for 
anti-tumor effector function: IFNg and CD107a (Chapter 4 and 5). We hypothesized that 
multifunctional T cells, which express several of these markers simultaneously, would lead 
to more efficient tumor control by countering tumor heterogeneity using multiple immune 
effector pathways simultaneously. We observed in chapter 4 and 5 of this thesis, however, that 
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the functionality of tumor-specific T cells was rather low in melanoma patients. Nevertheless, 
many patients, that displayed prolonged overall survival, seemed to harbor high fractions of 
multifunctional T cells and DC vaccination therapy had a positive impact on T cell functionality. 
Although the analyzed patient cohort is not suited to be conclusive on clinical impact, our 
data suggest that multifunctional T cells might serve as a biomarker to predict responses to 
immunotherapy. Yet, further steps need to be taken to proof the definite value of multifunctional 
T cells as biomarker.
 Future efforts need to improve the sensitivity of the employed flow cytometry assay. Tumor-
specific T cell responses occur often at low frequency, due to the negative selection of self-
antigen specific T cells in thymus as well as immunosuppressive measures of the tumor, and 
are thus difficult to detect. We applied here a stringent threshold to separate antigen-specific 
responses from background signal and to avoid considering false positive responses. This 
might have prevented the detection of modest but valid multifunctional T cell responses. In 
several patients, for instance, we detected functional T cell responses early after vaccination, 
which then decreased below the detection threshold and re-emerged at later time points. Faint 
T cell responses might thus be hidden within the background signal. The droplet-microfluidic 
assay, that we present in chapter 10 of this thesis might pose a possible solution for this. 
Our studies on cytokine secretion by plasmacytoid dendritic cells showed great separation 
between cytokine-secreting and non-secreting cells possibly due to the high local cytokine 
concentration in the small droplets. Furthermore, we observed minimal levels of background 
staining possibly due to the use of a sandwich antibody assay, which requires the specific 
recognition of the cytokine by two different antibodies. Those factors proof the high sensitivity 
and a good signal-to-noise ratio of the assay making it an ideal tool for the detection of rare 
cytokine-producing cells.
 Finally, to facilitate T cell functionality as a biomarker in large patient cohorts, improved 
analysis pipelines need to be established that capture the observed heterogeneity in univariate 
measures and are suited for easy correlation with clinical parameters. The COMPASS analysis 
pipeline (Chapter 3) is an important step in this direction and allows to summarize expression 
patterns of various functional markers using univariate scores.14 These scores describe the 
multifunctional T cell response of an individual in an unbiased way and allowed correlation 
with vaccine responses. Computational models that take the subset composition of immune 
responses into account might be a different strategy to predict the efficiency of immune 
responses as indicated by Oved et al.15
 Ideally, COMPASS in combination with our droplet-microfluidic tool for sensitive detection 
of cytokine secretion would be employed in a large cohort of melanoma patients to test the 
impact of T cell functionality on tumor progression.
Much of the effort in immunotherapy is focused on T cell responses. In contrast, less is known 
about antigen-specific B cell responses as the link between antibody production and induction 
of tumor cell apoptosis is less direct than for T cell responses which are the primary cytotoxic 
cells of the immune system. Nevertheless, antibodies can have a profound effect on tumor 
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cells as well, as they are capable to mark tumor cells for destruction by NK cells in a process 
called antibody-depended cytotoxicity or facilitate the uptake of tumor antigens by phagocytic 
cells which can lead to enforced tumor-specific T cell responses.16, 17 Recent studies show that 
treatment-induced antibody responses can correlate with improved clinical outcome. Similar 
studies, that measure the naturally present antibody responses against tumor antigens, 
however, find negative or no correlation at all.18, 19, 20 Hence, the value of antibody responses 
as correlate for either favorable or unfavorable outcome appears to depend on factors such 
as the antigen, the type of cancer, and the type of antibody. These studies, however, are based 
on the detection of secreted antibodies. Antibody secretion only poses a small fraction of a B 
cell’s functional spectrum and regulatory B cells are emerging as important orchestrators of 
immunology, especially in cancer.21, 22 Analysis and deep profiling of the tumor-specific B cell 
repertoire in melanoma patients would give insight into this neglected arm of the immune 
system but is so far lacking.
 In chapter 6 of this thesis, we investigated the vaccine-specific B cell responses in melanoma 
patients using fluorescently-labeled antigen in combination with a panel of fluorescently-
labeled antibodies against cell surface antigens. Flow cytometric analysis allowed the detection 
of antigen-specific B cell responses at various magnitudes ranging from several rare cells 
to massive B cell responses. Using fluorescence activated cell sorting (FACS), we isolated 
antigen-specific B cells and differentiated them ex vivo into antibody producing cells to verify 
the specificity of our assay using ELISPOT. Finally, we employed this technique to profile and 
monitor DC vaccination-induced B cell responses which allowed us to follow maturation and 
differentiation processes within the antigen-specific B cell compartment at high resolution. 
 In comparison to traditional ELISPOT and ELISA assays, the assay presented here allows for 
monitoring of a wide range of phenotypic and functional markers on the single cell level using 
established flow cytometry approaches. This enables deep insights into B cell complexity and 
heterogeneity and will help to elucidate the regulatory role of B cells in cancer. Furthermore, 
isolation of antigen-specific B cells allows for analysis in downstream assays that can a) help 
to investigate the functional consequences of heterogeneity observed in flow cytometry, and b) 
explore the regulatory origins of detected features.
 Together, monitoring of antigen-specific B cells and the evaluation of their regulatory 
function will give important insight into the mechanisms of tumor immunology and might help 
to establish B cell responses as biomarkers for treatment outcome.
NOVEL APPROACHES FOR THE ANALYSIS OF FUNCTIONAL 
HETEROGENEITY AND ENVIRONMENTAL IMPACT ON CELLULAR 
BEHAVIOR AT THE SINGLE CELL LEVEL
Immune cells typically act in a complex microenvironment which has important implications for 
immunotherapy.13, 23 Much of the cellular heterogeneity that we observe in the immune system is 
thought to originate or at least be influenced by signals from the microenvironment. Measuring 
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the influence of environmental factors on immune cell heterogeneity and investigating 
regulatory strategies of cell populations, however, is difficult with traditional methods as they 
don’t give much opportunity for the control or design of the microenvironment (Chapter 3). 
Microfluidics promise to fill this gap by enabling the compartmentalization of single cells or 
small cell groups in chambers or droplets. This allows for the design of minimal environments 
under the omission of most external factors that could influence cellular behavior. Similarly, 
complex artificial microenvironments can be designed and synthesized to assess the behavior 
of single cells in response to e.g. soluble messengers and nutrients, available space or number 
of potential interaction partners. Droplet-microfluidic assays are an ideal platform for the 
investigation of single cell heterogeneity and influences from the microenvironment as they 
allow for high-throughput and easy tuning of environmental factors. By changing the droplet size 
and the number of cells per droplet, for instance, the influence of auto-, para-, and juxtacrine 
factors can be investigated. By adding soluble molecules to the droplets, the effect of distal 
communication can be explored. To measure functional activity of immune cells, it is of special 
interest to detect the secretion of molecules such as cytokines. An important distinction can be 
made between detecting the production of these cytokines inside the cell or measuring their 
actual secretion. Many cells pre-produce cytokines and store them in vesicles for rapid release 
upon activation. Cytokine production alone is thus sometimes not an adequate indicator for 
functional activity.24 Yet, traditional methods for the inference of immune function on the single 
cell level rely on methods that only detect cytokine production, mRNA transcription or promoter 
activity. In this thesis, we present three microfluidic approaches for the detection of cytokine 
secretion by single cells in droplets which enable the investigation of functional heterogeneity 
at the single cell level while giving ample possibilities to explore the influence of a designed, 
customized microenvironment on cell function (Figure 1, Chapter 8, 9, 10).
 
Detecting cytokine secretion in droplets poses several challenges as most established bulk 
assays rely on washing steps and are therefore not suited for the transfer to droplets. Only few 
assays are published that measure the secretion of proteins by single cells in droplets and most 
of them rely on co-encapsulated microbeads as detection beacon. Mazutis et al, for instance, 
developed an assay for the detection of antibody secretion that was based on fluorescence 
focusing.25 Antigen-coated microbeads were co-encapsulated with antibody producing cells 
and fluorescent detection antibodies. If specific antibodies were secreted by the cell, they were 
captured by the microbead in the droplet and the detection antibodies would concentrate on 
the beads surface leading to a local increase in the fluorescence signal. Fluorescence was 
measured by a laser photodiode system which was focused on the microfluidic device and 
allowed to sort droplets based on fluorescence signal. This pioneering technique revealed the 
possibilities of droplet microfluidics; its practical application, however, was hindered by high 
technological demands and low sensitivity.
 We here developed three alternative droplet microfluidic approaches that allow the detection 
of cytokine secretion and, at the same time, employ traditional analysis pipelines based on 
flow cytometry or fluorescent microscopy for seamless integration in existing experimental 
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protocols. For the detection of cytokine secretion, we relied on 1) an aptamer sensor, 2) capture 
beads in combination with agarose hydrogels, and 3) cytokine capture beads that directly bind 
to the surface of encapsulated cells.
Figure 1 – Schematic overview of the different droplet-microfluidic techniques that were developed as part of this 
thesis. A) Aptamer-based assay for the live detection of IFNg detection by single T cells. B) Agarose hydrogel-based assay 
to detect the secretion of multiple cytokines by single Jurkat T cells. C) Capture reagent-based droplet-microfluidic assay 
for the detection and isolation of cytokine-secreting immune cells.
The developed aptamer sensor was anchored in the cell membrane and initially self-quenched 
(Figure 1A, Chapter 9). Binding of the analyte led to a conformational change turning the molecule 
fluorescent. This allows for the live detection of cytokine secretion using time lapse microscopy 
which makes this technique ideally suited for the investigation of temporal cytokine secretion 
patterns and the analysis of dynamic single cell processes at high-throughput. Nevertheless, 
we observed some stability issues with the aptamer leading to reduced fluorescence intensity, 
the improvement of which should be the focus of future efforts. 
 An alternative approach for the detection of cytokine secretion by single cells offer agarose 
hydrogel droplets which enable the implementation of heterologous assays that include 
washing steps (Figure 1B, Chapter 8). Here, the cells were encapsulated in droplets containing 
agarose that was liquid at room temperature. Co-encapsulated, antibody-coated beads caught 
secreted cytokines during cell incubation. Subsequently, the droplets were cooled to 4°C and 
the agarose gelled entrapping cell and cytokine capture beads in the same hydrogel droplet. 
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Gelled agarose droplets were washed and incubated with fluorescent detection antibodies 
which bound to beads that caught cytokines during incubation. Using standard flow cytometry, 
the fluorescence of these agarose hydrogel droplets could be assessed which allowed the 
detection of up to 3 secreted cytokines by Jurkat T cells. Agarose hydrogel-based systems 
have the advantage that they preserve some information of the droplet microenvironment and 
link it directly to functional activity – e.g. number, type and phenotype of contained cells can be 
measured together with cytokine secretion in the same droplet. At the same time, this technique 
allows for much higher throughput than microscopy based approaches. In combination with a 
flow cytometry-based approach for the co-encapsulation of different cell types, as presented in 
Chapter 7 of this thesis, this cytokine secretion assay could enable the analysis of single cell-
cell interactions in droplets. Analysis of cell-cell interactions is an important area of research 
in biology and especially in immunology many crucial processes, such as the induction of T cell 
responses by dendritic cells or the induction of apoptosis by T cells, rely on crosstalk between 
two single cells. Analyzing how heterogeneity within both cell types but also environmental 
factors influences this process on the single interaction level is an important goal.
 The third approach, that we developed, focuses on the fast, robust, and high-throughput 
analysis of primary immune cells (Figure 1C, Chapter 10). If the investigation of complex 
multicell-interactions is not the primary research aim, it is faster and more feasible to 
employ approaches that are not based on agarose hydrogels. We employed cytokine capture 
reagents that consisted of two fused antibodies binding to CD45 – a cell surface protein that 
is ubiquitously expressed by all immune cells – on one side and the cytokine of choice on 
the other side. Cells were coated with these capture reagents prior to encapsulation, and 
the secreted cytokines in the droplets were bound on the cell surface. After incubation, the 
emulsion was broken and the single cells were stained and analyzed using flow cytometry. 
As the staining and analysis procedure was conducted at 4°C, no further biochemical activity 
occurred. This cytokine detection approach allows fast and efficient encapsulation of cells and 
is therefore highly suited for scarce primary and clinical cell samples. This comes at the price 
of information loss as it is now not possible to deduce the actual droplet environment of a 
particular cell. For the investigation of many processes of cellular heterogeneity, it is, however, 
sufficient to modify environmental variables for the whole droplet population and deduce 
the effect of these changes on the cells by looking at population-wide shifts in investigated 
parameters. For instance, we employed the capture reagent-based cytokine secretion assay 
successfully in this thesis to investigate the influence of various microenvironmental factors on 
the stochastic gene expression of single plasmacytoid dendritic cells. Importantly, in contrast 
to the previously mentioned assays, the capture reagent-based assay allows for effortless 
isolation and sorting of individually stimulated cells based on cytokine secretion and surface 
marker expression using FACS. Those cells can be further investigated in down-stream 
applications such as RNA sequencing or epigenetic analysis to link functional heterogeneity to 
the regulatory landscape.
 Adapting droplet-microfluidic assays for the routine application within an immunological 
pipeline comes, however, with challenges. Most published microfluidic assays were designed 
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by employing cell lines with quasi unlimited supply and not necessarily with the efficient use 
of scarce samples in mind. When conducting biologically relevant experiments, researchers 
depend on using primary or clinical samples with often very limited cell numbers. During initial 
experiments with plasmacytoid dendritic cells, which are present at very low frequency in 
blood (<0.1% of immune cells), we lost high fractions of the samples due to inefficient delivery 
of the cells to the microfluidic chip. Amendments to the procedure enhanced encapsulation 
efficiency and reduced cell loss dramatically eventually enabling us to incorporate as few as 
40,000 cells per condition. This drastically increased the throughput of the assay and allowed 
us to employ primary cells on a routine base.
 In summary, droplet microfluidic assays are an important tool for the investigation of single 
cell behavior and cellular heterogeneity. The assays that we developed in this thesis enabled us 
to detect cytokine production by single immune cells derived from scarce primary and clinical 
samples. Future applications will focus even more on integrating different omics techniques 
for the analysis of various regulatory and functional layers in the same single cell with the goal 
of a multilayered 3D map of cellular regulation and heterogeneity in mind.
FUNCTIONAL HETEROGENEITY DURING DENDRITIC CELL ACTIVATION
Cellular heterogeneity is a fundamental property of the human immune system and decoding 
heterogeneity is crucial to understand the complex interactions between immune and tumor cells 
(Chapter 3). Dendritic cells are key regulators of innate and adaptive immune responses and are 
a critical target in the efforts to develop efficient immunotherapies against cancer (Chapter 1, 2, 
4).6, 7, 26 Especially pDCs show great promise in immunotherapeutic approaches as their ability 
to induce strong IFNa responses is thought to be critical for the induction of efficient anticancer 
immunity.6, 26, 27 However, the regulation of this type I IFN response is not well understood. We 
show in this thesis that stochastic expression of IFNa causes functional heterogeneity within 
pDC populations (Chapter 10). Hence, the detection of pathogenic stimuli alone does not ensure 
that a cell will produce IFNa but rather it renders the possibility to randomly produce the 
cytokine. Furthermore, type I IFNs, in a positive feedforward loop, determine the magnitude 
of the induced IFNa response. The strength of pathogenic stimulation does not appear to be 
directly involved in this process. Hence, the induction of robust IFNa population responses is not 
an isolated decision made by each pDC on its own but rather depends on environmental factors 
which can highly increase the probability of a pDC to produce IFNa. 
 These discoveries open up new treatment avenues in immunotherapy. Serum IFNa levels 
emerge as possible regulators for pDC-focused interventions and might be exploited to enhance 
IFNa responses during DC vaccination. One could imagine to administer small amounts of IFNa 
together with pDC-based DC vaccines to further increase the induced responses. Alternatively, 
injection of IFNa prior to administering pDC-targeted TLR stimuli could boost IFNa production 
by intratumoral pDCs which often display a tolerizing phenotype and fail to produce type I 
IFNs.28, 29 An important question in that respect concerns the maintenance of high IRF7 levels 
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in pDCs in vivo. Are the tonic, low levels of type I IFN found in serum sufficient to keep IRF7 
expression high or are there other signals in the body that cause this unique property of pDCs.30
 Further research has to determine the molecular mechanisms that regulate the stochastic 
IFNa production by pDCs. Multilayered single cell analysis that simultaneously investigates the 
epigenome, transcriptome and proteome of individual pDCs would give important insights into 
the origin of IFNa production. In the course of these investigations, researchers also need to 
rethink current definitions of cell type and cell state. At what moment are variations between a 
subgroup of cells and the rest of the population significant enough to call for a new cell type? 
How plastic are cell states and is cell differentiation reversible?
 In summary, by carefully modifying various environmental factors during activation in 
droplets, we showed that the expression of IFNa by human pDCs is highly stochastic and 
that this stochasticity is regulated by paracrine signaling mechanisms. PDC populations thus 
integrate signals of pathogenic and host origin to tune the magnitude of their responses.
CONCLUSION
Together, in this thesis, we caught a glimpse at functional heterogeneity of immune cells in 
the setting of immunotherapy against cancer and we established functional heterogeneity as 
important features of T cell and pDC responses. Future work will further establish cellular 
heterogeneity as a crucial biological feature that impacts human wellness and treatment of 
various diseases. Cost reduction and increasing throughput will help single cell omics tools 
to establish themselves as the standard analytical assay in biology and medicine akin to and 
possibly replacing flow cytometry. Abundant availability of single cell information will create 
further challenges in respect to handling and analysis of large datasets. Bioinformatic tools 
need to be established that allow easy summary and interpretation of abstract measures such 
as heterogeneity or functionality. This will facilitate wider use in clinical practice and might 
one day inform treatment decisions. Finally, in light of increasing reports on heterogeneity and 
variation between seemingly identical cells, it will be an important task for biologists to rethink 
concepts of what determines cellular identity.
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DUTCH SUMMARY
Introductie
Ons afweersysteem bestaat uit een uitgebreid netwerk van cellen en moleculen die ons lichaam 
tegen infecties en kanker beschermen. Om bedreigingen voor het lichaam efficiënt tegen te 
gaan, heeft het immuunsysteem krachtige wapens ter beschikking. Het kan bijvoorbeeld een 
ontstekingsreactie induceren, kankercellen en lichaamscellen geïnfecteerd door virussen 
doden of bacteriën vangen in een web van DNA of antistoffen. Echter, als deze mechanismen 
ongecontroleerd geactiveerd worden, dan kan het immuunsysteem het eigen lichaam ook 
beschadigen. Wat bijvoorbeeld kan leiden tot allergieën of auto-immuunziekten. Om het risico 
van schadelijke neveneffecten te beperken, zorgen complexe communicatienetwerken tussen 
het immuunsysteem, de lichaamscellen, de bacteriën die in onze darmen en op onze huid 
leven, en het micromilieu ervoor, dat het immuunsysteem alleen op de juiste plaats en op het 
juiste moment wordt geactiveerd en gebruikt.
 De fundamentele bouwstenen van het immuunsysteem zijn de immuuncellen, die 
voortdurend informatie vanuit de omgeving opnemen en steeds opnieuw beslissen of ze in 
actie moeten komen. Er is een grote variatie tussen de cellen van het immuunsysteem. Zelfs 
binnen dezelfde type cellen blijven er altijd verschillen bestaan tussen individuele cellen, zodat 
geen twee cellen zich ooit precies hetzelfde gedragen. Een verschil kan bijvoorbeeld zijn, het 
aantal moleculen op het celoppervlak die virussen kunnen detecteren. Dit verschijnsel, ook 
wel cellulaire heterogeniteit genoemd, is een grondbeginsel van alle biologische organismen. 
Het is echter op dit moment onduidelijk welke impact dit verschijnsel heeft op het functioneren 
van het immuunsysteem en welke factoren het beïnvloeden. Hoe bepaal je bijvoorbeeld, in 
hoeverre het aantal moleculen die virussen detecteren op het celoppervlak varieert? En welke 
invloed heeft dit op de werking van immuuncellen?
 Dendritische cellen behoren tot de aangeboren immuunrespons en zijn de schakelcentrales 
van het immuunsysteem. Met een verscheidenheid aan sensoren nemen zij signalen uit de 
omgeving op en scannen deze voor ziekteverwekkers. Als ze een bedreiging voor het lichaam 
opsporen, activeren ze de verworven of adaptieve immuunrespons die met krachtige wapens 
de ziekteverwekkers snel elimineert. De adaptieve immuunreactie bestaat enerzijds uit de 
T-cellen omvattende cellulaire respons, die in geïnfecteerde lichaamscellen of kankercellen 
apoptose kan veroorzaken, en anderzijds uit de humorale respons, geleid door B-cellen die 
antilichamen tegen pathogenen produceren om deze te neutraliseren. Dendritische cellen 
kunnen, afhankelijk van de signalen die zij uit de omgeving ontvangen, specifieke delen van 
de adaptieve immuunrespons activeren en daarmee bijvoorbeeld gerichte T-celresponsen 
induceren. Dit maakt dendritische cellen van bijzonder belang voor de behandeling van 
kanker, waar massieve T-cel reacties nodig zijn om kankercellen te vernietigen. Eén 
behandelingsmethode isoleert dendritische cellen uit patiënten en activeert ze buiten het 
lichaam met behulp van speciale materialen. Vervolgens worden de cellen als vaccin in de 
patiënt geïnjecteerd. In het lichaam induceren de dendritische cellen dan een krachtige T-cel 
respons die de kanker bestrijdt. Een nieuwe aanpak gebruikt hiervoor zeldzame dendritische 
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cellen uit het bloed van kankerpatiënten. Eerste klinische studies suggereren dat vooral deze 
zeldzame cellen sterke immuunreacties veroorzaken.
 De cellulaire heterogeniteit speelt een belangrijke rol in deze context. Dendritische cellen 
die in het bloed circuleren, bevatten veel verschillende subtypen die worden gekenmerkt 
door verschillende functies. Een recent ontdekt subtype, de plasmacytoide dendritische cel, 
wordt gekenmerkt door een bijzonder hoge productie van interferon alfa. Interferon alfa is een 
signaalstof die de vernietiging van geïnfecteerde cellen en kankercellen bevordert en daarom 
een rol speelt in veel therapieën tegen kanker. Nieuwe studies suggereren ook dat subtypes 
van plasmacytoide dendritische cellen in staat zijn om andere functies uit te oefenen, zoals het 
direct activeren van T-cellen. Extra diversiteit wordt gegenereerd tijdens het activeringsproces 
van de adaptieve immuunrespons, aangezien geactiveerde T-cellen verschillende functies 
kunnen hebben.
 Veel aspecten van de cellulaire heterogeniteit in verband met immuunreacties zijn momenteel 
niet goed bekend. Dit wordt mede veroorzaakt doordat geschikte onderzoeksmethoden 
ontbreken. In het bijzonder zijn er werkwijzen nodig voor het analyseren van ‘de single cell’, 
dus een enkele, individuele immuuncel. Eerdere pogingen om individuele cellen te isoleren, te 
activeren en te onderzoeken mislukten vaak ten gevolge van hun geringe aantal. Microfluidics, 
een techniek die het gedrag van vloeistoffen met een zeer laag volume bestudeert, opent 
nieuwe mogelijkheden voor single cell analyse. Microfluïdische opstellingen kunnen kleine 
druppeltjes genereren die enkele cellen bevatten.  Deze kunnen als een bioreactor voor de 
studie van het gedrag van single cells dienen. Dit maakt het mogelijk om te onderzoeken hoe 
kleine verschillen tussen de afzonderlijke cellen tot significante gedragsveranderingen van het 
immuunsysteem leiden.
Doel van deze studie
Het doel van deze studie was ten eerste de ontwikkeling en optimalisatie van nieuwe technieken 
voor single cell analyse, om de kleinste verschillen tussen vrijwel identieke cellen te ontdekken. 
Ten tweede werden de ontwikkelde methoden gebruikt om te onderzoeken hoe deze kleine 
verschillen tot significante veranderingen in het gedrag van individuele cellen leiden en hoe dit 
het functioneren van het immuunsysteem tijdens kankertherapie beïnvloedt.
Resultaten
Eerst werd in een klinische studie onderzocht, welke invloed dendritische cellen op de cellulaire 
heterogeniteit van T-cellen hebben. Met name werd onderzocht of dendritische cellen in staat 
zijn om multifunctionele T-cellen te induceren. Deze T-cellen worden gekenmerkt doordat zij 
meerdere wapens tegelijkertijd tegen kankercellen gebruiken. Dit zorgt, althans theoretisch, 
voor een  voordeel bij de strijd tegen kanker. In een volgende stap werd vervolgens onderzocht of 
multifunctionele T-cellen inderdaad effectiever zijn in de strijd tegen kanker. Om deze vragen te 
beantwoorden, werd een flowcytometrische analysemethode geoptimaliseerd, die het mogelijk 
maakt individuele T-cellen gelijktijdig op hun productie van verschillende signaalstoffen en 
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anti-kanker eiwitten te onderzoeken. Uit de resultaten bleek dat vaccinatie met dendritische 
cellen daadwerkelijk tot een verhoogde frequentie van multifunctionele T-cellen leidt. Zoals 
studies in een uitgebreide patiëntenpopulatie toonden, verschenen deze multifunctionele 
T-cellen voornamelijk bij patiënten die na behandeling met dendritische cel vaccinatie langer 
dan gemiddeld overleefden. Daarnaast zijn de dendritische cellen van individuele patiënten 
gedifferentieerd in hun vermogen om multifunctionele T-cellen te induceren.
Door deze variaties en op basis van nieuwe studies die grote verschillen tussen dendritische 
cellen in humane bloedmonsters beschrijven, werd vervolgens cellulaire heterogeniteit tijdens 
het activeren van dendritische cellen onderzocht. Eerder verrichtte laboratoriumexperimenten 
met proefdieren en modelorganismen hebben aangetoond dat de cellulaire heterogeniteit met 
name tijdens interferon-alfa-productie een cruciale rol speelt. Helaas belemmeren technische 
verschillen tussen de modelsystemen een directe vertaling van deze resultaten naar menselijke 
cellen. Hierdoor was het niet bekend of cellulaire heterogeniteit invloed heeft op de interferon 
alfa productie in humane plasmacytoide dendritische cellen. Met name was het onduidelijk 
of alle plasmacytoide dendritische cellen in staat zijn om onafhankelijk interferon alpha te 
produceren, of dat communicatie tussen heterogene cellen en de omgeving noodzakelijk is 
voor dit verschijnsel.
 Om dit fenomeen te bestuderen, werden eerst nieuwe methoden voor single cell analyse 
met menselijke bloedmonsters ontwikkeld. Microfluïdische systemen werden op de behoeften 
van deze analyse toegesneden en maakten het mogelijk om onder ‘high-throughput’ single 
cells in druppeltjes op hun productie van signaalstoffen en eiwitten te onderzoeken. De 
druppels verschaften een reproduceerbare en gestandaardiseerde omgeving die nauwkeurig 
kon worden gemanipuleerd met de microfluïdische opstellingen. Hierdoor konden bijvoorbeeld 
diverse omgevingsfactoren als oorzaken van cellulaire heterogeniteit worden getest, om 
vervolgens conclusies te trekken over de regulering van het cellulaire gedrag.
 Daarna werden individuele plasmacytoide dendritische cellen geactiveerd in deze 
druppeltjes. Verrassenderwijs produceerden slechts weinig cellen interferon alfa. Deze 
resultaten van individueel gestimuleerde cellen staan haaks op de resultaten van experimenten 
met duizenden cellen gelijk die dus niet in druppeltjes werden uitgevoerd. Vele van die 
cellen produceerden interferon alfa. Door het selectief variëren van omgevingsvariabelen 
in de druppels kon in de volgende experimenten worden aangetoond dat de celdichtheid 
bepalend is voor het aantal interferon-alfa producerende cellen, via een positief feed-forward 
mechanisme. In dit model produceren enkele vroegrijpe cellen snel na stimulatie interferon-
alfa. Deze interferon alfa verspreidt zich dan naar naburige cellen en vergroot hier, door 
intracellulaire signaleringsmechanismen, de waarschijnlijkheid dat deze cellen ook met 
de productie van interferon alfa beginnen. Als de cellen in druppeltjes worden geactiveerd, 
kan deze communicatie niet plaatsvinden en zullen alleen de enkele vroegrijpe cellen 
interferon alfa produceren. Deze resultaten dragen eraan bij dat in de toekomstige kanker 
vaccins, dendritische cellen effectiever worden geactiveerd en dus in staat zijn om sterkere 
immuunreacties te induceren.
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Elders in dit werk zijn nieuwe werkwijzen voor de single cell analyse van de humorale 
immuunrespons geoptimaliseerd en gebruikt om B-cellen in huidkankerpatiënten te 
onderzoeken. Daarnaast zijn modificaties van de microfluïdische analysemethodes ontwikkeld, 
waarmee de productie van signaalstoffen door individuele cellen live kan worden geobserveerd.
Conclusie
De resultaten van deze studie versterken het idee dat cellulaire heterogeniteit een belangrijke 
rol in het immuunsysteem speelt. T-cellen kunnen verschillen in hun functionaliteit, wat van 
invloed is op de effectiviteit van behandelingen tegen kanker. Dendritische cellen worden 
beïnvloed door verscheidene oorzaken. Ten eerste speelt cellulaire heterogeniteit een 
belangrijke rol tijdens hun activering en regelt het de productie van de signaalstof interferon 
alfa. Voorts kunnen verschillen tussen dendritische cellen tot verschillende T-cel responsen 
leiden en aldus tot verschillen in de effectiviteit van behandelingen tegen kanker. Dit werk legt 
een belangrijke basis voor de ontwikkeling van methoden voor de single cell analyse en het 
onderzoek naar het gedrag van individuele cellen tijdens de activeringsfase. Deze resultaten 
kunnen in de toekomst worden gebruikt om effectiever immuunreacties bij patiënten met 
kanker te induceren en dus leiden tot een betere controle van de ziekte.
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Einführung
Unser Immunsystem besteht aus einem weitverzweigten Netz von Zellen und Teilchen, die 
unseren Körper vor Infektionen und der Entstehung von Krebs schützen. Um Bedrohungen für 
den Körper effizient zu begegnen, besitzt das Immunsystem effektive Waffen und kann zum 
Beispiel Entzündungen hervorrufen, Krebszellen töten oder Bakterien in einem Netz aus DNS 
und antibiotischen Proteinen einfangen. Werden diese Mechanismen jedoch unkontrolliert 
aktiviert, kann das Immunsystem dem eigenen Körper schaden und zum Beispiel Allergien 
oder Autoimmunerkrankungen auslösen. Um dieses Risiko zu minimieren, sorgen komplexe 
Kommunikationsnetzwerke zwischen dem Immunsystem, den Körperzellen, den Bakterien, die 
in unserem Darm oder auf unserer Haut leben, und der Umwelt dafür, dass das Immunsystems 
nur am richtigen Ort und zum richtigen Zeitpunkt aktiviert wird.
 Die fundamentalen Bausteine des Immunsystems sind die einzelnen Zellen, welche 
kontinuierlich Informationen aufnehmen und in jedem Moment aufs Neue entscheiden, 
ob sie ihre Abwehrmechanismen einsetzen sollen. Kleinste Unterschiede zwischen den 
einzelnen Zellen, zum Beispiel in der Anzahl der Detektoren für Viren auf der Zelloberfläche, 
sorgen dafür, dass sich zwei Zellen in einer gegebenen Situation niemals exakt identisch 
verhalten. Dieses Phänomen, welches auch als zelluläre Heterogenität bezeichnet wird, ist 
ein grundlegendes Prinzip aller biologischer Organismen. Es ist derzeit aber noch unklar, 
welchen Einfluss dieses Phänomen auf die Funktionsweise des Immunsystems hat und durch 
welche Faktoren es kontrolliert wird. Hierbei stellen sich unter anderem folgende Fragen: Wie 
wird festgelegt, in welchem Rahmen die Anzahl an Detektoren für Viren auf der Zelloberfläche 
variiert? Und welchen Einfluss hat das auf die Funktionsweise der Immunzellen während 
Aktivierungsprozessen?
 Dendritische Zellen sind Teil der so genannten angeborenen Immunantwort und die 
Schaltzentralen des Immunsystems. Über eine Vielzahl von Sensoren nehmen sie Signale aus 
der Umwelt auf und scannen diese nach Krankheitserregern. Erkennen sie eine Bedrohung 
für den Körper, aktivieren sie die erworbene oder adaptive Immunantwort welche die 
Krankheitserreger effektiv und schnell eliminiert. Die adaptive Immunantwort unterteilt sich in 
die zelluläre Antwort, bestehend aus T-Zellen, welche infizierte Körperzellen oder Krebszellen 
töten, und die humorale Antwort, angeführt von B-Zellen, welche Antikörper produzieren um 
Krankheitserreger zu neutralisieren. Dendritische Zellen können, abhängig von den Signalen, 
die sie aus der Umwelt empfangen, spezifische Teile der adaptiven Immunantwort aktivieren 
und so zum Beispiel gezielt T-Zell-Reaktionen auslösen. Dies macht dendritische Zellen 
besonders interessant für die Krebstherapie, bei der solide T-Zell-Reaktionen notwendig 
sind, um Krebszellen zu zerstören. Eine Behandlungsmethode im Bereich der Krebstherapie 
zielt darauf ab, dendritische Zellen von Patienten zu isolieren, diese außerhalb des Körpers 
mit speziellen Stoffen zu aktivieren, und dann als Vakzin wieder dem Patienten zu injizieren. 
Dort induzieren die dendritischen Zellen dann eine potente T-Zell-Antwort, die den Krebs 
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bekämpft. Ein neuer wissenschaftlicher Ansatz verwendet hierfür seltene dendritische Zellen 
aus dem Blut von Krebspatienten; erste klinische Studien deuten darauf hin, dass diese Zellen 
besonders starke Immunantworten auslösen. 
 Eine wichtige Rolle spielt in diesem Zusammenhang auch die zelluläre Heterogenität. 
Dendritische Zellen, die im Blut zirkulieren, enthalten viele verschiedene Subtypen, welche 
sich durch unterschiedliche Funktionen auszeichnen, die von der besonders effektiven 
Aktivierung der T-Zellen bis hin zur Ausschüttung von anti-Krebsbotenstoffen reichen. Die erst 
vor kurzem entdeckten plasmazytoiden dendritische Zellen sind ein Subtyp, der sich durch die 
besonders hohe Produktion des Botenstoffs Alpha-Interferon auszeichnet. Alpha-Interferon 
besitzt Eigenschaften, die die Zerstörung von Virus-infizierten Zellen und Krebszellen fördert 
und spielt deswegen eine wichtige Rolle in vielen Krebstherapien. Neueste Studien legen aber 
auch nahe, dass Subtypen der plasmazytoiden dendritischen Zellen in der Lage sind, andere 
Funktionen auszuüben und hierbei zum Beispiel in der Lage sind, T-Zellen direkt zu aktivieren. 
Zusätzliche Heterogenität entsteht während der Aktivierung der adaptiven Immunantwort. 
Aktivierte T-Zellen können hierbei verschiedene Funktionen aufweisen und zum Beispiel 
Wachstumshormone oder Entzündungsstoffe ausschütten.
 Viele Aspekte der zellulären Heterogenität im Zusammenhang mit Immunantworten 
sind heute noch nicht ausreichend erforscht, was auch daran liegt, dass geeignete 
Untersuchungsmethoden fehlen. Insbesondere Methoden für die Einzelzellanalyse von 
Immunzellverhalten werden für die Erforschung der zellulären Heterogenität benötigt. 
Bisherige Versuche scheiterten aber oft daran, dass einzelne Zellen auf Grund ihrer geringen 
Größe nur unzureichend isoliert und aktiviert werden können. Die Mikrofluidik, welche das 
Verhalten von Flüssigkeiten mit sehr geringem Volumen erforscht, eröffnet aktuell neue 
Möglichkeiten für die Einzelzellanalyse und kann das oben beschriebene Defizit im Bereich 
der Erforschung der zellulären Heterogenität vermutlich abbauen. Mikrofluidische Geräte 
können winzige Tröpfchen erzeugen, welche einzelne Zellen enthalten und als Bioreaktor für 
die Untersuchung des Einzelzellverhaltens dienen. Dies ermöglicht es dann zu erforschen, wie 
winzige Unterschiede zwischen den einzelnen Zellen zu signifikanten Verhaltensänderungen 
des Immunsystems führen.
Zielsetzung der Arbeit
Ziel dieser Arbeit war zum einen, die Entwicklung und Optimierung von neuen Techniken für die 
Einzelzellanalyse, welche es ermöglichen, kleinste Unterschiede zwischen nahezu identischen 
Zellen zu entdecken. Zum anderen wurden die entwickelten Methoden angewandt, um zu 
untersuchen, wie diese kleinsten Unterschiede zu signifikanten Veränderungen im Verhalten 
einzelner Zellen führen und welchen Einfluss dies auf die Funktionsweise des Immunsystems 
während der Krebstherapie hat.
Ergebnisse
Zunächst wurde im Rahmen einer klinischen Studie untersucht, welchen Einfluss dendritische 
Zellen auf die zelluläre Heterogenität von T-Zellen haben. Insbesondere wurde erforscht, ob 
268
APPENDIX
dendritische Zellen in der Lage sind, multifunktionelle T-Zellen zu induzieren. Diese T-Zellen 
zeichnen sich dadurch aus, dass sie multiple Waffen gegen Krebszellen einsetzen und aus 
diesem Grund zumindest theoretisch einen Vorteil in der Krebsbehandlung darstellen. In 
einem nächsten Schritt wurde dann untersucht, ob multifunktionelle T-Zellen tatsächlich 
effektiver in der Krebsbekämpfung sind. Um diese Fragen zu beantworten, wurde eine 
durchflusszytometrische Untersuchungsmethode optimiert, die es ermöglichte einzelne 
T-Zellen gleichzeitig auf ihre Produktion verschiedener Botenstoffe und krebsbekämpfender 
Proteine hin zu untersuchen. Es stellte sich heraus, dass eine Impfung mit dendritischen Zellen 
tatsächlich zu einer erhöhten Frequenz an multifunktionelle T-Zellen führt. Wie anschließende 
Untersuchungen in einer erweiterten Patientengruppe zeigten, waren diese multifunktionellen 
T-Zellen hauptsächlich in Patienten nachweisbar, die nach der Impfung überdurchschnittlich 
lange überlebten. Außerdem unterschieden sich die dendritischen Zellen von einzelnen 
Patienten deutlich in ihrer Fähigkeit, multifunktionelle T-Zellen zu induzieren.
Auf Grund dieser Variationen und basierend auf neuen Studien, die eine große Diversität 
unter den dendritischen Zellen in menschlichen Blutproben beschreiben, wurde in dieser 
Arbeit als nächstes die zelluläre Heterogenität während der Aktivierung von dendritischen 
Zellen untersucht. Laborexperimente mit Versuchstieren und Modelorganismen zeigten, 
dass die zelluläre Heterogenität besonders während der Alpha-Interferon Produktion 
eine entscheidende Rolle spielt. Technische Unterschiede zwischen den Modellsystemen 
verhindern jedoch eine direkte Übertragung dieser Ergebnisse auf menschliche Zellen und 
es war zu diesem Zeitpunkt nicht bekannt, ob die zelluläre Heterogenität die Alpha-Interferon 
Produktion in menschlichen plasmazytoiden dendritischen Zellen beeinflusst. Dabei stellte 
sich insbesondere die Frage, ob alle plasmazytoiden dendritischen Zellen in der Lage sind 
selbstständig Alpha-Interferon zu produzieren oder ob Kommunikation zwischen einzelnen 
Zellen und Signale aus der Umwelt für diesen Prozess notwendig sind.
 Um dieses Phänomen zu erforschen, wurden zunächst neue Methoden für die 
Einzelzellanalyse menschlicher Blutproben entwickelt. Mikrofluidische Systeme wurden auf 
die Bedürfnisse für diese Analyse zugeschnitten und diese ermöglichten es unter hohem 
Durchsatz, einzelne Zellen in winzige Tröpfchen einzuschließen und auf die Produktion von 
Botenstoffen und Proteinen hin zu untersuchen. Die Tröpfchen boten dabei eine standardisierte 
und reproduzierbare Umgebung, die mit den mikrofluidischen Geräten präzise kontrolliert 
werden konnte. Dies ermöglichte es zum Beispiel, verschiedene Umgebungsfaktoren 
als Ursachen für zelluläre Heterogenität zu erproben und dadurch Rückschlüsse auf die 
Regulierung des zellulären Verhaltens zu ziehen.
 Als nächstes wurden einzelne plasmazytoide dendritische Zellen in diesen Tröpfchen 
aktiviert. Erstaunlicherweise produzierten jedoch nur wenige Zellen Alpha-Interferon. Diese 
Resultate stehen im Gegensatz zu Experimenten mit Gruppen von tausenden Zellen, die 
nicht in Tröpfchen, sondern größeren Behältern ausgeführt wurden. Hier produzierten viele 
Zellen Alpha-Interferon. Durch gezieltes variieren von Umgebungsvariablen in den Tröpfchen 
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konnte in folgenden Experimenten gezeigt werden, dass die Zelldichte über einen positiven 
Vorwärtskopplungsmechanismus die Anzahl der Alpha-Interferon-produzierenden Zellen 
kontrolliert. Wenige frühreife Zellen beginnen in diesem Modell unmittelbar nach der 
Stimulation mit der Produktion von Alpha-Interferon. Dieses Alpha-Interferon diffundiert dann 
zu den benachbarten Zellen und erhöhte hier durch intrazelluläre Signalmechanismen die 
Wahrscheinlichkeit, dass diese Zellen auch mit der Alpha-Interferon Produktion beginnen. 
Werden die Zellen jedoch in Tröpfchen aktiviert, kann diese Kommunikation nicht stattfinden 
und nur die wenigen frühreifen Zellen produzieren Alpha-Interferon. Diese Resultate werden 
dazu beitragen, dass in zukünftigen Krebsvakzinen die dendritischen Zellen effektiver aktiviert 
werden können und so in der Lage sind, stärke Immunantworten auszulösen.
In weiteren Teilen dieser Arbeit wurden neue Methoden für die Einzelzellanalyse der humoralen 
Immunantworten optimiert und angewandt um B-Zellen in Hautkrebspatienten zu untersuchen. 
Außerdem wurden Abwandlungen der mikrofluidischen Untersuchungsmethoden entwickelt, 
die es erlauben, einzelne Zellen direkt bei der Produktion von Botenstoffen zu beobachten oder 
zwei Zellen gezielt in einem Tröpfchen zusammenzubringen um ihre Interaktionen in einer 
kontrollierten Umgebung zu beobachten.
Fazit
Die Ergebnisse dieser Arbeit bestärken die Annahme, dass zelluläre Heterogenität eine 
wichtige Rolle für die Funktion des Immunsystems spielt. T-Zellen können sich in ihrer 
Funktionalität unterscheiden, was Einfluss auf die Effektivität von Krebsbehandlungen hat. 
In dendritischen Zellen beeinflusst die zelluläre Heterogenität gleich mehrere Prozesse. Zum 
einen spielt die zelluläre Heterogenität eine wichtige Rolle während ihrer Aktivierungsprozesse 
und reguliert die Produktion des Botenstoffes Alpha-Interferon. Zum anderen können 
Unterschiede zwischen dendritischen Zellen zu unterschiedlichen T-Zellantworten führen und 
somit zu Unterschieden in der Effektivität von Krebsbehandlungen. Diese Arbeit legt wichtige 
Grundlagen für die Entwicklung von Methoden zur Einzelzellanalyse und der Erforschung 
des Verhaltens einzelner Zellen während der Aktivierungsphase. Diese Ergebnisse können in 
Zukunft dazu genutzt werden, noch effektiver Immunantworten in Krebspatienten zu induzieren 
und somit eine bessere Kontrolle dieser Krankheit ermöglichen.
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